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Abstract 
 
In the present work the total synthesis of miharamycin B has been investigated, and 
the unprecedented construction of its core was successfully achieved. The unique 
bicyclic sugar amino acid moiety has been elaborated by means of a SmI2- based 
keto–alkyne coupling, followed by elongation of its C-6 position using a non-
stereoselective chain extension methodology. The lower degree of stereocontrol 
allowed the synthesis of both epimers at C-6’ for SAR purposes. Conversion of the 
bicyclic sugar amino acid into a suitable glycosyl donor enabled efficient regio- and 
stereoselective N-glycosylation with 2-aminopurine to take place furnishing the 
nucleoside moiety of miharamycins. Final peptide coupling with L-arginine afforded for 
the first time the skeleton of miharamycin B.  Debenzylation of this scaffold proved to 
be inefficient under hydrogenation conditions optimized for the bicyclic sugar amino 
acid, for the bicyclic peptide and for a structurally less complex nucleoside.  
 
 
 
Noteworthy, the configuration at C-6’ of the nucleoside antibiotic miharamycin A has 
been elucidated for the first time by NMR spectroscopy and proved to be S. NMR 
conformational analysis further suggested a folding of the arginine appendage above 
the sugar ring towards the 2-aminopurine nucleobase. 
The key subunits of miharamycins antibiotics such as the bicyclic sugar moiety, the 
elongated sugar amino acid, the nucleoside and the peptide unit, as well as the 
corresponding epimers at C-6’, were successfully synthesized and their antimicrobial 
activity evaluated. Since no relevant results were obtained with respect to the 
Abstract 
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antimicrobial activity, a new perspective for the application of these compounds was 
found. Some of the new synthetic compounds, in particular the benzyl protected N7-
nucleosides, revealed to be potent inhibitors of human butyrylcholinesterase. Toxicity 
studies were also performed and the low values for cytotoxicity and genotoxicity 
encourage the investigation of these compounds for the control of neurodegenerative 
pathologies such as Alzheimer’s disease. 
 
Keywords:  antibiotics · natural products · nucleosides · structure elucidation · total 
synthesis · miharamycins 
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Resumo 
 
Os antibióticos nucleosídicos são na sua maioria produtos naturais de grande 
complexidade estrutural. As mi-haraminicinas A e B são nucleósidos bastante 
complexos, que foram isolados pela primeira vez em 1967 a partir do microorganismo 
Streptomyces miharaensis. Estes produtos naturais apresentam um largo espectro de 
actividade antimicrobiana no qual se destaca a forte inibição do fungo Pyricularia 
Oryzae, o qual é responsável pela doença do arroz. 
A estrutura química destes compostos foi proposta há vinte e cinco anos atrás com 
base em dados experimentais obtidos por técnicas espectroscópicas e de degradação 
química. No entanto não foi possível determinar a configuração absoluta do centro de 
quiralidade em C-6’.  
Apesar de isoladas há mais de 40 décadas, a complexidade estrutural das mi-
haramicinas tem constituído um desafio para vários químicos orgânicos, sendo que até 
à data não foi reportada a síntese total destes antibióticos naturais. 
No âmbito deste projecto de doutoramento foi investigada a síntese total das mi-
haramicinas, incluindo a construção de ambos os diastereoisómeros em C-6’, tendo 
sido concretizada pela primeira vez a síntese da estrutura da mi-haramicina B 
totalmente protegida.  
 
 
Atendendo a que esta classe de nucleósidos bioactivos é tipicamente constituída por 
unidades estruturais bem definidas tais como uma base purina ou pirimidina, um 
monossacárido complexo e uma cadeia peptídica, a estratégia de síntese englobou 
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numa primeira fase a preparação individual destes diferentes componentes, os quais 
foram convenientemente protegidos. Subsequentemente procedeu-se à ligação entre 
as diversas unidades estruturais com a estereoquímica adequada.  
Deste modo, a estratégia de síntese envolveu as seguintes etapas: 
i) Construção do sistema bicíclico da unidade sacarídica 
ii) Aumento da cadeia carbonada e formação do aminoácido 
iii) N-glicosilação da base heterocíclica (2-aminopurina) 
iv) Introdução do aminoácido adequado (L-arginina) 
v) Desprotecção final 
A síntese do sistema bicíclico da unidade sacarídica foi realizada de acordo com o 
procedimento anteriormente desenvolvido no laboratório do Professor Sinaÿ. 
A preparação de ambos os monossacáridos alongados 6R e 6S foi então investigada. 
Apesar de existirem métodos de síntese estereosselectivos na literatura, com vista à 
homologação da posição C-6 do açúcar e construção do respectivo aminoácido, a 
estratégia desenvolvida durante este trabalho não foi estereoselectiva. A formação de 
ambos os isómeros em C-6’ era necessária não somente para a elucidação da 
configuração deste centro estereogénico mas também para a avaliação da influência 
da estereoquímica em C-6’ na actividade biológica. O grupo vinilo foi então 
seleccionado como precursor directo da função ácido carboxílico. A síntese de ambos 
os aminoácidos com distintos grupos protectores (benzilo e acetilo) foi conseguida 
com sucesso através de ozonólise, oxidação e protecção do ácido carboxílico. O grupo 
azoteto, precursor da amina, foi introduzido através da substituição nucleófila de um 
triflato intermediário. Durante esta primeira fase foi também elucidada de forma 
inequívoca a configuração absoluta do centro em C-6 dos azidoésteres peracetilados 
através da realização de cristalografia de raio-X. No entanto, a desbenzilação dos 
azidoésteres utilizando o ácido de Lewis tricloreto de boro deu origem à contracção do 
anel da piranose, obtendo-se desta forma um composto contendo dois anéis tetra-
hidrofurano fundidos. A sua estrutura foi também inequivocamente confirmada por 
cristalografia de raio-X para ambos os isómeros em C-6.  
Com vista à introdução da base 2-aminopurina na posição anomérica foi necessário 
transformar o grupo metoxilo, em condições suaves, num grupo acetoxilo, o que 
permitiu obter o dador de glicosilo adequado à reacção de acoplamento com a base.
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De salientar que a reacção teve que ser meticulosamente optimizada de forma a 
minimizar a formação de produtos resultantes da contracção do anel piranose. No 
entanto, no caso dos derivados azidoésteres peracetilados apenas foram detectadas 
misturas complexas de produtos resultantes da contracção do anel.  
A introdução estéreo- e regiosselectiva da base heterocíclica foi estudada em seguida, 
tendo sido utilizadas as condições clássicas para a formação de nucleósidos 
(glicosilação Vorbrüggen). Contudo, a glicosilação directa da base 2-aminopurina 
protegida, recorrendo aos procedimentos descritos na literatura, não conduziu ao 
nucleósido pretendido. Por conseguinte, utilizou-se uma base mais reactiva, a 2-
amino-6-cloropurina, a qual, após um extenso estudo de optimização das condições 
experimentais, levou à obtenção do tão desejado nucleósido (β-N9-nucleósido). 
Durante o estudo da introdução da base heterocíclica, verificou-se que a utilização de 
triflato de trimetilsililo como ácido de Lewis, solventes apolares, nomeadamente o  
tolueno, e temperaturas da ordem dos 85 ºC permitia maximizar a formação do 
regioisómero N9 pretendido. De salientar que em todas reacções de acoplamento 
foram isolados exclusivamente os anómeros β, o que poderá ser explicado, na 
ausência da participação do grupo vizinho, pelo impedimento estereoquímico da face 
α do sistema bicíclico.  
De forma a evitar eventuais problemas no que respeita à função amida do péptido 
durante a N-glicosilação, a unidade do aminoácido arginina só foi introduzida na última 
etapa da síntese. A redução selectiva dos azidoésteres foi então investigada. Após 
optimização das condições reaccionais verificou-se que Pd/C 10% na presença de 
trietilamina levava à redução do grupo azoteto e em simultâneo à remoção do átomo 
de cloro até então presente na base. Dada a instabilidade de ambos os aminoésteres 
formados, estes foram directamente utilizados na reacção com o aminoácido sem 
prévia purificação por coluna cromatográfica. Seguidamente procedeu-se ao estudo da 
formação da ligação peptídica. A reacção do aminoácido L-arginina totalmente 
protegido e os aminoésteres, previamente sintetizados, foi realizada com sucesso na 
presença de cloroformato de isobutilo e trietilamina em THF, o que conduziu pela 
primeira vez à obtenção da molécula de mi-haramicina B totalmente protegida.  
A desprotecção final e consequente síntese total da mi-haramicina B revelou-se 
extremamente complicada. Enquanto a hidrogenação dos ésteres benzílicos presentes 
no aminoácido ocorreu facilmente, a clivagem dos grupos benzilo existentes na 
unidade sacarídica provou ser bastante complexa. A desprotecção de éteres 
benzílicos em compostos modelo foi então investigada, tendo-se verificado que a 
Resumo 
Total Synthesis and Stereochemical Assignment of Miharamycins viii
desbenzilação ocorria sem problemas em todas as unidades à excepção do 
nucleósido. Contudo a desbenzilação desta unidade foi conseguida por hidrogenação 
a alta pressão (400 psi). Concluiu-se portanto que a presença da base heterocíclica 
impede de algum modo a hidrogenação dos grupos benzilo, que é em geral conduzida 
facilmente a 30 psi. Infelizmente, tentativas no sentido de obter uma desbenzilação 
limpa e completa do produto total protegido revelaram-se infrutíferas. 
Sendo a determinação da configuração absoluta em C-6’ das mi-haramicinas um dos 
principais objectivos deste trabalho, foi realizado um estudo conformacional em 
solução por RMN do produto natural mi-haramicina A, acompanhado por cálculos de 
mecânica molecular. Esta investigação permitiu ilustrar pela primeira vez que a 
configuração absoluta em C-6’ da mi-haramicina A é S. O pequeno valor da constante 
de acoplamento JH-5’H-6’, a contrastar com a grande constante de acoplamento entre H-
5’ e o carbonilo do ácido carboxílico (JH-5’C-7’) e a existência de uma correlação espacial 
(NOE) entre H-2’’ do aminoácido e o protão anomérico H-1’ possibilitaram a dedução 
da configuração em C-6’. Verificou-se também que a conformação maioritária do 
produto natural em solução contém a cadeia lateral do aminoácido L-arginina do 
mesmo lado da base heterocíclica, observação que só poderá ser explicada caso a 
configuração em C-6’ seja S.    
A síntese das diferentes unidades estruturais das mi-haramicinas foi de igual modo 
executada, tendo-se construído com sucesso a unidade açúcar, o monossacárido 
complexo alongado, o nucleósido com a orientação estereoquímica adequada e a 
unidade contento o aminoácido L-arginina, bem como os respectivos epímeros em C-
6. A actividade microbiana de cada uma destas unidades, e de alguns dos precursores 
obtidos no decorrer da síntese, foi avaliada com o intuito de verificar se alguma destas 
unidades, estruturalmente mais simples, seria bioactiva. Infelizmente, nenhum registo 
positivo de actividade microbiana foi detectado, de onde se concluiu que 
provavelmente será essencial que todas as unidades estruturais que compõem este 
tipo de antibióticos estejam presentes. 
A ausência de resultados positivos no que respeita à actividade microbiana, e uma vez 
que enzimas tais como a acetilcolinesterase (origem bovina) e a butirilcolinesterase 
(origem humana) se encontravam disponíveis no laboratório, foi dada uma nova 
perspectiva ao trabalho. Deste modo, análogos e precursores das mi-haramicinas 
foram avaliados como inibidores colinérgicos. Nenhum dos compostos mostrou inibir a 
AChE, no entanto, no que respeita à BChE obtiveram-se para alguns dos compostos 
valores de IC50 na ordem de nanomolar, da mesma ordem de grandeza de alguns 
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fármacos usados no mercado para combater a doença de Alzheimer. A avaliação da 
citotoxicidade e da genotoxicidade dos compostos activos foi de igual modo realizada 
tendo-se verificado que nenhum dos compostos sintetizados apresentava valores de 
toxicidade divergentes dos fármacos actualmente disponíveis no mercado.  
 
Palavras chave: antibióticos · produtos naturais · nucleósidos · elucidação estrutural · 
síntese total · mi-haramicinas 
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Introduction 
 
1.1 Carbohydrates Everywhere… 
 
The field of carbohydrate chemistry has occupied the minds and hearts of many 
scientists for over a hundred years and in the beginning of the twenty-first century, it 
continues to be a vigorous and challenging field to explore.  
The generic term “carbohydrates” (from “hydrates of carbon”) includes 
monosaccharides, oligo- and polysaccharides and covers fairly well-defined organic 
substances, namely aliphatic polyhydroxy aldehydes and ketones, their cyclic 
derivatives as well as compounds obtained from them by reduction of carbonyl groups 
(alditols), oxidation of one or more terminal groups to form carboxylic acids, and 
replacement of one or more hydroxyl groups by hydrogen (deoxy derivatives), amino, 
thiol or with similar heteroatomic groups.1,2 The term “sugar” is frequently applied to 
monosaccharides and lower oligosaccharides.2  As examples we can mention glucose 
1, a very common sugar, or sialic acid 2, which is absolutely crucial throughout biology 
(Figure 1). 
 
 
Figure 1 – Structure of glucose (β-D-glucopyranose) 1 and sialic acid 2. 
 
The abundance of carbohydrates in nature and their diverse roles in biological systems 
make them attractive as subjects for chemical and biological research.3 They are 
everywhere… they fill numerous roles in living organisms, such as storage and 
transport of energy (glycogen), and are important structural components (cellulose in 
plants, chitin in animals). Furthermore, they have been implicated in many cellular 
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processes, including cell-cell recognition, cellular transport and adhesion; they appear 
in all cells in some form or another, for example, as peptide- and proteoglycans, 
glycoproteins, nucleic acids, lipopolysaccharides or glycolipids. Due to their importance 
as building blocks, synthetic targets, biological tools, the carbohydrates are useful and 
important templates for total synthesis, to invent and develop new synthetic 
technologies.3  
 
1.2 Complex Nucleoside Antibiotics 
 
The chemical study of substances collectively termed as nucleosides has proven to be 
the most fruitful over the years. Nucleosides are present in a wide range of life 
processes, and for that reason it is not surprising that a number of these compounds 
exhibit antibiotic properties.4 
Complex peptidyl nucleoside antibiotics is a class of compounds that comprise an 
extensive array of natural products and which exhibit a variety of biological activities 
including antitumor, antiviral, antibacterial and antifungal properties.5  
Structures of four representative complex peptidyl nucleoside antibiotics are illustrated 
in Figure 2.  
Typically, each complex molecule consists of a purine or pyrimidine nucleobase 
attached to a central carbohydrate framework of varying complexity that may also 
include an unusual amino acid appendage.4 The magnitude of the synthetic challenge 
associated to each target molecule will be related with the structure complexity of the 
monosaccharide, which necessarily incorporate sensitive functionalities, and with the 
size of the final array. One general and obviously strategy to access these molecules 
could be (1) to prepare the individual components in suitably protected form, (2) to 
couple them with the required stereochemistry, (3) to deprotect and isolate the target 
molecule. This simplification means that the synthesis will be convergent to some 
degree, since steps involved in preparing one or more of the components will not be 
part of the longest linear sequence. Optimally, one might like to join two nearly equally 
complex and fully elaborated moieties as close to the end of the route as possible, but 
this has only occasionally been realized in practice.5a  
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Figure 2 – Representative examples of complex peptidyl nucleoside antibiotics. 
 
Part of any strategy for the synthesis of a complex nucleoside antibiotic is the use of 
protecting groups. Their role is unusually critical in this context because they serve a 
dual purpose: they must facilitate the synthesis of their own particular component (the 
higher sugar, the peptidyl portion, the nucleoside, etc.), and also they must direct the 
site and stereochemistry of the joining steps.5a Despite the structural differences, 
completed syntheses of nucleosides antibiotics showed a protection pattern where few 
exotic hydroxyl protecting groups are present and O-acetyls, O-benzyls and acetonides 
predominate.5a The nitrogen protecting or precursor groups (N-Cbz, N-BOC, -N3, -NO2) 
are also fairly standard. 
Regarding the compounds illustrated in Figure 2 an α-amino acid moiety is always 
presented, consisting the major structural difference on the existence of a furanosyl 
nucleosidic core, in polyoxins and nikkomycins, whereas amipurimycin and 
miharamycins display a pyranosyl nucleosidic core. Interestingly, while several total 
syntheses of polyoxins6 and nikkomycins7 have been reported in the literature, there 
are still notable targets that had been approached but not yet synthesized, which 
include the amipurimycin and miharamycins. The structures of polyoxins and 
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nikkomycins (Figure 2) have been marked with letters showing the order in which the 
key bonds were formed in each successful synthesis. Noteworthy, all the syntheses of 
these compounds take advantage by forming the centrally located peptide bond later in 
the route. 
With respect to the biological activity, complex peptidyl nucleoside antibiotics are the 
secondary microbial metabolites with potent antifungal activity against several human 
pathogenic fungi.8 In a novel mode of action, many of these compounds strongly and 
selectively inhibit chitin synthase, the enzyme responsible for the biosynthesis of chitin, 
an essential component of the fungal cell wall.9 Because chitin is absent in humans 
and other vertebrates, inhibition of chitin biosynthesis could be a therapeutic strategy 
for combating various opportunistic fungal infections.10 Therefore, the peptidyl 
nucleoside antibiotics represent promising leads for the development of novel and 
nontoxic antifungal therapeutics. 
Among these compounds, the polyoxins and the nikkomycins are the best known and 
most effective inhibitors of chitin synthase.8 Regarding the sugar moiety, the 
structurally more complex amipurimycin and miharamycins also exhibit a broad range 
of antifungal activities, although the modes of action of these compounds are yet to be 
determined.8 Therefore, extensive efforts have been directed towards synthesis and 
structure-activity relationship (SAR) studies of these peptidyl nucleosides in order to 
perform their pharmacophore elucidation, improvement of inhibitory potencies, and 
enhancement of antifungal properties.11 
Hence, the biological significance and the structural complexity of amipurimycin and 
miharamycins make them fascinating and challenging targets for total synthesis. 
 
1.3 Miharamycins 
 
The complex peptidyl nucleoside antibiotics miharamycin A and B (Figure 3) were 
isolated forty years ago from Streptomyces miharaensis sp., a new strain of 
Streptomyces that was discovered in soil samples collected from Mihara City of 
Hiroshima and Toyonaka City of Osaka in Japan.12 
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Figure 3 – Proposed structures for miharamycins A (3) and B (4). 
 
 
1.3.1  Structural elucidation  
 
The structure of miharamycins A and B has remained unclear for over 16 years until 
Seto and his co-workers in 1983 reported extensive spectroscopic studies of these 
novel antibiotics.13 Some physicochemical properties are summarized in the following 
table (Table 1). 
 
Table 1 – Physicochemical properties of miharamycins A (3) and B (4).13 
miharamycin A dihydrochloride miharamycin B hydrochloride
[α]D -59 (c  1, H2O) -63 (c 1, H2O)
Elementary analysis experimental calculated experimental calculated
Cl 40.07 38.28 39.89 41.78
H 6.02 5.14 5.97 5.44
N 21.59 22.32 22.08 24.36
Cl 9.12 11.30 4.98 6.17
p.f. 210 - 214 ºC 215 - 218 ºC
m/z [M+H+] 555 539
molecular formulae C20H30N10O9 .2HCl C20H30N10O8 .HCl
U.V. (λmax/nm) 217.5 (ε=22900) 218 (ε=21200)
244 (ε=6580) 244 (ε=6100)
307 (ε=6770) 307 (ε=6320)
I.V. (νmax KBr/cm-1) 3341 3341
1660 1659
1620 1621
1585 1585
1090 1089
1050 1063
 
 
Due the unsatisfactory elemental analysis obtained for these compounds, related to the 
paucity of the samples and the basic nature of 3 and 4, their molecular structure was 
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investigated based on spectroscopic methods, particularly 1H and 13C NMR, mass 
spectrometry, and considerations obtained for partial structures.   
The presence of a 9-substituted 2-aminopurine base was identified from the UV and 
13C NMR spectra of both antibiotics.14  
They conducted the amino acid analysis to detect arginine and an unknown basic 
amino acid in the acid hydrolysates of 3 and 4, respectively. The stereochemistry of 
arginine was established to be L based on its optical rotation, [α]D = +10.3 º (c 0.5, 1N 
HCl) at 20 ºC. The 13C NMR spectra (downfield shift of C-5’’ and upfield shift of C-4’’ in 
3) and the difference of the molecular formula between 3 and 4, allowed to conclude 
that 3 displayed a hydroxyl group on N5’’. In addition the 13C NMR spectral data of this 
amino acid residue, the N5-hydroxyarginine, was in a good agreement with the 
literature values.15 N5-hydroxyarginine is expected to share the same L configuration as 
the natural amino acid arginine. Furthermore, N5-hydroxy-L-arginine is known as a 
metabolite isolated from microorganisms, namely Nannizzia gypsea and Bacillus 
cereus.16 
The remaining part, common to 3 and 4, was assigned to the sugar moiety which 
contains a free carboxylic acid (δC = 174.8 ppm). Three partial structures A-C were 
proposed (Figure 4) based on 1H and 13C spectral analysis. The characteristic chemical 
shift of the proton H-1’ (δ = 6.01 ppm) and its coupling constant (J1’,2’ = 9.6 Hz) showed 
that C-1’(δ = 78.1 ppm) was an anomeric carbon and a trans diaxial relationship for H-
1’ and H-2’ on a pyranose ring system was demonstrated. The chemical shift of C-6’ in 
partial structure C (δH = 4.71 ppm, δC = 56.1 ppm) can be compared with those of the 
acylated α-carbons in amino acids suggesting the substituent on C-6’ to be a carboxylic 
acid. After an extensive spectral analysis based on long range selective proton 
decoupling irradiations, the authors concluded that the sugar moiety contained only 
one quaternary carbon (-C-O-, δ = 81.3 ppm) and that A, B and C must be combined 
via this carbon to give pyranoses D or E in Figure 4.  
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Figure 4 – Partial structures of miharamycins. 
 
The structure E was readily excluded, since the chemical shift of the oxymethylene 
carbon (C-5’, δ = 76.8 ppm) was not in agreement with the corresponding carbon in α-
L-lyxopyranose (δ = 64.2 ppm) or α-L-arabinopyranose (δ = 66.1 ppm).17 Comparison 
of the chemical shift of C-9’ (δ = 76.8 ppm) with those of the hydroxymethyl carbons of 
polyols18 suggested that carbon C-9’ is part of an ether structure. In addition, the 
downfield shift of C-2’ (δ = 76.9 ppm) vs. that of C-4’ (δ = 66.6 ppm) indicates alkylation 
of hydroxyl group at C-2’. Thus, C-2’ and C-9’ should be connected through an oxygen. 
Additionally, the structure D was supported by a strong NOE observed between H-1’ 
and H-5’. The magnitude of the coupling constant (J4’,5’ = 9.5 Hz) indicated a trans 
diaxial relationship of H-4’ and H-5’. Interestingly, the sugar moiety of miharamycins is 
closely related to a cyclic derivative of amipurimycin 519 obtained by treatment of N-
acetyl amipurimycin methyl ester with mesyl chloride (Figure 5).20 Similarity of the 
coupling constants and chemical shifts for the protons present on these five-membered 
ether rings not only support their presence in structures 3 and 4 but also assign the 
stereochemistry of C-8’ as being S.  
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Figure 5 – Similarity between bicyclic sugar moiety of miharamycins and the bicyclic derivative 
of amipurimycin. 
 
Despite all these spectroscopic studies, the absolute configuration of miharamycins, as 
well as that of amipurimycin at C-6’ remained to be elucidated.  
 
1.3.2  Biological activity 
 
Miharamycins exhibit a broad range of antimicrobial activity compiled in Table 2. The 
inhibitory profile of miharamycin A is almost the same as the one obtained for 
miharamycin B and both antibiotics exhibit potent activity against several 
phytopathogenic fungi. 
 
Table 2 – Antimicrobial activity of miharamycins and amipurimycin, using the paper disk 
diffusion method.8a,b;12 
Inhibitory diameter  (mm)
Microbes tested T (º C) Time (h) Miharamycin A Miharamycin B Amipurimycin
500 µg/mL 500 µg/mL 1000 µg/mL
Pseudomonas tabaci 28 20 26.0 25.5 0
Pseudomonas aeruginosa 37 20 25.4 17.2 0
Pseudomonas fluorescens 28 20 12.3 11.3 0
Pyricularia Oryzae 28 72 69.5 61.5 45
Colletotrichum lagenarium 28 72 45.0 30.0 0
Aspergillus niger 28 72 15.0 0.0 60
Glomerella cingulata 28 72 20.0 15.0 0
Fusarium oxysporum 28 72 15.0 0.0 0
Penicillium expansum 28 72 15.0 10.0 0
Guignardia laricina 28 72 50.0 30.0 63
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These natural products also exhibit antibacterial activity against Pseudomonas 
aeruginosa, an opportunistic pathogen for plants and humans, namely in patients 
diagnosed with cystic fibrosis, that display resistance to several antibiotics.21   
Regarding toxicity, miharamycins A and B proved to have no effect on adult of Scarlet 
Killifish (8 months after hatching) even when added in a concentration of 10 ppm. In 
experiments with rabbits they exerted no irritation on cornea, conjunctiva and etc… 
even when dropped as 0.01 percent solution in the eyes. On the other hand, for high 
animal toxicity the LD50 values of miharamycins, in experiments with mice, were found 
to be in the range of 10-15 mg/kg (intravenous).12   
Above all, miharamycins A and B display a very high antifungal activity against rice 
blast disease caused by Pyricularia oryzae and surpass the structural related antibiotic 
amipurimycin (Table 2). 
 
1.3.2.1 Pyricularia oryzae 
   
The rice blast fungus Pyricularia oryzae was named by Cavara in 1891,22 and since 
then has been referenced in the literature under several names. The name Pyricularia 
oryzae was used to refer to the asexual stages of rice blast fungus as it was found in 
the field. The rice pathogen was morphologically indistinguishable from pathogens of 
other hosts, and the entire group was defined under the name Pyricularia grisea. The 
sexual stage was named Magnaporthe grisea until it was shown by phylogenetic 
analysis and interstrain fertility tests that Magnaporthe should be separated into 
species that infect Digitaria sp (M. grisea), whereas M. oryzae collectively refers to the 
other characterized isolates, including the rice pathogen.23  
Rice blast, caused by Pyricularia oryzae, is the most important disease affecting rice 
worldwide, both in terms of distribution and damage caused. It is present in all 
continents, and about 85 countries, where the rice plant is cultivated, and its 
remarkable ability to overcome plant defenses is responsible for the destruction of an 
amount of rice crops that would feed 60 million people annually.24   
Pyricularia oryzae damages any aerial part of a rice plant, although leaves and 
panicles (necks) are the most commonly affected organs. Leaf infection reduces the 
photosynthetic area of the plant, which can lead to its death. Panicle infection is 
responsible for the most important economic losses via yield reduction.25 
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Figure 6 – Symptoms caused by Pyricularia oryzae in rice: A spots on leaves; B node damage; 
C ligule lesion; D panicle base damage.25 
 
Pyricularia oryzae infection materialized by whitish or green-grayish spots with darker 
greenish necrotic edges appears on the leaves in all cultivars (Figure 6A). Node 
damage (Figure 6B) is much more common and harmful than internodes; this 
sometimes breaks the culms either partially or completely. The spreading of Pyricularia 
oryzae is frequently occasioned by dewdrops carrying the fungus and sliding down the 
flag leaf, collecting at the collar and affecting the ligules (Figure 6C). Infection of the 
panicle base (Figure 6D) is usually the most destructive form of infection.25 
 
 1.4 Synthetic Approaches towards the Miharamycins 
 
The structure of miharamycins is a notable synthetic target to reach by total synthesis, 
a task only approached so far. Regarding the structure of these nucleosides (Figure 3) 
three major units are easily definable, an elongated bicyclic sugar moiety, an amino 
acid portion and an atypical 2-aminopurine nucleobase.  
 
1.4.1 Approaches towards the sugar moiety 
 
The first synthetic challenge to accept is the construction of the unusual bicyclic 
carbohydrate core of miharamycins. Since 1987 several approaches have been 
devised to build up this scaffold.  
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1.4.1.1 Hara’s work  
 
The first approach to the bicyclic moiety of miharamycins was made by Hara and co-
workers in 198726 and is based on the construction of a branched-chain derivative 
through a Horner-Wadsworth-Emmons alkenation of the methyl 2-O-benzoyl-4,6-O-
benzylidene-α-D-ribo-hexopyranosid-3-ulose 6 (Scheme 1). 
The alkenation of 6 with ethyl diethylphosphonoacetate was complicated since two 
unwanted 2-C-(ethoxycarbonylmethylene) isomers (8a and 8b), resulting from 
rearrangement of 6 to the corresponding 3-O-benzoyl-D-arabino-hexopyranosid-2-
ulose 6’ via benzoyl migration, were obtained in addition to a mixture of the two 
expected 3-C-(ethoxycarbonylmethylene) isomers (7a and 7b). This migration was 
considerably reduced by addition of the less-polar tetrahydrofuran (THF). The best 
result was obtained in a mixture of DMF and THF, with a ratio of 4 to 5 that gave 
predominantly the mixture 7a,b in 72% yield. 
 
 
 
Scheme 1 – Horner-Wadsworth-Emmons alkenation. Reagents and conditions: a) 
(EtO)2POCH2CO2Et, tBuOK, DMF/THF (4:5); 7a,b (72%), 8a,b (24%). 
 
Conversion of 7a and 7b (Z/E mixture) into the corresponding 3-C-(2-
hydroxyethylidene) derivatives 9a and 9b (Z/E mixture) was achieved by reduction 
using lithium aluminium hydride (LiAlH4) (Scheme 2). The geometrical compounds 9a 
and 9b was first separated as acetates derivatives 10a and 10b. The assignment of the 
Z/E isomers was achieved after formation of the corresponding O-isopropylidene 
Introduction 
Total Synthesis and Stereochemical Assignment of Miharamycins 12
derivatives. The Z-isomer resulting from the Wittig olefination proved to be the major 
product.  
 
 
Scheme 2 – Synthesis of both Z and E 3-C-(2-hydroxyethylidene). Reagents and conditions: a) 
LiAlH4, Et2O, r.t. b) Ac2O, pyridine, 52% of 10a, 17% of 10b. 
 
The subsequent stereoselective cis-dihydroxylation of 11 (Z-isomer) with osmium 
tetroxide gave the diol 12, which after deacetylation cyclized to afford the 2,2’-anhydro 
derivative 13 (Scheme 3). In order to obtain the correct stereoisomer at C-8, an 
inversion at this centre was necessary. Swern oxidation followed by reduction using 
NaBH4 afforded the bicyclic derivative 14, which structure proved to be erroneous 8 
years later according to the work of Sinaÿ and Fairbanks. 
 
 
Scheme 3 – Synthesis of the protected bicyclic derivative. Reagents and conditions: a) OsO4, 
NMO, tBuOH/THF/H2O 2:1:1, 57% b) NaOMe, MeOH, quant. c) Camphorsulfonyl chloride, 
pyridine, r.t., 72% d) (COCl)2, DMSO, Et3N, CH2Cl2 -78 ºC, 78% e) NaBH4, acetone, MeOH, 
95%. 
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1.4.1.2 Fairbanks and Sinay’s work 
 
In 1995, Fairbanks and Sinaÿ described the first synthesis of the bicyclic sugar moiety 
of miharamycins,27 which was accomplished in five steps with an overall yield of 40% 
from the easily available methyl 4,6-O-benzylidene-α-D-glucopyranoside 15 (Scheme 
4). 
Propargylation of 15, under phase transfer conditions, produced the desired 2-O-
propargyl derivative 16a along with a smaller amount of the 3-O-propargyl isomer  
(29% yield). PCC oxidation of the remaining free hydroxyl group at C-3 proceeded 
smoothly to yield the ketone 17. Reductive cyclization of the ketone with SmI2 in THF in 
the presence of HMPA as Lewis basic additive and tBuOH as proton source took place 
to yield exclusively the desired alkene in 94% yield. Ozonolysis to the ketone and 
subsequent reduction with NaBH4 occurred exclusively from the exo face of the bicyclic 
system to provide the desired kinetic diol 14.  
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Scheme 4 – Synthesis of the protected miharamycins sugar moiety 14. Reagents and 
conditions: a) Propargyl bromide, Bu4NHSO4, NaOH aq., CH2Cl2, reflux, 61% b) PCC, CH2Cl2, 
MS 4Å, r.t., 89% c) SmI2, HMPA, tBuOH, THF, r.t., 94%, d) O3, CH2Cl2, then DMS, -78 ºC, 90% 
e) NaBH4, EtOH, 0 ºC, 87%. 
 
The key step of this sequence was the high yielding intramolecular reductive cyclization 
of ketoalkyne 17 promoted by SmI2. Favourable conformational bias is undoubtedly 
responsible for the astonishing yield of the cyclization on an inactivated alkyne. A 
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proposed mechanism for the reductive cyclization induced by SmI2 is illustrated in 
Scheme 5.   
 
 
Scheme 5 – Proposed mechanism for the reductive cyclization induced by SmI2. 
 
Compound 14 that had allegedly previously been reported by Hara and co-workers 
revealed to be distinct in terms of physical and NMR properties, from the one obtained 
by Fairbanks and Sinaÿ. To unambiguously establish the structure of compound 14, the 
authors obtained an X-ray crystal structure of the molecule (Figure 7). Thus, this work 
represents the first synthesis of the bicyclic moiety of miharamycins.  
 
 
Figure 7 - X-Ray crystallography of diol 14. 
 
Fairbanks and Sinaÿ also confirmed the stereochemistry of the hydroxyl group at C-8’ 
which was first assigned by Seto in 1983 by analogy with a derivative related antibiotic 
amipurimycin (Figure 5). For that purpose, the authors synthesized the diacetate 20 
(Scheme 6) and compared the coupling constants J8,9a and J8,9b (J8,9a = 2.5 Hz and  J8,9b 
= 5.9 Hz) with those reported by Seto (J8’,9’a = 1.5 Hz and  J8’,9’b = 5.0 Hz) (Figure 8). 
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The authors also found that compound 14 was complete unreactive under conventional 
acetylation (Ac2O, pyridine, r.t.) contradicting the results indicated by Hara’s group. 
 
 
Scheme 6 – Synthesis of diacetate 20. Reagents and conditions: a) Ac2O, pyridine, r.t. b) Ac2O, 
pyridine, DMAP, r.t, 50%. 
Despite the similarity of the coupling constants, the authors focused on the synthesis of 
the epimer at C-8 of the bicyclic derivative of miharamycins, in order to compare the 
coupling constants between H-8, H-9a and H-9b for this molecule (Scheme 7). 
However, reduction of ketone 19 with SmI2 occurred with concomitant reduction of the 
tertiary alcohol to give an inseparable mixture of isomeric alcohols 21 and 22. 
Acetylation of this mixture produced the exo acetate 23 together with unreacted endo 
alcohol 21 (Scheme 7). Acetylation of 21 required more forcing conditions, namely the 
addition of DMAP.  
 
 
Scheme 7 – Synthesis of monoacetate 23. Reagents and conditions: a) SmI2, tBuOH, Et3N, 
THF, r.t, b) Ac2O, pyridine, r.t. 57% of 21, 31% of 23.  
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The coupling constants observed between H-8, H-9a, H-9b for the exo acetate 23, J8,9a 
= 5.7 Hz and  J8,9b = 8.4 Hz were significantly different from those observed for the 
diacetate 20 and the acetate derivative of the natural product 5 (Figure 8). These 
studies provide further evidence that the configuration of the natural products 
miharamycins at C-8’ assigned by Seto and co-workers was correct.  
 
 
Figure 8 – Comparison of coupling constants observed between H-8, H-9a, H-9b for the two 
bicyclic units 20 and 23 and the amipurimycin acetate derivative 5. 
 
1.4.1.3 Rauter’s work 
 
In 2000, Rauter and co-workers accomplished the first synthesis of a protected epimer 
at C-8 of the miharamycins sugar moiety, starting from the spiroepoxide 24 (Scheme 
8).28 Reaction of the epoxide 24 with lithium cyanide, followed by hydrolysis and 
spontaneous cyclization, afforded the intermediate deoxylactone 26. Stereoselective 
hydroxylation with MoO5.py.HMPA, reduction of the lactone with LiAlH4 and cyclization 
with diethyl azodicarboxylate (DEAD) and triphenylphosphine gave the target epimer at 
C-8 13.  
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Scheme 8 – Synthesis of the protected miharamycin sugar moiety analogue 13. Reagents and 
conditions: a) CH2N2, Et2O, 80% b) LiCN 0.5M in DMF, THF, 78% c) H2O, silica gel, 82% d) 
LDA, THF, -78 ºC, then MoO5.py.HMPA, -78 ºC, 50% e) LiAlH4, THF, reflux then DEAD-Ph3P, 
CHCl3, MS 4Å, 5 ºC, 23%. 
  
Direct reduction of deoxylactone 26 yield other analogs as shown in Scheme 9.  
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Scheme 9 – Synthesis of miharamycins deoxy analogs 29 and 30. Reagents and conditions: a) 
DIBAL, toluene-THF, -78 ºC  -40 ºC, 34% of 27a,b and 52% of 28 b) LiAlH4, THF, 40 ºC  
reflux, 4% of 27a,b and 82% of 28 c) BF3.Et2O, Et3SiH, CH3CN, -30 ºC, 36% d) DEAD-Ph3P, 
CHCl3, MS 4Å, 5 ºC, 82%. 
 
A second strategy to access epimer 13 was also reported by Rauter’s group in 2000 
(Scheme 10). Wittig olefination of an appropriate ketosugar 6 with 
[(ethoxycarbonyl)methylene]triphenylphosphorane led to a 7:3 Z/E mixture of esters 
7a,b, which was not separated and directly engaged in the dihydroxylation step to 
afford diols 31a,b. Reduction conducted by LiAlH4 in THF produced the desired tetrols 
32a,b as well as the tricyclic structures 33a,b and 34.  
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Scheme 10 – Synthesis of the tetrols 32a and 32b. Reagents and conditions: a) 
Ph3P=CHCO2Et, CHCl3, reflux, 88% b) OsO4, pyridine, r.t., quant. c) LiAlH4, THF, reflux, 48% 
for 32a,b; 14% for 33a,b and 9% of 34.  
 
Cyclization of the mixture of compounds 32a and 32b with diethyl azodicarboxylate and 
triphenylphosphine afforded the target structure 13, as well as a small amount of the 
miharamycins sugar moiety 14. 
 
 
Scheme 11 – Synthesis of miharamycins sugar moiety analogue 13. Reagents and conditions: 
a) DEAD-Ph3P, CHCl3, MS 4Å, 52% for 13 and 16% for 14. 
 
Examination of X-ray structure (Figure 9) and comparison of NMR spectroscopic data 
for 13 with data given by Hara and co-workers for the protected miharamycins sugar 
moiety 14 allowed Rauter’s group to prove that the compound reported in 1987 was in 
fact the epimer at C-8 of miharamycins sugar moiety 13. 
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Figure 9 – X-Ray crystallography of diol 13. 
 
In 2002, Rauter and co-workers published an optimized synthesis of the epimer at C-8 
of the miharamycins sugar unit (Scheme 12).29 A stereoselective synthesis of the 
bicyclic unit 13 was achieved in high yield starting from an appropriate (Z)-Wittig 
product, synthesized by Wittig reaction of a 4,6-O-benzylidene protected 
hexopyranosid-3-ulose 6. Isomerization of the (E)-olefin into the (Z)-olefin was 
performed by iodine, subsequent reduction of the (Z)-isomer followed by cyclization 
and dihydroxylation furnished the target molecule 13 with an overall yield of 63%.  
 
 
Scheme 12 – Stereoselective synthesis of the miharamycins sugar moiety 13. Reagents and 
conditions: a) Ph3P=CHCO2Et, CHCl3, Z/E (7:3), quant. b) I2, CH2Cl2, quant. c) LiAlH4, THF, 0 
ºC  r.t., 90 %, d) DEAD-PPh3, CHCl3, MS 4Å, 5 ºC, 88%, e) OsO4, pyridine, r.t., 80%. 
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1.4.1.4 Ethève and Valéry’s work 
 
Valéry and co-workers in 2004 described the construction of the bicyclic moiety of 
miharamycins employing a ring closing metathesis (RCM) strategy.30 Starting from the 
known 3-C-methylene sugar 37, the allylation of the free hydroxyl group at C-2 afforded 
the desired diene 38 (Scheme 13). Unfortunately RCM with both Grubbs catalysts of 1st 
and 2nd generation performed on this scaffold did not furnish the cyclized product 36, 
instead a homodimer, resulting from a cross coupling reaction, was obtained.  
 
 
Scheme 13 – Attempt to the synthesis of the cyclic olefin 36. Reagents and conditions: a) allyl 
bromide, NaH, DMF, 0 ºC, 97% b) Grubb 1st generation (20 mol%) or Grubbs 2nd generation (20 
mol%), CH2Cl2, reflux. 
 
In order to achieve the desired cyclized product the authors replaced the 4,6-O-
benzylidene protecting group by acetates. Compound 39 was then submitted to the 
RCM reaction affording the desired cyclized product 40 which was engaged in the 
dihydroxylation step to afford the diol 41. Epimerization at C-7 of compound 41 was 
then investigated. The formation of ketone 42 was attempted by Swern and Mitsunobu 
conditions but only “TEMPO” oxidation proved to be effective. Finally, reduction with 
NaBH4, with concomitant deacetylation at C-4, yielded the monoacetylated bicyclic 
compound 43 with the correct stereochemistry. 
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Scheme 14 – Synthesis of monoacetylated miharamycins sugar moiety 43. Reagents and 
conditions: a) H2SO4 (0.01 M), dioxane, reflux then Ac2O, pyridine, r.t., 90% b) Grubbs 2nd 
generation (20 mol%), CH2Cl2, reflux then Pb(OAc)4, r.t., 76% c) OsO4 (2.5% in tBuOH), NMO, 
CH2Cl2, r.t., 94% d) TEMPO, NaHCO3, KBr, NaOCl, CH2Cl2, 0 ºC e) NaBH4, EtOH, 0 ºC, 45% 
over two steps. 
 
 1.4.2 Approaches towards the sugar amino acid unit 
 
Sugar amino acids (SAAs) are molecules that combine the structural features of simple 
amino acids (amino and carboxylic acid functions) with those of simple carbohydrates 
(cyclic polyols, which may contain additional acetamido or amino functions), which are 
linked by a carbon-carbon bond resistant to chemical and enzymatic hydrolysis.31   
As other complex nucleoside antibiotics, miharamycins A and B contain a 6-amino-6-
deoxyheptopyranuronic acid, a moiety that exhibits the characteristics of SAAs.32  
In the last 30 years, various strategies have been devised to access this complex sugar 
amino acid moiety. Carbohydrate-based approaches include: Strecker cyano-amination 
of a protected dialdo sugar in the synthesis of lincomycin;33 stereoselective Sharpless 
epoxidation of an allylic alcohol, followed by an azide oxirane opening and a periodate 
cleavage in the synthesis of aminoacyl heptoglycosides;34 acid catalyzed ring 
contraction of a seven-membered ring lactone into a furanose derivative and 
subsequent functionalization of the secondary alcohol in the synthesis of polyoxin J;6a 
condensation of phenylthionitromethane with a dialdo sugar to afford a nitro olefin 
further modified in the synthesis of polyoxin C;6b stereoselective addition of 2-
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furyllithium to sugar nitrones;35  and diastereoselective chain extension of an imine.36 
Non carbohydrate-based approaches that condense Garner’s aldehyde,37 as a masked 
amino acid, are also reported in the literature. This aldehyde was used by Casiraghi in 
an approach that involves enantiomerically pure butenolides to reach the 6-amino-6-
deoxyheptopyranuronic acid derivate.38 Garner also used this functional building block 
to achieve the synthesis of branched 6-amino-4,6-deoxyheptopyranuronic acid 
component of amipurimycin.39  
 
1.4.2.1 Czernecki’s work 
 
Czernecki and co-workers reported the synthesis of a sugar amino acid based on a 
glucopyranose scaffold, which involves a stereocontrolled ethynylation of the methyl 
2,3,4-tri-O-benzyl-α-D-gluco-hexodialdo-1,5-pyranoside 44 (Scheme 15).40 This 
synthesis provides a direct and stereoselective route to the 6-amino-6-
deoxyheptopyranuronic acid with a control of the stereochemistry at C-6.  
 
 
Scheme 15 – Synthesis of the acetylenic alcohols 47 and 48 and elucidation of configuration at 
C-6. Reagents and conditions: a) MgBr2, Et2O then Me3SiC≡CMgBr b) TBAF, THF, 82% over 
two steps c) H2, Pd/C, MeOH, 95% d) PhCH(OMe)2, TsOH, DMF, 79%. 
 
In this sequence the ethynyl group was employed as a synthetic equivalent of the 
carboxylic acid function. The diastereoselective ethynylation of compound 44 with 
Grignard reagent of (trimethylsilyl)acetylene in the presence of magnesium bromide 
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followed by desilylation afforded acetylenic alcohols 47 and 48 (19:1). The L-glycero 
configuration at C-6 of the major isomer 47 was proved by analysis of the 1H NMR of its 
4,6-benzylidene derivative 50 (Scheme 15).  
Transformation of the resulting acetylenic alcohol 47 (L-glycero derivative) into the 
corresponding benzyl (6S)-heptopyranosiduronate 53 was achieved by two different 
routes (Scheme 16): (1) oxidative cleavage of the triple bond, esterification, 
introduction of the azide group and its reduction into an amine, and N-acetylation or (2) 
azide displacement of the free hydroxyl group, reduction into the corresponding amine, 
N-acetylation, oxidative cleavage of the triple bond and protection of the resulting 
carboxylic acid into an ester.  
 
 
 
Scheme 16 – Synthesis of the protected heptopyranosiduronic acid 53. Reagents and 
conditions: a) OsO4, NaIO4, THF-H2O, b) PhCHN2, CH2Cl2, 49%  for sequence 1 and 58% for 
sequence 2 c) DIAD, Zn(N3)2.2py.PPh3, toluene, 75% for sequence 1 and 77% for sequence 2 
d) H2, Raney Ni, THF, 83% e) Ac2O, pyridine, 86% for sequence 1 and quant. for sequence 2 f) 
HS(CH2)3SH, Et3N, MeOH, 77%. 
 
Final debenzylation afforded [methyl 6-(N-acetylamino)-6-deoxy-L-glycero-α-D-gluco-
heptopyranosid]uronic acid 54 (Scheme 17).  
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Scheme 17 – Synthesis of the (6S)-heptopyranosiduronic acid 54. Reagents and conditions: a) 
H2, 10% Pd/C, MeOH, quant. 
 
The epimeric D-glycero amino acid derivative was obtained using the same sequence 
of reactions, after inversion of the absolute configuration of compound 47 at C-6 by a 
Mitsunobu reaction (Scheme 18).  
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Scheme 18 – Inversion of configuration at C-6 through Mitsunobu reaction. Reagents and 
conditions: a) p-O2NC6H4COOH, DEAD-PPh3, THF, 95% b) K2CO3, MeOH, 95%. 
 
1.4.3  Approaches towards the nucleoside 
 
Purine is the most widely distributed nitrogen heterocycle in nature.41 The name 
“purine” (purum uricum) was coined by Emil Fischer, who synthesized this colorless 
crystalline weak base for the first time in 1899.42 Shortly after their discovery in 1977, it 
was recognized that amipurimycin and miharamycins A (3) and B (4) contain the 2-
aminopurine base (2AP), which is otherwise not found in nature.41 This base is an 
atypical nucleoside base which induces transition mutations (A:T  G:C and G:C  
A:T),43 being also a component of antiviral prodrugs such as 6-deoxyacyclovir44 and 
famcyclovir.45  
Progress in the synthesis of complex nucleoside has paralleled improvements in 
methods for N-glycosylation of purines and pyrimidines.5a The classic Hilbert-Johnson 
synthesis, involving an O-alkylated pyrimidine acceptor and a glycosyl halide donor, 
was used throughout the 1960s and 1970s to prepare simple nucleosides. However, it 
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was really Vorbrüggen’s glycosylation reaction conditions46 that stimulated the 
widespread incorporation of N-glycosylation into long synthetic routes.  
A typical Vorbrüggen glycosylation (Scheme 19) requires the presilylation of the base 
(step 1) and the coupling with the Lewis acid activated sugar to form the desired 
nucleoside (step 2).  An alternative route to synthesize 2AP nucleosides is through 
glycosylation of the more reactive silylated 2-amino-6-chloropurine (2A6CP) derivative, 
followed by dechlorination of the resulting nucleoside under hydrogenolysis conditions.   
  
 
Scheme 19 – Glycosylation of 2AP and 2A6CP derivatives. 
 
The main advantage of this method is that frequently, regioselective base glycosylation 
occurs, due to the kinetic vs. thermodynamic control. In the case of this purine base, 
the N9-isomer is the thermodynamic product and the N7-isomer the kinetic product. The 
regioselectivity of the nucleoside formation (N7 vs. N9) can be controlled by carefully 
tuning the reaction conditions, namely the choice of the Lewis acid, the solvent, and the 
temperature.  
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1.4.3.1 Garner’s work 
 
Garner47 has reported the synthesis of the glucose-derived N7-isomers under kinetic 
control. To this purpose the N2-acetyl-protected 2-aminopurine 56 or 2-amino-6-
chloropurine 57 were persilylated with a mixture of trimethylsilyl chloride (TMSCl) and 
hexamethyldisilazane (HDMS) and subsequently condensed with the desired sugar in 
the presence of SnCl4, as Lewis acid, in CH3CN at low temperature (Scheme 19 and 
Table 3). Additionally, the N9-isomers were synthesised under reaction conditions 
leading to a product distribution under thermodynamic control. The silylated bases 
were coupled to the sugar with trimethylsilyl trifluoromethanesulfonate (TMSOTf) as 
Lewis acid in (CH2Cl)2 at higher temperatures to afford the N9-isomer (Scheme 19 and 
Table 3). The authors also demonstrated that the use of O-benzoylated glucose 
derivatives resulted in an improvement of the N9:N7 ratio.  
 
Table 3 - Glycosylation of 2AP and 2A6CP according to Garner and co-workers.47 
Entry Sugar substrate Silylated base Coupling conditions Products N9:N7 ratio Combined yield (%)
1 58 60 SnCl4/CH3CN-(CH2Cl)2 reflux 62/66 98:2 78
2 58 60 TMSOTf/(CH2Cl)2 reflux 62/66 96:4 51
3 58 60 SnCl4/CH3CN r.t. 62/66 0:100 11
[a]
4 58 61 SnCl4/CH3CN-(CH2Cl)2 reflux 64/68 50:50 66
5 58 61 TMSOTf/(CH2Cl)2 reflux 64/68 83:17 67
6 58 61 SnCl4/CH3CN r.t. 64/68 12:88 68
7 59 60 SnCl4/CH3CN-(CH2Cl)2 reflux 63/67 >98:2 67
8 59 61 TMSOTf/(CH2Cl)2 reflux 65/69 75:25 64
9 59 61 SnCl4/CH3CN r.t. 65/69 41:59 22
[b]
 
[a] Crude NMR showed 89 mol % of unreacted sugar substrate 58. [b] Corrected yield based on reacted 
starting material 59, recovered in 33% yield.     
  
Garner and co-workers also used a mild procedure developed by Knapp48 for 
nucleoside synthesis which involved iodonium-mediated activation of peracetylated 1-
thioglycosides followed by trapping with the requisite silylated base. According to the 
authors this method could be more suitably for N-glycosylation with functionalized 
glycosides like amipurimycin and miharamycins glycosides. Thus, both silylated purine 
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bases (2AP and 2A6CP) were coupled with the β-thioglucoside 70 to give 
predominantly the N9-nucleosides 62 and 64 (Scheme 20).  
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Scheme 20 – Synthesis of purine nucleosides from a thioglycoside. Reagents and conditions: 
a) NIS, TfOH, (CH2Cl)2, r.t., N9:N7 (98:2) 60% for X = H and N9:N7 (98:2) 64% for X = Cl. 
   
The regioselectivity of the N-glycosylation was deduced from NOE experiments, which 
established space proximity between proton H-8 of the base and protons H-1’, H-2’ of 
the sugar unit in the case of a N9-isomer (Figure 10). However, additional off-diagonal 
interactions between H-6 of the base and H-1’, H-2’ were observed for the N7 
regioisomer.   
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Figure 10 – NOE correlactions expected for a N9-regioisomer and N7-regioisomer. 
 
The simultaneous correlations of the proton H-8 of the nucleobase and both protons H-
1’ and H-2’ of the sugar moiety presume an existence of a conformational equilibrium 
around the nucleosidic linkage.    
 
1.4.4  Synthesis of a non-branched miharamycin B analogue    
 
After the successful elaboration of the 6-amino-6-deoxyhepturonic acid from D-
glucopyranose, Czernecki’s group explored the base and the amino acid coupling 
reactions.49 Starting from the available azido compound 51, they carried out the 
cleavage of the benzyl ethers using boron trichloride followed by acetolysis of the 
anomeric methoxy group (Scheme 21). Oxidative cleavage of the triple bond and 
subsequent treatment with diazomethane afforded the desired anomers 72a and 72b. 
Glycosylation with the silylated 2-aminopurine promoted by SnCl4 afforded a single 
nucleoside 73, which exclusive N9-substitution was confirmed by 2D NOESY 
experiments.  
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Scheme 21 – Synthesis of the elongated nucleoside 73. Reagents and conditions: a) BCl3, 
CH2Cl2, -78 ºC b) Ac2O, H2SO4, AcOH, 68% over two steps c) RuCl3, NaIO4, CCl4/CH3CN/H2O 
d) CH2N2, Et2O, 83% over two steps e) SnCl4, (CH2Cl)2, 135 ºC, 74% 
 
Reduction of the azido group proceeded smoothly and the resulting amine was directly 
engaged in the peptide coupling step with the protected L-arginine in the presence of 
DCC and HOBt to afford 74 in a 40% yield (Scheme 22). Final ester hydrolysis with 
lithium hydroxide followed by hydrogenolysis produced the peptidyl nucleoside 75, a 
monocyclic analogue of miharamycins. 
 
 
Introduction 
Total Synthesis and Stereochemical Assignment of Miharamycins 31
N
NN
N
NHAc
9
O
(S)
AcO
AcO
AcO
COOMeN3
73
N
NN
N
NHAc
9
O
(S)
AcO
AcO
AcO
COOMeHN
74
ZHN N
Z ZHN
NH O
N
NN
N
NH2
9
O
(S)
HO
HO
HO
COOHHN
75
H2N N
H H2N
NH O
a), b)
c), d)
 
Scheme  22 – Synthesis of the nucleoside 75 analogue of miharamycin B. Reagents and 
conditions: a) H2, Ni Raney, THF b) protected L-arginine, DCC, HOBt, CH2Cl2, 0 ºC, 40% over 
two steps c) LiOH, THF/H2O, 0 ºC d) H2, 10% Pd/C, MeOH, 60%, over two steps. 
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1.5  Main Objectives 
 
 
Although considerable effort has been devoted to the total synthesis of miharamycins 
because of their unique and complex structure none of these attempts has yet been 
successful.  
The unknown stereochemistry at C-6’ and the structural complexity of these 
nucleosides prompted us to investigate the synthesis of both epimers at C-6’ of this 
molecule in order to firmly establish its absolute configuration and achieve for the first 
time the total synthesis of miharamycins antibiotics. Careful comparison of the 
spectroscopy data of these synthetic molecules with those of the natural products 
should lead to the exact structure of miharamycins with concomitant assignment of the 
absolute configuration at C-6’.  
The broad range of antimicrobial activity displayed by these natural products added to 
the undetermined mechanism of action and the absence of structure – activity 
relationship studies (SAR) render miharamycins an attractive target to explore as new 
antimicrobial agents of potential utility.  
Furthermore, determination of the antimicrobial activity over Pyricularia oryzae, among 
other fungi and a variety of bacteria of the diastereoisomeric final compounds and 
precursors, obtained along the synthesis, is also relevant for SAR studies. A question 
to be answered relies on the importance of each subunit structure and the 
stereochemistry at C-6’ to assess the moiety required for bioactivity. 
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Results and Discussion 
 
The synthetic challenge of miharamycins stands in its unique elongated bicyclic sugar 
moiety and in the presence of an unusual 2-aminopurine nucleobase that suggest four 
disconnections listed in Figure 11.  
Tactics harvested in previously completed nucleoside antibiotics syntheses usually 
place the sugar moiety construction early in the synthesis and the N-glycosylation step 
before the peptide coupling due to the Lewis basicity of the amide bond that can 
sometimes interfere with glycosylation conditions.5a  We therefore relied on the 
following retrosynthetic strategy: 1) construction of the bicyclic carbohydrate unit, 2) 
elaboration of the amino acid at C-6’, 3) nucleoside synthesis, 4) peptide coupling 
followed by final deprotection.   
 
 
Figure 11 – Key disconnections planned for the synthesis of miharamycins framework. 
 
Accordingly to this retrosynthetic pathway we launched a program towards the total 
synthesis of miharamycins.  
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2.1 Elaboration of the Sugar Amino Acid Precursors  
 
 
In order to establish the absolute configuration at C-6’ of miharamycins we explored the 
synthesis of both diastereomeric SAAs at this centre.   
 
2.1.1 Construction of the bicyclic carbohydrate unit  
 
The synthesis of this moiety was carried out according to the strategy developed by 
Fairbanks and Sinaÿ and previously described in the introduction (chapter 1.4.1.2). A 
SmI2-mediated 5-exo-dig ketyl-alkyne cyclization led to the formation of the bicyclic 
core of the miharamycin antibiotics (Scheme 23).27  
Since its introduction as reagent for organic synthesis by Kagan in 1977,50 SmI2 has 
been widely embraced in reactions involving cyclization for the construction of natural 
products.51 Due to the propensity of Sm(II) to revert to the more stable Sm(III) oxidation 
state, SmI2 is a powerful electron-transfer reagent. 
The reaction of the α-propargyloxy ketone 17 with SmI2 in the presence of HMPA as 
Lewis basic additive and tBuOH as the proton source afforded the bicyclic ether 18 in 
high yield and as single diastereoisomer through intramolecular keto-alkyne coupling 
(Scheme 23). The potential reductive cleavage of either the α-propargyloxy group or 
the α-acetal group was not observed. Oxidative cleavage of the exocyclic olefin 
followed by its subsequent reduction yielded the partially protected sugar moiety of 
miharamycins 14.  
 
 
Scheme 23 – Synthesis of protected bicyclic miharamycins sugar moiety 14. Reagents and 
conditions: a) SmI2, HMPA, tBuOH, THF, r.t., 94%, b) O3, CH2Cl2, DMS, -78 ºC, c) NaBH4, 
EtOH, 0 ºC  r.t., 84% over two steps. 
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2.1.2 Elaboration of the sugar amino acid core 
 
Construction of the SAA core was then investigated. Besides non carbohydrate-based 
approaches that condense Garner’s aldehyde11,38,39 as a masked amino acid, several 
methods are available to homologate the C-6 position of a sugar pyranoside and 
construct the amino acid (Chapter 1.4.2). Although stereocontrolled ethynylation of a 
dialdosugar has been reported,40a,b we focused on a chain extension methodology, 
using the vinyl group as a synthetic equivalent of the carboxylic acid functionality, with 
a lower degree of stereocontrol in order to obtain both epimers at C-6’.52  
Thus, the bicyclic derivative 14 was benzylated with benzyl bromide and sodium 
hydride in DMF to afford the fully protected derivative 76 in 98% yield (Scheme 24). 
Regioselective opening of the benzylidene group using LiAlH4-AlCl3 in 
ether/dichloromethane53 gave the primary alcohol 77 in 88% yield.  
 
 
Scheme 24 – Synthesis of the primary alcohol 77. Reagents and conditions: a) NaH (60% w/w), 
BnBr, DMF, 95% b) LiAlH4-AlCl3, Et2O/CH2Cl2 (2:1), 50 ºC, 88%.  
 
The synthesis of the epimeric allylic alcohols 79a and 79b (Scheme 25) was then 
investigated. Swern oxidation of 77 proceeded efficiently to give the crude aldehyde 78, 
which was used directly without further purification. In order to obtain both 
diastereoisomers at C-6’ of miharamycins, vinylation of the aldehyde 78 in the absence 
of chelating species, proved to be the method of choice. When 78 was treated with 
vinyl magnesium bromide in anhydrous THF, allylic alcohols 79a and 79b were 
obtained in 65% yield from 77 and in a 3/2 ratio. Since vinylation of similar hexodialdo-
1,5-pyranoses was found to give predominantly the 6S configured alcohol,54 the same 
configuration could be expected for the major isomer 79a and this hypothesis was 
unambiguously confirmed by X-ray crystallography of the compounds 84a, 85, 89a and 
89b (see pages 38, 40 and 41).  
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Scheme  25 – Synthesis of allylic alcohols 79a and 79b. Reagents and conditions: a) (COCl)2, 
DMSO, Et3N, CH2Cl2, -78 ºC b) CH2=CHMgBr, THF, -78 ºC  r.t. , 65% over two steps. 
 
Conversion of allylic alcohols into the corresponding azido esters was then studied. 
Since the azido group is usually stable in the presence of oxidants, it could be either 
introduced early in the synthesis, before the oxidative cleavage of the vinyl group, or 
after the introduction of the carboxylic acid function. Preliminary studies showed that 
azide displacement of the intermediate triflate derived from allylic alcohol 79a mainly 
afforded the regioisomeric azide through an allylic rearrangement. Czernecki also 
reported an allylic rearrangement when he tried to introduce the azide via Mitsunobu 
reaction on a hexodialdo-1,5-pyranose.40c These results prompted us to synthesize the 
hydroxy esters first. Ozonolysis of the allylic alcohols 79a and 79b followed by sodium 
chlorite oxidation in tBuOH/H2O/2-methylbut-2-ene (2:2:1) afforded the corresponding 
carboxylic acids, which were not isolated. Esterification with methyl iodide or benzyl 
bromide in the presence of potassium hydrogenocarbonate afforded the corresponding 
methyl esters 80a and 80b or benzyl esters 81a and 81b (Scheme 26).  
 
 
 
Scheme 26 – Synthesis of both diastereoisomeric methyl esters 80a and 80b and benzyl esters 
81a and 81b. Reagents and conditions: a) O3, DMS, CH2Cl2, -78 ºC b) NaClO2, NaH2PO4.H2O, 
tBuOH/H2O/2-methylbut-2-ene (2:2:1) c) MeI, KHCO3, DMF, 65% over three steps or BnBr, 
KHCO3, Bu4NI, DMF, 68% over three steps. 
 
Results and Discussion 
Total Synthesis and Stereochemical Assignment of Miharamycins 37
The hydroxy esters 80a,b and 81a,b were activated by treatment with triflic anhydride 
in dry dichloromethane at – 78 ºC to produce the corresponding triflates, which were 
displaced with sodium azide in DMF at room temperature to afford the corresponding 
inverted azido esters as oils in good yield (Scheme 27).55 
 
 
Scheme  27 – Synthesis of both diasteroisomeric azido esters 82a,b and 83a,b. Reagents and 
conditions: a) Tf2O, pyridine, CH2Cl2, -78 ºC b) NaN3, DMF 82% for  82a over two steps, 72% 
for 83a over two steps, 68% for 82b over two steps, 86% for 83b over two steps. 
 
To firmly establish the absolute configuration at C-6 for both azido esters 82a and 82b, 
the synthesis of the corresponding triacetylated azido esters was planned for X-ray 
crystallography purposes. In addition, the replacement of the benzyl ethers by ester 
functions might also be useful since two classes of hydroxyl protecting groups (ester 
type and ether type) could be available for further glycosylation studies.  
Swapping hydroxyl protecting groups while keeping the azido group, as a masked 
amine, required the initial removal of the benzyl groups in the presence of boron 
trichloride56 at low temperature (Scheme 28).  
 
 
Scheme 28 – Synthesis of the methyl (6S)-heptofuranosiduronate 84a. Reagents and 
conditions: a) BCl3 (1M in CH2Cl2), CH2Cl2, -78 ºC  0 ºC, 65%.  
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Cleavage of the benzyl ethers using these conditions induced slight changes in the 
NMR spectra, especially for the sugar anomeric proton, of the debenzylated azido ester 
84a (Table 4). A modification of the multiplicity of proton signals for H-5 and H-8 was 
also observed. 
 
Table 4 – Selected 1H and 13C NMR data for methyl (6S)-heptopyranosiduronate 82a and 
methyl (6S)-heptofuranosiduronate 84a. 
Sugar substrate H-1 H-4 H-5 H-8 C-1 C-4 C-5 C-8
 4.89, s 4.34 - 4.30, m [a]
1H  and  13C  NMR   Data (δ / ppm)
85.6
108.9 74.279.5 78.84.74,  d                   J 5,4 = 5.6 Hz
4.45,  t                   
J  = 5.6 Hz
5.02, d               
J 1,2 = 5.7 Hz
4.36,  d                   
J 4,5 = 10.3 Hz
5.01, dd                
J 5,6 = 2.5 Hz                   
J 5,4 = 10.3 Hz
4.31, dd                  
J 8,9b = 1.7 Hz                 
J 8,9a = 4.5 Hz
99.6 68.973.7
 
[a]
 The proton H-4 of compound 84a appeared in a multiplet together with H-6.  
 
The structural elucidation of compound 84a was unequivocally established by X-ray 
crystallography (Figure 12). This unexpected skeleton rearrangement occurred via ring 
contraction of the pyranoside form to give the bis(tetrahydrofuran) derivative 84a as a 
single product. The C-6 azido ester moiety of compound 82a was not implicated in this 
transformation and its S configuration was confirmed at this point.52 
 
Figure 12 – X-Ray structure of the methyl (6S)-heptofuranosiduronate 84a. 
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This skeleton rearrangement could be tentatively explained by a BCl3-induced 
endocyclic cleavage of the pyranoside ring to form an acyclic oxonium ion followed by 
an intramolecular nucleophilic attack of the hydroxyl group at position 4 onto the 
oxonium leading to an inversion of configuration at anomeric position (Scheme 29). 
This problematic ring contraction should be addressed because the key N-glycosylation 
step requires similar Lewis acidic conditions.  
 
 
 
Scheme 29 – Proposed mechanism for the skeleton rearrangement of azido ester 84a.  
 
When the same conditions were applied to the other epimeric azido ester 82b, a similar 
transformation was observed (Scheme 30).  
 
 
 
Scheme 30 – Synthesis of methyl (6R)-heptofuranosiduronate 85. Reagents and conditions: a) 
BCl3 (1M in CH2Cl2), CH2Cl2, -78 ºC  0 ºC, 55% b) Ac2O, pyridine, DMAP, 79%. 
 
In this particular case elucidation of the structure of the compound 84b was 
accomplished by X-ray crystallography of the corresponding peracetylated derivative 
85 (Figure 13). 
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Figure 13 - X-Ray structure of the methyl (6R)-heptofuranosiduronate 85. 
 
Based on these results, a modified protection/deprotection sequence was investigated 
in order to obtain the desired triacetylated azido esters in the pyranoside form.  
Starting from the mixture of hydroxy esters 80a and 80b, silylation with TBDMSOTf in 
pyridine produced the corresponding separable silylated compounds 86a and 86b in 
89% yield (Scheme 31).   
 
 
Scheme 31 – Synthesis of the silylated derivatives 86a,b. Reagents and conditions: a) 
TBDMSOTf, pyridine, 0 ºC, 89%.  
 
Conventional hydrogenolysis of the benzyl groups in compounds 86a and 86b followed 
by acetylation of the resulting triols afforded the desired triacetates 87a and 87b. 
Desilylation, triflation of the resulting free hydroxyl group and reaction with sodium 
azide provided the corresponding inverted azido esters 89a and 89b (Scheme 32). 
Noteworthy, the desilylation step required a slight modification of the classical 
procedure57 by adding AcOH (5.5 eq.) prior to TBAF (4.5 eq.) in order to avoid acyl 
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groups migration during deprotection of the (6R)-isomer 87a. However, for 87b only the 
use of a 40% aqueous solution of HF58 led to the desired compound 89b in 66% yield.  
 
 
Scheme  32 – Synthesis of triacetylated azido esters 89a,b. Reagents and conditions: a) H2, 
10% Pd/C, EtOAc/MeOH b) Ac2O, pyridine, DMAP, 82% for 87a over two steps and 84% for 
87b over two steps c) TBAF, AcOH, 80 ºC, 92% for 88a and HF (40% aq.), CH3CN 66% for 88b 
d) Tf2O, pyridine, CH2Cl2, -78 ºC e) NaN3, DMF, 79% for 89a over two steps and 81% for 89b 
over two steps.  
 
The structures of azido esters 89a and 89b were unambiguously confirmed by X-ray 
crystallography (Figure 14).  
 
Figure 14 – X-ray structure of the peracetylated azido esters 89a and 89b. 
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Hence, for the first time, both higher 6R and 6S monosaccharides comprising different 
protecting groups, which are suitable direct precursors of the SAA moiety of 
miharamycins, have been synthesized and their stereochemistry unequivocally 
assigned. This result is very important since it will enable to assign unequivocally the 
configuration at C-6’ of the final natural product.  
 
2.2 Nucleoside Synthesis 
 
With the epimeric (6S and 6R) sugar amino acids in hand, the next step in our strategy 
consisted in the nucleoside synthesis. Hence, being miharamycins β-N9-nucleosides, 
the stereo- and regioselective introduction of the unusual 2-aminopurine at the 
anomeric position was then investigated.  
 
2.2.1 Anomeric activation 
 
The introduction of the heterocyclic base required preliminary conversion of the 
available SAAs precursors into suitable glycosyl donors. Methyl glycosides are 
comparatively less reactive than their acyl counterparts. For that purpose acetolysis 
reaction under mild conditions was studied.  
 
2.2.1.1 Acetolysis reaction with model compounds 
 
Demonstration of a ring contraction, which occurred when debenzylation was mediated 
by BCl3, prompted us to initially investigate the acetolysis reaction of the anomeric 
substituent on two model compounds, namely the peracetylated and the perbenzylated 
sugar moieties 91 and 92, which were synthesized according to the following Scheme 
33.  
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Scheme 33 – Synthesis of the peracetylated methyl glycoside 91 and perbenzylated methyl 
glycoside 92. Reagents and conditions: a) AcOH (80% aq.), 50 ºC, quant. b) Ac2O, pyridine, 
DMAP, 92% for 91 over two steps c) NaH (60% w/w), BnBr, DMF, 85% for 92 over two steps. 
 
The acetolysis of the anomeric methoxy group was first examined with H2SO4/Ac2O.59 
Starting from the peracetylated sugar, the β-furanose 93 was obtained in high yield 
along with a small amount of the expected β-pyranose 94. As illustrated in Scheme 34, 
modification of the reaction conditions (conc. H2SO4 5% in AcOH /Ac2O) did not 
improve significantly the quantity of desired glucopyranosyl donor 94.   
 
 
 
Scheme 34 – Acetolysis of the peracetylated methyl glycoside 91. Reagents and conditions: a) 
H2SO4 conc, Ac2O, 0 ºC, 85% for 93 and 10% for 94 b) H2SO4 5% in AcOH, Ac2O, 0 ºC, 70% for 
93 and 20% for 94.  
 
However, acetolysis of the anomeric methoxy group starting from the perbenzylated 
compound 92 produced the suitable pyranose diacetate 95 as the major compound 
(48%) among compound 96 resulting from the contraction of the pyranose ring 
(Scheme 35).  
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Scheme 35 – Acetolysis of the perbenzylated methyl glycoside 92. Reagents and conditions: a) 
conc. H2SO4 5% in AcOH, Ac2O, 0 ºC  20 ºC, 48% for 95 and 32% for 96.  
 
The furanoside structures were monitored by careful examination of NMR data. Several 
peracetylated compounds were analysed and J1,2 coupling constant, 1H and 13C 
chemical shifts of furanoside and pyranoside forms were compared (Table 5). The low 
J1,2 value for the anomeric proton is characteristic of a β-glucofuranose form, as 
exemplified with compound 98. Furthermore, a change on the multiplicity of some 
proton signals was also recorded when moving from a pyranose structure to a furanose 
scaffold. Moreover an inversion of the chemical shifts for C-5 and C-4 was noticed.  
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Table 5 – Selected 1H and 13C NMR data for the acyl glycopyranoses and acyl glycofuranoses 
58, 97, 98, 99, 93, 94.60 
Sugar substrate H-1 H-4 H-5 H-7 C-1 C-4 C-5 C-7
3.86, ddd
5.72, d J 5 ,6a = 2.0 Hz
J 1,2 = 8.3 Hz J 5 ,6b = 4.3 Hz
J 5 ,4 = 9.8Hz
5.29, ddd
6.12, brs J 5 ,6a = 2.5 Hz
J 1,2 < 1 Hz J 5 ,6b = 5.0 Hz
J 5 ,4 = 9.1 Hz
5.24, ddd
6.46, d J 5 ,6a = 2.6 Hz
J 1,2 = 4.6 Hz J 5 ,6b = 5.6 Hz
J 5 ,4 = 8.5 Hz
4.85, ddd
6.19, s 4.85, d J 5 ,6a = 2.5 Hz
J 1,2 = 0 Hz J 4,5 = 8.9 Hz J 5 ,6b = 6.3 Hz
J 5 ,4 = 8.9 Hz
…88.8 69.76.34, d         J 1,2 = 3.7 Hz
5.14, t                         
J = 10.1 Hz 4.08 - 5.14, m 
[a]
… 68.0
5.12 - 5.17, m [b]                                     … 68.0 …
98.8 68.2
91.4 72.9
4.56, dd         
J 4,3 = 4.8 Hz            
J 4,5 = 9.1 Hz    
… 79.5
…93.8 67.7
4.51, dd          
J 4,3 = 4.8 Hz         
J 4,5 = 8.5 Hz    
…
76.56.02, d                 J 4,5 = 10.2 Hz
5.61, d         
J 7,8a = 4.0 Hz
1H  and  13C  NMR   Data (δ / ppm)
6.13, dd      
J 7,8b = 6.1 Hz    
J 7,8a = 7.2 Hz    
80.2 74.099.5 69.0
5.85, d         
J 1,2 = 7.8 Hz 4.16 - 4.10, m 
[c] 93.2 73.066.6
… 76.5
 
[a]
 The proton H-5 of compound 58 appeared in a multiplet together with H-6b. [b]The proton H-4 of 
compound 97 appeared in a multiplet together with H-2. [c]The proton H-5 of compound 94 appeared in a 
multiplet together with H-6b. 
 
As in the case of BCl3 mediated deprotection, an endocyclic cleavage of the acetal is 
probably responsible for the rearrangement of the pyranose ring into a furanose, but 
now promoted by a BrØnsted acid (Scheme 36).  
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Scheme 36 – Proposed mechanism for the skeleton rearrangement of the peracetylated methyl 
glycoside 91 during acetolysis.  
 
The higher propensity of the peracetylated compound 91 to undergo ring contraction 
compared to the perbenzylated compound 92 should be related to the migration ability 
of the acetyl group, leading to transesterifications reactions, while removal of the 
benzyl group from an ether under acidic conditions is more difficult.  
A perbenzoylated bicycle 100 was also synthesized as a model to study ring 
contraction in more detail (Scheme 37).  
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Scheme 37 – Synthesis of the perbenzoylated compound 100. Reagents and conditions: a) 
BzCl, pyridine, DMAP, r.t.  80 ºC, 72%. 
 
Ring contraction was investigated with the methyl glycosides 91, 92 or 100 using 
different reaction conditions. Distinct acids, namely 70% aqueous solution of HClO4,61 
TMSOTf 62 and BF3.Et2O,63 different temperatures (-20 ºC, 0 ºC) and reaction times 
were explored. Unfortunately, none of these experiments resulted in an improvement of 
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the yield of the acyl pyranose forms. The acetolysis best result was achieved for the 
miharamycins sugar moiety perbenzylated, in Ac2O and in the presence of a catalytic 
amount of conc. H2SO4 5% in AcOH.    
 
2.2.1.2 Acetolysis reaction with epimeric sugar amino acids 
 
With the potential problem of ring contraction during acetolysis in mind, we explored 
conditions to cleanly perform acetolysis of the anomeric substituent, while maintaining 
the six-membered ring in the bicyclic system. Hence, acetolysis conditions, already 
described in chapter 2.2.1.1, were applied to both epimeric azido esters (82a,b and 
89a,b).  
Acetolysis of the tribenzylated S diastereoisomer 82a took place under the conditions 
previously optimized, namely in the presence of catalytic concentrated sulphuric acid 
5% in acetic acid at low temperature.52 However, acetolysis of its epimer at C-6 
occurred smoothly and in high yield under catalysis of concentrated sulphuric acid 
(Scheme 38). Thus, the 6S isomer showed to be more sensible to the acetolysis 
conditions when compared to its 6R diastereoisomer.  
 
 
Scheme  38 – Synthesis of 6S and 6R glycosyl donors 101a,b. Reagents and conditions: a) 5% 
conc. H2SO4  in AcOH, Ac2O, -20 ºC  0 ºC, 39% b) conc H2SO4, Ac2O, 0 ºC, 72%.  
 
Disappointingly, acetolysis of the peracetylated compounds 89a,b led to a mixture of 
products, containing mainly compounds resulting from the ring contraction, namely α 
and β anomers (Scheme 39). In this mixture was also detected a negligent amount of 
an α/β mixture of suitable glycosyl donors (pyranose forms) as well as unreacted 
starting material.   
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Scheme 39 – Acetolysis attempt of peracetylated SAAs 89a,b. Reagents and conditions: a) 5% 
H2SO4 in AcOH, Ac2O, - 20 ºC  0 ºC, 5% for (6S)-pyranose form and 7% for (6R)-pyranose 
form. 
 
2.2.2 N-Glycosylation 
 
N-Glycosylation was then investigated using classical Vorbrüggen’s reaction 
conditions.46 As discussed in chapter 1.4.3, a typical “Vorbrüggen” glycosylation 
(Scheme 19) requires presilylation of the base and Lewis acid activation of the sugar to 
form the desired nucleoside.   
 
2.2.2.1 Base protection 
 
Two routes can be envisaged to obtain the 2AP nucleosides: direct N-glycosylation of 
2AP or, in alternative, glycosylation of the more reactive silylated 2A6CP derivative, 
followed by dechlorination of the resulting nucleoside by hydrogenolysis. Hence, the 
synthesis of both 2-acetamidopurine and 2-acetamido-6-chloropurine was undertaken 
for further base coupling studies (Scheme 40).   
 
 
 
Scheme 40 – N2-acetyl protection of 2-aminopurine 102 and 6-chloro-2-aminopurine 103. The 
numbering used for these purine bases is also shown. Reagents and conditions: a) Ac2O, DMA, 
150 ºC b) EtOH/H2O (4:1), 90 ºC  r.t., 39% for 56 and 42% for 57. 
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N-acetylation of the heterocyclic base was accomplished by acetylation with acetic 
anhydride (3.5 eq) in DMA at high temperature in order to achieve complete dissolution 
of the base and consequent full protection. After 45 min., the solution EtOH/water (4:1) 
was slowly added, at 90 ºC, and selective deacetylation furnished the free secondary 
amine.64  
 
2.2.2.2 N-Glycosylation of the epimeric sugar amino acids  
 
In a first approach, the classical Vorbrüggen methodology for N-glycosylation directly 
with 2-aminopurine was investigated. However, all attempts to glycosylate this base as 
its bis(silylated) N-acetyl derivative using Garner’s47 and Czernecki’s49 procedures 
[SnCl4, (CH2Cl)2/CH3CN, reflux and TMSOTf, (CH2Cl)2, reflux], reported with glucose 
peracetate, failed, leading either to decomposition or recovery of the corresponding 
lactol 106 with no trace of the expected nucleoside (Scheme 41).  
 
 
Scheme 41 – Attempts to glycosylate the bis(silylated) 2-aminopurine. Reagents and 
conditions: a) SnCl4, (CH2Cl)2/CH3CN, 85 ºC b) TMSOTf, (CH2Cl)2, 85 ºC, 45% for 106. 
 
This lack of reactivity of 2-aminopurine nucleobase has also been experienced by other 
groups.65 Apurba Datta and co-workers in 2008 described multiple attempts for the 
synthesis of the amipurimycin nucleoside involving different combinations of Lewis acid 
promoters, solvents and temperatures that failed to provide the target molecule 
(Scheme 42). Instead, only starting material or degradation products were recovered. 
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Scheme 42 – N-Glycosylation attempts reported by Datta’s group. Reagents and conditions: a) 
TMSOTf, (CH2Cl)2, r.t. b) TMSOTf, CH3CN, r.t.  80 ºC c) SnCl4, CH3CN, r.t. d) SnCl4, 
CH3CN/(CH2Cl)2, 120 ºC. 
 
Hence, the more reactive 6-chloro-2-aminopurine 57 was used as a masked 2-
aminopurine. Coupling of the bis(trimethylsilyl) N-acetyl derivative of 6-chloro-2-
aminopurine 61 with both the 6S and 6R glycosyl donors 101a,b was then investigated 
in order to generate the correct stereo- and regioisomer present in miharamycins, 
namely the N9-linked β-isomer (Scheme 43). It is important to notice that due to the 
sensitivity of the bis(trimethylsilyl) base derivatives, handling of this base is difficult and 
it was then decided to use it directly without purification.  
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Scheme  43 – N-Glycosylation of epimeric glycosyl donors 101a,b. Reagents and conditions: a) 
TMSOTf, solvent and temperature (see Table 6).  
 
Glycosylation of purines is rarely regiospecific and usually produces mixtures of N9 and 
N7 products, despite the numerous efforts to maximize N9 glycosylation.66 While 
Garner47 devised conditions leading mainly to the thermodynamic N9 regioisomer 
starting from glucose peracetate, the same conditions applied to the perbenzylated 
glycosyl donors 101a,b afforded the kinetic N7 regioisomers 108 and 110 as major 
products (Table 6, entries 5, 6, 7 and 8). Since pyranosidic ring contraction was 
observed either by BCl3-mediated deprotection of benzyl ethers or acetolysis of the 
peracetylated methyl glycosides 89a,b, the benzyl groups were kept during the 
synthesis. Therefore glycosylation conditions (solvent and temperature) need to be 
encountered to finely tune the reaction in favour of the N9 regioisomer.52 
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Table 6 – TMSOTf-mediated N-glycosylation of persilylated N2-acetyl-6-chloropurine 61 with 
glycosyl donors 101a,b. 
Entry[a] Sugar substrate Solvent T (ºC) Reaction time (h) N9:N7 ratio[b] Combined yield (%)
1 (6S ) 101a CH3CN 65 3 0:1 55
2 (6R ) 101b CH3CN 65 3 0:1 58
3 (6S ) 101a CH3CN/(CH2Cl)2 85 3 1:8 53
4 (6R ) 101b CH3CN/(CH2Cl)2 85 3 1:9 55
5 (6S ) 101a (CH2Cl)2 85 3 1:2 43
6 (6R ) 101b (CH2Cl)2 85 3 1:3 41
7 (6S ) 101a (CH2Cl)2 85 7 1:2 40
8 (6R ) 101b (CH2Cl)2 85 7 1:3 40
9 (6S ) 101a (CH2Cl)2 85 16 …[c] …[c]
10 (6R ) 101b (CH2Cl)2 85 16 …[c] …[c]
11 (6S ) 101a Toluene 110 4 4:1[d] 32
12 (6R ) 101b Toluene 110 4 3:1[d] 33
13 (6S ) 101a Toluene 85 4 3:1 58
14 (6R ) 101b Toluene 85 4 2:1 48
 
[a]
 All reactions were carried out on a 0.05 mmol scale of sugar substrate and yielded exclusively β-
anomers. [b] The regioselectivity of the N-glycosylation was determined by HMBC. [c] Decomposition of the 
nucleobase and the glycosyl donor. [d] Deacetylation of the purine nucleobase was observed. 
 
Non-polar solvents and high reaction temperatures usually lead to the thermodynamic 
N9 glycosylation product as the major regioisomer,67 but such harsh conditions 
(prolongated reaction times, temperatures above 100 ºC) resulted in decomposition of 
the nucleobase and of the glycosyl donors 101a,b (Table 6, entries 9, 10, 11 and 12).  
Finally, glycosylation performed with TMSOTf in toluene at 85 ºC gave the best yield 
and N9/N7 ratio of the corresponding diastereomeric β-N9-nucleosides 107 and 109 
(Table 6, entries 13 and 14). The experimental procedure involved silylation of 57 with 
N,O-bis(trimethylsilyl)acetamide (BSA) in (CH2Cl)2 at 80 ºC, which was complete in 30 
min. The clear solution of the bis(trimethylsilyl) N-acetyl derivative of 6-chloro-2-
aminopurine 61 was evaporated and the syrup residue dissolved in dry toluene under 
argon. To this solution the glycosyl donors 101a or 101b in dry toluene were then 
added, and the reaction mixture was stirred in the presence of TMSOTf at 85 ºC for 4 
hours.   
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It should be noticed that a remarkable difference between the Rf values of N9 and N7 
regioisomers was observed (Figure 15), indicating a great polarity divergence for the 
two nucleosides, which can be understood if we consider the dipole moments either 
experimental68 and theoretical69 of both purine tautomers (µN9 = 3.5 D vs µN7 = 5.6 D).  
 
Rf N9 = 0.63 
Rf N7 = 0.16 
Solvent: Cyhex / EtOAc 1:1
Stain: Hanessian
 
 
Figure 15 –TLC of both N9- and N7 regioisomers 107 and 108, respectively, from which the 
polarity difference of these nucleosides can be deduced. 
 
The expected large difference of dipole moments may explain why N7 isomers are 
stabilized in solvents with large dielectric constant (37.570 for CH3CN), while N9 isomers 
are stabilized in solvents with lower dielectric constant (2.470 for toluene).71 Thus, 
acetonitrile is expected to favor the base tautomeric equilibrium towards the N7 isomer 
and also stabilize the transition state in N7-glycosylation. When toluene is the reaction 
solvent, the thermodynamic controlled N9 product is the major tautomer and N9-
glycosylation is favoured.  
The regioselectivity of the base coupling reaction (the N9 and N7 attachment positions 
of the purine ring) was established via careful analysis of the NMR spectra, which differ 
in 1H and 13C NMR chemical shifts, and interpretation of HMBC 2D experiments. The 
selected NMR data presented in Table 7 show that signals for H-8, C-4, C-8, and H-1’ 
are shielded, while signal for C-5 is deshielded in the N9 substituted purines compared 
to their N7 substituted counterparts.  
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Table 7 – Selected 1H and 13C chemical shifts differences for a N9 regioisomer and a N7 
regioisomer. 
Nucleoside H-1' |∆δ| H-8 |∆δ| C-8 |∆δ| C-4 |∆δ| C-5 |∆δ|
(6S ) N9 regioisomer 107 6.08 8.05 142.5 152.2 128.1
(6S ) N7 regioisomer 108 6.54 8.45 146.0 163.2 119.1
(6R ) N9 regioisomer 109 6.07 8.00 142.4 152.1 127.6
(6R ) N7 regioisomer 110 6.42 8.35 146.1 162.7 118.9
N9 regioisomer (64) 5.83 8.18 142.1 152.4 127.8
N7  regioisomer (68) 6.08 8.23 147.1 163.4 118.5
1H  and  13C  NMR   Data (δ / ppm)
9.0
8.7
9.3
3.5
3.7
5.0
11.0
10.6
11.0
0.46
0.35
0.25
0.40
0.35
0.05
 
 
Although the chemical shifts of key protons and carbons of the nucleoside regioisomers 
are different, the most characteristic chemical shifts that differentiate both isomers are 
those of C-4 and C-5. However, a more reliable method was required for the 
unambiguous determination of the regioselectivity of the N-glycosylation. Hence, 
HMBC spectra were recorded for each nucleoside. For the N9 and N7 nucleosides 107 
and 108 respectively (Figures 16 and 17), we observed a correlation of the proton H-8 
of the base with the carbons C-5 and C-4 of the same base, in both regioisomers. 
Alternatively, we noticed correlations between the signals of H-1’ and carbons C-4 and 
C-8 for the N9-regioisomer, while for the N7-regioisomer H-1’ correlates with C-5 
instead of C-4. Such observations were crucial for the assignment of the nucleoside 
regioisomers and similar correlations were observed for nucleosides 109 and 110.  
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Figure 16 – HMBC spectrum for the N9 regioisomer 107. 
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Figure 17 – HMBC spectrum for the N7 regioisomer 108. 
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Noteworthy is the exclusive β-N-nucleoside formation observed in all cases, which was 
easily deduced from 1H NMR vicinal coupling data (J1’,2’ = 9 – 10 Hz). Since 
neighbouring group participation is absent in our scaffold, this result could be 
tentatively explained by the steric hindrance of the pyranosidic ring α face due to the 
presence of the bulky tetrahydrofuran ring. As a consequence, the approach of 
heterocyclic base by the β-face is favoured. 
In order to have insight into the glycosylation mechanism and to understand why the 
same coupling conditions applied to glucose peracetate furnished the thermodynamic 
N9 regioisomer (TMSOTf, (CH2Cl)2, 85 ºC, Garner conditions), while the perbenzylated 
glycosyl donors 101a,b led to the kinetic N7 regioisomers 108 and 110 as the major 
products, we performed two simple experiments. When TMSOTf was added to a 
solution of N7 glucose nucleoside 68 in dry toluene at 85 ºC, its conversion into the N9 
regioisomer 64 occurred after 2 hours (Scheme 44). This rearrangement probably 
proceeds via dissociation of the N7 nucleoside into the nucleobase and the sugar Lewis 
acid-activated intermediate 111, which rearrange at high temperature and in non-polar 
solvents to the thermodynamically controlled N9 purine nucleoside.   
  
 
Scheme 44 – Rearrangement of the N7 nucleoside into the N9 nucleoside. Reagents and 
conditions: a) TMSOTf, toluene, 85 ºC, 31%.  
 
When applying the same conditions to the N7 regioisomer 110, only decomposition of 
the starting material was observed (Scheme 45). This result suggests that the 
formation of the activated sugar intermediate 111 is crucial to convert a N7 kinetic 
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product into a N9 thermodynamic product.  This observation was also reported by 
Robins’s group67a when they applied similar reaction conditions (TMSOTf, toluene, 80 
ºC, 2 h) to rearrange a N7 purine furanonucleoside into a N9 purine furanonucleoside. In 
fact, formation of such a highly stable ionic intermediate is not possible starting from 
the N7 isomer 110, due to the absence of neighbouring group participation.  
 
 
 
Scheme 45 – Attempt to rearrange the N7 nucleoside 110 into N9 nucleoside 109. Reagents 
and conditions: a) TMSOTf, toluene, 85 ºC. 
 
When the coupling reaction of the glycosyl donors 101a,b proceeded in dichloroethane, 
the N7 kinetic product was the major nucleoside formed, suggesting that the reaction 
transition state is not stable enough nor stabilized by the solvent, hampering 
interconvertion of the N7 kinetic product into the N9 isomer. 
 
2.3 Peptide Coupling 
 
In order to complete the synthesis of the unprecedented core of the miharamycins and 
according to the our retrosynthetic pathway (Figure 11) the peptidyl coupling reaction 
was then investigated.   
 
2.3.1 Synthesis of the core of miharamycin B 
 
The only difference between miharamycins A and B consists on the structure of the 
amino acid moiety (Figure 18). Miharamycin A contains a non-commercially available 
N5-hydroxy-L-arginine residue, while miharamycin B incorporates the natural L-arginine 
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amino acid. Despite the fact that the synthesis of N5-hydroxy-L-arginine has been 
reported in the literature,16c we focused on the easily available L-arginine in order to 
obtain miharamycin B. 
 
 
Figure 18 – N5-hydroxy-L-arginine and L-arginine present in miharamycins A and B, 
respectively. 
 
2.3.1.1 L-Arginine protection 
 
The introduction of the L-arginine moiety required preliminary protection of its amino 
groups. The benzyloxy carbamates (Z or CBz) were chosen as the amino protecting 
groups. The classic Schotten-Bauman conditions,72 typically used for 
benzyloxycarbonyl protection, are generally low yielding (15-32%) and were observed 
to produce only the dibenzyloxy carbonyl derivatives. A more recent one pot 
methodology for the protection of L-arginine was reported by Jetten and co-workers 
(Scheme 46).73  
 
 
 
Scheme 46 – Protection of the L-arginine 113. Reagents and conditions: a) DiPEA, TMSCl, 
(CH2Cl)2, 40ºC b) DiPEA, ZCl, then acidic work-up, 55%.  
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Treatment of the commercially available L-arginine 113 with N,N-diisopropylethylamine 
(DiPEA) and trimethylsilyl chloride (TMSCl) under anhydrous conditions produced the 
intermediate 114, which was not isolated. After cooling the solution at 0 ºC, an 
additional portion of base followed by benzyl chloroformate (ZCl) were added to afford 
the fully protected L-arginine 115. 
 
2.3.1.2 Synthesis of the amino ester nucleosides  
 
In order to accomplish the peptidyl coupling reaction it was necessary perform the 
reduction of the azido group presented in nucleosides 107 and 109 into an amine.  
In the search for a mild and convenient method for the reduction of azides into amines 
compatible with our structures, we investigated several reaction conditions described in 
the literature, such as Staudinger conditions (PPh3/THF)74, SnCl2 in MeOH75 and 
hydrogenolysis using Lindlar catalyst.76 Staudinger reaction furnished a small amount 
of the desired amine along with the corresponding iminophosphorane derivative. On 
the other hand, reduction using SnCl2 in MeOH failed resulting in an extensive 
degradation of the starting nucleoside, while hydrogenolysis with Lindlar catalyst 
proved to be inefficient since only starting azides were isolated.  
Finally, all these disappointingly results prompted us to investigate this reduction step 
via a hydrogenolysis like reaction by replacing the Lindlar catalyst by 10% Pd/C in 
EtOAc and in the presence of Et3N77 (Scheme 47). We exploited this reduction step to 
the concomitant removal of the chlorine atom on the nucleobase in order to unmask the 
2-aminopurine moiety.52 Thus, hydrogenation of 107 and 109 under the mentioned 
conditions was successful and the tribenzylated amino esters 116 and 117, 
respectively, were obtained.  
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Scheme 47 – Synthesis of the tribenzylated amino esters 116 and 117. Reagents and 
conditions: a) H2, 10% Pd/C, Et3N, EtOAc.   
 
Formation of the amines 116 and 117 was confirmed by mass spectrometry and they 
were directly engaged in the peptide coupling reaction without purification, since they 
were rather sensitive to column chromatographic separation. 
 
2.3.1.3 Peptide coupling reaction 
 
In a typical peptide coupling reaction,78 the carboxylic acid moiety of the amino acid I is 
first activated by an appropriate peptide coupling reagent, and then reacted with the 
amine moiety of the amino acid II to produce a desired peptide as illustrated in Scheme 
48.   
 
 
Scheme  48 – A general peptide coupling reaction. 
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Another significant development in the field of peptide coupling reactions was the 
discovery of the racemisation suppressants. Racemisation can occur at the C-terminal 
of the amino acid residue in the course of a coupling reaction, due to the ionisation of 
the α-hydrogen.79   
A peptide coupling reagent with an appropriate racemisation suppressing agent 
ensures suppression of the undesired racemisation and other side reactions, and thus 
minimises the loss of the optical integrity at chiral centre.80 In some cases, 
racemisation suppressants are also used as additives to the peptide coupling reagent.  
DCC is one of the peptide-coupling reagents and has been largely used by organic 
chemists to construct complex molecules.81 The successful launch of DCC/HOBt82  
system, which minimizes side reactions in peptide synthesis, encouraged us to apply 
these conditions for the coupling of L-arginine. Surprisingly, such conditions gave 
unsatisfactory yields of the desired peptide and we therefore moved to a different 
procedure.  
Chloroformates have also been applied in peptide chemistry via their mixed carbonic 
anhydride intermediates.83 Hence, the S configurated amino ester 116 was then 
smoothly coupled after activation of N-benzyloxycarbonyl protected L-arginine 115 with 
isobutyl chloroformate84 affording the unprecedented core of miharamycin B 118 in a 
satisfying 70% over two steps (Scheme 49).  
 
 
Scheme 49 – Synthesis of the core of miharamycin B 118. Reagents and conditions: a) isobutyl 
chloroformate, Et3N, THF, -20 ºC, 70% over two steps. 
 
The R configurated amino ester 117 was also coupled to L-arginine after activation with 
isobutyl chloroformate yielding the desired peptide. Unfortunately, since very minor 
quantities were obtained for the final R protected compound, its complete 
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characterization by NMR techniques was not accomplished, and the product was only 
identified by mass spectrometry.  
 
2.4 Final Deprotection Step  
 
Removal of all the protecting groups to afford miharamycin B proved to be highly 
problematic. While deprotection of the Z groups present on L-arginine moiety seemed 
to occur easily under hydrogenation conditions, benzyl groups present on the bicycle 
proved to be reluctant.  
Successful hydrogenolysis under similar conditions of nucleobase-free sugar amino 
acid precursor 82a and peptide 119a afforded the trihydroxylated structures 120a and 
121a, respectively, but the nucleoside 122 was totally inert to hydrogenolysis 
performed with 10% Pd/C,85,6a Pd black,86 Pearlman’s catalyst87 at 30 psi or catalytic 
hydrogen transfer,88 a behaviour also reported by other authors for benzylated 
nucleosides (Scheme 50).89  
We can hypothesize two possible reasons to explain the difficulties arisen during 
hydrogenolysis of O-benzyl-protected nucleosides. The amino functionalities of 
nucleosides may inhibit hydrogenolysis even in the presence of an acid. Free amines 
have been shown to inhibit the hydrogenolysis of O-benzyl ethers,90 presumably by 
formation of a complex91 between the amine and the palladium catalyst, thereby 
deactivating the catalyst. Another possibility is that the nucleoside adsorbs to the 
catalyst in some fashion, thus hindering hydrogenolysis.  
Nevertheless, hydrogenolysis of the N9 nucleoside 122 in glacial AcOH for 8 h under 
pressure (400 psi) with 10% Pd/C afforded the fully deprotected nucleoside 123 
(Scheme 50), after acetamide and ester hydrolysis.52  
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Scheme 50 – Removal of O-benzyl groups in different miharamycins precursors. Reagents and 
conditions: a) H2, (30 psi), 10% Pd/C, glacial AcOH, 2.5h, quant. for 120a and 121a; b) H2 (400 
psi), 10% Pd/C, glacial AcOH, 8h; c) NH4OH-MeOH (1:1), 60 ºC, 86% over two steps. 
 
Unfortunately, high pressure hydrogenolysis applied to the protected miharamycin B 
118 removed first the Z groups on the arginine moiety and only one benzyl ether. 
Iteration of this process, controlled by NMR and mass spectrometry, failed at the 
complete removal the last benzyl group present in the bicycle, with concomitant 
decomposition of the fully debenzylated molecule already formed. The mass spectrum 
below (before the last iteration) shows a mixture of a fully debenzylated compound and 
a molecule containing one benzyl group (Figure 19).52 
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Figure 19 – Mass spectrum (ESI Mode) of the mixture of the fully debenzylated compound and 
the monobenzylated compound. 
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2.5 Assignment of Miharamycin A Stereochemistry  
 
Although considerable efforts to obtain the target molecule have been performed, the 
last unexpected synthetic problem concerning debenzylation of the last remaining 
benzyl group prevented us to reach the total synthesis of miharamycin B. As a 
consequence, determination of the absolute configuration at C-6’ of miharamycins 
antibiotics, by simple 1H NMR comparison with the natural product, was not possible. 
A sample of the natural product miharamycin A was kindest given to Prof Sinaÿ by Dr. 
Masato Tani from Meiji Seika Kaisha, Lda and therefore available for conformational 
analysis performed by NMR, combining complementary standard 2D methods at 500 
and 700 MHz, in order to establish the absolute configuration at C-6’ of the 
miharamycins.   
 
2.5.1 Combining NMR and computational methods in 
conformational analysis 
 
The full stereochemical knowledge of a given system is of fundamental importance in 
many different fields, spanning from chemical physics to biochemistry. For this reason, 
the assignment of the configurational pattern in chiral organic compounds containing 
more than one stereocenter is undoubtedly a key step of the structure elucidation 
process. Due to the challenge typically posed by such configurational assignments, the 
search for new and more effective methods for the stereochemical analysis of complex 
molecular systems has stimulated great attention within the chemical community, 
having relevant implications to several distinct research areas, such as natural product 
chemistry, asymmetric synthesis, medicinal chemistry, chemical biology, and material 
sciences.92  
The two most commonly applied experimental structural methods, NMR and X-ray 
crystallography, deserve to be highlighted. In the particular case of NMR spectroscopy 
it can provide information that is directly related to the 3-D structure of a molecule, and 
for that reason it remains the most widely used experimental method for studying the 
conformational properties of molecules in solution, namely the carbohydrates.93 
In the last few decades there are several examples where we can observe that NMR 
spectroscopic experiments became a powerful technique and a practical alternative to 
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X-ray crystallography allowing the assignment of several natural products94 and 
synthetic creations.95  
Parameters such as NOE intensities, scalar J-couplings, residual dipolar couplings and 
chemical shifts depend each one of the molecule’s 3-D structure.  Nevertheless, it is 
generally necessary to assume a model and iteratively adjust it until the resultant 
computed NMR parameters are in agreement with those obtained experimentally. For 
molecules that exist primarily in a single conformation this approach is very 
effective.93,96  
Noteworthy, solution NMR data represent only the average molecular structure over 
the time course of the NMR experiment, and for flexible molecules it is extremely 
difficult to decompose the data into contributions from the individual conformations. It is 
in this situation that modeling methods are often used to complement the NMR data.    
 
2.5.2 NMR conformational analysis of miharamycin A 
 
In order to establish the absolute configuration at C-6’ of miharamycins, a combination 
of NMR spectroscopy and molecular mechanics calculations was applied. 
The formula given below shows the structure of miharamycin A (3), along with the 
atomic numbering employed throughout this work (Figure 20).  
 
 
 
Figure 20 – Miharamycin A and numbering used to describe the NMR parameters. 
 
First, the different conformations around the dihedral angle O5’-C5’-C6’-C7’ for both 
absolute configurations at C-6’ were analysed. Hence, a total of six staggered Newman 
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projections around the previous angle were taken into account (three for each 
diastereomeric arrangement) (Scheme 51). 
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Scheme 51 – The six staggered Newman projections (three for each diastereomeric 
arrangement). 
 
Then, all the possible six conformers were built and minimized using the MMFF9497 
force field (ε= 1.0), as integrated in the MAESTRO package. The parameters 
calculated based on the geometries obtained in this manner were compared to the 
experimental NMR data.     
The NMR experiments in D2O solution were carried out at 500 and 700 MHz and at 298 
K and 288 K. A concentration of ca. 18 mM of 3 was used. The complete assignment of 
the 1H NMR resonance signals of miharamycin A (3) was achieved on the basis of 
TOCSY, HMQC and HMBC experiments. NMR experiments were also performed in a 
mixture of H2O/D2O (90:10) to detect the NH resonance. In this case a sample 
concentration ca. of 7 mM was used and the experiments were recorded at 500 MHz, 
288 K and with the watergate pulse sequence for water suppression. 
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Table 8 presents NMR data of miharamycin A in D2O and Figure 21 shows its 1H NMR 
spectrum.  
 
Table 8 – NMR data [1H chemical shifts (δ, ppm) and coupling constants (J, Hz)] for 
miharamycin A in D2O at 500 MHz and at 298 K. 
Proton / Quaternary carbon δ 1H (ppm) Multiplicity; J  (Hz) δ 13C (ppm)
H-6 8.46 s 149.9
H-8 8.25 s 142.1
H-1' 5.97 d; 9.5 77.6
H-6' 4.56 d; 1.8 55.6
H-4' 4.50 d; 9.7 66.1
H-8' 4.38 d; 4.3 73.9
H-9'a 4.29 dd; 4.3, 10.4 76.3
H-5' 4.23 dd; 9.7, 1.8 78.1
H-2' 4.17 d; 9.5 76.3
H-2'' 3.87 d; 6.3 53.1
H-9'b 3.72 d; 10.4 76.3
H-5''a, H-5''b 3.31 - 3.21 m 50.7
H-3''a, H-3''b 1.78 - 1.73 m 27.8
H-4''a, H-4''b 1.61 - 1.51 m 21.6
C-3' … … 80.8
C-2 … … 159.8
C-4 … … 152.9
C-5 … … 126.4
C=O (COOH) … … 174.3
C=O (CONH) … … 169.5
C=NH … … 158.0
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Figure 21 – 1H NMR spectrum of miharamycin A in D2O at 500 MHz and 298 K. 
 
Figure 22 shows the 1H NMR spectrum of the sample in a mixture H2O/D2O (90:10) 
with watergate recorded at 500 MHz and 288 K. This 1H NMR spectrum of 
miharamycin A provided additional information, namely the JH6’,NH coupling constant of 
5.9 Hz. This intermediate coupling value indicates that there is conformational 
equilibrium around the C-6’-NH bond.  
 
 
 
 
 
 
 
 
H-1’
H-8
H-6
H-2’’ H-5’’a,b
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Figure 22 – 1H NMR of miharamycin A in H2O/D2O (90:10) at 500 MHz and 288 K (with 
watergate). 
 
Comparison between the experimental J5’6’ coupling constant and those constants 
calculated for the MMFF94-based conformers is presented in the Table 9.  
 
Table 9 – Comparison of the experimental J5’6’ coupling constant with those deduced from 
molecular mechanics calculations for the local minima around the C5’-C6’ linkage of 
miharamycin A. 
J exp (Hz) J RconfA  (Hz) J RconfB  (Hz) J RconfC  (Hz) J SconfA  (Hz) J SconfB (Hz) J SconfC  (Hz)
1.8 1.5 0.2 7.4 8.7 2.5 0.4
 
 
 
 
H-2’’
H-1’NH2base
NH
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To notice that the experimental value of JH5’,H6’ is the average of each JH5’,H6’ 
contribution of all conformers with a precise configuration R or S. The following formula 
explains exactly this concept: 
 
Jexp = X1 3JconfA + X2 3JconfB + X3 3JconfC 
 
where X means the percentage of each conformer in solution. 
However, the small experimental value of the JH5’H6’ coupling strongly indicates that 
there is a very major conformation around the O5’-C5’-C6’-C7’ torsion angle. Indeed, 
an important presence of rotamers RconfC and SconfA can be safely discarded. Thus, four 
possible major conformers are left, as depicted in Scheme 52.    
 
 
 
Scheme 52 – The four possible conformers. 
 
Then, a quantitative analysis of HMBC spectra recorded with different long range 
evolution periods was performed. The analysis indicated that the long range JH5’C7’ is 
large, larger than 8 Hz, thus indicating that these two atoms hold an anti-type 
relationship, as shown in Figure 23.  
 
 
 
Results and Discussion 
Total Synthesis and Stereochemical Assignment of Miharamycins 72
 
H2’’–CONH
H5’–COOHH6’–COOH
H6’–CONH
H1’–C8
H6’–C4’
H1’–C2
H1’–C4
H6–C5
H8–C5
H8–C4
H6–C2
H6–C8
H4’–C6’
H5’
H6’
H4’
H1’
H8
H6
JH5’,C7’ > 8 Hz
JH6’,C4’ < 4 Hz
 
Figure 23 – HMBC spectrum (30 ms evolution) of miharamycin A in D2O at 500 MHz and 298K. 
 
Hence, after this analysis, only two rotamers may account for the experimental NMR 
data, namely RconfA, and SconfC (Scheme 53). 
 
Scheme 53 – The two possible conformers. 
 
According to the HMBC analysis, the long range JH6’C4’ coupling is small, smaller than 4 
Hz, which could indicate that the actual conformer is SconfC. Nevertheless, this 
conclusion was further assessed and justified by using NOE-type experiments. Since 
the intensities of NOE signals and proton-proton distances are strongly related, 1D and 
2D T-ROESY experiments with different mixing times (350 ms and 500 ms) at two 
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magnetic fields (500 and 700 MHz) and 1D T-ROESY were conducted in D2O. Those 
performed in H2O/D2O (90:10) did not show any additional information. The intensities 
of the NOEs were translated into inter-proton distances, which were compared to those 
deduced from the molecular mechanics calculations for both possible conformers. 
Figures 24 and 25 contain the 2D-T-ROESY maps recorded with mixing time of 350ms 
and 500ms, respectively. The H-8 of the heterocyclic moiety correlates with both H-2’ 
(strong) and H-1’ (weak) of the sugar moiety. This fact evidences the presence of a 
major rotamer around the nucleosidic linkage, but also states the existence of 
conformational equilibrium at this part of the molecule. Nevertheless, the key NOE for 
stereochemical assignment purposes was that observed between the anomeric H-1’ of 
the sugar unit and H-2’’ of the arginine residue. This NOE can only be explained if the 
configuration at C-6’ is S. Indeed, only this (S)-type configuration could accommodate 
the possibility for spatial proximity for the H-1’/H-2’’ proton pair.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 – 2D T-ROESY spectrum of miharamycin A in D2O at 500 MHz, 298 K and 350 ms of 
mixing time. 
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Figure 25 – 2D T-ROESY spectrum of miharamycin A in D2O at 500 MHz, 298 K and 500 ms of 
mixing time. 
 
The same information was deduced from 2D-T ROESY at 700 MHz magnetic field and 
from selective 1D T-ROESY experiments, upon inversion of H-1’, H-4’ and H-6’ protons 
(Figure 26).  
A semi-quantitative analysis of the NOE intensities to yield inter-proton distances was 
based on the isolated spin pair approximation.  
 
rref
6
 x NOEref = rexp6 x NOEexp 
 
All experimental distances (r, Å; ±10%) are estimated according to the analysis of the 
1D and 2D T-ROESY data. The intra-residue distances between the H-9’a and H-9’b 
proton pair (rref= 1.8 Å) or between the H-1’ and H-5’ (rref= 2.4 Å) was taken as internal 
reference. The experimental distances were then compared to those obtained after 
H-1’
H-2’’H-8H-6
H1’–H2’’
H1’–H8
H2’–H8
ROESY 500ms
H1’–H2’’
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molecular mechanics calculations for the two assumed conformers RconfA and SconfC 
(Table 10).  
 
 
 
Figure 26 – 1H NMR spectrum between 4.65 and 3.60 ppm of miharamycin A and a 1D-
ROESYs spectrums of H-4’, H-6’ and H-1’ in D2O at 500 MHz and 298 K. 
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Table 10 – Comparison between the experimental (NOE-based) and expected distances (from 
molecular mechanics) for the two key conformers of miharamycin A. 
Proton Observed NOE NOE - based MMFF94 MMFF94
Pair Intensity (D2O) experimental Minimization Minimization
r (Å, ± 15%) (R confA) (S confC)
H-1' - H-8 weak 3.4 3.8 3.8
H-1' - H-2' weak 3.1 3.1 3.1
H-1' - H-5' strong 2.4 2.4 2.4
H-1' - H-2'' very weak 4.2 6.1 4.7
H-2' - H-8 strong 2.6 2.9 2.8
H-2' - H-4' strong 2.6 2.9 2.9
H-6' - H-5' very strong 2.4 2.5 2.4
H-6' - H-4' medium strong 2.7 3.7 3.3
 
 
Observing the Table 10 we conclude that only the rotamer SconfC could explain the NOE 
detected between the anomeric H-1’ and H-2’’ of arginine moiety. The experimental 
distance between H-6’ and H-4’ also corroborate this hypothesis. To underline that 
there is no difference between the distances estimated from the experimental NOEs
 
using the 2D T-ROESY, spectra were recorded with mixing times of 350 ms or 500 ms. 
Thus, the combination of all the experimental data permits to ensure that rotamer C, 
with S absolute configuration at C-6’, is the major conformer in solution. 
A view of this conformer is shown in Figure 27. 
 
Figure 27 – The major conformer of miharamycin A in water solution. 
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Since NMR data, namely the coupling constant JH5’,H6’, is represented by the average of 
the molecular structures over the time course of the NMR experiment, we believe that 
the experimental value of JH5’,H6’ could be explain through following expression: 
 
Jexp = 0.17 3JconfA + 0.83 3JconfC 
 
In conclusion, the conformational analysis of miharamycin A confirmed the structure 
established by Seto and co-workers13 in 1983 and allowed us to elucidate, for the first 
time, the stereochemistry at C-6’ of this natural product. NMR studies further suggested 
a folding of the arginine appendage above the sugar ring towards the 2-aminopurine 
nucleobase.  
Despite no sample of miharamycin B has been available to us for NMR studies, it is 
really expected  that miharamycins A and B share the same S configuration at C-6’ 
since both antibiotics have been isolated from the same microorganism and S 
configurated natural amino acids are dominant in members of the peptidyl nucleoside 
family of antibiotics.4,5,8 
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2.6 Synthesis of the Key Units for Further SAR Studies  
 
The broad range of antimicrobial activity displayed by miharamycins, and our interest to 
perform structure-activity relationship studies towards their pharmacophore elucidation 
prompted us to synthesize the key subunits of these natural products.  For that purpose 
the construction of each unit, such as the bicyclic sugar moiety, the elongated sugar 
amino acids, the nucleoside and the diastereomeric peptides was envisaged. The 
synthesis of both epimeric isomers at C-6 was desired in order to study the influence of 
the stereochemistry at this centre on the bioactivity. 
 
2.6.1 Bicyclic sugar unit 
 
Deprotection of the benzylidene acetal with aqueous acetic acid furnished the fully 
deprotected sugar moiety of miharamycins and the first molecule for further SAR 
studies (Scheme 54).  
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Scheme 54 - Synthesis of the bicyclic miharamycins sugar moiety 90. Reagents and conditions: 
a) AcOH (80% aq.), 50 ºC, quant.  
 
2.6.2  Sugar amino acid epimers   
 
In order to obtain the fully deprotected epimeric SAAs two different routes were 
investigated (Figure 28). A saponification-hydrogenolysis sequence starting from 
methyl azido esters 82a (6S) or 82b (6R) was firstly applied. Alternatively, sequence B 
starting from the benzyl azido esters 83a (6S) or 83b (6R) and including a unique 
hydrogenolysis step is also possible.   
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Figure 28 – Two distinct accesses to the unprotected epimeric SAAs. 
 
Starting from the 6S azido ester 82a the saponification of the methyl ester was assayed 
using different bases [LiOH.H2O in THF98 and Ba(OH)2.H2O in dioxane,6a,b] however 
with these bases only complex mixtures of products were obtained. In order to 
overcome this problem and obtain the free carboxylic acid we tried the saponification 
using NH4OH in MeOH.99 Interestingly, the major compound obtained was the amide 
derivative 124a, resulting from the nucleophilic attack of NH3 to the carbonyl group 
(Scheme 55).   
 
 
Scheme 55 – Attempt to the saponification of the methyl azido ester 82a. Formation of the 
amide 124a. Reagents and conditions: a) NH4OH (30% NH3), MeOH, 0 ºC, 70 %.  
 
When the same reaction sequence was applied to the 6R azido ester 82b, 
epimerization at C-6 was observed, the free carboxylic acid was not isolated and in 
addition a chromatographically irresoluble mixture of both epimeric amides 124a,b in  
1:5 ratio in favor of the 6S isomer was obtained (Scheme 56).  
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Scheme 56 – Attempt to the saponification of the methyl benzyl ester 82b. Formation of the 
amides 124a,b. Reagents and conditions: a) NH4OH (30% NH3), MeOH, 0º C, 10% for 124b 
and 50 % for 124a. 
 
A possible explanation for the epimerization issue of the 6R azido ester 82b can be 
related with the abstraction of the acidic proton, α to the carbonyl, and concomitant 
formation of the intermediate 125, which is then transformed into the thermodynamic 
more stable epimer, as illustrated in Scheme 57.  
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Scheme 57 – Proposed mechanism for epimerization at C-6. 
  
 
Results and Discussion 
Total Synthesis and Stereochemical Assignment of Miharamycins 81
We tried, as well, first the hydrogenolysis of the azido esters 82b followed by 
saponification of the methyl ester using NH4OH in MeOH (Scheme 58).99 However, in 
this particular case a mixture containing the desired SAA 126b and the corresponding 
amide 126’b that results from the nucleophilic attack of the NH3 was identified. No 
epimerization at C-6 was detected indicating that the presence of the azide seems to 
be related to the epimerization issue at this centre by enhancing the acidity of the H-6 
proton.      
 
Scheme 58 – Attempt to the synthesis of the 6R SAA 126b. Reagents and conditions: a) H2 (30 
psi), 10% Pd/C, glacial AcOH, quant. b) NH4OH (30% NH3), MeOH, 0º C, (126b/126’b ≈ 2:3), 
92% over two steps. 
To circumvent all these problems and in order to accomplish the synthesis of both 
epimeric sugar amino acids 126a,b containing either the free amine and the carboxylic 
acid we carried sequence B. Starting from the corresponding benzyl azido ester 83a,b 
hydrogenolysis conditions using 10% Pd/C under acidic conditions uneventfully yielded 
both SAAs 126a,b (Scheme 59).100  
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Scheme 59 – Synthesis of epimeric sugar amino acids 126a and 126b. Reagents and 
conditions: a) H2 (30 psi), 10% Pd/C, EtOAc/MeOH/HCl 1M, quant. for 126a and 126b. 
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2.6.3  Nucleoside unit 
 
In order to obtain the bicyclic nucleoside 123 (Figure 29), an important target for further 
SAR studies, N-glycosylation of glycosyl donor 95 with the persilylated N2-acetyl-
protected 2-amino-6-chloropurine was investigated. 
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Figure 29 – Bicyclic nucleoside for further SAR studies. 
 
Thus, base coupling reaction was performed using standard conditions, TMSOTf as 
Lewis acid at high temperature (Scheme 60, Table 11). 
 
 
Scheme 60 – N-Glycosylation of the glycosyl donor 95. Reagents and conditions: a) TMSOTf, 
solvent and temperature (see Table 11). 
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N-Glycosylation gave both regioisomeric N9 and N7 nucleosides, exclusively as β-
anomers. The best yield and N9/N7 ratio was obtained using toluene as solvent (Table 
11). 
 
Table 11 – TMSOTf-mediated N-glycosylation of persilylated N2-acetyl-6-chloropurine 61 with 
glycosyl donor 95. 
Entry[a] Solvent T (ºC) Reaction time (h) N9:N7 ratio[b] Combined yield (%)
1 CH3CN 65 3 0:1 58
2 (CH2Cl)2 85 4 2:3 62
3 Toluene 85 4 2:1 64
 
[a]
 All reactions were carried out on a 0.05 mmol scale of sugar substrate and yielded exclusively β-
anomers. [b] The regioselectivity of the N-glycosylation was determined by HMBC. 
 
In parallel we also attempted the synthesis of N7 and N9 nucleosides starting from the 
peracetylated derivative 96 but disappointing results were obtained with both purine 
bases (Scheme 61). Using the bis(silylated) N2-acetyl-protected 2-amino-6-
chloropurine 61 the unreacted starting material was recovered accompanied by a 
complex anomeric mixture of α and β of N9 and N7 isomers. The use of the 
bis(silylated) N2-acetyl-protected 2-aminopurine also led to the absence of nucleoside 
formation and only degradation of starting material.  
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Scheme 61 – Attempts to synthesize N7 and N9 nucleosides starting from the peracetylated 
derivative 94. Reagents and conditions: a) TMSOTf, (CH2Cl)2, 85 ºC, b) SnCl4, CH3CN/(CH2Cl)2, 
85 ºC.  
 
Dechlorination of the nucleosides 127 and 128 proceeded smoothly to yield the 
expected 2-aminopurine derivatives 122 and 129, respectively (Scheme 62). It is 
interesting to notice that chlorine in the N7 regioisomer was much more reluctant to 
hydrogenolysis than in its N9 regioisomer (2 days required for the N7 isomer vs 4 hours 
in the case of the N9 isomer). 
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Scheme  62 – Dechlorination step of nucleosides 127 and 128. Reagents and conditions: a) H2 
(30 psi), 10% Pd/C, Et3N, EtOAc, 69% for 122 and 66% for 129.   
 
Hydrogenolysis of the N9 nucleoside 122 in glacial AcOH under pressure (400 psi) over 
8h afforded the corresponding debenzylated nucleoside 130 (Scheme 63). However, all 
attempts to remove the benzyl groups of the N7 nucleoside 129 failed resulting either in 
recovery (48 h) or decomposition of starting material, when the reaction conditions 
were forced (longer reaction times or using catalytic hydrogen transfer). Subsequently, 
NH4OH (30% NH3) treatment at 60 ºC of the debenzylated nucleoside 130 was 
accomplished and provided the desired unprotected N9 nucleoside 123. 
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Scheme 63 – Synthesis of the miharamycins nucleoside precursor 123 and attempt to the 
debenzylation of the N7-regioisomer 129. Reagent and conditions: a) H2 (400 psi), 10% Pd/C, 
glacial AcOH b) NH4OH (30% NH3)/MeOH 1:1, 60ºC, 86% over two steps. 
 
Comparison of selected NMR data of this nucleoside and miharamycins A and B 
showed a high level of similarity between our synthetic nucleoside 123 and the target 
natural products (Table 12). 
 
Table 12 – Comparison of selected 1H and 13C NMR chemical shifts of the synthetic nucleoside 
123, miharamycins A (3) and B (4). 
Nucleoside H-1' H-8 H-6 C-8 C-6 C-2 C-4 C-5
N9 regioisomer 123 6.05 8.29 8.64 142.3 149.5 159.9 152.4 126.9
miharamycin A (3) 5.97 8.25 8.46 142.2 150.0 159.9 153.0 126.4
miharamycin B (4) 6.01 8.28 8.62 142.5 150.5 160.5 153.1 127.1
1H  and  13C  NMR  Data  (δ / ppm)
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2.6.4  Peptide epimers 
 
The search for bioactive antibiotic subunits has encouraged us to also devise the 
synthesis of both miharamycins L-arginine SAAs (Figure 30). 
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Figure 30 – Miharamycins L-arginine SAAs. 
 
Reduction of the azido group presented on the SAA derivatives 82a,b was performed 
under hydrogenolysis conditions (Scheme 64).  
 
 
 
Scheme 64 – Reduction step, synthesis of amino esters 131a,b. Reagents and conditions: a) 
H2, Pd Lindlar, EtOAc, 95% for 131a and 88% for 131b.  
 
It should be noticed that hydrogenolysis of the nucleobase-free bicyclic sugars 82a,b 
with Pd Lindlar catalyst to yield the corresponding amines 131a,b occurred easily, 
when compared to that of the azido nucleosides 116 and 117. Peptidyl coupling 
conditions using chloroformate coupling reagent gave the desired peptides 119a,b in 
satisfying yields (Scheme 65).  
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Scheme 65 – Peptide coupling reaction of amines 131a,b. Reagents and conditions: a) isobutyl 
chloroformate, Et3N, THF, -20 ºC, 92% for 119a and 89% for 119b. 
 
In order to obtain the fully deprotected epimeric peptides a saponification-
hydrogenolysis sequence was explored (Scheme 66). Disappointingly several 
conditions for the saponification of the methyl ester on L-arginine derivatives 119a,b 
were assayed, but none of these attempts gave the free carboxylic acid. Partial 
deprotection of L-arginine was observed followed by product decomposition. In 
alternative, hydrogenolysis followed by saponification was also tried without any 
success. Due to these problems only the debenzylated methyl peptides 121a,b were 
isolated. A possible solution to achieve the fully deprotected peptides could be the 
replacement of the methyl ester by a benzyl ester to further carry out a unique 
hydrogenolysis step as observed for the SAAs 126a,b (Scheme 59), or perform an 
enzymatic hydrolysis, screening different lipases.   
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Scheme 66 – Hydrogenation and saponification attempts of L-arginine SAAs. Reagents and 
conditions: a) H2, 10% Pd/C, glacial AcOH, quant. b) NH4OH, MeOH, 0 ºC or Ba(OH)2.H2O, 
dioxane, 0 ºC or LiOH.H2O, THF, 0 ºC; c) NH4OH, MeOH, 0 ºC   
 
Despite the presence of the methyl ester, the molecules 121a,b were considered still 
attractive for further SAR studies. 
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2.7  Screening for Bioactive Compounds and Further 
Synthetic Studies 
 
Along the synthesis of miharamycins, several bicyclic related compounds were 
constructed for SAR purposes towards the pharmacophore elucidation of these natural 
nucleoside antibiotics. The activity of the synthetic compounds over fungi and bacteria 
was first screened in order to find out a lead structurally less complex and easier to 
prepare than miharamycins. 
 
2.7.1 Antimicrobial activity  
 
The four deprotected miharamycins subunits and the corresponding epimers given in 
Figure 31, as well as twentyi protected precursors including related bicyclic 
compounds, obtained along the synthesis, were screened for their antimicrobial 
activity, using the paper disk diffusion method.101 The microbes tested were Pyricularia 
oryzae among other fungi, namely Aspergillus niger, Candida Albicans, Alternataria 
alternate, Botrytis spp., Colltotrichum coffeanum, Rhizopus spp. and the bacteria 
Bacillus cereus, Bacillus subtilis, Enterococcus faecalis, Escherichia coli, Listeria 
monocytogenes, Pseudomonas aeruginosa, Salmonella enteritidis and Staphylococcus 
aureus. 
Unfortunately, none of the twenty six compounds tested showed a relevant 
antimicrobial activity, which suggests that miharamycins subunits such as the bicyclic 
sugar moiety, the nucleobase or the amino acid part, as individual components, are not 
responsible for the antimicrobial properties. Hence, the presence of all structural units 
in the molecule seems to be important for the antimicrobial activity. Regrettably, the 
absence of positive results with each subunit prevented the elucidation of 
miharamycins mechanism of action as antifungal and antibacterial agents.   
                                                
i
 The miharamycins related compounds screened for antimicrobial activies were: 14, 76, 77, 79a,b, 81a,b; 
83a,b, 91, 92, 100, 120a,b, 127, 128, 119a,b, 132, 133.   
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Figure 31 – Key deprotected miharamycins subunits synthesized. 
 
2.7.2 Anticholinesterase activity  
 
Since no promising results were obtained with respect to the antimicrobial activity, the 
new synthetic compounds, including miharamycins bicyclic analogues and precursors, 
were tested as cholinesterase inhibitors, in the search for potential insecticidal 
compounds. However, the enzymes available to us were bovine acetylcholinesterase 
and human butyrylcholinesterase, which are important for the control of 
neurodegenerative diseases. Thus, evaluation of the mammalian anticholinesterase 
activity could provide a new biological perspective for the application of these 
compounds.   
 
2.7.2.1 Cholinesterases and Alzheimer’s disease 
 
There are two major forms of cholinesterases, acetylcholinesterase (AChE, EC  
3.1.1.7)  and  butyrylcholinesterase (BChE, EC 3.1.1.8) in mammalian tissues. Both 
AChE and BChE belong to the enzymes group of serine hydrolases and they are 
responsible for the breakdown of the neurotransmitter acetylcholine (ACh) and of 
butyrylcholine (BCh), respectively.102  
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In Alzheimer’s disease (AD) the loss of cholinergic neurotransmission in the brain is 
accompanied by reduced concentration of ACh and contributes to the salient cognitive 
and behavioral disturbances characteristic of AD.103  
AD is the most common type of dementia in western societies, which has been causing 
profound economic and social impact as the ageing population increases.104 The 
cholinergic hypothesis105 represents one of the most useful approaches involved in the 
design of new agents for the treatment of AD. This strategy is based on the 
development of drugs with an AChE inhibition profile in order to rectify the deficit of 
cerebral ACh. However, in advanced AD, AChE levels in the brain have already 
decreased, while BChE activity is elevated suggesting that ACh hydrolysis may occur 
to a greater extent via BChE catalysis.106 In this regard, it has been reported that the 
specific inhibition of BChE is important in raising acetylcholine levels and improving 
cognition.107  
Cholinesterase inhibitors such as tacrine,108 rivastigmine,109 donepezil110 and 
galanthamine111 (Figure 32), currently  in  use  to  treat  AD,  inhibit  both  AChE  and 
BChE,112 and with these drugs it is difficult to determine whether  the  positive  effects  
observed  are  a  result  of inhibition of AChE, BChE or both enzymes. For this reason,  
it  is  important  to  test  selective,  potent  and well-tolerated inhibitors of each 
individual cholinesterase  in  order  to  determine  which  enzyme  needs  to  be 
targeted for maximum effect in treating AD.113 
 
 
Figure 32 – Structures of cholinesterase inhibitors approved to AD therapeutics. 
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2.7.2.2 AChE and BChE inhibition of miharamycins analogues and 
precursors 
 
Each synthetic compound was evaluated for its ability to inhibit BChE human serum 
and AChE bovine erythrocytes (BoAChE) using Ellman’s spectrophotometric 
method.114 None of the compounds tested showed a significant inhibition of BoAChE.  
It should be noted that BoAChE and human AChE (HuAChE) display identical structure 
characteristics. Itay Mendelson and co-workers have mapped onto the three-
dimensional model of HuAChE, where all divergent amino acids between BoAChE and 
HuAChE were shown (Figure 33).115 In the figure the enzyme is presented in two 
orientations: with the gorge entrance (marked by an arrow) parallel to the plane of the 
picture (left panel) and a rotate view (right panel, rotate 120º around the y-axis).   
All 34 divergent amino acids are only located on the molecule surface and these 
structural differences could only lead to functional manifestations related to the non-
cholinergic activities. For this reason identical kinetic behavior of BoAChE and HuAChE 
with respect to hydrolysis and to interactions with different inhibitors is really expected.   
 
 
Figure 33 – Mapping of divergent amino acids between BoAChE and HuAChE onto the three-
dimensional model of HuAChE. The protein backbone is depicted as a line ribbon and the C-α 
atoms of the divergent residue are shown as full circles.115  
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Noteworthy, inhibition of BChE was detected and for some compounds the nanomolar 
concentration range was achieved.  
The first series of evaluated compounds included only substrates containing the 
bicyclic sugar unit (Table 13) and it can be observed that the presence of benzyl 
groups enhances BChE inhibition. 
 
Table 13  – Inhibition (%) of BChE for different substrate concentrations and IC50 values. 
Substrate Concentration (µg/mL) BChE inhibition (%) BChE IC50 ± SEM (µM)[a]
100.00 60***
10.00 <5
100.00 100***
10.00 100***
Rivastigmine[b] 1.00 100*** 0.17 ±  0.01
0.10 76***
0.01 NI
100.00 <5 ….
100.00 <5 …
100.00 7 …
148.00 ±  43.00
 
[a] IC50 is an estimate of the compound concentration which inhibits 50% of the enzyme activity; values are 
expressed as mean ± standard error of the mean (SEM). [b]Rivastigmine is a standard drug to treat AD 
patients and was used as positive control. *** P<0.001, **P<0.01, *P<0.05. 
 
The second series of assayed compounds comprised the SAA derivatives and their 
precursors (Table 14). The results obtained showed that the azido group improves the 
inhibition of the BChE and apparently, the stereochemistry at C-6 is not particularly 
relevant for the inhibitory profile of all the compounds reported in table 14.  
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Table 14  - Inhibition (%) of BChE for different substrate concentrations and IC50 values. 
Substrate Concentration (µg/mL) BChE inhibition (%) BChE IC50 ± SEM (µM)[a]
100.00 60***
10.00 54*** 31.00 ± 2.90
1.00 4
50.00  ± 4.60
100.00 95***
10.00 56*** 16.10 ± 0.90
1.00 7
133.00 ± 27.00
4.20 ± 0.40
100.00 98***
10.00 73*** 13.40 ± 0.80
1.00 14**
…
…
100.00 37***
10.00 19** …
1.00 <5
100.00 78***
10.00 18** 94.00 ± 12.00
1.00 <5
100.00 100***
10.00 100***
Rivastigmine[b] 1.00 100*** 0.17 ±  0.01
0.10 76***
0.01 NI
100.00                                                
10.00
18                                                      
5
100.00                                         
10.00
55***                                               
8
100.00                                          
10.00                                           
1.00                                           
0.10
91***                                                  
64***                                                 
36***                                                 
15*
100.00                                                 
10.00
18                                                  
5
100.00                                             
10.00
73***                                             
23
79b
O
BnO
OMeO
(R)
BnO
BnO
HO
 
[a] IC50 is an estimate of the compound concentration which inhibits 50% of the enzyme activity; values are 
expressed as mean ± standard error of the mean (SEM). [b]Rivastigmine is a standard drug to treat AD 
patients and was used as positive control. *** P<0.001, **P<0.01, *P<0.05. 
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Miharamycins nucleosides and peptide analogues were the next group of compounds 
assayed (Table 15). Regarding the BChE inhibitory profile of the nucleosides 127 and 
128, only the N7 regioisomer proved to be a good inhibitory agent. On the other hand, 
concerning to the experimental biological activities of both peptides, it should be 
noticed that the 6R isomer offered a better IC50 value when compared to its epimer at 
C-6. 
 
Table 15 – Inhibition (%) of BChE for different substrate concentrations and IC50 values. 
Substrate Concentration (µg/mL) BChE inhibition (%) BChE IC50 ± SEM (µM)[a]
100.00 48*** …
0.76 ± 0.05
115.00 ± 27.00
100.00 97***
10.00 72*** 7.80 ± 0.50
1.00 <5
100.00 100***
10.00 100***
Rivastigmine[b] 1.00 100*** 0.17 ±  0.01
0.10 76***
0.01 NI
100.00                                           
10.00                                              
1.00                                                
0.10
84***                                                        
85***                                                        
70***                                          
20***
100.00                                                
10.00
52***                                           
<5
127
O
BnO
O
BnO
BnO
OAc
N
NN
N
Cl
NHAc
 
[a] IC50 is an estimate of the compound concentration which inhibits 50% of the enzyme activity; values are 
expressed as mean ± standard error of the mean (SEM). [b]Rivastigmine is a standard drug to treat AD 
patients and was used as positive control. *** P<0.001, **P<0.01, *P<0.05. 
 
The N7 regioisomer 128 was the most promising compound and for that purpose, regio- 
and stereoselective coupling conditions were devised in order to obtain only N7 
nucleosides.  
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2.7.2.3 Regio- and stereoselective synthesis of N7 nucleosides and 
cholinesterase inhibition 
 
Synthetic procedures previously discussed in chapter 2.2.2.2 were considered aiming 
at the regio- and stereoselective synthesis of the N7 nucleosides 132 and 133 (Figure 
34).  
 
 
Figure 34 – Epimeric N7 nucleosides for further evaluation of ChE inhibition. 
 
Firstly, acetolysis was performed to cleanly obtain both epimeric glycosyl donors 134a 
and 134b (Scheme 67).   
 
 
Scheme 67 - Synthesis of 6S and 6R glycosyl donors 134a,b. Reagents and conditions: a) 5% 
conc. H2SO4  in AcOH, Ac2O, -20 ºC  0 ºC, 36% b) conc. H2SO4, Ac2O, 0 ºC, 63%. 
 
As described in introduction (chapter 1.4.3) the synthesis of N7 nucleosides under 
kinetic control (SnCl4 as Lewis acid, CH3CN as polar solvent and at low temperature) 
was previously reported by Garner47 in 1992. Thus, these experimental conditions were 
initially applied, but unfortunately unsatisfactory yields were obtained (Table 16, entries 
1 and 2). Therefore, in order to improve the yield different conditions were employed 
and it was found that using TMSOTf as promoter at 65 ºC exclusively β-N7-nucleosides 
were obtained in reasonable yield (Scheme 68, Table 16 entries 3 and 4).  
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Scheme 68 – N-Glycosylation of epimeric glycosyl donors 134a,b. Reagents and conditions: a) 
TMSOTf, CH3CN, 60 ºC, 65% for 132 and 58% for 133. 
 
Table 16 - N-Glycosylation of persilylated N2-acetyl-6-chloropurine 61 with epimeric glycosyl 
donors 134a,b. 
Entry[a] Sugar substrate Lewis acid Solvent T (ºC) Reaction time (h) N9:N7 ratio[b] Combined yield (%)
1 (6S ) 134 a SnCl4 CH3CN 0 1 0:1 32
2 (6R ) 134 b SnCl4 CH3CN 0 1 0:1 28
3 (6S ) 134 a TMSOTf CH3CN 65 1.5 0:1 65
4 (6R ) 136 b TMSOTf CH3CN 65 1.5 0:1 58
 
[a]
 All reactions were carried out on a 0.05 mmol scale of sugar substrate and yielded exclusively β-
anomers. [b] The regioselectivity of the N-glycosylation was determined by HMBC. 
 
With the (6R) and the (6S)-configurated nucleosides 132 and 133 in hand, the 
anticholinesterase activity was evaluated. As for the other miharamycins bicyclic 
related compounds, the nucleosides 132 and 133 did not inhibit AChE. Remarkably, 
BChE inhibition was observed in both cases (Table 17), and especially compound 133 
with R configuration at C-6’ showed an IC50 of the same order of magnitude as that of 
the control, rivastigmine.  
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Table 17  – Inhibition (%) of BChE for different substrate concentrations and IC50 values. 
Substrate Concentration (µg/mL) BChE inhibition (%) BChE IC50 ± SEM (µM)[a]
100.00 81***
10.00 34*** 22.00 ± 1.60
1.00 9
100.00 91***
10.00 79***
1.00 77*** 0.14 ± 0.01
0.10 63***
0.01 10
100.00 100***
10.00 100***
Rivastigmine[b] 1.00 100*** 0.17 ±  0.01
0.10 76***
0.01 NI
 
[a] IC50 is an estimate of the compound concentration which inhibits 50% of the enzyme activity; values are 
expressed as mean ± standard error of the mean (SEM). [b]Rivastigmine is a standard drug to treat AD 
patients and was used as positive control. *** P<0.001, **P<0.01, *P<0.05.   
 
2.7.2.4 Reading the bioactivity… 
 
The experimental results showed a BChE selective inhibition by the miharamycins 
bicyclic related compounds that could be related to the fact that the volume of the 
BChE active-gorge is ca. 200 Å3 larger than that of the AChE gorge. In AChE, the 
estimated volume is relatively small (302 Å3), being lined with 14 bulky aromatic amino 
acid residues, while that of BChE, with only 8 aryl residues, is considerably larger in 
volume (502 Å3) (Figure 35).116 For that reason, it is expected that the molecular 
volumes of the presented active compounds are bigger when compared to the volume 
of the AChE active site gorge. In contrast, the active-site gorge of BChE is large 
enough to accommodate these miharamycins related compounds. This hypothesis 
should be confirmed by computational calculations of the molecular volumes of each 
active compound.   
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Figure 35 – Active-site gorges of cholinesterases. The figure was generated using Pymol 
program and crystal structures available in the protein database.107a,117 
 
The bioactivity showed by the benzyl protected derivatives also indicates that the active 
site of BChE seems to be highly lipophilic, a result also reported by other authors.118 
Additionally, in BChE, pi-pi interaction has been reported to take place between the 
heterocyclic ring system of known inhibitors and the aromatic amino acid residues 
F329 and Y332.119 Thus, pi-pi interaction could explain the better inhibition found for the 
compounds containing the heterocyclic purine base. Finally, it should be noted that the 
pattern of activity of a N7 and a N9 regioisomer revealed undoubtedly divergent. 
Apparently, the structural differences between these two regioisomers play an 
important role in BChE profile inhibition and future docking studies may give an 
important contribution to clarify these results.  
 
2.7.3 Cytotoxicity and genotoxicity 
 
Considering the inhibition activity of some of the miharamycins bicyclic related 
compounds towards butyrylcholinesterase it becomes interesting to explore further 
their application in the treatment or palliation of Alzheimer’s disease symptoms. The 
first concern in this matter would be the potential toxicity of such compounds, and 
therefore a preliminary screening of direct toxicity and genotoxicity was performed. 
Cytotoxicity, or direct toxicity, was assessed by the quantification of viable and 
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metabolically active continuous culture human cells following a 24 h exposure to the 
drug by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] cell 
proliferation assay. Delayed toxicity or genotoxicity was evaluated by the frequency of 
chromosomal aberrations in human peripheral blood lymphocytes from healthy donors. 
Mitotic index was also scored as an indirect measure of direct toxicity of the drug. The 
miharamycins related compounds tested showed a low toxicity, not significantly 
different from the standard drugs currently used in Alzheimer’s disease. 
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Conclusion 
 
Total synthesis of miharamycin B was undertaken and has led to the first synthesis of 
the core of miharamycins. The ambitious and challenging goals consisting of 
construction of a unique bicyclic sugar amino acid, regio- and stereoselective 
introduction of an unusual 2-aminopurine nucleobase at the anomeric position and 
peptide coupling were successfully achieved in this work. In addition, this work has 
revealed and solved unexpected synthetic problems (ring contraction, N-glycosylation) 
arising from the unique structure of miharamycins. Conversion of the bicyclic moiety 
into a glycosyl donor and its subsequent N-glycosylation with 2-aminopurine proved to 
be difficult and required finely tuned conditions to obtain the desired β-N9-nucleoside. 
Final peptide coupling with arginine allowed the synthesis of the unprecedented core of 
miharamycin B. Unfortunately, attempts to deprotect this scaffold failed to afford the 
complex nucleoside antibiotic. 
Moreover, we have established the absolute configuration at C-6’ of the miharamycins, 
which was performed by NMR techniques assisted by molecular mechanics 
calculations. The assignment of the 1H and 13C NMR resonance signals collected for 
miharamycin A supported the structure proposed by Seto in 1983. Three key features 
allowed the unambiguously deduction of an S configuration for C-6’: a small JH5’,H6’ 
value (1.8 Hz, gauche-type major orientation), a large JH5’,C7’ value ( >8 Hz, anti-type 
major orientation with C-7’, which is the carboxylic carbon atom), and the existence of a 
H-1’/H-2’’ NOE (associated distance ca. 4Å). These three observations can only be 
accommodated by the S configuration of the C-6’ stereogenic centre, along with the 
existence of a major conformer in which the lateral chain of arginine is folded towards 
the aminopurine moiety.  
The results presented herein, combining the spectroscopic studies and the synthetic 
efforts for miharamycins core synthesis could be helpful for the construction of related 
complex nucleoside natural products such as amipurimycin, a synthetic target under 
investigation39,65,120  but still to be reached by total synthesis.  
Synthesis of the key subunits of miharamycins was also accomplished towards the 
pharmacophore elucidation of these natural products for the generation of active 
molecules structurally less complex and of easier preparation than miharamycins.
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Disappointingly, none of these key moieties showed a relevant antimicrobial activity, 
which seems to indicate that the presence of all structural units in the molecule is 
crucial to provide the antimicrobial properties characteristic of miharamycins.  
Noteworthy, for some of the miharamycins bicyclic related compounds a strong and 
selective antibutyrylcholinesterase activity was detected, when compared to the control 
(rivastigmine). The experimental results showed that the presence of the benzyl groups 
and the purine nucleobase connected through N7 position increase the compounds 
ability to inhibit the BChE. Toxicity studies were also performed and the low values for 
cytotoxicity and genotoxicity encourage the investigation of these compounds for the 
control of pathologies like Alzheimer’s disease. 
 
 Total Synthesis and Stereochemical Assignment of Miharamycins 105
Experimental Part 
 
4.1  General Methods 
 
Solvents and reagents were purchased from Fluka, Merck, Aldrich or Acros Organics. 
Solvents were freshly distilled under argon from Na/benzophenone (THF, Et2O) or P2O5 
(CH2Cl2, (CH2Cl)2) or only Na (toluene). Other solvents were dried over a bed of 
activated molecular sieves (MS) 4 Å (DMF, EtOH) or KOH (pyridine). Solvents for 
column chromatography (cyclohexane, EtOAc, CH2Cl2, toluene) were distilled before 
use. Anhydrous DMSO was purchased from Aldrich. HMPA purchased from Aldrich 
was distilled before use but all the other reagents, commercially obtained, were used 
as received. 
All transfers (reagents in solution or solvents) were carried out with oven dried needle 
or cannula.   
Solutions were concentrated below 45 ºC in vacuo on Büchi rotary evaporators. 
Reactions were monitored by thin-layer chromatography (TLC) on a precoated plate of 
Silica Gel 60 F254 (layer thickness 0.2 mm; E. Merck, Darmstadt, Germany) and 
detection by UV light (254 nm) and by charring with H2SO4 10% in EtOH or with 0.2% 
w/v cerium sulphate and 5% ammonium molybdate in 2M H2SO4 (Hanessian stain). 
Flash column chromatography was performed on silica gel 60 (230-400 mesh, E. 
Merck). 
Melting points (m.p.) were determined with a Büchi B-510 capillary apparatus and are 
uncorrected.  
Optical rotations ([α]D) were measured at 20±2 °C with a Perkin Elmer Mode l 241 
digital polarimeter, using a 10 cm, 1 mL cell, either at Faculdade de Ciências da 
Universidade de Lisboa (FCUL) and Université Pierre et Marie Curie, 75252 Paris 
cedex 05, France (UPMC-Paris VI).  
Mass spectra (MS) and high resolution mass spectra (HRMS) using chemical ionization 
(CI, ammonia) or fast atom bombardment (FAB) were obtained with a JMS-700 
spectrometer at École Normale Supérieure de Paris (ENS-Paris) or using positive 
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electrospray ionization (ESI) recorded on an Apex Ultra FTICR mass spectrometer 
equipped with an Apollo II Dual ESI/MALDI ion source, from Brüker Daltonics, and 7T 
actively shielded magnet from Magnex Scientific at FCUL.  
Elemental analyses were performed by the service d’analyse of UPMC-Paris VI.  
NMR spectres were recorded on Brüker spectrometers: 1H NMR spectra were recorded 
at 400 MHz with a DRX 400 at ENS-Paris, or with an Avance 400 (fitted with a BBFO 
probe) at UPMC-Paris VI or with an Avance 400 (fitted with a QNP probe) at FCUL for 
solns in CDCl3, d6- DMSO or D2O at room temperature. Assignments were confirmed 
by COSY experiments. 13C NMR spectra were recorded at 100 MHz with a DRX 400 
spectrometer at ENS-Paris, or with an Avance 400 (fitted with a BBFO probe) at 
UPMC-Paris VI or with an Avance 400 (fitted with a QNP probe) at FCUL. Assignments 
were confirmed by J-mod technique, HMQC and HMBC. Chemical shifts (δ) are given 
in ppm relative to tetramethylsilane (TMS) or to the residual solvent signal. Coupling 
constants (J) are reported in Hertz (Hz).  
Data for 1H NMR spectra are reported as follows: chemical shift (δ ppm), [multiplicity, 
integration, coupling constant (Hz)]. Multiplicities are indicated as follows: s (singlet), d 
(doublet), t (triplet), dd (doublet of doublets), br s (broad singlet), etc. 
Crystallographic analyses were performed at the Institute Lavoisier-IREM at Université 
Versailles Saint Quentin.  
 
4.2  NMR Studies 
 
NMR experiments, carried out during the stereochemical assignment of miharamycin 
A, were accomplished on Brücker Avance spectrometers operating at 500 MHz and 
700 MHz. NMR experiments were performed in D2O and in a mixture of H2O/D2O 
(90:10) to detect the NH resonance.  
Molecular mechanics calculations were achieved using the MMFF9497 force field (ε= 
1.0), as integrated in the MAESTRO package. 
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4.3  Antimicrobial Activity Assays 
 
The antimicrobial activity of several synthetic compounds (structural units and 
precursors of miharamycins) was evaluated using the paper disk diffusion method.101 
The microorganisms used in the tests belong to the American Type Culture Collection 
(ATCC) and Centraalbureau voor Schimmel cultures (CBS) collections, from United 
States and Netherlands, respectively. Concerning to fungi, the yeast Candida albicans 
(ATCC 10231) and the following filamentous fungi were used: Aspergillus niger (ATCC 
16404), Alternaria alternata (CBS 108.41), Botrytis spp., Colletotrichum coffeanum 
(CBS 396.67), Pyricularia oryzae (CBS 433.70) and Rhizopus spp.. Regarding 
bacteria, tests were carried out with Bacillus cereus (ATCC 11778), Bacillus subtilis 
(ATCC 6633), Enterococcus faecalis (ATCC 29212), Escherichia coli (ATCC 25922), 
Listeria monocytogenes (ATCC 7644), Pseudomonas aeruginosa (ATCC 27853), 
Salmonella enteritidis (ATCC 13076) and Staphylococcus aureus (ATCC 25923). The 
culture medium and incubation temperature used for fungal growth was potato 
dextrose agar and 25ºC, whereas for bacteria, nutrient agar incubated at 37ºC was 
used.  
Paper disks of 6.4 mm were placed on the agar and the solution of each substance 
(300 µg) in DMSO (15 µL) was applied on each disk. Chloramphenicol and actidione 
were used as antimicrobial controls for bacteria and fungi, respectively. After 
incubation, the nearest diameter of the inhibition zone was measured. At least three 
replicates were made. 
 
4.4  Anticholinesterase Activity Assays 
 
The Ellman’s assay114 was used to screen the anticholinesterase activities in vitro of 
some structural units and precursors of miharamycins. The activity of the enzymes 
produces a yellow compound that is detected with a spectrophotometer (λ=410 nm) 
along the reaction time. The enzyme activity (%) and the enzyme inhibition (%) were 
calculated from the rate of absorbance change with time (V = ∆Abs/ ∆t) data as 
follows:  
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Enzyme Inhibition (%) = 100 – Enzyme Activity (%) 
Enzyme Activity (%) = 100 × V/Vmax 
 
Maximum rates (Vmax) are obtained when no inhibitor is used while V is the rate 
obtained in the presence of the inhibitor.  
 
4.4.1  Spectrophotometer and chemicals 
 
A double beam spectrophotometer Shimadzu equipped with thermostatic cell holders 
was used on visible range and operated on the kinetic mode. The absorbance data 
were acquired in a computer by means of UV Probe software. Appropriate disposable 
plastic cuvettes Plastibrand were used in the kinetic experiments. 
The following materials were purchased from Aldrich: enzymes acetylcholinesterase 
(AChE) from bovine erythrocytes and butyrylcholinesterase (BChE) from human serum, 
substrates acetylthiocholine iodide (ATchI) and S-butyrylthiocholine iodide (BTchI) and 
5,5’-dithiobis-2-nitrobenzoic acid (DTNB). Other Aldrich reagents used for the 
preparation of buffers and solutions were KH2PO4, KOH and NaHCO3. Deionized water 
was used to prepare the buffer pH 8.0, the substrate and DTNB solutions.  
 
4.4.2  Solutions preparation 
 
Preparation of 0.1 M phosphate buffer pH 8.0: KH2PO4 (136.1 mg) was dissolved in 
water (10 mL) and adjusted with KOH to a pH of 8.0±0.1. Buffer was freshly prepared 
and stored in the refrigerator.  
AChE solution 1.32 U/mL: the enzyme (1.02041U, 10µL, 4.4 mg) was dissolved in 
freshly prepared buffer pH 8.0 (1.0 mL).  
BChE solution 0.44 U/mL: The enzyme (2.9762 U, 1.0 mg) was dissolved in freshly 
prepared buffer pH 8.0 (6.764 mL). 
DTNB solution 0.01 M: DTNB (3.96 mg) was dissolved in water (1 mL) containing 
sodium hydrogen carbonate (1.5 mg). 
ATchI solution 0.022 M: ATchI (6.4 mg) was dissolved in water (1 mL). 
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BTchI solution 0.022 M: BTchI (7.0 mg) was dissolved in water (1 mL). 
All solutions were stored in eppendorf caps (100 µL aliquots) in the refrigerator. 
The pure compounds and the control (rivastigmine) were initially dissolved in DMSO 
and diluted with distilled water until concentrations decrease to values between 4.4 
mg/mL and 0.00044 mg/mL, to yield the final concentrations for the enzymatic test 
between 100 µg/mL and 0.01 µg/mL. No inhibition was detected by residual DMSO 
(<0.5%) at the reaction cuvette. 
 
4.4.3  AChE and BChE activity assay 
 
A mixture of the buffer (200 µL), enzyme (5 µL), DTNB (5 µL) and new synthetic 
compounds (5 µL) solutions was prepared and kept for 15 min at 30 ºC in a heated 
water bath, and then the substrate reagent (5 µL) was added to start the enzymatic 
reaction. The absorbance data along reaction time was taken for 4 min under a 
controlled temperature of 30 ºC. At least four replicates were made. Several blank 
assays without the new synthetic compounds were carried out in order to determine the 
average Vmax. Also assays without the enzyme and the inhibitor compound were 
carried out to check for any non-enzymatic hydrolysis of the substrate. The final 
concentrations of chemicals in the test were as follows: [AChE] = 0.03 U/mL, 
[BChE]=0.01 U/mL, [compound]= 0.01 to 100 µg/mL, [DTNB]=0.0002273 M, 
[ATchI]=[BTchI]=0.0005 M.   
 
4.4.4  Statistical data analysis and regression 
 
The t-test (one sided) was carried out in order to evaluate if the average inhibition of 
the enzymes with compounds tested and the positive control rivastigmine (drug 
available on the market), are significantly higher than the average inhibition (0%) 
obtained in the assay without any inhibitor. The t-test gives a probability between 0.00 
and 1.00. When the probability ≤0.05 or 5%, this means that the inhibition obtained with 
the compound at a certain concentration is significant.  
The IC50 is an estimate value of the compound concentration which inhibits 50% of the 
enzyme activity. The IC50 were determined for the active compounds and reference 
substances using non-linear regression analysis (Statistica 8.0 by StatSoft, Inc., USA) 
Experimental Part 
Total Synthesis and Stereochemical Assignment of Miharamycins 110
toward a dose-response curve (enzyme inhibition vs. substance concentration) and 
fitting an appropriate mathematical model.  
 
4.5  Cytotoxicity and Genotoxicity 
 
Direct cytotoxicity measures were performed by the MTT method.121 The 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed to 
quantify metabolically viable cells in all samples. Adherent cells (A549 human lung 
fibroblasts) were seeded onto 96-well plates, allowed to attach for 24h and exposed to 
the test compound for the following 24h. Positive controls (hydrogen peroxide) and 
negative controls (pure solvent) were also included. At 48h of culture MTT was added 
to the cells at a final concentration of 0.5 mg/ml, followed by an incubation period of 3 
hours to allow the formazan crystals to form. After incubation medium was removed, 
cells were washed twice to remove traces of medium and un-metabolized MTT, and 
100 µl of DMSO were added to each well. Solubilization of formazan crystals was 
performed by agitation in a 96-well plate shaker for 20 minutes at room temperature. 
Absorbance of each well was quantified at 550nm using 620nm as reference 
wavelength on a scanning multiwell spectrophotometer (automated plate reader). 
Genotoxicity was assessed by the short-term in vitro chromosomal aberration assay.122 
Briefly, cell cultures of peripheral blood lymphocytes from healthy donors were set up, 
and lympho-proliferation was induced with phytohemaglutinnin (2% v/v, 24h 
incubation). Cells were exposed to the test compounds for 24h, then colcemid (to stop 
the dividing cells in the metaphase stage of mitosis) at final concentration of 0.5 µg/ml 
was added during the 3 final hours of culture. Metaphase spreads were obtained in 
standard glass microscopy slides, pre-washed and covered with a thin water film, and 
scoring was performed in a Zeiss optical microscope at 1,250x magnification, by 
observing 100 complete metaphases (presenting 46 centromeres) per case. 
Classification of chromosomal aberrations was done according to criteria described in 
Rueff’s group.122 The mitotic index was also quantified by counting the number of 
metaphases per 1000 nuclei. 
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4.6 Note on Nomenclature 
 
The IUPAC names of the complex molecules reported herein were tentatively given 
according to the IUPAC-IUBMB “Nomenclature of carbohydrates” (recommendations 
1996). For a better understanding of the proposed names we indicate below the 
molecules structure, the corresponding locants and the compound’s name for some of 
the molecules described along the experimental part (chapter 4.8).  
  
Methyl 2,2’-anhydro-4,6-O-benzylidene-3-C-(2’-hydroxyethyl-1’-methylene)-α-D-
glucopyranoside 18: 
 
 
Methyl (1’S)-2,2’-anhydro-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-hydroxyethyl)-7,8-
dideoxy-L-glycero-α-D-gluco-oct-7-enopyranoside 79a: 
 
 
Methyl [methyl (1’S)-2,2’-anhydro-6-azido-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-
hydroxyethyl)-6-deoxy-L-glycero-α-D-gluco-heptopyranosid]uronate 82a: 
82a
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Methyl [(1’S)-1-(2-acetamido-6-chloropurin-9-yl)-2,2’-anhydro-6-azido-3,4-di-O-benzyl-
3-C-(1’-benzyloxy-2’-hydroxyethyl)-1,6-di-deoxy-L-glycero-β-D-gluco-hepto 
pyran]uronate 107: 
 
 
(2S)-2-(benzyloxycarbonyl)amino-5-[1,3-di(benzyloxycarbonyl)guanidino] pentanoic 
acid 115: 
 
 
Methyl [(1’S)-1-(2-acetamidopurin-9-yl)-2,2’-anhydro-3,4-di-O-benzyl-3-C-(1’-
benzyloxy-2’-hydroxyethyl)-6-{(2S)-2-(benzyloxycarbonyl)amino-5-[1,3-di(benzyloxy 
carbonyl)guanidino]pentanoylamino}-1,6-di-deoxy-L-glycero-β-D-gluco-heptopyran] 
uronate 118:  
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4.7  Atoms Numbering for NMR Purposes   
 
The NMR numbering of all compounds synthesized along this work and described in 
chapter 4.8 was not based on IUPAC rules and followed the numbering first given by 
Seto’s group for comparative purposes. They were numbered as follows:  
O
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4.8  Synthesis 
 
Methyl 4,6-O-benzylidene-α-D-glucopyranoside (15): 
 
Benzaldehyde dimethylacetal (78.4 mL, 515 mmol) and para-
toluene sulfonic acid monohydrate (980 mg, 5.15 mmol) were 
added to a solution of methyl α-D-glucopyranoside (50 g, 258 
mmol) in anhydrous DMF (250 mL). The reaction mixture was 
heated to 60 ºC at 240 mbar in order to remove the methanol from the reaction mixture. 
After 4h, TLC showed the complete consumption of starting material. The reaction 
mixture was partitioned between CH2Cl2 (300 mL) and water (200 mL). The aqueous 
layer was extracted with CH2Cl2 (2 x 300 mL). The combined organic layers were 
washed with brine (2 x 200 mL), dried over MgSO4, filtered and concentrated under 
reduced pressure. The residue obtained was recrystallized from isopropanol to yield 
methyl 4,6-O-benzylidene-α-D-glucopyranoside 15 (48 g, 98%) as a white solid. 
Rf 0.50 (CH2Cl2-MeOH, 9:1); 
1H NMR (CDCl3, 400MHz): δ 7.52 - 7.36 (m, 5H, H arom.), 5.53 (s, 1H, H-7), 4.79 (d, 
1H, J1,2 = 3.9 Hz, H-1), 4.28 (dd, 1H, J6a,5 = 3.8 Hz, J6a,6b = 9.2 Hz, H-6a), 3.93 (t, 1H, 
J3,2 = J3,4 = 9.2 Hz, H-3), 3.80 – 3.70 (m, 1H, H-5), 3.74 (dd, 1H, J6a,b = 9.2 Hz, J6a,5 = 
10.3 Hz, H-6b), 3.62 (dd, 1H, J2,1 = 3.9 Hz, J2,3 = 9.2 Hz, H-2), 3.49 (dd, 1H, J4,5 = 9.2 
Hz, H-4), 3.46 (s, 3H, OCH3), 2.91 (br s, 1H, OH), 2.41 (br s, 1H, OH);  
MS (CI) m/z: [M+H]+ calcd for C14H19O6, 283, found: 283. 
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Methyl 4,6-O-benzylidene-2-O-propargyl-α-D-glucopyranoside (16a) and Methyl 
4,6-O-benzylidene-3-O-propargyl-α-D-glucopyranoside (16b): 
 
The methyl 4,6-O-benzylidene-α-D-glucopyranoside 15 (1.0 g, 
3.5 mmol) and tetrabutylammonium hydrogen sulphate (241 
mg, 0.71 mmol) were vigorously stirred in a mixture of CH2Cl2 
(60 mL) and 20% aqueous sodium hydroxide (5 mL). 
Propargyl bromide (0.8 mL, 7.1 mmol, 80% in toluene) was 
added and the resultant mixture heated to reflux overnight. 
After 16h, TLC indicated the formation of two major products 
together with a small amount of starting material and a small 
amount of a less polar material. The mixture was then cooled and diluted with further 
CH2Cl2 (50 mL) and water (50 mL). The organic layer was separated, washed with 
brine (50 mL), dried (MgSO4), filtered, the solvent removed and the residue purified by 
flash column chromatography (cyclohexane-EtOAc, 3:1) to yield firstly the 2-O-
propargyl compound 16a (550 mg, 48%, 61% based on recovered starting material) as 
a white solid. Further elution afforded the more polar compound the 3-O-propargyl 16b 
(261 mg, 23%, 29% based on recovered starting material) as a white solid. 
Compound 16a:  
Rf 0.60 (cyclohexane-EtOAc, 3:1);  
m.p. 107 – 109 ºC (cyclohexane/EtOAc);  
[α]D +54.0 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.55 - 7.38 (m, 5H, H arom.), 5.57 (s, 1H, H-7), 4.98 (d, 
1H, J1,2 = 4.0 Hz, H-1), 4.45 – 4.41 (m, 2H, H-8a, H-8b), 4.34 (dd, 1H, J6a,5 = 4.5 Hz, 
J6a,6b = 10.0 Hz, H-6a), 4.17 (dt, 1H, J3,OH = 2.5 Hz, J3,2 = J3,4 = 10.0 Hz, H-3), 3.88 (dt, 
1H, J5,6a = 4.5 Hz, J5,4 = J5,6b = 10.0 Hz, H-5), 3.78 (t, 1H, J6b,5 = J6b,6a = 10.0 Hz, H-6b), 
3.72 (dd, 1H, J2,1 = 4.0 Hz, J2,3 = 10.0 Hz, H-2), 3.58 (t, 1H, J4,3 = J4,5 = 10.0 Hz, H-4), 
3.40 (s, 3H, OCH3), 2.69 (d, 1H, JOH,3 = 2.5 Hz, OH), 2.54 (t, 1H, J10,8a = J10,8b = 2.5 Hz, 
H-10);  
13C NMR (CDCl3, 100MHz): δ 136.98 (C arom. quat.), 129.24, 128.31, 126.29 (5CH 
arom.), 102.00 (C-7), 98.47 (C-1), 81.47 (C-4), 79.99 (C-9), 78.85 (C-2), 75.27 (C-10), 
70.24 (C-3), 68.96 (C-6), 61.95 (C-5), 58.96 (C-8), 55.33 (OCH3);  
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MS (CI) m/z: [M+H]+ calcd for C17H21O6, 321, found: 321;  
Anal. Calcd for C17H20O6: C, 63.74; H, 6.29. Found: C, 63.71; H, 6.38.  
 
Compound 16b: 
Rf 0.50 (cyclohexane/EtOAc 3:1);  
m.p. 141 – 143 ºC (cyclohexane/EtOAc);  
[α]D +148.0 (c 0.9, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.53 - 7.40 (m, 5H, H arom.), 5.58 (s, 1H, H-7), 4.87 (d, 
1H, J1,2 = 4.0 Hz, H-1), 4.58 (dd, 1H, J8a,10 = 2.5 Hz, J8a,8b = 16.0 Hz, H-8a), 4.48 (dd, 
1H, J8b,10 = 2.5 Hz, J8b,8a = 16.0 Hz, H-8b), 4.33 (dd, 1H, J6a,5 = 4.5 Hz, J6a,6b = 10.0 Hz, 
H-6a), 3.93 (t, 1H, J3,2 = J3,4 = 10.0 Hz, H-3), 3.87 (dt, 1H, J5,6a = 4.5 Hz, J5,4 = J5,6b = 
10.0 Hz, H-5), 3.79 (t, 1H, J6b,5 = J6b,6a = 10.0 Hz, H-6b), 3.73 (ddd, 1H, J2,1 = 4.0 Hz, 
J2,OH = 7.5 Hz, J2,3 = 10.0 Hz, H-2), 3.64 (t, 1H, J4,3 = J4,5 = 10.0 Hz, H-4), 3.50 (s, 3H, 
OCH3), 2.52 (t, 1H, J10,8a = J10,8b = 2.5 Hz, H-10), 2.52 (d, 1H, JOH,2 = 7.5 Hz, OH);  
13C NMR (CDCl3, 100MHz): δ 137.14 (C arom. quat.), 129.01, 128.23, 126.01 (5CH 
arom.), 101.30 (C-7), 99.75 (C-1), 81.68 (C-4), 80.00 (C-9), 77.94 (C-3), 74.76 (C-10), 
71.82 (C-2), 68.93 (C-6), 62.35 (C-5), 59.88 (C-8), 55.42 (OCH3);  
MS (CI) m/z: [M+H]+ calcd for C17H21O6, 321, found: 321;  
Anal. Calcd for C17H20O6: C, 63.74; H, 6.29. Found: C, 63.60; H, 6.39. 
 
Methyl 4,6-O-benzylidene-2-O-propargyl-α-D-ribo-hexopyranosid-3-ulose (17): 
 
The 2-O-propargyl derivative 16a (232 mg, 0.73 mmol) and 4 
Å molecular sieves (500 mg) were stirred in CH2Cl2 (10 mL) at 
room temperature under argon during 15 min. Pyridinium 
chlorochromate (469 mg, 2.2 mmol) was then added and the 
resulting mixture stirred for 3 h. Ether (10 mL) was then added 
OOO
Ph
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and the resulting suspension filtered through a silica plug topped with celite (eluting 
with ether). The solvent was then removed to afford the ulose 17 (206 mg, 89%) as a 
white solid.  
Rf 0.70 (CH2Cl2-EtOAc 5:1);  
m.p. 164 – 166 ºC (CH2Cl2/cyclohexane);  
[α]D -21.0 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.57 - 7.38 (m, 5H, H arom.), 5.60 (s, 1H, H-7), 5.28 (d, 
1H, J1,2 = 4.5 Hz, H-1), 4.57 (dd, 1H, J2,4 = 1.0 Hz, J2,1 = 4.5 Hz, H-2), 4.56 (dd, 1H, J8a,10 
= 2.5 Hz, J8a,8b = 16.0 Hz, H-8a), 4.41 – 4.48 (m, 2H, H-6a, H-8b), 4.34 (dd, 1H, J4,2 = 
1.0 Hz, J4,5 = 10.0 Hz, H-4), 4.15 (dt, 1H, J5,6a = 4.5 Hz, J5,4 = J5,6b = 10.0 Hz, H-5), 3.98 
(t, 1H, J6b,5 = J6b,6a = 10.0 Hz, H-6b), 3.50 (s, 3H, OCH3), 2.54 (t, 1H, J10,8a = J10,8b = 2.5 
Hz, H-10);  
13C NMR (CDCl3, 100MHz): δ 195.93 (C-3), 136.24 (C arom. quat.), 129.38, 128.30, 
126.36 (5CH arom.), 102.37 (C-1), 101.98 (C-7), 82.04 (C-4), 78.62 (C-2), 78.46 (C-9), 
76.20 (C-10), 69.44 (C-6), 65.44 (C-5), 57.88 (C-8), 55.62 (OCH3);  
MS (CI) m/z: [M+H]+ calcd for C17H19O6, 319, found: 319;  
Anal. Calcd for C17H18O6: C, 64.14; H, 5.70. Found: C, 63.96; H, 5.67. 
 
Methyl 2,2’-anhydro-4,6-O-benzylidene-3-C-(2’-hydroxyethyl-1’-methylene)-α-D-
glucopyranoside (18): 
 
A suspension of samarium (II) iodide (170 mL of a 0.1M 
solution in THF, 17.28 mmol), HMPA (13.8 mL, 79.49 mmol) 
and tBuOH (2.2 mL, 22.80 mmol) were stirred at room 
temperature under argon. A solution of ulose 17 (2.2 g, 6.91 
mmol) in anhydrous THF (100 mL) was added via syringe 
and the resulting mixture stirred at room temperature for 45 min under argon. At this 
point, TLC indicated the complete consumption of starting material and the formation of 
a single compound. Diluted HCl (20 mL, 0.1M) was added and the reaction mixture 
was then filtered through a celite plug. The reaction mixture was concentrated under 
reduced pressure and the residue obtained was then diluted with CH2Cl2 (250 mL) and 
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water (75 mL). The aqueous layer was further washed with CH2Cl2 (3 x 150 mL). The 
organic layers were combined, washed with brine, dried (MgSO4), filtered and the 
solvent removed under reduced pressure. The residue obtained was purified by flash 
column chromatography (cyclohexane-EtOAc, 2:1) to yield the alkene 18 (2.1 g, 94%) 
as a white solid.  
Rf 0.40 (cyclohexane-EtOAc, 1:1);  
m.p. 125 – 127 ºC (ether / cyclohexane);  
[α]D +151.0 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.55 - 7.41 (m, 5H, H arom.), 5.87 (t, 1H, J8’a,9a = J8’a,9b = 
2.5 Hz, H-8’a), 5.58 (s, 1H, H-7), 5.10 (t, 1H, J8’b,9a = J8’b,9b = 2.5 Hz, H-8’b), 4.84 (d, 1H, 
J1,2 = 5.5 Hz, H-1), 4.72 (m, 2H, H-9a, H-9b), 4.36 (dd, 1H, J6a,5 = 5.0 Hz, J6a,6b = 10.0 
Hz, H-6a), 4.16 (d, 1H, J2,1 = 5.5 Hz, H-2), 4.08 (d, 1H, J4,5 = 10.0 Hz, H-4), 3.95 (dt, 1H, 
J5,6a = 5.0 Hz, J5,4 = J5,6b = 10.0 Hz, H-5), 3.77 (t, 1H, J6b,5 = J6b,6a = 10.0 Hz, H-6b), 3.41  
(s, 3H, OCH3), 2.60 (s, 1H, OH);  
13C NMR (CDCl3, 100MHz): δ 147.47 (C-8), 137.24 (C arom. quat.), 129.24, 128.36, 
126.21 (5CH arom.), 108.36 (C-8’), 102.57 (C-7), 100.05 (C-1), 83.68 (C-2), 82.83 (C-
4), 76.30 (C-3), 73.18 (C-9), 69.24 (C-6), 59.74 (C-5), 55.47 (OCH3);  
MS (CI) m/z: [M+H]+ calcd for C17H21O6, 321, found: 321;  
Anal. Calcd for C17H20O6: C, 63.74; H, 6.29. Found: C, 63.38; H, 6.29. 
 
Methyl (1’S)-2,2’-anhydro-4,6-O-benzylidene-3-C-(1’,2’-dihydroxyethyl)-α-D-
glucopyranoside (14): 
 
Alkene 18 (0.75 g, 2.34 mmol)ii was dissolved in CH2Cl2 (120 
mL) and cooled to – 78 ºC. Ozone was bubbled through the 
reaction mixture until the persistence of a blue coloration 
(typically 8 minutes). Dimethylsulphide (0.05 mL) was added 
and the mixture allowed warming to room temperature over a 
                                                
ii
 This reaction can not be performed on a large scale (above 1 g) since monitoring of reaction 
(detection of the blue coloration) is difficult resulting in a partial reaction or overoxidation of the 
product.  
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period of 1h. The solvent was then removed under reduced pressure and the crude 
ketone was used in the next step without further purification. Sodium borohydride (98 
mg, 2.58 mmol) was added carefully to a solution of the crude ketone in ethanol (50 
mL) at 0 ºC. The reaction mixture was allowed to reach the room temperature. After 1 h 
TLC indicated the complete consumption of starting material and the formation of a 
single compound. Methanol (50 mL) was added, the solvent removed and the residue 
obtained co-evaporated with methanol (3 x 25 mL). Purification by flash column 
chromatography (cyclohexane-EtOAc 2:1 then cyclohexane-EtOAc 1:1) afforded the 
corresponding diol 14 (0.64 g, 84%, over two steps) as a white crystalline solid.  
Rf 0.20 (cyclohexane-EtOAc 1:1);  
m. p. 167 – 169 ºC (CH2Cl2 / cyclohexane);  
[α]D +94 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.58 - 7.41 (m, 5H, H arom.), 5.55 (s, 1H, H-7), 4.92 (d, 
1H, J1,2 = 5.5 Hz, H-1), 4.42 (dd, 1H, J9a,8 = 4.5 Hz, J9a,9b = 9.5 Hz, H-9a), 4.40 (d, 1H, 
JOH,8 = 11.5 Hz, OH), 4.35 (dd, 1H, J6a,5 = 5.0 Hz, J6a,6b = 10.0 Hz, H-6a), 4.25 (dt, 1H, 
J5,6a = 5.0 Hz, J5,4 = J5,6b = 10.0 Hz, H-5), 4.21 (dd, 1H, J8,9a = 4.5 Hz, J8,OH = 11.5 Hz, H-
8), 4.10 (d, 1H, J2,1 = 5.5 Hz, H-2), 3.99 (d, 1H, J9b,9a = 9.5 Hz, H-9b), 3.92 (d, 1H, J4,5 = 
10.0 Hz, H-4), 3.68 (t, 1H, J6b,5 = J6b,6a = 10.0 Hz, H-6b), 3.58  (s, 3H, OCH3), 2.63 (s, 
1H, OH);  
13C NMR (CDCl3, 100MHz): δ  137.03 (C arom. quat.), 129.45, 128.37, 126.52 (5CH 
arom.), 102.97 (C-7), 99.24 (C-1), 83.33 (C-4), 88.87 (C-2), 79.87 (C-3), 78.50 (C-9), 
77.14 (C-8), 69.92 (C-6), 60.49 (C-5), 55.83 (OCH3);  
MS (CI) m/z: [M+NH4]+ calcd for C16H24O7N, 342, found: 342;  
Anal. Calcd for C16H20O7: C, 59.25; H, 6.22. Found: C, 59.19; H, 6.22. 
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Methyl (1’S)-2,2’-anhydro-3-O-benzyl-4,6-O-benzylidene-3-C-(1’-benzyloxy-2’-
hydroxyethyl)-α-D-glucopyranoside (76): 
 
Sodium hydride (2.30 g, 45.35 mmol, 60% w/w) was added 
by portions to a solution of diol 14 (3.68 g, 11.35 mmol) in 
anhydrous DMF (40 mL) at 0ºC. After 30 min, BnBr (8.10 mL, 
68.09 mmol) was added at 0 ºC. After stirring 2.5h at room 
temperature, MeOH (30 mL) was added and the mixture was concentrated under 
reduced pressure. The residue was then diluted with ether (200 mL) and water (80 
mL). The aqueous layer was extracted with ether (3 x 150 mL), the organic layers were 
combined, dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (cyclohexane-EtOAc, 5:1) afforded the 
benzylated compound 76 (5.45 g, 95%) as a colorless oil.  
Rf 0.40 (cyclohexane-EtOAc 3:1);  
[α]D +73.6 (c 1.0, CHCl3); 
1H NMR (CDCl3, 400MHz): δ 7.48 - 7.24 (m, 15H, H arom.), 5.48 (s, 1H, H-7), 4.94 (d, 
1H, J1,2 = 5.8 Hz, H-1), 4.85 (d, 1H, J = 12.2 Hz, CHPh), 4.77 (d, 1H, J = 12.3 Hz, 
CHPh), 4.75 (d, 1H, J = 12.2 Hz, CHPh), 4.66 (d, 1H, J = 12.3 Hz, CHPh), 4.55 (dt, 1H, 
J5,6a = 5.1 Hz, J5,4 = J5,6b = 10.8 Hz, H-5), 4.38 (dd, 1H, J 8,9a = 2.1 Hz, J 8,9b = 4.9 Hz, H-
8), 4.36 – 4.28 (m, 3H, H-6a, H-9a, H-9b), 4.27 (d, 1H, J2,1 = 5.8 Hz, H-2), 4.11 (d, 1H, 
J4,5 = 10.8 Hz, H-4), 3.67 (t, 1H, J6b,5 = J6b,6a = 10.8 Hz, H-6b), 3.46 (s, 3H, OCH3); 
13C NMR (CDCl3, 100MHz): δ 138.82, 138.57, 137.60 (3C arom. quat.), 129.05 - 
126.16 (15CH arom.), 102.09 (C-7), 99.46 (C-1), 86.03 (C-3), 82.59 (C-2), 81.90 (C-4), 
81.51 (C-8), 75.62 (C-9), 72.60 (CH2Ph), 69.99 (C-6), 66.95 (CH2Ph), 59.27 (C-5), 
55.18 (OCH3);  
HRMS (CI) m/z: [M+NH4]+ calcd for C30H36O7N, 522.2486, found: 522.2480;  
Anal. Calcd for C30H32O7: C, 71.41; H, 6.39. Found: C, 71.27; H, 6.48. 
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Methyl (1’S)-2,2’-anhydro-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-hydroxyethyl)-α-D-
glucopyranoside (77): 
 
LiAlH4 (1.88 g, 49.54 mmol) was carefully added in three portions 
to a solution of the benzylated compound 76 (5.0 g, 9.91 mmol) 
in a 1:1 CH2Cl2 – Et2O mixture (100 mL) at 0 ºC under argon. 
After 10 min, the reaction mixture was warmed to 50 ºC, and a 
solution of AlCl3 (3.96 g, 29.73 mmol) in Et2O (50 mL) was added 
dropwise under argon. After stirring for 2.5h at 50 ºC, TLC revealed no trace of starting 
material. The reaction mixture was cooled to 0 ºC and quenched by slow addition of 
EtOAc followed by water. The organic layer was separated, dried (MgSO4), filtered and 
concentrated under reduced pressure. Purification by flash column chromatography 
(cyclohexane-EtOAc 3:1 then cyclohexane-EtOAc 1:1) afforded the corresponding 
alcohol 77 (4.38 g, 88%) as a colorless oil. 
Rf 0.30 (cyclohexane-EtOAc 1:1);  
[α]D +123.2 (c 1.0, CHCl3); 
 
1H NMR (CDCl3, 400MHz): δ 7.38 - 7.27 (m, 15H, H arom.), 4.94 (d, 1H, J1,2 = 5.9 Hz, 
H-1), 4.95 (d, 1H, J = 11.3 Hz, CHPh), 4.78 (d, 1H, J = 11.3 Hz, CHPh), 4.67 (d, 1H, J 
= 12.2 Hz, CHPh), 4.66 (d, 1H, J = 11.9 Hz, CHPh), 4.63 (d, 1H, J = 11.9 Hz, CHPh), 
4.57 (d, 1H, J = 12.2 Hz, CHPh), 4.38 – 4.30 (m, 4H, H-2, H-5, H-7, H-8a), 4.23 (dd, 
1H, J8b,7 = 6.1 Hz, J8b,8a = 13.7 Hz, H-8b), 4.17 (d, 1H, J4,5 = 10.1 Hz, H-4), 3.90 (ddd, 
1H, J6a,5 = 2.9 Hz, J6a,OH = 4.9 Hz, J6a,6b = 11.6 Hz, H-6a), 3.83 (ddd, 1H, J6b,5 = 3.7 Hz, 
J6b,OH = 7.9 Hz, J6b,6a = 11.6 Hz, H-6b), 3.44 (s, 3H, OCH3), 1.83 (dd, 1H, JOH,6a = 4.9 Hz, 
JOH,6b  = 7.9 Hz, OH);  
13C NMR (CDCl3, 100MHz): δ 138.96, 138.52, 138.23 (3C arom. quat.), 128.40-127.03 
(15CH arom.), 99.13 (C-1), 89.64 (C-3), 85.03 (C-7), 78.30 (C-2), 75.28 (C-8), 74.76 
(C-4), 74.48 (CH2Ph), 72.78 (CH2Ph), 68.31 (C-5), 64.77 (CH2Ph), 62.17 (C-6), 55.01 
(OCH3);  
HRMS (CI) m/z: [M+NH4]+ calcd for C30H38O7N, 524.2643, found: 524.2640;  
Anal. Calcd for C30H34O7: C, 71.13; H, 6.76. Found: C, 70.85; H, 7.01. 
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Methyl (1’S)-2,2’-anhydro-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-hydroxyethyl)-7,8-
dideoxy-L-glycero-α-D-gluco-oct-7-enopyranoside (79a) and Methyl (1’S)-2,2’-
anhydro-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-hydroxyethyl)-7,8-dideoxy-D-
glycero-α-D-gluco-oct-7-enopyranoside (79b): 
 
Anhydrous DMSO (0.82 mL, 11.61 mmol) was added dropwise to 
a solution of oxalyl chloride (0.84 mL, 9.67 mmol) in anhydrous 
CH2Cl2 (30 mL) at -78 ºC under argon. After 15 min, a solution of 
the primary alcohol 77 (0.98 g, 1.93 mmol) in anhydrous CH2Cl2 
(20 mL) was added dropwise. After 1h, Et3N (2.16 mL, 15.48 
mmol) was added and the reaction mixture was allowed to reach 
room temperature. After 1.5h, water was added (20 mL) and the 
aqueous layer was extracted with CH2Cl2 (3 x 80 mL). The 
organic layers were combined, dried (MgSO4), filtered and 
concentrated under reduced pressure. The crude aldehyde was co-evaporated with 
toluene and used without further purification. Crude aldehyde was dissolved in 
anhydrous THF (10 mL) under argon and the solution cooled to -78 ºC. Vinyl 
magnesium bromide (9.65 mL, 9.65 mmol, 1M in THF) was added dropwise to the 
solution and the reaction mixture was allowed to reach room temperature. After 1h, the 
reaction mixture was quenched by slow addition of a saturated aqueous NH4Cl solution 
(10 mL) at 0 ºC and was diluted with ether (50 mL). The organic layer was separated, 
and the aqueous layer extracted with ether (3 x 50 mL). The organic layers were 
combined, dried over MgSO4, filtered and concentrated. Purification by flash column 
chromatography (cyclohexane-EtOAc, 3:1 then cyclohexane-EtOAc, 2:1) afforded the 
allylic alcohol 6S 79a (402 mg, 39%) as a colorless oil. Further elution afforded the 
allylic alcohol 6R 79b (268 mg, 26%) as a colorless oil.  
Compound 79a:  
Rf 0.66 (cyclohexane-EtOAc 1:1); 
[α]D +101.5 (c 10, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.38 - 7.29 (m, 15H, H arom.), 5.96 (ddd, 1H, J7,6 = 5.1 
Hz, J7,8b = 10.6 Hz, J7,8a = 17.3 Hz, H-7), 5.33 (dt, 1H, J8a,8b = J8a,6 = 1.5 Hz, J8a,7 = 17.3 
Hz, H-8a), 5.23 (dt, 1H, J8b,8a = J8b,6 = 1.5 Hz, J8b,7 = 10.6 Hz, H-8b), 4.99 (d, 1H, J = 
11.2 Hz, CHPh), 4.94 (d, 1H, J1,2 = 6.0 Hz, H-1), 4.82 (d, 1H, J = 11.2 Hz, CHPh), 4.67 
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(d, 1H, J = 11.8 Hz, CHPh), 4.66 (s, 2H, CH2Ph), 4.58 (d, 1H, J = 11.8 Hz, CHPh), 4.49 
– 4.45 (m, 1H, H-6), 4.37 (dd, 1H, J5,6 = 1.4 Hz, J5,4 = 10.2 Hz, H-5), 4.34 – 4.19 (m, 5H, 
H-2, H-4, H-9, H-10a, H-10b), 4.01 (d, 1H, JOH,6 = 9.1 Hz, OH), 3.38 (s, 3H, OCH3);  
13C NMR (CDCl3, 100MHz): δ 139.01 (C arom. quat.), 138.78 (C-7), 138.64, 138.30 (2C 
arom. quat.), 128.44 - 127.06 (15CH arom.), 115.25 (C-8), 99.25 (C-1), 89.99 (C-3), 
85.33 (C-9), 78.05 (C-2), 75.27 (C-10), 74.97 (C-5), 74.23 (CH2Ph), 72.90 (CH2Ph), 
70.46 (C-6), 70.02 (C-4), 64.80 (CH2Ph), 55.07 (OCH3);  
HRMS (CI) m/z: [M+NH4]+ calcd for C32H40O7N, 550.2799, found: 550.2803;  
Anal. Calcd for C32H36O7: C, 71.98; H, 6.81. Found: C, 72.16; H, 6.81.  
 
Compound 79b:  
Rf 0.59 (cyclohexane-EtOAc 1:1);  
[α]D +94.2 (c 10, CHCl3); 
1H NMR (CDCl3, 400MHz): δ 7.39 - 7.27 (m, 15H, H arom.), 6.00 (app ddd, 1H, J7,6 = 
6.3 Hz, J7,8a = 10.4 Hz, J7,8b = 17.0 Hz, H-7), 5.35 (dt, 1H, J8a,8b = J8a,6 = 1.2 Hz, J8a,7 = 
17.0 Hz, H-8a), 5.26 (dt, 1H, J8b,8a = J8b,6 = 1.5 Hz, J8b,7 = 10.4 Hz, H-8b), 4.97 (d, 1H, 
J1,2 = 5.8 Hz, H-1), 4.73 (d, 1H, J = 10.9 Hz, CHPh), 4.68 (s, 2H, CH2Ph), 4.66 (d, 1H, J 
= 12.0 Hz, CHPh), 4.57 (d, 1H, J = 12.0 Hz, CHPh), 4.48 (d, 1H, J2,1 = 5.8 Hz, H-2), 
4.46 – 4.42 (m, 2H, H-4, H-6), 4.34 – 4.27 (m, 2H, H-9, H-10a), 4.22 (dd, 1H, J
 10b,9 = 
1.7 Hz, J
 10b,10a = 8.7 Hz, H-10b), 4.08 (dd, 1H, J 5,6 = 2.3 Hz, J 5,4  = 11.7 Hz, H-5), 3.44 
(s, 3H, OCH3), 2.68 (d, 1H, J OH,6 = 5.1 Hz, OH);  
13C NMR (CDCl3, 100MHz): δ 138.73, 138.10, 137.96, (3C arom. quat.), 136.43 (C-7), 
128.38 - 126.98 (15CH arom.), 116.81 (C-8), 98.86 (C-1), 89.88 (C-3), 85.33 (C-9), 
77.60 (C-2), 76.50 (C-5), 75.15 (C-10), 74.25 (CH2Ph), 73.61 (C-4 or C-6), 72.90 
(CH2Ph), 70.08 (C-4 or C-6), 64.66 (CH2Ph), 55.03 (OCH3);  
HRMS (CI) m/z: [M+NH4]+ calcd for C32H40O7N, 550.2799, found: 550.2801;   
Anal. Calcd for C32H36O7: C, 71.98; H, 6.81. Found: C, 71.90; H, 6.63.     
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Methyl [methyl (1’S)-2,2’-anhydro-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-
hydroxyethyl)-D-glycero-α-D-gluco-heptopyranosid]uronate (80a) and Methyl 
[methyl (1’S)-2,2’-anhydro-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-hydroxyethyl)-L-
glycero-α-D-gluco-heptopyranosid]uronate (80b): 
 
A mixture of both epimeric allylic alcohols 6S 79a and 6R 79b 
(ratio 1:1, 0.80 g, 1.50 mmol) was dissolved in CH2Cl2 (120 mL) 
and cooled to – 78 ºC. Ozone was bubbled through the reaction 
mixture until persistence of a blue color (typically 10 min). 
Dimethylsulphide (0.1 mL) was added and the reaction mixture 
was allowed to reach the room temperature. The solvent was 
removed under reduced pressure and the mixture of epimeric 
aldehydes was used in the next step without further purification. 
NaH2PO4.H2O (2.69 g, 19.5 mmol) and NaClO2 (2.44 g, 27 mmol) 
were added to a solution of the crude aldehydes in 2-methylbut-2-ene (3 mL), tBuOH (6 
mL) and water (6 mL). After stirring overnight at room temperature the reaction mixture 
was diluted with EtOAc (50 mL) and water (20 mL). The aqueous layer was extracted 
with EtOAc (3 x 50 mL). The organic layers were combined, dried (MgSO4), filtered and 
concentrated. The carboxylic acids obtained were directly engaged in the next step. To 
a solution of both epimeric carboxylic acids in DMF (8 mL) was added KHCO3 (1.50 g, 
15 mmol) followed by slowly addition of methyl iodide (0.79 ml, 12.75 mmol). After 
stirring overnight the solvent was removed under reduced pressure and the crude 
residue diluted with Et2O (80 mL) and water (30 mL). The aqueous layer was extracted 
with ether (3 x 80 mL), the organic layers were combined, dried (MgSO4), filtered and 
concentrated under reduced pressure. Purification by flash column chromatography 
(cyclohexane-EtOAc, 3:1 then cyclohexane-EtOAc, 2:1) afforded the methyl ester 6R 
80a (280 mg, 33% over three steps) as a colorless oil. Further elution afforded the 
methyl ester 6S 80b (271 mg, 32%, over three steps) as a colorless oil.  
Compound 80a: 
Rf 0.23 (cyclohexane-EtOAc 2:1);  
[α]D +80.5 (c 1.0, CHCl3); 
1H NMR (CDCl3, 400MHz): δ 7.41 - 7.32 (m, 15H, H arom.), 5.03 (d, 1H, J = 11.2 Hz, 
CHPh), 4.96 (d, 1H, J1,2 = 5.8 Hz, H-1), 4.86 (d, 1H, J = 11.2 Hz, CHPh), 4.82 (dd, 1H, 
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J5,6 = 1.6 Hz, J5,4 = 10.1 Hz, H-5), 4.75 (d, 1H, J = 11.9 Hz, CHPh), 4.69 (s, 2H, CH2Ph), 
4.65 – 4.59 (m, 2H, H-6, CHPh), 4.41 (d, 1H, J4,5 = 10.1 Hz, H-4), 4.39 – 4.35 (m, 3H, 
H-2, H-8, H-9a), 4.28 – 4.24 (m, 1H, H-9a), 3.37 (s, 3H, OCH3), 3.12 (s, 3H, OCH3), 
3.12 (d, 1H, JOH,6 = 7.6 Hz, OH);  
13C NMR (CDCl3, 100MHz): δ 173.56 (C=O), 138.85, 138.50, 138.10 (3C arom. quat.), 
128.31 - 126.85 (15CH arom.), 99.42 (C-1), 89.62 (C-3), 85.04 (C-2 or C-8), 77.79 (C-2 
or C-8), 75.09 (C-9), 74.59 (CH2Ph), 74.23 (C-4), 72.67 (CH2Ph), 69.29 (C-5 and C-6), 
64.68 (CH2Ph), 54.89 (OCH3), 52.24 (OCH3);  
HRMS (CI) m/z: [M+NH4]+ calcd for C32H40O9N, 582.2698, found: 582.2694;  
Anal. Calcd for C32H36O9: C, 68.07; H, 6.43. Found: C, 68.27; H, 6.58.  
 
Compound 80b:  
Rf 0.15 (cyclohexane-EtOAc 2:1);   
[α]D +92.8 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.39 - 7.26 (m, 15H, H arom.), 5.03 (d, 1H, J1,2 = 5.9 Hz, 
H-1), 4.95 (d, 1H, J = 9.8 Hz, CHPh), 4.86 (dd, 1H, J5,6 = 2.0 Hz, J5,4 = 10.0 Hz, H-5), 
4.72 (d, 1H, J = 11.5 Hz, CHPh), 4.68 (d, 1H, J = 11.5 Hz, CHPh), 4.58 (d, 1H, J = 12.2 
Hz, CHPh), 4.56 (d, 1H, J = 9.8 Hz, CHPh), 4.51 (d, 1H, J = 12.2 Hz, CHPh), 4.45 – 
4.42 (m, 3H, H-2, H-4, H-6), 4.38 (dd, 1H, J9a,8 = 5.1 Hz, J9a,9b = 8.8 Hz, H-9a), 4.29 – 
4.24 (m, 2H, H-8, H-9b), 3.53 (s, 3H, OCH3), 3.18 (s, 3H, OCH3);  
13C NMR (CDCl3, 100MHz): δ 172.74 (C=O), 139.11, 138.03, 137.95 (3C arom. quat.), 
128.50 - 126.50 (15CH arom.), 99.45 (C-1), 90.18 (C-3), 85.83 (C-8), 77.32 (C-2), 
75.33 (C-9), 74.31 (CH2Ph), 72.66 (CH2Ph), 72.30 (C-4 or C-6), 70.38 (C-4 or C-6), 
69.37 (C-5), 64.56 (CH2Ph), 55.23 (OCH3), 52.02 (OCH3);  
HRMS (CI) m/z:  [M+NH4]+ calcd for C32H40O9N, 582.2698, found: 582.2701;  
Anal. Calcd for C32H36O9: C, 68.07; H, 6.43. Found: C, 68.17; H, 6.50. 
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Benzyl [methyl (1’S)-2,2’-anhydro-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-
hydroxyethyl)-D-glycero-α-D-gluco-heptopyranosid]uronate (81a) and Benzyl 
[methyl (1’S)-2,2’-anhydro-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-hydroxyethyl)-L-
glycero-α-D-gluco-heptopyranosid]uronate (81b): 
 
A mixture of both epimeric allylic alcohols 6S 79a and 6R 79b 
(ratio 1:1, 0.36 g, 0.67 mmol) was dissolved in CH2Cl2 (80 mL) 
and cooled to – 78 ºC. Ozone was bubbled through the reaction 
mixture until persistence of a blue color (typically 5 min). 
Dimethylsulphide (0.1 mL) was added and the reaction mixture 
was allowed to reach the room temperature. The solvent was 
removed under reduced pressure and the mixture of epimeric 
aldehydes was used in the next step without further purification. 
NaH2PO4.H2O (1.20 g, 8.71 mmol) and NaClO2 (1.09 g, 12.06 
mmol) were added to a solution of the crude aldehydes in 2-methylbut-2-ene (1.5 mL), 
tBuOH (3 mL) and water (3 mL). After stirring overnight at room temperature the 
reaction mixture was diluted with EtOAc (50 mL) and water (20 mL). The aqueous layer 
was extracted with EtOAc (3 x 50 mL). The organic layers were combined, dried 
(MgSO4), filtered and concentrated. The carboxylic acids obtained were directly 
engaged in the next step. To a solution of both epimeric carboxylic acids in DMF (8 mL) 
was added sequentially Bu4NI (0.99 g, 2.68 mmol) and KHCO3 (0.37 g, 3.68 mmol) 
followed by slowly addition of benzyl bromide (0.32 ml, 2.68 mmol). After stirring 
overnight the solvent was removed under reduced pressure and the crude residue 
diluted with Et2O (80 mL) and water (30 mL). The aqueous layer was extracted with 
ether (3 x 80 mL), the organic layers were combined, dried (MgSO4), filtered and 
concentrated under reduced pressure. Purification by flash column chromatography 
(cyclohexane-EtOAc, 5:1 then cyclohexane-EtOAc, 3:1) afforded the benzyl ester 6R 
81a (154 mg, 36% over three steps) as a colorless oil. Further elution afforded the 
benzyl ester 6S 81b (140 mg, 32%, over three steps) as a colorless oil.  
Compound 81a:  
Rf 0.61 (cyclohexane-EtOAc 2:1);  
[α]D +76 (c 1.0, CHCl3);  
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1H NMR (CDCl3, 400MHz): δ 7.38 - 7.22 (m, 20H, H arom.), 5.36 (d, 1H, J = 12.2 Hz, 
CHPh), 5.13 (d, 1H, J = 12.2 Hz, CHPh), 4.99 (d, 1H, J = 11.2 Hz, CHPh), 4.96 (d, 1H, 
J = 11.8 Hz, CHPh), 4.89  (d, 1H, J1,2 = 5.8 Hz, H-1), 4.82 (d, 1H, J = 11.8 Hz, CHPh), 
4.78 (dd, 1H, J5,6 = 1.7 Hz, J5,4  = 10.0 Hz, H-5), 4.69 (d, 1H, J = 11.8 Hz, CHPh), 4.67 
(d, 1H, J = 11.2 Hz, CHPh), 4.60 (d, 1H, J6,5 = 1.7 Hz, H-6), 4.57 (d, 1H, J = 11.8 Hz, 
CHPh), 4.39 (d, 1H, J4,5 = 10.0 Hz, H-4), 4.35 – 4.31 (m, 3H, H-2, H-8, H-9a), 4.21 (dd, 
1H, J9b,8 = 4.1 Hz, J9b,9a = 7.2 Hz, H-9b), 3.16 (s, 3H, OCH3);  
13C NMR (CDCl3, 100MHz): δ 173.10 (C=O), 138.86, 138.56, 138.16, 134.82 (4C arom. 
quat.), 129.58 - 126.98 (20CH arom.), 99.53 (C-1), 88.82 (C-3), 85.31 (C-2 or C-8), 
77.82 (C-2 or C-8), 75.19 (C-9), 74.76 (CH2Ph), 74.38 (C-4), 72.95 (CH2Ph), 69.60 (C-
6), 69.32 (C-5), 67.45 (CH2Ph), 64.74 (CH2Ph), 55.01 (OCH3); 
HRMS (CI) m/z: [M+NH4]+ calcd for C38H44O9N, 658.3016, found: 658.3022;  
Anal. Calcd for C38H44NO9: C, 71.23; H, 6.29. Found: C, 69.27; H, 6.41.  
 
Compound 81b:  
Rf 0.51 (cyclohexane-EtOAc 2:1); 
[α]D +50.5 (c 0.5, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.38 - 7.15 (m, 20H, H arom.), 5.02 (d, 1H, J = 12.0 Hz, 
CHPh), 4.99 (d, 1H, J1,2 = 5.8 Hz, H-1), 4.96 (d, 1H, J = 10.1 Hz, CHPh), 4.83 (dd, 1H, 
J5,6 = 2.1 Hz, J5,4  = 10.2 Hz, H-5), 4.58 (d, 1H, J = 10.1 Hz, CHPh), 4.56 (s, 2H, 
CH2Ph), 4.55 (d, 1H, J = 12.5 Hz, CHPh), 4.40 (m, 2H, H-6, CHPh), 4.40 (d, 1H, J4,5 = 
10.2 Hz, H-4), 4.35 (d, 1H, J2,1 = 5.8 Hz, H-2), 4.31 (dd, 1H, J9a,8 = 5.4 Hz, J9a,9b = 8.8 
Hz, H-9a), 4.26 (dd, 1H, J8,9a = 5.4 Hz, J8,9b = 1.5 Hz, H-8), 4.19 (dd, 1H, J9b,8 = 1.5 Hz, 
J9b,9a = 8.8 Hz, H-9b), 3.50 (s, 3H, OCH3), 3.29 (d, 1H, JOH,6 = 3.7 Hz, OH);  
13C NMR (CDCl3, 100MHz): δ 172.29 (C=O), 139.04, 138.19, 137.93, 135.05 (4C arom. 
quat.), 128.59 -126.80 (20CH arom.), 99.34 (C-1), 90.06 (C-3), 85.63 (C-8), 77.28 (C-
2), 75.34 (C-9), 74.37 (CH2Ph), 72.80 (C-4), 72.72 (CH2Ph), 70.52 (C-6), 69.97 (C-5), 
67.32 (CH2Ph), 64.49 (CH2Ph), 55.31 (OCH3);  
HRMS (CI) m/z: [M+NH4]+ calcd for C38H44O9N, 658.3016, found: 658.3010;  
Anal. Calcd for C38H44NO9: C, 71.23; H, 6.29. Found: C, 70.98; H, 6.18. 
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Methyl [methyl (1’S)-2,2’-anhydro-6-azido-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-
hydroxyethyl)-6-deoxy-L-glycero-α-D-gluco-heptopyranosid]uronate (82a): 
 
To a solution of methyl ester 6R 80a (610 mg, 1.08 mmol) in dry 
CH2Cl2 (18 mL), anhydrous pyridine (1.40 mL, 17.28 mmol) was 
added followed by slow addition of Tf2O (1.45 mL, 8.64 mmol) at 
– 78 ºC under argon. After stirring 90 min at room temperature, 
water (10 mL) and CH2Cl2 (20 mL) were added. The organic 
layer was separated, dried (MgSO4), filtered and concentrated under reduced pressure. 
The crude triflate compound was directly engaged in the next step. Sodium azide (420 
mg, 6.48 mmol) was added to a solution of the crude triflate in anhydrous DMF (12 mL) 
at room temperature. After stirring overnight the reaction mixture was concentrated 
under reduced pressure. The residue was then diluted with ether (80 mL) and water 
(30 mL). The aqueous layer was extracted with ether (3 x 80 mL), the organic layers 
were combined, dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (cyclohexane-EtOAc, 4:1) afforded the 
methyl azido ester 6S 82a (522 mg, 82% over two steps) as a colorless oil.  
Rf 0.58 (cyclohexane-EtOAc 1:1);  
[α]D +89.3 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.42 - 7.29 (m, 15H, H arom.), 5.02 (d, 1H, J1,2 = 5.7 Hz, 
H-1), 5.01 (dd, 1H, J5,6 = 2.5 Hz, J5,4 = 10.3 Hz, H-5), 4.97 (d, 1H, J = 10.0 Hz, CHPh), 
4.74 – 4.67 (m, 3H, CH2Ph, CHPh), 4.68 (d, 1H, J = 12.3 Hz, CHPh), 4.53 (d, 1H, J = 
12.3 Hz, CHPh), 4.43 – 4.41 (m, 2H, H-2, H-6), 4.38 (dd, 1H, J9a,8 = 5.4 Hz, J9a,9b = 8.9 
Hz, H-9a), 4.36 (d, 1H, J4,5 = 10.3 Hz, H-4), 4.31 (dd, 1H, J8,9a = 5.4 Hz, J8,9b = 1.7 Hz, 
H-8), 4.26 (dd, 1H, J9b,8 = 1.7 Hz, J9b,9a = 8.9 Hz, H-9b), 3.56 (s, 3H, OCH3), 3.29 (s, 3H, 
OCH3);  
13C NMR (CDCl3, 100MHz): δ 167.78 (C=O), 138.90, 137.96, 137.77 (3C arom. quat.), 
128.36 - 126.57 (15CH arom.), 99.55 (C-1), 89.78 (C-3), 85.55 (C-8), 77.21 (C-2), 
75.32 (C-9), 74.41 (CH2Ph), 73.72 (C-4), 72.67 (CH2Ph), 68.85 (C-5), 64.54 (CH2Ph), 
63.08 (C-6), 55.54 (OCH3), 51.96 (OCH3);  
HRMS (CI) m/z: [M+NH4]+ calcd for C32H39O8N4, 607.2762, found: 607.2761;  
Anal. Calcd for C32H35N3O8: C, 65.18; H, 5.98. Found: C, 65.39; H, 5.96.     
O
BnO
OMeO
(S)N3
BnO
BnO
COOMe
82a
Experimental Part 
Total Synthesis and Stereochemical Assignment of Miharamycins 129
 
Methyl [methyl (1’S)-2,2’-anhydro-6-azido-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-
hydroxyethyl)-6-deoxy-D-glycero-α-D-gluco-heptopyranosid]uronate (82b): 
 
To a solution of methyl ester 6S 80b (250 mg, 0.44 mmol) in dry 
CH2Cl2 (8 mL), anhydrous pyridine (0.57 mL, 7.08 mmol) was 
added followed by slow addition of Tf2O (0.60 mL, 3.54 mmol) at 
– 78 ºC under argon. After stirring 1h at room temperature, water 
(5 mL) and CH2Cl2 (15 mL) were added. The organic layer was 
separated, dried (MgSO4), filtered and concentrated under reduced pressure. The 
crude triflate compound was directly engaged in the next step. Sodium azide (173 mg, 
2.66 mmol) was added to a solution of the crude triflate product in anhydrous DMF (5 
mL) at room temperature. After stirring overnight the reaction mixture was concentrated 
under reduced pressure. The residue was then diluted with ether (30 mL) and water 
(10 mL). The aqueous layer was extracted with ether (3 x 30 mL), the organic layers 
were combined, dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (cyclohexane-EtOAc, 4:1) afforded the 
methyl azido ester 6R 82b (178 mg, 68% over two steps) as a colorless oil.  
Rf 0.54 (cyclohexane-EtOAc 1:1);  
[α]D +103.2 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.44 - 7.30 (m, 15H, H arom.), 5.07 (d, 1H, J = 11.2 Hz, 
CHPh), 5.52 (dd, 1H, J5,6 = 2.2 Hz, J5,4 = 10.1 Hz, H-5), 4.98 (d, 1H, J1,2 = 5.9 Hz, H-1), 
4.76 (d, 1H, J = 11.2 Hz, CHPh), 4.72 (d, 1H, J = 11.8 Hz, CHPh), 4.71 (s, 2H, CH2Ph), 
4.62 (d, 1H, J = 11.8 Hz, CHPh), 4.42 – 4.36 (m, 3H, H-2, H-8, H-9a), 4.30 – 4.27 (m, 
3H, H-4, H-6, H-9b), 3.81 (s, 3H, OCH3), 3.40 (s, 3H, OCH3);  
13C NMR (CDCl3, 100MHz): δ 169.24 (C=O), 138.68, 138.11, 137.88 (3C arom. quat.), 
128.39 - 126.90 (15CH arom.), 99.37 (C-1), 89.53 (C-3), 85.08 (C-2 or C-8), 77.48 (C-2 
or C-8), 75.15 (C-9), 75.04 (C-4 or C-6), 74.74 (CH2Ph), 72.70 (CH2Ph), 69.37 (C-5), 
64.73 (CH2Ph), 61.10 (C-4 or C-6), 55.10 (OCH3), 52.38 (OCH3);  
HRMS (CI) m/z: [M+NH4]+ calcd for C32H39O8N4, 607.2762, found: 607.2759;  
Anal. Calcd for C32H35N3O8: C, 65.18; H, 5.98. Found: C, 65.45; H, 5.69.  
O
BnO
OMeO
(R)N3
BnO
BnO
COOMe
82b
Experimental Part 
Total Synthesis and Stereochemical Assignment of Miharamycins 130
 
Benzyl [methyl (1’S)-2,2’-anhydro-6-azido-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-
hydroxyethyl)-6-deoxy-L-glycero-α-D-gluco-heptopyranosid]uronate (83a): 
 
To a solution of benzyl ester 6R 81a (175 mg, 0.27 mmol) in dry 
CH2Cl2 (5.5 mL), anhydrous pyridine (0.35 mL, 4.37 mmol) was 
added followed by slow addition of Tf2O (0.37 mL, 2.19 mmol) at 
– 78 ºC under argon. After stirring 2h at room temperature, water 
(10 mL) and CH2Cl2 (20 mL) were added. The organic layer was 
separated, dried (MgSO4), filtered and concentrated under reduced pressure. The 
crude triflate compound was directly engaged in the next step. Sodium azide (106 mg, 
1.64 mmol) was added to a solution of the crude triflate product in anhydrous DMF (6 
mL) at room temperature. After stirring overnight the reaction mixture was concentrated 
under reduced pressure. The residue was then diluted with ether (80 mL) and water 
(30 mL). The aqueous layer was extracted with ether (3 x 80 mL), the organic layers 
were combined, dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (cyclohexane-EtOAc, 5:1) afforded the 
benzyl azido ester 6S 83a (131 mg, 72% over two steps) as a colorless oil.  
Rf 0.66 (cyclohexane-EtOAc 1:1);  
[α]D +85.0 (c 0.6, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.42 - 7.28 (m, 20H, H arom.), 5.08 (d, 1H, J = 12.1 Hz, 
CHPh), 5.00 (d, 1H, J1,2 = 5.8 Hz, H-1), 4.98 (dd, 1H, J5,6 = 1.7 Hz, J5,4  = 10.1 Hz, H-5), 
4.85 (d, 1H, J = 12.1 Hz, CHPh), 4.69 (d, 1H, J = 10.5 Hz, CHPh), 4.61 (d, 1H, J = 12.4 
Hz, CHPh), 4.53 (s, 2H, CH2Ph), 4.52 (d, 1H, J = 12.4 Hz, CHPh), 4.40 (d, 1H, J6,5 = 
1.7 Hz, H-6), 4.34 (d, 1H, J2,1 = 5.8 Hz, H-2), 4.35 (d, 1H, J4,5 = 10.1 Hz, H-4), 4.34 – 
2.28 (m, 2H, H-8, H-9a), 4.23 (dd, 1H, J9b,8 = 1.4 Hz, J9b,9a = 8.8 Hz, H-9b), 3.56 (s, 3H, 
OCH3);  
13C NMR (CDCl3, 100MHz): δ 167.49 (C=O), 138.79, 138.12, 137.74, 134.86 (4C arom. 
quat.), 128.64 - 126.86 (20CH arom.), 99.47 (C-1), 89.60 (C-3), 85.40 (C-8), 77.11 (C-
2), 75.27 (C-9), 74.39 (CH2Ph), 74.08 (C-4), 72.74 (CH2Ph), 69.71 (C-5), 66.98 
(CH2Ph), 64.49 (CH2Ph), 62.49 (C-6), 55.69 (OCH3);  
HRMS (CI) m/z: [M+NH4]+ calcd for C38H43O8N4, 683.3081, found: 683.3073. 
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Benzyl [methyl (1’S)-2,2’-anhydro-6-azido-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-
hydroxyethyl)-6-deoxy-D-glycero-α-D-gluco-heptopyranosid]uronate (83b): 
 
To a solution of benzyl ester 6S 81b (137 mg, 0.21 mmol) in dry 
CH2Cl2 (5 mL), anhydrous pyridine (0.28 mL, 3.42 mmol) was 
added followed by slow addition of Tf2O (0.29 mL, 1.71 mmol) at 
– 78 ºC under argon. After stirring 2h at room temperature, water 
(10 mL) and CH2Cl2 (20 mL) were added. The organic layer was 
separated, dried (MgSO4), filtered and concentrated under reduced pressure. The 
crude triflate compound was directly engaged in the next step. Sodium azide (83 mg, 
1.28 mmol) was added to a solution of the crude triflate product in anhydrous DMF (5 
mL) at room temperature. After stirring overnight the reaction mixture was concentrated 
under reduced pressure. The residue was then diluted with ether (80 mL) and water 
(30 mL). The aqueous layer was extracted with ether (3 x 80 mL), the organic layers 
were combined, dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (cyclohexane-EtOAc, 5:1) afforded the 
benzyl azido ester 6R 83b (122 mg, 86% over two steps) as a colorless oil.  
Rf 0.68 (cyclohexane-EtOAc 1:1);  
[α]D +19.1 (c 0.2, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.42 - 7.26 (m, 20H, H arom.), 5.34 (d, 1H, J = 12.2 Hz, 
CHPh), 5.19 (d, 1H, J = 12.2 Hz, CHPh), 5.05 (d, 1H, J = 11.3 Hz, CHPh), 5.02 (dd, 
1H, J5,6 = 2.2 Hz, J5,4 = 10.4 Hz, H-5), 4.92 (d, 1H, J1,2 = 5.9 Hz, H-1), 4.74 (d, 1H, J = 
11.3 Hz, CHPh), 4.70 (d, 1H, J = 12.0 Hz, CHPh), 4.69 (s, 2H, CH2Ph), 4.58 (d, 1H, J = 
12.0 Hz, CHPh), 4.38 (d, 1H, J2,1 = 5.9 Hz, H-2), 4.37 – 4.33 (m, 2H, H-8, H-9a), 4.31 
(d, 1H, J6,5 = 2.2 Hz, H-6), 4.28 (d, 1H, J4,5 = 10.4 Hz, H-4), 4.24 (dd, 1H, J9b,8 = 4.6 Hz, 
J9b,9a = 9.8 Hz, H-9b), 3.19 (s, 3H, OCH3);  
13C NMR (CDCl3, 100MHz): δ 168.80 (C=O), 138.68, 138.16, 137.95, 134.81 (4C arom. 
quat.), 128.53 - 127.06 (20CH arom.), 99.47 (C-1), 89.56 (C-3), 85.30 (C-8), 77.56 (C-
2), 75.24 (C-9), 75.21 (C-4), 74.90 (CH2Ph), 72.96 (CH2Ph), 69.49 (C-5), 67.53 
(CH2Ph), 64.79 (CH2Ph), 61.37 (C-6), 55.23 (OCH3);  
HRMS (CI) m/z: [M+NH4]+ calcd for C38H43O8N4, 683.3081, found: 683.3076. 
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Methyl [methyl (1’S)-2,2’-anhydro-6-azido-6-deoxy-3-C-(1’,2’-dihydroxyethyl)-L-
glycero-β-D-gluco-heptofuranosid]uronate (84a): 
 
Boron trichloride (3.4 mL, 3.40 mmol, 1M in CH2Cl2) was added 
dropwise to a stirred solution of methyl azido ester 6S 82a (100 mg, 
0.17 mmol) in anhydrous CH2Cl2 (4.5 mL) at – 78 ºC under argon. 
The reaction mixture was allowed to reach 0 ºC over a period of 7 
hours, then quenched with a solution of CH2Cl2/MeOH 1:1 (12 mL) 
and concentrated under reduced pressure. Purification by flash column 
chromatography (cyclohexane-EtOAc, 1:2) afforded the debenzylated methyl azido 
ester 6S 84a (35 mg, 65%) as a white crystalline solid.  
Rf 0.30 (cyclohexane-EtOAc, 1:2);  
m.p. 82 ºC (EtOAc);   
[α]D - 26.7 (c 1.0, MeOH);  
1H NMR (CDCl3, 400MHz): δ  4.89 (s, 1H, H-1), 4.74 (d, 1H, J5,4 = 5.6 Hz, H-5), 4.45 (t, 
1H, J8,9a = J8,9b = 5.6 Hz, H-8), 4.34 – 4.30 (m, 2H, H-4, H-6), 4.22 (s, 1H, H-2), 4.13 
(dd, 1H, J9a,8 = 5.6 Hz, J9a,9b = 9.5 Hz, H-9a), 3.88 (s, 3H, OCH3), 3.84 (dd, 1H, J9b,8 = 
5.6 Hz, J9b,9a = 9.5 Hz, H-9b), 3.46 (s, 3H, OCH3),  
13C NMR (CDCl3, 100MHz): δ 170.00 (C=O), 108.87 (C-1), 92.90 (C-2), 90.70 (C-3), 
79.49 (C-4), 78.78 (C-8), 74.21 (C-5), 74.11 (C-9), 63.40 (C-6), 56.36 (OCH3), 53.30 
(OCH3);  
HRMS (CI) m/z: [M+NH4]+ calcd for C11H21O8N4, 337.1359, found: 337.1343.  
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Methyl [methyl (1’S)-2,2’-anhydro-6-azido-6-deoxy-3-C-(1’,2’-dihydroxyethyl)-D-
glycero-β-D-gluco-heptofuranosid]uronate (84b): 
 
Boron trichloride (3.4 mL, 3.40 mmol, 1M in CH2Cl2) was added 
dropwise to a stirred solution of methyl azido ester 6R 82b (100 mg, 
0.17 mmol) in anhydrous CH2Cl2 (4.5 mL) at – 78 ºC under argon. 
The reaction mixture was allowed to reach 0 ºC over a period of 7 
hours, then quenched with a solution of CH2Cl2/MeOH 1:1 (12 mL) 
and concentrated under reduced pressure. Purification by flash column 
chromatography (cyclohexane-EtOAc, 1:2) afforded the debenzylated methyl azido 
ester 6R 84b (30 mg, 55%) as a colorless oil.  
Rf 0.32 (cyclohexane-EtOAc, 1:2);  
[α]D - 32.7 (c 1.0, MeOH);  
1H NMR (CDCl3, 400MHz): δ  4.90 (s, 1H, H-1), 4.59 – 4.49 (m, 3H, H-4, H-5, H-8), 
4.42 (d, 1H, J6,5 = 1.7 Hz, H-6), 4.27 (s, 1H, H-2), 4.16 (dd, 1H, J9a,8 = 6.6 Hz, J9a,9b = 9.4 
Hz, H-9a), 3.90 (s, 3H, OCH3), 3.82 (dd, 1H, J9b,8 = 6.9 Hz, J9b,9a = 9.4 Hz, H-9b), 3.43 
(s, 3H, OCH3),  
13C NMR (CDCl3, 100MHz): δ 169.98 (C=O), 108.48 (C-1), 91.52 (C-2), 89.15 (C-3), 
78.64 (C-4), 78.15 (C-8), 72.85 (C-9), 71.71 (C-5), 63.66 (C-6), 55.70 (OCH3), 55.15 
(OCH3); 
 HRMS (CI) m/z: [M+NH4]+ calcd for C11H21O8N4, 337.1359, found: 337.1350.  
 
Methyl [methyl (1’S)-3,5-di-O-acetyl-2,2’-anhydro-3-C-(1’-acetoxy-2’-
hydroxyethyl)-6-azido-6-deoxy-D-glycero-β-D-gluco-heptofuranosid]uronate (85): 
 
The azido ester 6R 84b (20 mg, 63 µmol) was dissolved in dry 
pyridine (3 mL), acetic anhydride (1 mL) were added followed by a 
catalytic amount of DMAP. The reaction mixture was stirred 
overnight at room temperature, then co-evaporated with toluene 
and concentrated. Purification by flash column chromatography 
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(cyclohexane-EtOAc, 2:1) afforded the triacetate derivative 6R 85 (22 mg, 79%) as a 
white crystalline solid. 
Rf 0.54 (cyclohexane-EtOAc, 1:1);  
m.p. 112 ºC (EtOH);  
[α]D - 125.9 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 6.21 (dd, 1H, J8,9b = 6.5 Hz, J8,9a = 7.2 Hz, H-8), 5.65 (dd, 
1H, J5,6 = 1.4 Hz, J5,4 = 10.3 Hz, H-5), 4.96 (d, 1H, J4,5 = 10.3 Hz, H-4), 4.97 (s, 1H, H-
1), 4.92 (s, 1H, H-2), 4.40 (dd, 1H, J9a,8 = 7.2 Hz, J9a,9b = 9.7 Hz, H-9a), 4.11 (d, 1H, J6,5 
= 1.4 Hz, H-6), 3.92 (dd, 1H, J9b,8 = 6.5 Hz, J9b,9a = 9.7 Hz, H-9b), 3.83 (s, 3H, OCH3), 
3.43 (s, 3H, OCH3), 2.06, 2.03, 2.02 (3 x s, 9H, 3 x OAc);  
13C NMR (CDCl3, 100MHz): δ 169.98, 169.81, 169.53, 169.03 (4 x C=O), 108.32 (C-1), 
93.19 (C-3), 87.08 (C-2), 77.96 (C-4), 73.77 (C-8), 72.44 (C-5), 70.63 (C-9), 60.43 (C-
6), 55.74 (OCH3), 53.11 (OCH3), 21.26, 20.79, 20.13 (3 x OAc);  
HRMS (CI) m/z: [M+NH4]+ calcd for C17H27O11N4, 463.1676, found: 463.1667.  
 
Methyl [methyl (1’S)-2,2’-anhydro-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-
hydroxyethyl)-6-O-terc-butyldimethylsilyl-D-glycero-α-D-gluco-heptopyranosid] 
uronate (86a) and Methyl [methyl (1’S)-2,2’-anhydro-3,4-di-O-benzyl-3-C-(1’-
benzyloxy-2’-hydroxyethyl)-6-O-terc-butyldimethylsilyl-L-glycero-α-D-gluco-hepto 
pyranosid]uronate (86b): 
 
TBDMSOTf (1.80 mL, 7.76 mmol) was added carefully at 0 ºC 
under argon to a mixture of epimeric methyl esters 6R 80a and 
6S 80b (ratio 1:1, 730 mg, 1.29 mmol) in dry pyridine (15 mL). 
After stirring for 90 min, TLC revealed no trace of starting 
material. Pyridine was then co-evaporated with toluene and the 
crude residue diluted with CH2Cl2 (100 mL) and washed with a 
1M aqueous solution of HCl (40 mL). The organic layer was 
separated, dried (MgSO4), filtered and concentrated under 
reduced pressure. Purification by flash column chromatography 
(cyclohexane-EtOAc, 9:1 then cyclohexane-EtOAc, 4:1) afforded the methyl ester 
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silylated 6R 86a (392 mg, 45%) as a colorless oil. Further elution afforded the methyl 
ester silylated 6S 86b (390 mg, 44%) as a colorless oil.  
Compound 86a:  
Rf 0.74 (cyclohexane-EtOAc, 2:1);  
[α]D +78.8 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.39 - 7.26 (m, 15H, H arom.), 4.99 (d, 1H, J1,2 = 5.8 Hz, 
H-1), 4.89 – 4.86 (m, 2H, H-5, CHPh), 4.80 (d, 1H, J = 10.0 Hz, CHPh), 4.69 (s, 2H, 
CH2Ph), 4.65 (d, 1H, J = 12.3 Hz, CHPh), 4.54 (d, 1H, J = 12.3 Hz, CHPh), 4.53 (d, 1H, 
J6,5 = 1.5 Hz, H-6), 4.50 (d, 1H, J4,5 = 10.0 Hz, H-4), 4.40 – 4.38 (m, 2H, H-2, H-9a), 
4.29 – 4.26 (m, 2H, H-8, H-9b), 3.52 (s, 3H, OCH3), 3.19 (s, 3H, OCH3), 1.03 (s, 9H, 
C(CH3)3), 0.18 (s, 3H, SiCH3), 0.13 (s, 3H, SiCH3);  
13C NMR (CDCl3, 100MHz): δ 171.73 (C=O), 139.78, 139.09, 138.64 (3C arom. quat.), 
128.89 – 127.09 (15CH arom.), 99.66 (C-1), 90.77 (C-3), 86.08 (C-8), 78.07 (C-2), 
75.85 (C-9), 74.78 (CH2Ph), 73.19 (C-4), 73.09 (CH2Ph), 75.52 (C-6), 70.76 (C-5), 
64.96 (CH2Ph), 55.48 (OCH3), 51.68 (OCH3), 26.19 (C(CH3)3), 18.91 (C(CH3)3), -4.63 
(SiCH3), -4.80 (SiCH3);  
HRMS (CI) m/z: [M+NH4]+ calcd for C38H54O9NSi, 696.3568, found: 696.3572.  
 
Compound 86b:  
Rf 0.59 (cyclohexane-EtOAc, 2:1);  
[α]D +44.9 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.43 - 7.30 (m, 15H, H arom.), 5.22 (d, 1H, J = 11.4 Hz, 
CHPh), 5.07 (d, 1H, J1,2 = 5.0 Hz, H-1), 4.81 (dd, 1H, J5,6 = 2.0 Hz, J5,4  = 9.7 Hz, H-5), 
4.76 – 4.69 (m, 3H, H-6, CHPh, CH2Ph ), 4.67 (d, 1H, J = 11.9 Hz, CHPh), 4.59 (d, 1H, 
J = 11.9 Hz, CHPh), 4.53 (d, 1H, J4,5 = 9.7 Hz, H-4), 4.36 (d, 1H, J2,1 = 5.0 Hz, H-2), 
4.31 – 4.24 (m, 3H, H-8, H-9a, H-9b), 3.75 (s, 3H, OCH3), 3.43 (s, 3H, OCH3), 1.07 (s, 
9H, C(CH3)3), 0.25 (s, 3H, SiCH3), 0.13 (s, 3H, SiCH3);  
13C NMR (CDCl3, 100MHz): δ 172.27 (C=O), 138.67, 138.54, 137.90 (3C arom. quat.), 
128.39 - 126.74 (15CH arom.), 98.88 (C-1), 90.45 (C-3), 85.53 (C-8), 77.96 (C-2), 
74.25 (C-9), 73.44 (CH2Ph), 72.96 (C-4), 72.66 (CH2Ph), 72.05 (C-6), 71.50 (C-5), 
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64.73 (CH2Ph), 55.33 (OCH3), 51.58 (OCH3), 26.02 (C(CH3)3), 18.42 (C(CH3)3), -4.10 
(SiCH3), -5.21 (SiCH3);  
HRMS (CI) m/z: [M+NH4]+ calcd for C38H54O9NSi, 696.3568, found: 696.3570.  
 
Methyl [methyl (1’S)-3-C-(1’-acetoxy-2’-hydroxyethyl)-3,4-di-O-acetyl-2,2’-
anhydro-6-O-terc-butyldimethylsilyl-D-glycero-α-D-gluco-heptopyranosid]uronate 
(87a): 
 
The 6R silylated derivative 86a (310 mg, 0.46 mmol) was 
dissolved in a 2:1 EtOAc-MeOH mixture (12 mL) and 10% Pd/C 
(137 mg, 300 mg / mmol of starting material) was added. The 
solution was degased three times and air was replaced by H2 
(30 psi). After stirring for 5h at room temperature, the mixture 
was filtered through a Rotilabo® Nylon 0.45 µm filter and the filtrate evaporated to 
afford the debenzylated derivative which was directly engaged in the next step. To the 
crude deprotected compound in dry pyridine (8 mL) and acetic anhydride (4 mL) 
followed by a catalytic amount of DMAP were added. The reaction mixture was stirred 
overnight at room temperature, then co-evaporated with toluene and concentrated. 
Purification by flash column chromatography (cyclohexane-EtOAc, 2:1) afforded the 
triacetate derivative 6R 87a (200 mg, 82% over two steps) as a colorless oil.  
Rf 0.32 (cyclohexane-EtOAc, 2:1);  
[α]D +95.5 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 6.26 (d, 1H, J4,5 = 9.5 Hz, H-4), 5.54 (dd, 1H, J8,9a = 1.3 
Hz, J8,9b = 3.5 Hz, H-8), 5.36 (d, 1H, J1,2 = 2.7 Hz, H-1), 4.46 (d, 1H, J2,1 = 2.7 Hz, H-2), 
4.42 (dd, 1H, J5,6 = 1.8 Hz, J5,4 = 9.5 Hz, H-5), 4.17 (d, 1H, J6,5 = 1.8 Hz, H-6), 3.99 – 
3.93 (m, 2H, H-9a, H-9b), 3.72 (s, 3H, OCH3), 3.47 (s, 3H, OCH3), 2.11, 2.01, 1.99 (3 x 
s, 9H, 3 x OAc), 0.93 (s, 9H, C(CH3)3), 0.31 (s, 3H, SiCH3), 0.03 (s, 3H, SiCH3);  
13C NMR (CDCl3, 100MHz): δ 171.44, 169.87, 169.56, 169.26 (4 x C=O), 98.12 (C-1), 
90.41 (C-3), 81.36 (C-2), 77.98 (C-8), 73.23 (C-5), 72.43 (C-6), 72.25 (C-9), 65.28 (C-
4), 56.46 (OCH3), 51.81 (OCH3), 25.47 (C(CH3)3), 21.51, 20.93, 20.44 (3 x OAc), 17.93 
(C(CH3)3), -5.25 (SiCH3), -5.82 (SiCH3);  
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HRMS (CI) m/z: [M+NH4]+ calcd for C23H42O12NSi, 552.2476, found: 552.2476.  
 
Methyl [methyl (1’S)-3-C-(1’-acetoxy-2’-hydroxyethyl)-3,4-di-O-acetyl-2,2’-
anhydro-6-O-terc-butyldimethylsilyl-L-glycero-α-D-gluco-heptopyranosid]uronate 
(87b): 
 
The 6S silylated derivative 86b (205 mg, 0.30 mmol) was 
dissolved in a 2:1 EtOAc-MeOH mixture (9 mL) and 10% Pd/C 
(91 mg, 300 mg / mmol of starting material) was added. The 
solution was degased three times and air was replaced by H2 
(30 psi). After stirring for 3h at room temperature, the mixture 
was filtered through a Rotilabo® Nylon 0.45 µm filter and the solvent evaporated to 
afford the debenzylated derivative which was directly engaged in the next step. The 
residue was dissolved in dry pyridine (5 mL) and acetic anhydride (2.5 mL) followed by 
a catalytic amount of DMAP were added. The reaction mixture was stirred overnight at 
room temperature, then co-evaporated with toluene and concentrated. Purification by 
flash column chromatography (cyclohexane-EtOAc, 2:1) afforded the triacetate 
derivative 6S 87b (136 mg, 84%, over two steps) as a colorless oil.  
Rf 0.43 (cyclohexane-EtOAc, 2:1);  
[α]D +98.6 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 6.35 (d, 1H, J4,5 = 10.4 Hz, H-4), 5.53 (dd, 1H, J8,9b = 2.1 
Hz, J8,9a = 5.7 Hz, H-8), 5.04 (d, 1H, J1,2 = 5.0 Hz, H-1), 4.89 (d, 1H, J2,1 = 5.0 Hz, H-2), 
4.65 (dd, 1H, J5,6 = 1.5 Hz, J5,4 = 10.4 Hz, H-5), 4.42 (d, 1H, J6,5 = 1.5 Hz, H-6), 4.21 
(dd, 1H, J9a,8 = 5.7 Hz, J9a,9b = 10.0 Hz, H-9a), 3.99 (dd, 1H, J9b,8 = 2.1 Hz, J9b,9a = 10.0 
Hz, H-9b), 3.72 (s, 3H, OCH3), 3.49 (s, 3H, OCH3), 2.11, 2.01, 1.90 (3 x s, 9H, 3 x 
OAc), 0.94 (s, 9H, C(CH3)3), 0.11 (s, 3H, SiCH3), 0.07 (s, 3H, SiCH3);  
13C NMR (CDCl3, 100MHz): δ 171.47, 170.00, 169.45, 169.06 (4 x C=O), 98.86 (C-1), 
90.00 (C-3), 79.42 (C-2), 77.31 (C-8), 73.44 (C-9), 72.48 (C-6), 70.19 (C-5), 65.20 (C-
4), 55.46 (OCH3), 51.75 (OCH3), 25.39 (C(CH3)3), 22.03, 20.76, 20.32 (3 x OAc), 18.11 
(C(CH3)3), -5.34 (SiCH3), -5.38 (SiCH3);  
HRMS (CI) m/z: [M+NH4]+ calcd for C23H42O12NSi, 552.2476, found: 552.2472.  
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Methyl [methyl (1’S)-3-C-(1’-acetoxy-2’-hydroxyethyl)-3,4-di-O-acetyl-2,2’-
anhydro-D-glycero-α-D-gluco-heptopyranosid]uronate (88a): 
 
Acetic acid (100 µL, 1.75 mmol) and TBAF (1.40 mL, 1.43 mmol, 
1M in THF) were added to a solution of 6R triacetate derivative 
87a (170 mg, 0.32 mmol) in THF (8 mL). After 24h at 70 ºC, the 
reaction mixture was diluted with water (8 mL) and CH2Cl2 (30 
mL) and the aqueous layer was extracted with CH2Cl2 (3 x 30 
mL). The organic layers were combined, dried (MgSO4), filtered and concentrated. 
Purification by flash column chromatography (cyclohexane-EtOAc, 1:2) afforded the 
(6R)-configurated alcohol 88a (123 mg, 92%) as a colorless oil.  
Rf 0.29 (cyclohexane-EtOAc, 1:2);  
[α]D +145.5 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 6.33 (d, 1H, J4,5 = 10.2 Hz, H-4), 5.62 (dd, 1H, J8,9b = 1.8 
Hz, J8,9a = 5.2 Hz, H-8), 5.13 (d, 1H, J1,2 = 4.6 Hz, H-1), 4.77 (d, 1H, J2,1 = 4.6 Hz, H-2), 
4.49 (dd, 1H, J5,6 = 1.7 Hz, J5,4 = 10.2 Hz, H-5), 4.20 – 4.16 (m, 2H, H-6, H-9a), 4.02 
(dd, 1H, J9b,8 = 1.8 Hz, J9b,9a = 10.2 Hz, H-9b), 3.84 (s, 3H, OCH3), 3.40 (s, 3H, OCH3), 
2.15, 2.06, 2.05 (3 x s, 9H, 3 x OAc);  
13C NMR (CDCl3, 100MHz): δ 172.85, 170.79, 170.14, 169.87 (4 x C=O), 99.34 (C-1), 
90.38 (C-3), 80.31 (C-2), 77.65 (C-8), 73.75 (C-9), 70.29 (C-5), 70.16 (C-6), 65.92 (C-
4), 56.23 (OCH3), 53.23 (OCH3), 22.43, 21.53, 20.99 (3 x OAc);  
HRMS (FAB) m/z: [M+Na]+ calcd for C17H24O12Na, 443.1165, found: 443.1169.  
 
Methyl [methyl (1’S)-3-C-(1’-acetoxy-2’-hydroxyethyl)-3,4-di-O-acetyl-2,2’-
anhydro-L-glycero-α-D-gluco-heptopyranosid]uronate (88b): 
 
A 40% aqueous solution of HF (96 µL, 4.8 mmol) was added to a 
solution of 6S triacetate derivative 87b (64 mg, 120 µmol) in 
CH3CN (4 mL) at room temperature. The reaction mixture was 
stirred during 4 days until the TLC revealed no trace of starting 
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material. The reaction mixture was neutralized by slow addition of saturated aqueous 
solution of NaHCO3. The organic layer was separated, and the aqueous layer was 
extracted with CH2Cl2 (20 mL). The organic layers were combined, dried (MgSO4), 
filtered and concentrated. Purification by flash column chromatography (cyclohexane-
EtOAc, 1:2) afforded the (6S)-configurated alcohol 88b (33 mg, 66%) as a colorless oil. 
Rf 0.31 (cyclohexane-EtOAc, 1:2);  
[α]D +165.8 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 6.38 (d, 1H, J4,5 = 10.5 Hz, H-4), 5.59 (dd, 1H, J8,9b = 2.1 
Hz, J8,9a = 5.6 Hz, H-8), 5.07 (d, 1H, J1,2 = 5.1 Hz, H-1), 4.88 (d, 1H, J2,1 = 5.1 Hz, H-2), 
4.53 (dd, 1H, J5,6 = 1.8 Hz, J5,4 = 10.5 Hz, H-5), 4.40 (d, 1H, J6,5 = 1.8 Hz, H-6), 4.25 
(dd, 1H, J9a,8 = 5.6 Hz, J9a,9b = 10.1 Hz, H-9a), 4.03 (dd, 1H, J9b,8 = 2.1 Hz, J9b,9a = 10.1 
Hz, H-9b), 3.85 (s, 3H, OCH3), 3.51 (s, 3H, OCH3), 2.15, 2.05, 1.99 (3 x s, 9H, 3 x 
OAc);  
13C NMR (CDCl3, 100MHz): δ 172.63, 170.71, 170.04, 169.83 (4 x C=O), 99.17 (C-1), 
90.35 (C-3), 79.82 (C-2), 77.36 (C-8), 74.04 (C-9), 71.00 (C-6), 70.28 (C-5), 65.70 (C-
4), 56.12 (OCH3), 53.20 (OCH3), 22.53, 21.36, 20.96 (3 x OAc);  
HRMS (FAB) m/z: [M+Na]+ calcd for C17H24O12Na, 443.1165, found: 443.1163.  
 
Methyl [methyl (1’S)-3-C-(1’-acetoxy-2’-hydroxyethyl)-3,4-di-O-acetyl-2,2’-
anhydro-6-azido-6-deoxy-L-glycero-α-D-gluco-heptopyranosid]uronate (89a): 
 
To a solution of (6R)-configurated alcohol 88a (50 mg, 119 µmol) 
in dry CH2Cl2 (2 mL), anhydrous pyridine (154 µL, 1.90 mmol) 
was added followed by slow addition of Tf2O (160 µL, 0.95 mmol) 
at – 78 ºC under argon. After stirring 90 min at room temperature, 
water (2 mL) and CH2Cl2 (10 mL) were added. The organic layer 
was separated, dried (MgSO4), filtered and concentrated under reduced pressure. The 
crude triflate was directly engaged in the next step. Sodium azide (46 mg, 0.71 mmol) 
was added to a solution of the crude triflate in anhydrous DMF (2 mL) at room 
temperature. After stirring overnight the reaction mixture was concentrated under 
reduced pressure. The residue was then diluted with ether (20 mL) and water (5 mL). 
The aqueous layer was extracted with ether (3 x 15 mL), the organic layers were 
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combined, dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (cyclohexane-EtOAc, 1:1) afforded the 
peracetylated azido ester 6S 89a (42 mg, 79% over two steps) as a white crystalline 
solid.  
Rf 0.63 (cyclohexane-EtOAc, 1:2);  
m.p. 102 ºC (EtOH);  
[α]D +141.6 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 6.31 (d, 1H, J4,5 = 10.3 Hz, H-4), 5.56 (dd, 1H, J8,9b = 1.8 
Hz, J8,9a = 5.5 Hz, H-8), 5.06 (d, 1H, J1,2 = 5.0 Hz, H-1), 4.86 (d, 1H, J2,1 = 5.0 Hz, H-2), 
4.67 (dd, 1H, J5,6 = 3.6 Hz, J5,4 = 10.3 Hz, H-5), 4.23 (dd, 1H, J9a,8 = 5.5 Hz, J9a,9b = 10.1 
Hz, H-9a), 4.08 (d, 1H, J6,5 = 3.6 Hz, H-6), 4.01 (dd, 1H, J9b,8 = 1.8 Hz, J9b,9a = 10.1 Hz, 
H-9b), 3.84 (s, 3H, OCH3), 3.52 (s, 3H, OCH3), 2.15, 2.06, 2.01 (3 x s, 9H, 3 x OAc);  
13C NMR (CDCl3, 100MHz): δ 170.84, 169.86, 169.78, 169.38 (4 x C=O), 99.31 (C-1), 
90.04 (C-3), 79.67 (C-2), 77.46 (C-8), 73.99 (C-9), 69.39 (C-5), 66.87 (C-4), 63.01 (C-
6), 56.58 (OCH3), 53.23 (OCH3), 22.48, 21.40, 20.84 (3 x OAc);  
HRMS (CI) m/z: [M+NH4]+ calcd for C17H27O11N4, 463.1676, found: 463.1680. 
 
Methyl [methyl (1’S)-3-C-(1’-acetoxy-2’-hydroxyethyl)-3,4-di-O-acetyl-2,2’-
anhydro-6-azido-6-deoxy-D-glycero-α-D-gluco-heptopyranosid]uronate (89b): 
 
To a solution of (6S)-configurated alcohol 88b (30 mg, 71.4 
µmol) in dry CH2Cl2 (2 mL), anhydrous pyridine (92 µL, 1.14 
mmol) was added followed by slow addition of Tf2O (96 µL, 0.57 
mmol) at – 78 ºC under argon. After stirring 90 min at room 
temperature, water (2 mL) and CH2Cl2 (10 mL) were added. The 
organic layer was separated, dried (MgSO4), filtered and concentrated under reduced 
pressure. The crude triflate was directly engaged in the next step. Sodium azide 
(28mg, 428 µmol) was added to a solution of the crude triflate in anhydrous DMF (2 
mL) at room temperature. After stirring overnight the reaction mixture was concentrated 
under reduced pressure. The residue was then diluted with ether (20 mL) and water (5 
mL). The aqueous layer was extracted with ether (3 x 15 mL), the organic layers were 
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combined, dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (cyclohexane-EtOAc, 1:1) afforded the 
peracetylated azido ester 6R 89b (26 mg, 81% over two steps) as a white crystalline 
solid.  
Rf 0.58 (cyclohexane-EtOAc, 1:2); 
m.p. 123 ºC (EtOH);  
[α]D +195.5 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 6.28 (d, 1H, J4,5 = 10.3 Hz, H-4), 5.62 (dd, 1H, J8,9b = 1.9 
Hz, J8,9a = 5.4 Hz, H-8), 5.10 (d, 1H, J1,2 = 4.9 Hz, H-1), 4.85 (d, 1H, J2,1 = 4.9 Hz, H-2), 
4.73 (dd, 1H, J5,6 = 2.4 Hz, J5,4 = 10.3 Hz, H-5), 4.23 (dd, 1H, J9a,8 = 5.4 Hz, J9a,9b = 10.2 
Hz, H-9a), 4.02 (dd, 1H, J9b,8 = 1.9 Hz, J9b,9a = 10.2 Hz, H-9b), 3.88 (s, 3H, OCH3), 3.85 
(d, 1H, J6,5 = 2.4 Hz, H-6), 3.45 (s, 3H, OCH3), 2.15, 2.07 (2 x s, 9H, 3 x OAc);  
13C NMR (CDCl3, 100MHz): δ 170.76, 169.94, 169.78, 169.15 (4 x C=O), 99.23 (C-1), 
90.07 (C-3), 79.94 (C-2), 77.34 (C-8), 73.92 (C-9), 70.08 (C-5), 66.83 (C-4), 61.79 (C-
6), 56.35 (OCH3), 53.42 (OCH3), 22.42, 21.46, 20.94 (3 x OAc);  
HRMS (CI) m/z: [M+NH4]+ calcd for C17H27O11N4, 463.1676, found: 463.1675. 
 
Methyl (1’S)-2,2’-anhydro-3-C-(1’,2’-dihydroxyethyl)-α-D-glucopyranoside (90): 
 
The bicyclic derivative 14 (0.73 g, 2.25 mmol) was dissolved in 
80% aqueous solution of acetic acid (25 mL) and warmed to 50 
ºC over a period of 2 h. The solvent was removed under reduced 
pressure and the residue obtained co-evaporated with toluene (3 
x 50 mL). Purification by flash column chromatography (CH2Cl2-MeOH 8:2) afforded 
the miharamycins bicyclic unit 90 (0.53 g, quant. yield) as a white solid.  
Rf 0.23 (EtOAc-MeOH, 9:1);  
m.p. 142 - 144 ºC (CH2Cl2 / MeOH);  
[α]D +125.3 (c 1.0, MeOH);  
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1H NMR (D2O, 400MHz): δ 4.95 (d, 1H, J1,2 = 5.4 Hz, H-1), 4.36 (dd, 1H, J8a,7 = 5.0 Hz, 
J8a,8b = 10.1 Hz, H-8a), 4.25 (d, 1H, J7,8a = 5.0 Hz, H-7), 4.04 (d, 1H, J2,1 = 5.4 Hz, H-2), 
3.93 (d, 1H, J
 4,5 = 10.0 Hz, H-4), 3.93 – 3.83 (m, 3H, H-5, H-6a, H-8b), 3.72 (dd, 1H, 
J6b,5 = 5.5 Hz, J6b,6a = 12.3 Hz, H-6b), 3.46 (s, 3H, OCH3);  
13C NMR (D2O, 100MHz): δ  98.13 (C-1), 82.30 (C-3), 81.74 (C-2), 77.29 (C-8), 76.78 
(C-7), 71.68 (C-5), 70.75 (C-4), 61.15 (C-6), 55.62 (OCH3);  
HRMS (CI) m/z: [M+NH4]+ calcd for C9H20O7N, 254.1234, found: 254.1241;  
Anal. Calcd for C9H16O7: C, 45.76; H, 6.83. Found: C, 45.80; H, 6.90. 
 
Methyl (1’S)-3-C-(1’-acetoxy-2’-hydroxyethyl)-3,4,6-tri-O-acetyl-2,2’-anhydro-α-D-
glucopyranoside (91): 
 
To the bicyclic compound 90 (0.27 g, 1.14 mmol) in dry pyridine 
(5 mL) were added acetic anhydride (2.5 mL) and a catalytic 
amount of DMAP. The reaction mixture was stirred overnight at 
room temperature, then co-evaporated with toluene and 
concentrated. The crude residue was dissolved in CH2Cl2 (80 mL) and washed with a 
1M aqueous solution of HCl (20 mL). The organic layer was separated, dried (MgSO4) 
and concentrated under reduced pressure. Purification by flash column 
chromatography (cyclohexane-EtOAc, 1:1) afforded the peracetylated compound 91 
(0.43 g, 92%) as a colorless oil.  
Rf 0.32 (cyclohexane-EtOAc, 1:1);  
[α]D +95.5 (c 0.7, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 5.91 (d, 1H, J4,5 = 10.3 Hz, H-4), 5.51 (dd, 1H, J7,8b = 2.2 
Hz, J7,8a  = 5.7 Hz, H-7), 4.92 (d, 1H, J1,2 = 5.2 Hz, H-1), 4.77 (d, 1H, J2,1 = 5.2 Hz, H-2), 
4.22 (ddd, 1H, J5,6b = 2.4 Hz, J5,6a = 5.4 Hz, J5,4  = 10.3 Hz, H-5), 4.17 – 4.13 (m, 2H, H-
6, H-8a), 4.04 (dd, 1H, J6b,5 = 2.4 Hz, J6b,6a = 12.6 Hz, H-6b), 3.91 (dd, 1H, J8b,7 = 2.2 Hz, 
J8b,8a = 10.0 Hz, H-8b), 3.36 (s, 3H, OCH3), 2.03, 1.99, 1.94, 1.93 (4 x s, 12H, 4 x OAc);  
13C NMR (CDCl3, 100MHz): δ 170.31, 169.92, 169.55, 169.12 (4 x C=O), 98.20 (C-1), 
89.49 (C-3), 79.03 (C-2), 76.58 (C-7), 73.18 (C-8), 66.22 (C-5), 65.93 (C-4), 62.41 (C-
6), 55.12 (OCH3), 21.74, 20.73, 20.35, 20.16 (4 x OAc);  
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HRMS (FAB) m/z: [M+Na]+ calcd for C17H28O11Na, 422.1662, found: 422.1671. 
 
Methyl (1’S)-2,2’-anhydro-3,4,6-tri-O-benzyl-3-C-(1’-benzyloxy-2’-hydroxyethyl)-α-
D-glucopyranoside (92): 
 
Sodium hydride (275 mg, 6.86 mmol, 60% w/w) was added to a 
solution of the bicyclic compound 90 (270 mg, 1.14 mmol) in 
anhydrous DMF (8 mL) at 0ºC. After 30 min, BnBr (1.1 mL, 9.15 
mmol) was added at 0ºC. After stirring for 2.5h at room 
temperature, MeOH (10 mL) was added and the mixture was concentrated under 
reduced pressure. The residue was then diluted with ether (80 mL) and water (30 mL). 
The aqueous layer was extracted with ether (3 x 80 mL), the organic layers were 
combined, dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (cyclohexane then cyclohexane-EtOAc, 
4:1) afforded the fully protected compound 92 (579 mg, 85%) as a colorless oil.  
Rf 0.56 (cyclohexane-EtOAc, 2:1); 
[α]D +115.8 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.54 - 7.43 (m, 20H, H arom.), 5.18 (d, 1H, J1,2 = 5.8 Hz, 
H-1), 5.07 (d, 1H, J = 11.2 Hz, CHPh), 4.86 – 4.77 (m, 5H, 3 x CHPh, CH2Ph), 4.72 – 
4.67 (m, 3H, 2 x CHPh, H-5), 4.56 (d, 1H, J2,1 = 5.8 Hz, H-2), 4.53 – 4.42 (m, 4H, H-4, 
H-7, H-8a, H-8b), 3.99 (dd, 1H, J
 6a,5 = 3.6 Hz, J 6a,6b = 10.8 Hz, H-6a), 3.90 (dd, 1H, J6b,5 
= 1.9 Hz, J6b,6a = 10.8 Hz, H-6b), 3.85 (s, 3H, OCH3);  
13C NMR (CDCl3, 100MHz): δ 138.73, 138.39, 138.12, 137.66 (4C arom. quat.), 
128.61-126.63 (20CH arom.), 98.86 (C-1), 89.38 (C-3), 84.96 (C-2), 77.90 (C-7), 74.76 
(C-8), 74.57 (C-4), 74.08 (CH2Ph), 72.98 (CH2Ph), 72.36 (CH2Ph), 68.55 (C-6), 67.48 
(C-5), 64.37 (CH2Ph), 54.60 (OCH3);  
HRMS (FAB) m/z: [M+Na]+ calcd for C37H40O7Na, 619.2666, found: 619.2668;  
Anal. Calcd for C37H40O7: C, 74.47; H, 6.76. Found: C, 74.45; H, 6.69.  
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(1’S)-3-C-(1’-acetoxy-2’-hydroxyethyl)-1,3,5,6-tetra-O-acetyl-2,2’-anhydro-β-D-
glucofuranose (93) and (1’S)-3-C-(1’-acetoxy-2’-hydroxyethyl)-1,3,4,6-tetra-O-
acetyl-2,2’-anhydro-β-D-glucopyranose (94): 
 
A solution of conc. sulfuric acid (5% in AcOH, 80 µL) was 
added dropwise at 0 ºC to a solution of peracetylated methyl 
glycoside 91 (212 mg, 0.52 mmol) in acetic anhydride (10 mL). 
The reaction mixture was stirred at this temperature over 45 
min and then neutralized by slow addition of a NaHCO3 
saturated aqueous solution.
 
The organic layer was separated, 
and the aqueous layer was extracted with CH2Cl2 (3 x 80 mL). 
The organic layers were combined, dried (MgSO4), filtered and 
concentrated. Purification by flash column chromatography 
(cyclohexane-acetone, 2:1) afforded the peracetylated bis(tetrahydrofuran) 93 (159 mg, 
70%) as a colorless oil. Further elution afforded the peracetylated glycosyl donor 94 
(45 mg, 20%) as a colorless oil. 
Compound 93: 
Rf 0.23 (cyclohexane-acetone, 2:1); 
[α]D +18.5 (c 0.3, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 6.19 (s, 1H, H-1), 6.13 (dd, 1H, J7,8b = 6.1 Hz, J7,8a = 7.2 
Hz, H-7), 5.44 (ddd, 1H, J5,6a = 2.5 Hz, J5,6b =6.3 Hz, J5,4 = 8.9 Hz, H-5), 4.94 (s, 1H, H-
2), 4.85 (d, 1H, J4,5 = 8.9 Hz, H-4), 4.64 (dd, 1H, J6a,5 = 2.5 Hz, J6a,6b = 12.2 Hz, H-6a), 
4.42 (dd, 1H, J8a,7 = 7.2 Hz, J8a,8b = 9.9 Hz, H-8a), 4.00 (dd, 1H, J6b,5 = 6.3 Hz, J6b,6a = 
12.2 Hz, H-6b), 3.88 (dd, 1H, J8b,7 = 6.1 Hz, J8b,8a = 9.9 Hz, H-8b), 2.14, 2.13, 2.07, 
2.06, 2.05 (5 x s, 15H, 5 x OAc);  
13C NMR (CDCl3, 100MHz): δ 170.41, 169.96, 169.63, 169.48, 169.02 (5 x C=O), 99.54 
(C-1), 92.98 (C-3), 86.82 (C-2), 80.16 (C-4), 73.99 (C-7), 71.09 (C-8), 68.99 (C-5), 
63.48 (C-6), 21.17, 20.98, 20.68, 20.63 (5 x OAc);  
HRMS (CI) m/z: [M+NH4]+ calcd for C18H28O12N, 450.1612, found: 450.1651. 
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Compound 94: 
Rf 0.20 (cyclohexane-acetone, 2:1);  
[α]D +23 (c 0.2, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 6.02 (d, 1H, J4,5 = 10.2 Hz, H-4), 5.85 (d, 1H, J1,2 = 7.8 Hz, 
H-1), 5.61 (d, 1H, J7,8a = 4.0 Hz, H-7), 4.84 (d, 1H, J2,1 = 7.8 Hz, H-2), 4.26 – 4.22 (m, 
2H, H-6a, H-8a), 4.16 – 4.10 (m, 2H, H-5, H-6b), 3.93 (d, 1H, J8b,8a = 10.7 Hz, H-8b), 
2.21, 2.18, 2.10, 2.07, 2.06 (5 x s, 15H, 5 x OAc);  
13C NMR (CDCl3, 100MHz): δ 170.80, 169.70, 169.60, 169.40, 186.60 (5 x C=O), 93.20 
(C-1), 89.60 (C-3), 80.00 (C-2), 76.50 (C-7), 73.00 (C-5 and C-8), 66.60 (C-4), 62.40 
(C-6), 22.00, 21.20, 21.00, 20.70, 20.50 (5 x OAc);  
HRMS (CI) m/z: [M+NH4]+ calcd for C18H28O12N, 450.1612, found: 450.1612. 
 
(1’S)-1,6-di-O-acetyl-2,2’-anhydro-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-hydroxy 
ethyl)-β-D-glucopyranose (95) and (1’S)-1,5,6-tri-O-acetyl-2,2’-anhydro-3-O-
benzyl-3-C-(1’-benzyloxy-2’-hydroxyethyl)-β-D-glucofuranose (96): 
 
To a solution of the perbenzylated derivative 92 (450 mg, 0.76 
mmol) in acetic anhydride (15 mL) was added dropwise 
sulfuric acid 5% in AcOH (0.4 mL) at – 20 ºC. The reaction 
mixture was stirred at this temperature over 25 min and then 
neutralized by slowly addition of a NaHCO3 saturated aqueous 
solution.
 
The organic layer was separated, and the aqueous 
layer was extracted with CH2Cl2 (3 x 150 mL). The organic 
layers were combined, dried (MgSO4), filtered and 
concentrated. Purification by flash column chromatography 
(cyclohexane-CH2Cl2-EtOAc, 8:1:1) afforded the suitable glycosyl donor 95 (209 mg, 
48%) as a colorless oil. Further elution (cyclohexane-CH2Cl2-EtOAc, 8:1:1) afforded a 
product resulting from the contraction of the pyranose ring 96 (139 mg, 32%) as a 
colorless oil.  
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Compound 95:  
Rf 0.54 (cyclohexane-CH2Cl2-EtOAc, 2:1:1);  
[α]D +33.9 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.40 - 7.28 (m, 15H, H arom.), 6.10 (d, 1H, J1,2 = 7.8 Hz, 
H-1), 4.91 (d, 1H, J = 11.0 Hz, CHPh), 4.71 – 4.60 (m, 5H, CHPh, 2 x CH2Ph), 4.38 – 
4.25 (m, 5H, H-2, H-5, H-7, H-6a, H-6b), 4.20 (dd, 1H, J
 8a,7 = 3.5 Hz, J 8a,8b  = 9.3 Hz, H-
8a), 4.10 -4.04 (m, 2H, H-4, H-8b), 2.18, 2.09 (2 x s, 6H, OAc);  
13C NMR (CDCl3, 100MHz): δ 171.22, 169.78 (2 x C=O), 138.27, 137.97, 137.75 (C 
arom. quat.), 128.99 - 127.72 (15CH arom.), 93.90 (C-1), 90.35 (C-3), 84.84 (C-2 or C-
7), 78.36 (C-2 or C-7), 75.03 (CH2Ph), 74.33 (C-4), 74.01 (C-8), 73.89 (C-5), 73.25 
(CH2Ph), 65.39 (CH2Ph), 63.80 (C-6), 21.57 (OAc), 21.35 (OAc);  
HRMS (FAB) m/z: [M+Na]+ calcd for C33H36O9Na, 599.2257, found: 599.2252.  
 
Compound 96:  
Rf 0.31 (cyclohexane-CH2Cl2-EtOAc, 2:1:1);  
[α]D +43.2 (c 1.2, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.40 - 7.30 (m, 10H, H arom.), 6.15 (s, 1H, H-1), 5.63 
(ddd, 1H, J5,6a = 2.5 Hz, J5,6b = 5.9 Hz, J5,4 = 8.8 Hz, H-5), 5.09 (d, 1H, J4,5 = 8.7 Hz, H-
4), 4.78 (d, 1H, J = 11.7 Hz, CHPh), 4.69 (dd, 1H, J6a,5 = 2.5 Hz, J6a,6b = 12.1 Hz, H-6a), 
4.66 – 4.62 (m, 4H, H-2, H-7, CH2Ph), 4.51 (d, 1H, J = 11.7 Hz, CHPh), 4.14 (dd, 1H, J 
8a,7 = 7.4 Hz, J 8a,8b  = 9.2 Hz, H-8a), 4.69 (dd, 1H, J6b,5 = 5.9 Hz, J6b,6a = 12.1 Hz, H-6b), 
4.72 (t, 1H, J8b,7 = J8b,8a = 9.2 Hz, H-8b), 2.15, 2.08, 1.86 (3 x s, 9H, OAc);  
13C NMR (CDCl3, 100MHz): δ 170.71, 169.54, 169.46 (3 x C=O), 138.30 (2 x C arom. 
quat.), 128.55 - 127.30 (10CH arom.), 101.62 (C-1), 94.36 (C-3), 85.20 (C-2), 81.03 (C-
4), 77.60 (C-7), 71.98 (CH2Ph), 69.66 (C-5), 69.48 (C-8), 67.67 (CH2Ph), 63.78 (C-6), 
21.12 (OAc), 20.91 (OAc), 20.79 (OAc);  
HRMS (ESI) m/z: [M+Na]+ calcd for C28H32O10Na, 551.18877, found: 551.18931. 
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Methyl (1’S)-2,2’-anhydro-3,4,6-tri-O-benzoyl-3-C-(1’-benzoyloxy-2’-hydroxyethyl)-
α-D-glucopyranoside (100): 
 
To the bicyclic compound 90 (0.16 g, 0.67 mmol) in anhydrous 
pyridine (2.5 mL) were added benzoyl chloride (0.78 mL, 6.71 
mmol) and a catalytic amount of DMAP. The reaction mixture 
was stirred over 8h at room temperature and then warmed to 80 
ºC. After stirring for 48h, TLC revealed no trace of starting material; then the reaction 
mixture was co-evaporated with toluene and concentrated. The crude residue was 
dissolved in CH2Cl2 (80 mL) and washed with a 1M aqueous solution of HCl (20 mL). 
The organic layer was separated, dried (MgSO4) and concentrated under reduced 
pressure. Purification by flash column chromatography (cyclohexane-EtOAc, 4:1) 
afforded the perbenzoylated compound 100 (0.32 g, 72%) as a colorless oil.  
Rf 0.58 (cyclohexane-EtOAc, 1:1);  
[α]D +105 (c 0.8, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 8.23 - 7.26 (m, 20H, H arom.), 6.83 (d, 1H, J4,5 = 10.3 Hz, 
H-1), 6.09 (dd, 1H, J7,8b = 1.8 Hz, J7,8a = 5.3 Hz, H-7), 5.31 (d, 1H, J2,1 = 5.4 Hz, H-2), 
5.27 (d, 1H, J1,2 = 5.4 Hz, H-1), 4.85 (ddd, 1H, J5,6a = 3.2 Hz, J5,6b = 5.3 Hz, J5,4 = 10.3 
Hz, H-5), 4.61 (dd, 1H, J6a,5 = 3.2 Hz, J6a,6b = 12.0 Hz, H-6a), 4.56 (dd, 1H, J8a,7 = 5.3 
Hz, J8a,8b = 10.3 Hz, H-8a), 4.43 (dd, 1H, J6b,5 = 5.3 Hz, J6b,6a = 12.0 Hz, H-6b), 4.29 (dd, 
1H, J8b,7 = 1.8 Hz, J8b,8a = 10.3 Hz, H-8b), 3.64 (s, 3H, OCH3);  
13C NMR (CDCl3, 100MHz): δ 166.51, 165.97, 165.90, 165.76 (4x C=O), 134.11 – 
133.46 (5CH arom.), 130.60, 130.57, 130.03, 129.14 (4C arom. quat.), 130.31 - 128.70 
(15CH arom.), 99.42 (C-1), 91.20 (C-3), 79.92 (C-2), 78.54 (C-7), 74.92 (C-8), 68.22 
(C-4), 67.20 (C-5), 64.34 (C-6), 56.31 (OCH3);  
HRMS (FAB) m/z: [M+Na]+ calcd for C37H32O11Na, 675.1842, found: 675.1849.  
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Methyl [(1’S)-1-O-acetyl-2,2’-anhydro-6-azido-3,4-di-O-benzyl-3-C-(1’-benzyloxy-
2’-hydroxyethyl)-6-deoxy-L-glycero-β-D-gluco-heptopyran]uronate (101a): 
 
A solution of conc. sulfuric acid (5% in AcOH, 70 µL) was 
added dropwise at – 20 ºC to a solution of methyl azido ester 
6S 82a (150 mg, 254 µmol) in acetic anhydride (5 mL). The 
reaction mixture was allowed to warm to 0 ºC over a period of 
15 min., and then neutralized by slow addition of a NaHCO3 
saturated aqueous solution.
 
The organic layer was separated, and the aqueous layer 
was extracted with CH2Cl2 (3 x 50 mL). The organic layers were combined, dried 
(MgSO4), filtered and concentrated. Purification by flash column chromatography 
(cyclohexane-CH2Cl2-EtOAc, 8:1:1) afforded the glycosyl donor 6S 101a (61 mg, 39%) 
as a colorless oil. 
Rf 0.44 (cyclohexane-CH2Cl2-EtOAc, 4:1:1);  
[α]D +23.9 (c 1.0, CHCl3); 
1H NMR (CDCl3, 400MHz): δ 7.37 - 7.22 (m, 15H, H arom.), 6.09 (d, 1H, J1,2 = 7.7 Hz, 
H-1), 4.94 (d, 1H, J = 9.7 Hz, CHPh), 4.79 (dd, 1H, J5,6 = 2.4 Hz, J5,4  = 9.7 Hz, H-5), 
4.69 (s, 2H, CH2Ph), 4.59 – 4.56 (m, 3H, CH2Ph, CHPh), 4.49 (d, 1H, J6,5 = 2.4 Hz, H-
6), 4.41 (d, 1H, J4,5 = 9.7 Hz, H-4), 4.28 (d, 1H, J2,1 = 7.7 Hz, H-2), 4.22 – 4.20 (m, 2H, 
H-8, H-9a), 4.04 (br d, 1H, J9b,9a = 9.2 Hz, H-9b), 3.38 (s, 3H, OCH3), 2.19 (s, 3H, OAc);  
13C NMR (CDCl3, 100MHz): δ 167.42, 167.59 (2 x C=O), 137.69, 137.42, 137.28 (3C 
arom. quat.), 128.56 - 127.45 (15CH arom.), 93.49 (C-1), 90.09 (C-3), 84.65 (C-8), 
77.49 (C-2), 74.75 (C-5), 74.55 (C-9), 73.79 (CH2Ph), 72.87 (C-4), 72.75 (CH2Ph), 
65.02 (CH2Ph), 63.05 (C-6), 52.31 (OCH3), 21.07 (OAc); 
HRMS (CI) m/z: [M+NH4]+ calcd for C33H39O9N4, 635.2712, found: 635.2719. 
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Methyl [(1’S)-1-O-acetyl-2,2’-anhydro-6-azido-3,4-di-O-benzyl-3-C-(1’-benzyloxy-
2’-hydroxyethyl)-6-deoxy-D-glycero-β-D-gluco-heptopyran]uronate (101b): 
 
To a solution of methyl azido ester 6R 82b (180 mg, 0.31 
mmol) in acetic anhydride (6 mL) was added dropwise sulfuric 
acid (22 µL) at 0 ºC. The reaction mixture was stirred at this 
temperature over 40 min and then neutralized by slow addition 
of a NaHCO3 saturated aqueous solution. The organic layer 
was separated, and the aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The 
organic layers were combined, dried (MgSO4), filtered and concentrated. Purification by 
flash column chromatography (cyclohexane-CH2Cl2-EtOAc, 8:1:1) afforded the glycosyl 
donor 6R 101b (136 mg, 72%) as a colorless oil.  
Rf 0.50 (cyclohexane-CH2Cl2-EtOAc, 4:1:1);  
[α]D +28.4 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.41 - 7.28 (m, 15H, H arom.), 5.92 (d, 1H, J1,2 = 7.8 Hz, 
H-1), 4.99 (d, 1H, J = 11.2 Hz, CHPh), 4.70 (dd, 1H, J5,6 = 2.3 Hz, J5,4 = 9.9 Hz, H-5), 
4.69 – 4.63 (m, 5H, CHPh, 2 x CH2Ph), 4.30 (d, 1H, J4,5 = 9.9 Hz, H-4), 4.27 – 4.20 (m, 
4H, H-2, H-6, H-8, H-9a), 4.06 (br d, 1H, J9b,9a = 9.3 Hz, H-9b), 3.75 (s, 3H, OCH3), 2.12 
(s, 3H, OAc);  
13C NMR (CDCl3, 100MHz): δ 169.59, 160.00 (2 x C=O), 138.32, 137.84, 137.75 (3C 
arom. quat.), 128.99 - 127.76 (15CH arom.), 94.08 (C-1), 90.46 (C-3), 84.80 (C-2 or C-
8), 78.05 (C-2 or C-8), 75.55 (C-5), 75.18 (CH2Ph), 74.56 (C-4), 73.95 (C-9), 73.20 
(CH2Ph), 65.51 (CH2Ph), 61.55 (C-6), 53.25 (OCH3), 21.44 (OAc);  
HRMS (FAB) m/z: [M+Na]+ calcd for C33H35O9N3Na, 640.2271, found: 640.2279. 
 
2-acetamidopurine54 (56): 
 
 A mixture of N,N-dimethylacetamide (21 mL) and Ac2O (2.4 mL, 25.9 
mmol) was stirred and heated to 150 ºC under argon. To this hot 
solution was added the 2-aminopurine nucleobase 102 (1.0 g, 7.4 
mmol) slowly with stirring. During the addition of the base the solution should be 
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homogeneous. The reaction mixture was stirred for 45 min at 150 ºC under argon and 
then cooled to 90 ºC. A mixture of EtOH-H2O 4:1 (15 mL) was then added at this 
temperature and the reaction mixture was cooled to room temperature. After 16 hours 
the resulting precipitate was collected by filtration and washed with a small amount of 
acetone (5 mL) to give the 2-acetamidopurine 56 (0.51 g, 39%) as yellow solid. 
1H NMR (DMSO-d6, 250MHz): δ 10.50 (s, 1H, NH), 8.96 (s, 1H, H-6), 8.46 (s, 1H, H-8), 
2.51 (s, 3H, NHAc); 
MS (CI) m/z: [M+H]+ calcd for C7H8ON5, 178, found: 178. 
 
2-acetamido-6-chloropurine54 (57): 
 
A mixture of N,N-dimethylacetamide (17 mL) and Ac2O (2 mL, 20.64 
mmol) was stirred and heated to 150 ºC under argon. To this hot 
solution was added the 2-amino-6-chloropurine nucleobase 103 (1.0 g, 
5.9 mmol) slowly with stirring. During the addition of the base the 
solution should be homogeneous. The reaction mixture was stirred for 45 min at 150 ºC 
under argon and then cooled to 90 ºC. A mixture of EtOH-H2O 4:1 (15 mL) was then 
added at this temperature and the reaction mixture was cooled to room temperature. 
After 16 hours the resulting precipitate was collected by filtration and washed with a 
small amount of acetone (5 mL) to give the 2-acetamido-6-chloropurine 57 (0.52 g, 
42%) as yellow solid. 
1H NMR (DMSO-d6, 250MHz): δ 10.80 (s, 1H, NH), 8.50 (s, 1H, H-8), 2.14 (s, 3H, 
NHAc); 
MS (CI) m/z: [M+H]+ calcd for C7H7ON5Cl, 212, found: 212. 
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Methyl [(1’S)-2,2’-anhydro-6-azido-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-
hydroxyethyl)-6-deoxy-D-glycero-β-D-gluco-heptopyran]uronate (106): 
 
BSA (24 µL, 97.1 µmol) was added to a suspension of the 
nucleobase 2-acetamidopurine 56 (8.6 mg, 48.6 µmol) in 
anhydrous 1,2-dichloroethane (0.4 mL) under argon. The 
mixture was heated to 80 ºC for 45 min to afford the crude 
silylated base. To this solution was added the glycosyl donor 6R 
101b (20 mg, 32.4 µmol) dissolved in dry 1,2-dichloroethane (0.4 mL) followed by slow 
addition of TMSOTf (30 µL, 162 µmol) under argon. The solution was stirred at 85 ºC 
for 4h. The mixture was cooled to room temperature, CH2Cl2 (10 mL) was added and 
the organic layer was washed with NaHCO3 saturated aqueous solution (2 x 5 mL). The 
aqueous layer was extracted with CH2Cl2 (3 x 15 mL), the organic layers were 
combined, dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (cyclohexane-EtOAc, 3:1 then 
cyclohexane-EtOAc, 2:1) afforded the lactol 6R 106 (8.4 mg, 45%) as a colorless oil.  
Rf 0.65 (cyclohexane-EtOAc, 2:1);  
[α]D +45.2 (c 0.3, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.30 - 7.21 (m, 15H, H arom.), 5.04 (d, 1H, J1,2 = 7.3 Hz, 
H-1), 4.94 (d, 1H, J = 11.2 Hz, CHPh), 4.63 – 4.47 (m, 6H, H-5, CHPh, 2 x CH2Ph), 
4.20 (d, 1H, J4,5 = 9.9 Hz, H-4), 4.17 – 4.14 (m, 2H, H-8, H-9a), 4.07 (d, 1H, J6,5 = 2.3 
Hz, H-6), 4.01 (dd, 1H, J9b,8 = 1.4 Hz, J9b,9a = 10.5 Hz, H-9b), 3.97 (d, 1H, J2,1 = 7.3 Hz, 
H-2), 3.65 (s, 3H, OCH3);  
13C NMR (CDCl3, 100MHz): δ 169.11 (C=O), 137.97, 137.51, 137.40 (3C arom. quat.), 
128.53 - 127.39 (15CH arom.), 96.02 (C-1), 89.55 (C-3), 84.81 (C-8), 80.47 (C-2), 
74.88 (C-5), 74.76 (CH2Ph), 74.40 (C-4), 73.45 (C-9), 74.00 (CH2Ph), 64.98 (CH2Ph), 
61.31 (C-6), 52.82 (OCH3);  
HRMS (FAB) m/z: [M+Na]+ calcd for C31H33O9N3Na, 598.2165, found: 598.2155. 
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Methyl [(1’S)-1-(2-acetamido-6-chloropurin-9-yl)-2,2’-anhydro-6-azido-3,4-di-O-
benzyl-3-C-(1’-benzyloxy-2’-hydroxyethyl)-1,6-di-deoxy-L-glycero-β-D-gluco-hepto 
pyran]uronate (107) and Methyl [(1’S)-1-(2-acetamido-6-chloropurin-7-yl)-2,2’-
anhydro-6-azido-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-hydroxyethyl)-1,6-di-deoxy-
L-glycero-β-D-gluco-heptopyran]uronate (108): 
 
BSA (30 µL, 123 µmol) was added to a suspension 
of the 2-acetamido-6-chloropurine 57 (13 mg, 61 
µmol) in anhydrous 1,2-dichloroethane (1 mL) under 
argon. The mixture was heated to 80 ºC for 45 min 
and then evaporated to dryness to afford the crude 
silylated base. The residue was then dissolved in dry 
toluene (0.5 mL) and a solution of glycosyl donor 6S 
101a (25 mg, 41 µmol) in dry toluene (0.5 mL) was 
added, followed by slow addition of TMSOTf (59 µL, 
328 µmol) under argon. The reaction mixture was stirred at 85 ºC for 4h, cooled to 
room temperature and diluted with CH2Cl2 (10 mL). The organic layer was neutralized 
with a NaHCO3 saturated aqueous solution (2 x 5 mL). The aqueous layer was 
extracted with CH2Cl2 (3 x 15 mL), and the organic layers were combined, dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by flash 
column chromatography (cyclohexane-EtOAc, 3:1 then cyclohexane-EtOAc, 2:1) 
afforded the N9 regioisomer 107 (13.5 mg, 43%) as a colorless oil. Further elution 
(cyclohexane-EtOAc, 1:1 then cyclohexane-EtOAc, 1:2) afforded the N7 regioisomer 
108 (4.5 mg, 15%) as a colorless oil.  
Compound 107:  
Rf 0.63 (cyclohexane-EtOAc, 1:1);  
[α]D +25 (c 0.4, CHCl3); 
1H NMR (CDCl3, 400MHz): δ 8.05 (s, 1H, H-8), 7.91 (br s, 1H, NH), 7.30 - 7.19 (m, 
15H, H arom.), 6.08 (d, 1H, J1’,2’ = 8.9 Hz, H-1’), 4.95 (d, 1H, J = 9.9 Hz, CHPh), 4.86 
(br d, 1H, J2’,1’ = 8.9 Hz, H-2’), 4.79 (dd, 1H, J5’,6’ = 2.3 Hz, J5’,4’ = 9.8 Hz, H-5’), 4.74 (d, 
1H, J = 11.2 Hz, CHPh), 4.70 (d, 1H, J = 11.2 Hz, CHPh), 4.58 (d, 1H, J = 11.3 Hz, 
CHPh), 4.57 – 4.55 (m, 2H, H-4’, CHPh), 4.52 (d, 1H, J = 11.3 Hz, CHPh), 4.37 (d, 1H, 
J6’,5’ = 2.3 Hz, H-6’), 4.27 (d, 1H, J8’,9’a = 3.5 Hz, H-8’), 4.45 (dd, 1H, J9’a,8’ = 3.5 Hz, J9’a,9’b 
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= 9.5 Hz, H-9’a), 4.04 (d, 1H, J9’b,9’a = 9.5 Hz, H-9’b), 3.36 (s, 3H, OCH3), 2.41 (s, 3H, 
NHAc);  
13C NMR (CDCl3, 100MHz): δ 170.51, 167.15 (2 x C=O), 152.59 (C-2 or C-6), 152.21 
(C-4), 151.71 (C-2 or C-6), 142.51 (C-8), 137.52, 137.07, 137.01 (3C arom. quat.), 
128.68 - 127.42 (15CH arom.), 128.05 (C-5), 89.86 (C-3’), 85.05 (C-8’), 82.77 (C-1’), 
77.42 (C-2’ or C-5’), 76.93 (C-2’ or C-5’), 74.78 (CH2Ph), 74.73 (C-9’), 73.50 (CH2Ph), 
72.72 (C-4’), 65.37 (CH2Ph), 63.12 (C-6’), 52.59 (OCH3), 25.13 (NHAc); 
HRMS (FAB) m/z: [M+Na]+ calcd for C38H37O8N835ClNa, 791.2321, and 
C38H37O8N837ClNa, 793.2291, found: 791.2328 and 793.2301 respectively.  
 
Compound 108: 
Rf 0.16 (cyclohexane-EtOAc, 1:1); 
[α]D +35 (c 0.3, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 8.45 (s, 1H, H-8), 8.05 (br s, 1H, NH), 7.41 - 7.30 (m, 
15H, H arom.), 6.54 (d, 1H, J1’,2’ = 8.8 Hz, H-1’), 5.05 (d, 1H, J = 10.1 Hz, CHPh), 4.87 
(dd, 1H, J5’,6’ = 2.2 Hz, J5’,4’ = 9.7 Hz, H-5’), 4.81 (d, 1H, J = 11.0 Hz, CHPh), 4.76 (d, 
1H, J = 11.0 Hz, CHPh), 4.66 – 4.55 (m, 5H, H-2’, H-4’, CHPh, CH2Ph), 4.50 (d, 1H, 
J6’,5’ = 2.2 Hz, H-6’), 4.39 (d, 1H, J8’,9’a = 3.3 Hz, H-8’), 4.35 (dd, 1H, J9’a,8’ = 3.3 Hz, J9’a,9’b 
= 9.4 Hz, H-9’a), 4.19 (d, 1H, J9’b,9’a = 9.4 Hz, H-9’b), 3.47 (s, 3H, OCH3), 2.63 (s, 3H, 
NHAc);  
13C NMR (CDCl3, 100MHz): δ 171.02, 167.13 (2 x C=O), 163.16 (C-4), 152.59 (C-2 or 
C-6), 145.97 (C-8), 143.91 (C-2 or C-6), 137.47, 136.83, 136.79 (3C arom. quat.), 
128.74 - 126.66 (15CH arom.), 119.12 (C-5), 89.97 (C-3’), 84.85 (C-8’), 83.01 (C-1’), 
77.48 (C-2’), 77.18 (C-5’), 74.67 (CH2Ph), 74.37 (C-9’), 73.55 (CH2Ph), 72.63 (C-4’), 
65.46 (CH2Ph), 63.05 (C-6’), 52.62 (OCH3), 25.19 (NHAc);  
HRMS (FAB) m/z: [M+Na]+ calcd for C38H37O8N835ClNa, 791.2321, and 
C38H37O8N837ClNa, 793.2291, found: 791.2317 and 793.2277 respectively. 
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Methyl [(1’S)-1-(2-acetamido-6-chloropurin-9-yl)-2,2’-anhydro-6-azido-3,4-di-O-
benzyl-3-C-(1’-benzyloxy-2’-hydroxyethyl)-1,6-di-deoxy-D-glycero-β-D-gluco-hepto 
pyran]uronate (109) and Methyl [(1’S)-1-(2-acetamido-6-chloropurin-7-yl)-2,2’-
anhydro-6-azido-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-hydroxyethyl)-1,6-di-deoxy-
D-glycero-β-D-gluco-heptopyran]uronate (110): 
 
BSA (30 µL, 123 µmol) was added to a suspension 
of the 2-acetamido-6-chloropurine 57 (13 mg, 61 
µmol) in anhydrous 1,2-dichloroethane (1 mL) under 
argon. The mixture was heated to 80 ºC for 45 min 
and then evaporated to dryness to afford the crude 
silylated base. This residue was then dissolved in dry 
toluene (1 mL) and a solution of glycosyl donor 6R 
101b (25 mg, 41 µmol) in dry toluene (1 mL) was 
added, followed by slow addition of TMSOTf (59 µL, 
328 µmol) under argon. The solution was stirred at 85 ºC for 4h, cooled to room 
temperature, diluted with CH2Cl2 (10 mL). The organic layer was neutralized with a 
NaHCO3 saturated aqueous solution (2 x 5 mL). The aqueous layer was extracted with 
CH2Cl2 (3 x 15 mL), and the organic layers combined, dried (MgSO4), filtered and 
concentrated under reduced pressure. Purification by flash column chromatography 
(cyclohexane-EtOAc, 3:1 then cyclohexane-EtOAc, 2:1) afforded the N9 regioisomer 
109 (9 mg, 29%) as a colorless oil. Further elution (cyclohexane-EtOAc, 1:1 then 
cyclohexane-EtOAc, 1:2) afforded the N7 regioisomer 110 (6 mg, 19%) as a colorless 
oil. 
Compound 109: 
Rf 0.66 (cyclohexane-EtOAc, 1:1);  
[α]D +18 (c 0.3, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 8.00 (s, 1H, H-8), 7.88 (br s, 1H, NH), 7.42 - 7.33 (m, 
15H, H arom.), 6.07 (d, 1H, J1’,2’ = 8.8 Hz, H-1’), 4.98 (d, 1H, J = 11.2 Hz, CHPh), 4.81 
– 4.78 (m, 2H, H-2’, H-5’), 4.70 (s, 2H, CH2Ph), 4.65 (d, 1H, J = 11.2 Hz, CHPh), 4.64 
(d, 1H, J = 11.2 Hz, CHPh), 4.58 (d, 1H, J = 11.2 Hz, CHPh), 4.43 (d, 1H, J4’,5’ = 9.9 
Hz, H-4’), 4.31 (d, 1H, J8’,9’a = 3.5 Hz, H-8’), 4.19 (dd, 1H, J9’a,8’ = 3.5 Hz, J9’a,9’b = 9.6 Hz, 
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H-9’a), 4.05 (d, 1H, J9’b,9’a = 9.6 Hz, H-9’b), 4.02 (d, 1H, J6’,5’ = 2.2 Hz, H-6’), 3.60 (s, 3H, 
OCH3), 2.39 (s, 3H, NHAc);  
13C NMR (CDCl3, 100MHz): δ 170.51, 168.43 (2 x C=O), 152.52 (C-2 or C-6), 152.12 
(C-4), 151.61 (C-2 or C-6), 142.39 (C-8), 137.56, 137.13, 136.91 (3C arom. quat.), 
128.86 - 127.30 (15CH arom.), 127.62 (C-5), 89.49 (C-3’), 84.60 (C-8’), 82.81 (C-1’), 
78.04 (C-2’ or C-5’), 77.51 (C-2’ or C-5’), 75.12 (CH2Ph), 74.24 (C-9’), 74.05 (C-4’), 
73.56 (CH2Ph), 65.45 (CH2Ph), 60.99 (C-6’), 53.05 (OCH3), 25.11 (NHAc);  
HRMS (FAB) m/z: [M+Na]+ calcd for C38H37O8N835ClNa, 791.2321, and 
C38H37O8N837ClNa, 793.2291, found: 791.2313 and 793.2287 respectively.  
 
Compound 110:  
Rf 0.25 (cyclohexane-EtOAc, 1:1); 
[α]D +13 (c 0.2, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 8.35 (s, 1H, H-8), 8.15 (br s, 1H, NH), 7.35 - 7.26 (m, 
15H, H arom.), 6.42 (d, 1H, J1’,2’ = 9.0 Hz, H-1’), 5.00 (d, 1H, J = 11.2 Hz, CHPh), 4.72 
(dd, 1H, J5’,6’ = 1.9 Hz, J5’,4’ = 9.8 Hz, H-5’), 4.69 (s, 2H, CH2Ph), 4.66 (d, 1H, J = 11.2 
Hz, CHPh), 4.61 (d, 1H, J = 10.1 Hz, CHPh), 4.53 – 4.51 (m, 2H, H-2’, CHPh), 4.39 (d, 
1H, J4’,5’ = 9.8 Hz, H-4’), 4.35 (d, 1H, J8’,9’a = 3.3 Hz, H-8’), 4.25 (dd, 1H, J9’a,8’ = 3.3 Hz, 
J9’a,9’b = 9.6 Hz, H-9’a), 4.10 (d, 1H, J9’b,9’a = 9.6 Hz, H-9’b), 4.07 (d, 1H, J6’,5’ = 1.9 Hz, H-
6’), 3.60 (s, 3H, OCH3), 2.51 (s, 3H, NHAc);  
13C NMR (CDCl3, 100MHz): δ 171.38, 167.13 (2 x C=O), 162.66 (C-4), 152.56 (C-2 or 
C-6), 146.06 (C-8), 143.76 (C-2 or C-6), 137.49, 136.92, 136.68 (3C arom. quat.), 
128.78 - 127.32 (15CH arom.), 118.86 (C-5), 89.58 (C-3’), 84.52 (C-8’), 82.56 (C-1’), 
77.76 (C-5’), 77.50 (C-2’), 75.02 (CH2Ph), 74.39 (C-9’), 73.77 (C-4’), 73.72 (CH2Ph), 
65.52 (CH2Ph), 60.85 (C-6’), 53.16 (OCH3), 25.23 (NHAc);  
HRMS (FAB) m/z: [M+Na]+ calcd for C38H37O8N835ClNa, 791.2321, and 
C38H37O8N837ClNa, 793.2291, found: 791.2318 and 793.2277 respectively.  
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2-acetamido-9-(2,3,4,6-tetra-O-acetyl-1-deoxy-β-D-glucopyranosyl)-6-chloro 
purine47 (64): 
 
BSA (0.16 mL, 0.63 mmol) was added to a 
suspension of the nucleobase 2-acetamido-6-
chloropurine 57 (68 mg, 0.32 mmol) in anhydrous 
1,2-dichloroethane (2 mL) under argon. The mixture 
was heated to 80 ºC for 45 min to afford the crude silylated base. To this solution was 
added the α-peracetylated glucose (80 mg, 0.21 mmol) dissolved in dry 1,2-
dichloroethane (2 mL) followed by slow addition of TMSOTf (0.19 mL, 1.05 mmol) 
under argon. The solution was stirred overnight at 85 ºC under argon. The mixture was 
cooled to room temperature, CH2Cl2 (20 mL) was added and the organic layer was 
washed with NaHCO3 saturated aqueous solution (2 x 10 mL). The aqueous layer was 
extracted with CH2Cl2 (3 x 50 mL), the organic layers were combined, dried (MgSO4), 
filtered and concentrated under reduced pressure. Purification by flash column 
chromatography (cyclohexane-EtOAc, 1:2 then cyclohexane-EtOAc, 1:4) afforded the 
N9 nucleoside 64 (64 mg, 55%) as a colorless oil. The N7 nucleoside 68 was also 
isolated in 8% yield. 
Rf 0.66 (EtOAc);  
1H NMR (CDCl3, 400MHz): δ 8.21 (br s, 1H, NH), 8.16 (s, 1H, H-8), 5.81 (d, 1H, J1’,2’ = 
9.3 Hz, H-1’), 5.67 (t, 1H, J2’3’ = J2’1’ = 9.3 Hz, H-2’), 5.46 (t, 1H, J3’2’ = J3’4’ = 9.3 Hz, H-
3’), 5.26 (t, 1H, J4’3’ = J4’5’ = 9.3 Hz, H-4’), 4.29 (dd, 1H, J6’a,5’ = 4.8 Hz, J6’a,6’b = 12.6 Hz, 
H-6’a), 4.13 (d, 1H, J6’b,5’ = 2.0 Hz, J6’a,6’b = 12.6 Hz, H-6’b), 4.03 (ddd, 1H, J5’,6’b = 2.0 
Hz, J5’,6’a = 4.8 Hz, J5’,4’ = 9.3 Hz, H-5’), 2.57 (s, 3H, NHAc), 2.07, 2.06, 2.03, 1.81 (4x s, 
12H, 4xOAc);  
13C NMR (CDCl3, 100MHz): δ 170.71, 169.91, 169.42, 169.01 (5 x C=O), 152.58 (C-2 
or C-6), 152.42 (C-4), 151.91 (C-2 or C-6), 142.14 (C-8), 127.84 (C-5), 80.89 (C-1’), 
75.12 (C-2’), 72.73 (C-3’), 69.84 (C-4’), 67.62 (C-5’), 61.46 (C-6’), 25.11 (NHAc), 20.72, 
20.59, 20.52, 20.22 (4x OAc);  
HRMS (FAB) m/z: [M+Na]+ calcd for C21H24O10N535ClNa, 564.1109, and 
C21H24O10N537ClNa, 566.1080, found: 564.1125 and 566.1098 respectively.  
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2-acetamido-7-(2,3,4,6-tetra-O-acetyl-1-deoxy-β-D-glucopyranosyl)-6-chloro 
purine47 (68): 
 
BSA (0.16 mL, 0.63 mmol) was added to a 
suspension of the nucleobase 2-acetamido-6-
chloropurine 57 (68 mg, 0.32 mmol) in anhydrous 
CH3CN (2 mL) under argon. The mixture was heated 
to 60 ºC for 45 min to afford the crude silylated base. To this solution at room 
temperature was added the α-peracetylated glucose (80 mg, 0.21 mmol) dissolved in 
dry CH3CN (2 mL) followed by slow addition of SnCl4 1M in CH2Cl2 (1.05 mL, 1.05 
mmol) under argon. The solution was stirred overnight at room temperature under 
argon. The reaction mixture was diluted with CH2Cl2 (20 mL) and neutralized with 
NaHCO3 saturated aqueous solution (2 x 10 mL). The aqueous layer was extracted 
with CH2Cl2 (3 x 50 mL), the organic layers were combined, dried (MgSO4), filtered and 
concentrated under reduced pressure. Purification by flash column chromatography 
(EtOAc) afforded the N7 nucleoside 68 (61 mg, 53%) as a colorless oil. The N9 
nucleoside 64 was also isolated in 5% yield.  
Rf 0.38 (EtOAc);  
1H NMR (CDCl3, 400MHz): δ 8.41 (br s, 1H, NH), 8.19 (s, 1H, H-8), 6.08 (d, 1H, J1’,2’ = 
7.8 Hz, H-1’), 5.69 (dd, 1H, J2’1’ = 7.8 Hz, J2’3’ = 9.5 Hz, H-2’), 5.48 (t, 1H, J3’2’ = J3’4’ = 
9.5 Hz, H-3’), 5.29 (t, 1H, J4’3’ = J4’5’ = 9.5 Hz, H-4’), 4.29 (dd, 1H, J6’a,5’ = 5.1 Hz, J6’a,6’b = 
12.6 Hz, H-6’a), 4.19 (dd, 1H, J6’b,5’ = 1.9 Hz, J6’a,6’b = 12.6 Hz, H-6’b), 4.07 (ddd, 1H, 
J5’,6’b = 1.9 Hz, J5’,6’a = 5.1 Hz, J5’,4’ = 9.5 Hz, H-5’), 2.61 (s, 3H, NHAc), 2.09, 2.06, 1.91 
(3x s, 12H, 4xOAc);  
13C NMR (CDCl3, 100MHz): δ 171.05, 170.51, 169.99, 169.31, 169.11 (5 x C=O), 
163.44 (C-4), 152.98 (C-2 or C-6), 147.14 (C-8), 143.42 (C-2 or C-6), 118.51 (C-5), 
82.68 (C-1’), 75.01 (C-2’), 73.05 (C-3’), 69.81 (C-4’), 67.58 (C-5’), 61.51 (C-6’), 25.28 
(NHAc), 20.72, 20.55, 20.31 (4x OAc); 
HRMS (FAB) m/z: [M+Na]+ calcd for C21H24O10N535ClNa, 564.1109, and 
C21H24O10N537ClNa, 566.1080, found: 564.1132 and 566.1099 respectively.  
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(2S)-2-(benzyloxycarbonyl)amino-5-[1,3-di(benzyloxycarbonyl)guanidino] 
pentanoic acid73 (115): 
 
To a suspension of the L-arginine 113 (2 g, 11.48 mmol) in dry 
1,2-dichloroethane (75 mL) was added dropwise DiPEA (16 
mL, 92 mmol) followed by slow addition of TMSCl (11.7 mL, 92 
mmol) at room temperature and under argon. After stirring 90 
min at 40 ºC the solution was cooled to 0 ºC and more DiPEA (8 mL, 46 mmol) was 
added dropwise followed by addition of ZCl (6.6 mL, 46 mmol). The reaction mixture 
was stirred at 0 ºC for 20 min and then was allowed to warm to room temperature. After 
stirring for 4h acidification with a 1M aqueous solution of HCl (70 mL) was performed in 
order to reach pH= 2. The organic layer was separated and the aqueous layer 
extracted with ether (3 x 100 mL). The organic layers were combined, dried over 
MgSO4 and concentrated. Purification of the residue obtained by flash column 
chromatography (toluene-ethanol, 8:1) afforded the protected L-arginine 115 (3.6 g, 
55%) as a white solid. 
Rf 0.60 (toluene-ethanol, 4:1);  
m.p. 138.6 ºC (tolunene/ethanol), [Lit. 138.9 ºC]73;  
[α]D + 16.7 (c = 1.0, CHCl3) [Lit. [α]D + 17.1 (c = 1.0, CHCl3)]73;  
1H NMR (400MHz, d6-DMSO): δ  9.31 (br s, 1H, NH (B)), 7.80 (d, 1H, JNH,2 = 8.1 Hz, NH 
(A)), 7.65 – 7.51 (m, 15H, H arom.), 5.45 (s, 2H, CH2Ph), 5.27 (s, 2H, CH2Ph), 5.25 (d, 
1H, J = 12.5 Hz, CHPh), 5.21 (d, 1H, J = 12.5 Hz, CHPh), 4.18 – 4.02 (m, 3H, H-2, H-
5a, H-5b), 1.92 -1.74  (m, 4H, H-3a, H-3b, H-4a, H-4b);  
13C NMR (100MHz, d6-DMSO): δ 173.71, 162.87, 159.70, 156.15, 154.94 (C=NH, 4 x 
C=O), 137.12, 136.97, 135.28 (3C arom. quat.), 128.52 - 127.70 (15CH arom.), 68.21 
(CH2Ph), 66.11 (CH2Ph), 65.40 (CH2Ph), 53.76 (C-2), 44.19 (C-5), 28.09 (C-3 or C-4), 
25.31 (C-3 or C-4);  
HRMS (CI) m/z: [M+H]+ calcd for C32H38O8N, 564.2597, found: 564.2598. 
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Methyl [(1’S)-1-(2-acetamidopurin-9-yl)-2,2’-anhydro-3,4-di-O-benzyl-3-C-(1’-
benzyloxy-2’-hydroxyethyl)-6-{(2S)-2-(benzyloxycarbonyl)amino-5-[1,3-di(benzy 
loxycarbonyl)guanidino]pentanoylamino}-1,6-di-deoxy-L-glycero-β-D-gluco-hepto 
pyran]uronate (118):  
 
10% Pd/C (18 mg, 750 mg / mmol of 
starting material) and Et3N (5 µL) 
were added to a solution of the N9 
nucleoside 107 (18 mg, 45 µmol) in 
EtOAc (1 mL). The solution was 
degased three times and air was 
replaced by H2 (30 psi). After stirring for 4h at room temperature, the mixture was 
filtered through a Rotilabo® Nylon 0.45 µm filter and the solvent evaporated under 
reduced pressure. The crude amine 116 was directly engaged in the next step. 
Triethylamine (16 µL, 115 µmol) was added at -20 ºC under argon to a solution of 
protected L-arginine 115 (53 mg, 92 µmol) in anhydrous THF (1 mL) followed by slow 
addition of isobutyl chloroformate (12 µL, 92 µmol). This solution was stirring for 45 min 
at -20 ºC and a solution of crude amine (45 µmol) in anhydrous THF (1 mL) was added 
at -20 ºC under argon. After stirring for 2 h at -20 ºC under argon, the reaction mixture 
was quenched by addition of 1:1 CH2Cl2/MeOH mixture (1 mL) and the solvent was 
removed under reduced pressure. Purification by flash column chromatography 
(CH2Cl2-EtOAc-MeOH, 8:2:0.1) afforded the core of miharamycin B 118 (20 mg, 70% 
over two steps) as a colorless oil.  
Rf 0.24 (CH2Cl2-EtOAc-MeOH, 8:2:0.1);  
[α]D +8 (c = 0.2, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 9.42, 9.30, 8.96 (br s, 3H, 3 x NH), 8.87 (s, 1H, H-6), 8.80 
(s, 1H, H-8), 7.40 - 7.21 (m, 30H, H arom.), 6.02 (d, 1H, J1’,2’ = 8.7 Hz, H-1’), 5.95 (d, 
1H, JNH,H6’ = 8.3 Hz, NH),  5.20 (d, 1H, J = 12.2 Hz, CHPh), 5.16 (d, 1H, J = 12.2 Hz, 
CHPh), 5.13 – 4.97 (m, 7H, H-2’, H-6’, CHPh, 2x CH2Ph), 4.79 – 4.57 (m, 7H, H-4’, H-
5’, CHPh, 2x CH2Ph), 4.39 – 2.29 (m, 1H, H-2”), 4.30 (d, 1H, J8’,9’a = 3.2 Hz, H-8’), 4.22 
(dd, 1H, J9’a,8’ = 3.2 Hz, J9’a,9’b = 9.4 Hz, H-9’a), 4.04 (d, 1H, J9’b,9’a = 9.4 Hz, H-9’b), 3.98 
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– 3.75 (m, 2H, H-5”a, H-5”b), 3.53 (s, 3H, OCH3), 2.19 (s, 3H, NHAc), 1.82 – 1.48 (m, 
4H, H-3”a, H-3”b, H-4“a, H-4”b);  
13C NMR (CDCl3, 100MHz): δ 171.77, 171.02, 168.81, 163.53 (4 x C=O), 160.75 
(C=NH), 156.44, 155.79 (2 x C=O), 152.88 (C-2), 152.18 (C-4), 149.82 (C-6), 142.96 
(C-8), 137.74, 137.51, 137.02, 136.36, 136.30, 134.51 (6C arom. quat.), 131.05 (C-5), 
128.81 - 127.24 (30CH arom.), 89.85 (C-3’), 84.59 (C-8’), 83.00 (C-1’), 76.25 (C-2’), 
77.46 (C-5’ or C-4’), 74.69 (CH2Ph), 74.21 (C-9’), 73.62 (C-4’ or C-5’), 73.75 (CH2Ph), 
68.92 (CH2Ph), 67.05 (CH2Ph), 66.77 (CH2Ph), 65.18 (CH2Ph), 54.47 (C-2”), 52.64 
(OCH3), 52.37 (C-6’), 44.26 (C-5”), 29.68 (C-3” or C-4”), 25.17 (C-3” or C-4”), 24.90 
(NHAc);  
HRMS (ESI) m/z: [M+Na]+ calcd for C68H70O15N10Na, 1289.49143, found: 1289.49328. 
 
Methyl [methyl (1’S)-6-amino-2,2’-anhydro-3-C-(1’,2’-dihydroxyethyl)-6-deoxy-L-
glycero-α-D-gluco-heptopyranosid]uronate (120a): 
 
10% Pd/C (17 mg, 500 mg / mmol of starting material) was added 
to a solution of the azido ester 6S 82a (20 mg, 34 µmol) in glacial 
AcOH (3 mL). The solution was degased three times and air was 
replaced by H2 (30 psi). After stirring 2.5h at room temperature, 
the mixture was filtered through a Rotilabo® Nylon 0.45 µm filter, 
eluted with MeOH and the solvent evaporated to afford the amine 6S 120a (10 mg, 
quant. yield) as a colorless oil. 
[α]D +57.2 (c 0.5, MeOH);  
1H NMR (D2O, 400MHz): δ 4.83 (d, 1H, J1,2 = 5.5 Hz, H-1), 4.43 (d, 1H, J6,5 = 2.4 Hz, H-
6), 4.34 (dd, 1H, J5,6 = 2.4 Hz, J5,4 = 10.7 Hz, H-5), 4.23 (dd, 1H, J9a,8 = 5.0 Hz, J9a,9b = 
9.9 Hz, H-9a), 4.16 (d, 1H, J8,9a = 5.0 Hz, H-8), 4.05 (d, 1H, J4,5 = 10.7 Hz, H-4), 3.89 (d, 
1H, J2,1 = 5.5 Hz, H-2), 3.81 (d, 1H, J9b,9a = 9.9 Hz, H-9b), 3.74 (s, 3H, OCH3), 3.37 (s, 
3H, OCH3);  
13C NMR (D2O, 100MHz): δ  167.45 (C=O), 98.66 (C-1), 81.89 (C-3), 81.04 (C-2), 76.95 
(C-9), 76.41 (C-8), 71.09 (C-4), 68.65 (C-5), 56.28 (OCH3), 53.70 (C-6), 53.13 (OCH3);  
HRMS (CI) m/z: [M+H]+ calcd for C11H20O8N, 294.1189, found: 294.1183. 
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[Methyl (1’S)-2,2’-anhydro-6-azido-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-
hydroxyethyl)-6-deoxy-L-glycero-α-D-gluco-heptopyranosid]uronic acid amide 
(124a): 
 
The azido ester 6S 82a (25 mg, 42.4 µmol) was dissolved in 
methanol (1mL) and ammonium hydroxide (0.5 mL) was added 
dropwise at 0 ºC. After 24 h TLC indicated the formation of a 
single compound, together with a small amount of starting 
material, more ammonium hydroxide (0.3 mL) was added and 
the reaction mixture was stirred another night. At this point, TLC indicated the complete 
consumption of starting material and only the formation of a single compound was 
detected. The solvent was removed under reduced pressure and the crude residue 
diluted with EtOAc (10 mL). The organic layer was washed with 10% aqueous solution 
of HCl (2 x 5 mL), separated, dried (MgSO4), filtered and concentrated under reduced 
pressure. Purification by flash column chromatography (cyclohexane-EtOAc, 2:1) 
afforded the acid 6S 124a (17 mg, 70%) as a colorless oil.  
Rf 0.39 (cyclohexane-EtOAc, 1:1);  
[α]D +21.5 (c 0.3, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.36 - 7.25 (m, 15H, H arom.), 5.91 (br s, 1H, NH), 5.59 
(br s, 1H, NH), 5.06 (d, 1H, J = 11.0 Hz, CHPh), 5.89 (d, 1H, J1,2 = 5.6 Hz, H-1), 4.88 
(dd, 1H, J5,6 = 1.9 Hz, J5,4 = 8.2 Hz, H-5), 4.67 – 4.53 (m, 5H, 2x CH2Ph, CHPh), 4.33 
(d, 1H, J2,1 = 5.6 Hz, H-2), 4.32 – 4.27 (m, 3H, H-6, H-8, H-9a), 4.20 – 4.16 (m, 2H, H-
4, H-9b), 3.34 (s, 3H, OCH3);  
13C NMR (CDCl3, 100MHz): δ 170.12 (C=O), 138.69, 137.98, 137.85 (3C arom. quat.), 
128.49 - 127.16 (15CH arom.), 99.49 (C-1), 89.84 (C-3), 85.22 (C-8), 77.49 (C-2), 
75.32 (C-9), 75.03 (C-4), 74.66 (CH2Ph), 72.91 (CH2Ph), 68.82 (C-5), 64.83 (CH2Ph), 
63.38 (C-6), 55.39 (OCH3);  
HRMS (ESI) m/z: [M+Na]+ calcd for C31H34O7N4Na, 597.23252, found: 597.23166. 
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Methyl [methyl (1’S)-6-amino-2,2’-anhydro-3-C-(1’,2’-dihydroxyethyl)-6-deoxy-D-
glycero-α-D-gluco-heptopyranosid]uronate (120b):  
 
10% Pd/C (17 mg, 500 mg / mmol of starting material) was added 
to a solution of the azido ester 6R 82b (20 mg, 34 µmol) in glacial 
AcOH (3 mL). The solution was degased three times and air was 
replaced by H2 (30 psi). After stirring 2.5h at room temperature, 
the mixture was filtered through a Rotilabo® Nylon 0.45 µm filter, 
eluted with MeOH and the solvent evaporated to afford the amine 6R 120b (10 mg, 
quant. yield) as a colorless oil. 
[α]D +73.4 (c 1.0, MeOH);  
1H NMR (D2O, 400MHz): δ 4.83 (d, 1H, J1,2 = 5.7 Hz, H-1), 4.46 – 4.42 (m, 2H, H-5, H-
6), 4.23 (dd, 1H, J9a,8 = 5.1 Hz, J9a,9b = 10.1 Hz, H-9a), 4.18 (d, 1H, J8,9a = 5.1 Hz, H-8), 
3.91 (d, 1H, J2,1 = 5.7 Hz, H-2), 3.80 (d, 1H, J9b,9a = 10.1 Hz, H-9b), 3.77 (d, 1H, J4,5 = 
10.7 Hz, H-4), 3.75 (s, 3H, OCH3), 3.26 (s, 3H, OCH3);  
13C NMR (D2O, 100MHz): δ  168.86 (C=O), 98.41 (C-1), 81.95 (C-3), 80.95 (C-2), 76.94 
(C-9), 76.40 (C-8), 71.15 (C-4), 67.70 (C-5), 55.74 (OCH3), 53.96 (C-6), 52.85 (OCH3);  
HRMS (CI) m/z: [M+H]+ calcd for C11H20O8N, 294.1189, found: 294.1184. 
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[Methyl (1’S)-6-amino-2,2’-anhydro-3-C-(1’,2’-dihydroxyethyl)-6-deoxy-L-glycero-
α-D-gluco-heptopyranosid]uronic acid (126a): 
 
The (6S)-configurated benzyl ester 83a (10 mg, 15 µmol) was 
dissolved in a 1:2 EtOAc-MeOH mixture (1.5 mL) and a 1M 
aqueous solution of HCl (0.02 mL) followed by 10% Pd/C (7.5 
mg, 500 mg / mmol of starting material) were added. The solution 
was degased three times and air was replaced by H2 (30 psi). 
After stirring overnight at room temperature, the mixture was filtered through a 
Rotilabo® Nylon 0.45 µm filter, eluted with MeOH and the solvent evaporated to afford 
the 6S SAA 126a (2.4 mg, quant. yield) as a colorless oil.  
[α]D +5.5 (c 0.4, MeOH);  
1H NMR (D2O, 400MHz): δ 4.92 (d, 1H, J1,2 = 5.4 Hz, H-1), 4.34 (dd, 1H, J5,6 = 1.9 Hz, 
J5,4 = 10.7 Hz, H-5), 4.29 – 4.25 (m, 2H, H-9a, H-6), 4.23 (d, 1H, J8,9a = 5.0 Hz, H-8), 
4.01 (d, 1H, J2,1 = 5.4 Hz, H-2), 3.94 (d, 1H, J4,5 = 10.7 Hz, H-4), 3.91 (d, 1H, J9b,9a = 9.9 
Hz, H-9b), 3.48 (s, 3H, OCH3);  
13C NMR (D2O, 100MHz): δ  170.28 (C=O), 98.05 (C-1), 81.63 (C-3), 80.86 (C-2), 76.58 
(C-9), 76.20 (C-8), 71.23 (C-4), 68.76 (C-5), 55.76 (OCH3), 52.92 (C-6);  
HRMS (ESI) m/z: [M+H]+ calcd for C10H18O8N, 280.10324, found: 280.10310. 
 
[Methyl (1’S)-6-amino-2,2’-anhydro-3-C-(1’,2’-dihydroxyethyl)-6-deoxy-D-glycero-
α-D-gluco-heptopyranosid]uronic acid (126b): 
 
To a solution of the (6R)-configurated benzyl ester 83b (10 mg, 15 
µmol) in a 1:2 EtOAc-MeOH (1.5 mL), a 1M aqueous solution of 
HCl (0.02 mL) was added followed by addition of 10% Pd/C (7.5 
mg, 500 mg / mmol of starting material). The solution was 
degased three times and air was replaced by H2 (30 psi). After 
stirring overnight at room temperature, the mixture was filtered through a Rotilabo® 
Nylon 0.45 µm filter, eluted with MeOH and the solvent evaporated to afford the 6R 
SAA 126b (2.4 mg, quant. yield) as a colorless oil.  
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[α]D +8.2 (c 0.3, MeOH);  
1H NMR (D2O, 400MHz): δ 4.92 (d, 1H, J1,2 = 5.5 Hz, H-1), 4.57 (dd, 1H, J5,6 = 1.5 Hz, 
J5,4 = 11.1 Hz, H-5), 4.37 – 4.33 (m, 2H, H-9a, H-6), 4.29 (d, 1H, J8,9a = 5.0 Hz, H-8), 
4.03 (d, 1H, J2,1 = 5.5 Hz, H-2), 3.92 (d, 1H, J9b,9a = 10.0 Hz, H-9b), 3.86 (d, 1H, J4,5 = 
11.1 Hz, H-4), 3.40 (s, 3H, OCH3);  
13C NMR (D2O, 100MHz): δ 170.74 (C=O), 98.15 (C-1), 81.95 (C-3), 80.94 (C-2), 76.90 
(C-9), 76.30 (C-8), 71.26 (C-4), 67.82 (C-5), 55.50 (OCH3), 52.83 (C-6);  
HRMS (ESI) m/z: [M+H]+ calcd for C10H18O8N, 280.10324, found: 280.10335. 
 
2-acetamido-9-[(1’S)-6-O-acetyl-2,2’-anhydro-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-
hydroxyethyl)-1-deoxy-β-D-glucopyranosyl]-6-chloropurine (127) and 2-
acetamido-7-[(1’S)-6-O-acetyl-2,2’-anhydro-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-
hydroxyethyl)-1-deoxy-β-D-glucopyranosyl]-6-chloropurine (128): 
 
BSA (70 µL, 291 µmol) was added to a suspension 
of the 2-acetamido-6-chloropurine 57 (31 mg, 146 
µmol) in anhydrous 1,2-dichloroethane (1 mL) under 
argon. The mixture was heated to 80 ºC for 45 min 
and then evaporated to dryness to afford the crude 
silylated base. This residue was then dissolved in dry 
toluene (1 mL) and a solution of the glycosyl donor 
95 (56 mg, 97 µmol) in dry toluene (1 mL) was 
added, followed by slow addition of TMSOTf (140 µL, 
777 µmol) under argon. The reaction mixture was stirred at 85 ºC for 4h, cooled to 
room temperature, diluted with CH2Cl2 (10 mL). The organic layer was neutralized with 
a NaHCO3 saturated aqueous solution (2 x 5 mL). The aqueous layer was extracted 
with CH2Cl2 (3 x 15 mL), and the organic layers were combined, dried (MgSO4), filtered 
and concentrated under reduced pressure. Purification by flash column 
chromatography (cyclohexane-EtOAc, 2:1 then cyclohexane-EtOAc, 1:1) afforded the 
N9 regioisomer 127 (30 mg, 43%) as a colorless oil. Further elution (cyclohexane-
EtOAc, 1:2 then cyclohexane-EtOAc, 1:4) afforded the N7 regioisomer 128 (15 mg, 
21%) as a colorless oil.  
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Compound 127:  
Rf 0.63 (cyclohexane-EtOAc, 1:1);  
[α]D +18.2 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 8.14 (s, 1H, H-8), 8.05 (br s, 1H, NH), 7.42 - 7.29 (m, 
15H, H arom.), 6.10 (d, 1H, J1’,2’ = 8.9 Hz, H-1’), 5.00 (m, 2H, H-2’, CHPh), 4.82 – 4.64 
(m, 5H, CHPh, 2 x CH2Ph), 4.47 – 4.38 (m, 3H, H-5’, H-7’, H-6’a), 4.29 – 4.21 (m, 3H, 
H-4’, H-6’b, H-8’a), 4.12 (app d, 1H, J8’b,8’a = 9.5 Hz, H-8’b), 2.49 (s, 3H, NHAc), 2.05 (s, 
3H, OAc);  
13C NMR (CDCl3, 100MHz): δ 170.51, 171.06 (2 x C=O), 153.01 (C-4), 152.49 (C-2 or 
C-6), 152.00 (C-2 or C-6), 143.35 (C-8), 137.94, 137.70, 137.39 (3C arom. quat.), 
129.15 - 127.63 (15CH arom.), 128.70 (C-5), 90.02 (C-3’), 85.19 (C-7’), 83.31 (C-1’), 
77.58 (C-2’), 76.27 (C-5’), 75.32 (CH2Ph), 74.58 (C-8’), 74.46 (C-4’), 73.97 (CH2Ph), 
65.73 (CH2Ph), 63.85 (C-6’), 25.62 (NHAc), 21.29 (OAc);  
HRMS (CI) m/z: [M+H]+ calcd for C38H39O8N535Cl, 728.2487, and C38H39O8N537Cl, 
730.2458, found: 728.2515 and 730.2465 respectively.  
 
Compound 128:  
Rf 0.14 (cyclohexane-EtOAc, 1:1); 
[α]D +28.8 (c 1.0, CHCl3); 
1H NMR (CDCl3, 400MHz): δ 8.47 (s, 1H, H-8), 8.37 (br s, 1H, NH), 7.41 - 7.29 (m, 
15H, H arom.), 6.45 (d, 1H, J1’,2’ = 9.1 Hz, H-1’), 5.00 (d, 1H, J = 10.9 Hz, CHPh), 4.80 
– 4.60 (m, 6H, H-2’, CHPh, 2 x CH2Ph), 4.45 – 4.41 (m, 3H, H-5’, H-6’a, H-7’), 4.34 (dd, 
1H, J8’a,7’ = 3.3 Hz, J8’a,8’b = 9.4 Hz, H-8’a), 4.24 (dd, 1H, J6’b,5’ = 5.6 Hz, J6’b,6’a = 12.6 Hz, 
H-6’b), 4.21 – 4.10 (m, 2H, H-4’, H-8’b), 2.60 (s, 3H, NHAc), 2.06 (s, 3H, OAc);  
13C NMR (CDCl3, 100MHz): δ 171.50, 170.63 (2 x C=O), 163.18 (C-4), 152.53 (C-2 or 
C-6), 146.36 (C-8), 143.95 (C-2 or C-6), 137.50, 137.11, 136.80 (3C arom. quat.), 
128.71 - 127.24 (15CH arom.), 118.97 (C-5), 89.73 (C-3’), 84.56 (C-7’), 82.95 (C-1’), 
77.55 (C-2’), 75.74 (C-5’), 74.80 (CH2Ph), 74.37 (C-8’), 73.86 (C-4’), 73.60 (CH2Ph), 
65.37 (CH2Ph), 63.23 (C-6’), 25.26 (NHAc), 20.89 (OAc);  
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HRMS (FAB) m/z: [M+Na]+ calcd for C38H38O8N535ClNa, 750.2307, and 
C38H38O8N537ClNa, 752.2277, found: 750.2310 and 752.2309 respectively. 
 
2-acetamido-9-[(1’S)-6-O-acetyl-2,2’-anhydro-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-
hydroxyethyl)-1-deoxy-β-D-glucopyranosyl]purine (122): 
 
10% Pd/C (35 mg, 750 mg / mmol of starting 
material) and Et3N (5 µL) were added to a solution of 
the N9 regioisomer 127 (34 mg, 45 µmol) in EtOAc (2 
mL). The solution was degased three times and air 
was replaced by H2 (30 psi). After stirring for 3h at room temperature, the mixture was 
filtered through a Rotilabo® Nylon 0.45 µm filter and the solvent evaporated under 
reduced pressure. Purification by flash column chromatography (cyclohexane-EtOAc, 
1:4) afforded the dechlorinated N9 nucleoside 122 (22 mg, 69 %) as a colorless oil. 
Rf 0.26 (cyclohexane-EtOAc, 1:4); 
[α]D +15.0 (c 0.5, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 9.03 (br s, 1H, NH), 8.96 (s, 1H, H-8), 8.17 (s, 1H, H-6), 
7.40 - 7.29 (m, 15H, H arom.), 6.14 (d, 1H, J1’,2’ = 8.8 Hz, H-1’), 5.05 (d, 1H, J2’,1’ = 8.8 
Hz, H-2’), 5.00 (d, 1H, J = 11.0 Hz, CHPh), 4.82 (d, 1H, J = 11.4 Hz, CHPh), 4.76 (d, 
1H, J = 11.0 Hz, CHPh), 4.74 (d, 1H, J = 11.4 Hz, CHPh), 4.68 (s, 2H, CH2Ph), 4.50 – 
4.39 (m, 3H, H-4’ or H-5’, H-6’a, H-7’), 4.30 – 4.23 (m, 3H, H-4’ or H-5’, H-6’b, H-8’a), 
4.14 (d, 1H, J8’b,8’a = 9.4 Hz, H-8’b), 2.51 (s, 3H, NHAc), 2.06 (s, 3H, OAc);  
13C NMR (CDCl3, 100MHz): δ 171.15, 170.75 (2 x C=O), 152.96 (C-2), 152.57 (C-4), 
149.34 (C-8), 143.51 (C-6), 137.75, 137.51, 137.18 (3C arom. quat.), 130.94 (C-5), 
128.76 - 127.35 (15CH arom.), 89.63 (C-3’), 84.83 (C-7’), 82.62 (C-1’), 77.18 (C-2’), 
75.84 (C-4’ or C-5’), 74.90 (CH2Ph), 74.18 (C-5’ or C-4’), 74.13 (C-8’), 73.52 (CH2Ph), 
65.31 (CH2Ph), 63.46 (C-6’), 25.17 (NHAc), 20.85 (OAc);  
HRMS (ESI) m/z: [M+Na]+ calcd for C38H39O8N5Na, 716.26908, found: 716.26820.  
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2-acetamido-7-[(1’S)-6-O-acetyl-2,2’-anhydro-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-
hydroxyethyl)-1-deoxy-β-D-glucopyranosyl]purine (129): 
 
10% Pd/C (50 mg, 750 mg / mmol of starting 
material) and Et3N (5 µL) were added to a solution of 
the N7 regioisomer 128 (48 mg, 66 µmol) in EtOAc (3 
mL). The solution was degased three times and air 
was replaced by H2 (30 psi). After stirring for 2 days at room temperature, the mixture 
was filtered through a Rotilabo® Nylon 0.45 µm filter and the solvent evaporated under 
reduced pressure. Purification by flash column chromatography (EtOAc) afforded the 
dechlorinated N7 nucleoside 129 (32 mg, 66 %) as a colorless oil. 
Rf 0.24 (EtOAc);  
[α]D +30.0 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 8.93 (br s, 1H, NH), 8.89 (s, 1H, H-8), 8.30 (s, 1H, H-6), 
7.30 - 7.19 (m, 15H, H arom.), 5.89 (d, 1H, J1’,2’ = 8.1 Hz, H-1’), 4.89 (d, 1H, J = 11.0 
Hz, CHPh), 4.65 (d, 1H, J = 11.0 Hz, CHPh), 4.61 – 4.55 (m, 4H, 2 x CH2Ph), 4.41 – 
4.33 (m, 3H, H-2’, H-4’ or H-5’, H-6’a), 4.28 (d, 1H, J7’,8’a = 3.3 Hz, H-7’), 4.24 – 4.15 (m, 
3H, H-4’ or H-5’, H-6’b, H-8’a), 4.08 (d, 1H, J8’b,8’a = 12.5 Hz, H-8’b), 2.50 (s, 3H, NHAc), 
2.01 (s, 3H, OAc);  
13C NMR (CDCl3, 100MHz): δ 170.73 (2 x C=O), 162.33 (C-4), 153.86 (C-6), 146.55 (C-
8), 143.36 (C-2), 137.59, 137.16, 137.00 (3C arom. quat.), 128.76 - 127.34 (15CH 
arom.), 120.88 (C-5), 89.59 (C-3’), 85.87 (C-1’), 84.76 (C-7’), 78.60 (C-2’), 76.00 (C-5’ 
or C-4’), 75.07 (CH2Ph), 74.35 (C-8’), 73.93 (C-5’ or C-4’), 73.64 (CH2Ph), 65.42 
(CH2Ph), 63.35 (C-6’), 25.31 (NHAc), 20.95 (OAc);  
HRMS (ESI) m/z: [M+Na]+ calcd for C38H39O8N5Na, 716.26908, found: 716.26890. 
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2-amino-9-[(1’S)-2,2’-anhydro-1-deoxy-3-C-(1’,2’-dihydroxyethyl)-β-D-gluco 
pyranosyl]purine (123): 
 
To a solution of the N9 regioisomer 122 (12 mg, 17 
µmol) in acetic acid (2 mL) was added 10% Pd/C (13 
mg, 750 mg / mmol of starting material). The solution 
was degased three times and air was replaced by H2 
(400 psi). After stirring for 8h at room temperature, the 
mixture was filtered through a Rotilabo® Nylon 0.45 µm filter and the solvent co-
evaporated with toluene to afford the debenzylated nucleoside 130 which was directly 
engaged in the next step. The crude debenzylated nucleoside was then dissolved in 
1:1 NH4OH-MeOH mixture (2 mL) and warmed to 60 ºC for 24 h. The reaction mixture 
was concentrated and the residue dissolved in water and washed with CH2Cl2. The 
aqueous layer was concentrated under reduced pressure to afford the nucleoside N9 
123 (5 mg, 86%) as a colorless oil.  
[α]D +20.5 (c 0.3, MeOH);  
1H NMR (D2O, 400MHz): δ 8.64 (br s, 1H, H-6), 8.29 (s, 1H, H-8), 6.05 (d, 1H, J1’,2’ = 
9.3 Hz, H-1’), 4.61 (d, 1H, J2’,1’ = 9.3 Hz, H-1’), 4.47 (d, 1H, J7’,8’a = 3.6 Hz, H-7’), 4.30 – 
4.22 (m, 2H, H-5’, H-8’a), 4.08 (d, 1H, J4’,5’ = 10.5 Hz, H-4’), 4.01 (d, 1H, J8’b,8’a = 10.1 
Hz, H-8’b), 3.88 (d, 1H, J6’a,6’b = 12.3 Hz, H-6’a), 3.72 (dd, 1H, J6’b,5’ = 5.0 Hz, J6’b,6’a = 
12.3 Hz, H-6’b);  
13C NMR (D2O, 100MHz): δ 159.86 (C-2), 152.35 (C-4), 149.54 (C-6), 142.29 (C-8), 
126.89 (C-5), 82.92 (C-3’), 81.47 (C-1’ and C-2’), 78.55 (C-5’), 76.16 (C-8’), 76.10 (C-
7’), 71.39 (C-4’), 60.49 (C-6’);  
HRMS (ESI) m/z: [M+H]+ calcd for C13H18O6N5, 340.12571, found: 340.12612. 
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Methyl [methyl (1’S)-6-amino-2,2’-anhydro-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-
hydroxyethyl)-6-deoxy-L-glycero-α-D-gluco-heptopyranosid]uronate (131a): 
 
Pd Lindlar (25 mg, 500 mg / mmol of starting material) was 
added to a solution of the azido ester 6S 82a (30 mg, 51 µmol) 
in EtOAc (2 mL). The solution was degased three times and air 
was replaced by H2 (30 psi). After stirring for 6h at room 
temperature, the mixture was filtered through a Rotilabo® Nylon 
0.45 µm filter and the solvent evaporated under reduced pressure. Purification by flash 
column chromatography (cyclohexane-EtOAc, 1:2 then cyclohexane-EtOAc, 1:3) 
afforded the amine 6S 131a (27 mg, 95%) as a colorless oil.  
Rf 0.24 (cyclohexane-EtOAc, 1:2); 
[α]D +94.3 (c 1.0, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.24 - 7.12 (m, 15H, H arom.), 4.85 – 4.83 (m, 2H, H-1, 
CHPh), 4.82 (dd, 1H, J5,6 = 3.1 Hz, J5,4 = 10.1 Hz, H-5), 4.62 (d, 1H, J = 11.4 Hz, 
CHPh), 4.59 (d, 1H, J = 10.1 Hz, CHPh), 4.54 (d, 1H, J = 11.4 Hz, CHPh), 4.47 (d, 1H, 
J = 12.3 Hz, CHPh), 4.39 (d, 1H, J = 12.3 Hz, CHPh), 4.34 (d, 1H, J4,5 = 10.1 Hz, H-4), 
4.27 (d, 1H, J2,1 = 5.9 Hz, H-2), 4.23 (dd, 1H, J9a,8 = 5.2 Hz, J9a,9b = 8.8 Hz, H-9a), 4.15 
(d, 1H, J8,9b = 1.8 Hz, J8,9a = 5.2 Hz, H-8), 4.10 (dd, 1H, J9b,8 = 1.8 Hz, J9b,9a = 8.8 Hz, H-
9b), 3.83 (d, 1H, J6,5 = 3.1 Hz, H-6), 3.37 (s, 3H, OCH3), 3.14 (s, 3H, OCH3), 2.51 (br s, 
2H, NH2);  
13C NMR (CDCl3, 100MHz): δ 172.10 (C=O), 139.14, 138.22, 138.04 (3C arom. quat.), 
128.54 - 126.73 (15CH arom.), 99.37 (C-1), 90.12 (C-3), 85.73 (C-8), 77.30 (C-2), 
75.42 (C-9), 74.29 (CH2Ph), 73.16 (C-4), 72.77 (CH2Ph), 69.53 (C-5), 64.69 (CH2Ph), 
55.37 (OCH3), 54.88 (C-6), 51.73 (OCH3); 
HRMS (CI) m/z: [M+H]+ calcd for C32H38O8N, 564.2597, found: 564.2598 
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Methyl [methyl (1’S)-6-amino-2,2’-anhydro-3,4-di-O-benzyl-3-C-(1’-benzyloxy-2’-
hydroxyethyl)-6-deoxy-D-glycero-α-D-gluco-heptopyranosid]uronate (131b): 
 
Pd Lindlar (51 mg, 500 mg / mmol of starting material) was 
added to a solution of the azido ester 6R 82b (60 mg, 102 µmol) 
in EtOAc (4 mL). The solution was degased three times and air 
was replaced by H2 (30 psi). After stirring for 3h at room 
temperature, the mixture was filtered through a Rotilabo® Nylon 
0.45 µm filter and the solvent evaporated under reduced pressure. Purification by flash 
column chromatography (cyclohexane-EtOAc, 1:1 then cyclohexane-EtOAc, 1:2) 
afforded the amine 6R 131b (49 mg, 88%) as a colorless oil.  
Rf 0.41 (cyclohexane-EtOAc, 1:2); 
[α]D +33.7 (c 0.5, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 7.29 - 7.11 (m, 15H, H arom.), 4.90 (d, 1H, J = 11.4 Hz, 
CHPh), 4.81 – 4.73 (m, 3H, H-1, H-5, CHPh), 4.61 (d, 1H, J = 11.6 Hz, CHPh), 4.59 (d, 
1H, J = 11.4 Hz, CHPh), 4.54 (d, 1H, J = 11.4 Hz, CHPh), 4.46 (d, 1H, J = 11.6 Hz, 
CHPh), 4.35 (d, 1H, J4,5 = 10.1 Hz, H-4), 4.25 – 4.19 (m, 3H, H-2, H-8, H-9a), 4.11 (d, 
1H, J9b,9a = 8.3 Hz, H-9b), 3.76 (d, 1H, J6,5 = 1.5 Hz, H-6), 3.55 (s, 3H, OCH3), 3.18 (s, 
3H, OCH3), 2.08 (br s, 2H, NH2);  
13C NMR (CDCl3, 100MHz): δ 175.05 (C=O), 139.08, 138.83, 138.32 (3C arom. quat.), 
128.40 - 126.89 (15CH arom.), 99.34 (C-1), 89.87 (C-3), 85.29 (C-8), 77.79 (C-2), 
75.30 (C-9), 74.37 (CH2Ph), 74.32 (C-4), 72.84 (CH2Ph), 68.99 (C-5), 64.77 (CH2Ph), 
54.80 (OCH3), 53.73 (C-6), 51.96 (OCH3);  
HRMS (CI) m/z: [M+H]+ calcd for C32H38O8N, 564.2597, found: 564.2598. 
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Methyl [methyl (1’S)-2,2’-anhydro-3,4-di-O-benzyl-6-{(2S)-2-(benzyloxycarbonyl) 
amino-5-[1,3-di(benzyloxycarbonyl)guanidino]pentanoylamino}-3-C-(1’-benzyloxy 
-2’-hydroxyethyl)-6-deoxy-L-glycero-α-D-gluco-heptopyranosid]uronate (119a): 
 
Triethylamine (26 µL, 184 µmol) was added at -
20 ºC under argon to a solution of protected L-
arginine 115 (53 mg, 92 µmol) in anhydrous 
THF (1 mL), followed by slow addition of isobutyl 
chloroformate (12 µL, 92 µmol). This solution 
was stirring for 45 min at -20 ºC and a solution 
of the amine 6S 131a (26 mg, 46 µmol) in anhydrous THF (1 mL) was added at -20 ºC 
under argon. After stirring for 2 h at -20 ºC under argon, the reaction mixture was 
quenched by addition of 1:1 CH2Cl2/MeOH mixture (2 mL) and the solvent was 
removed under reduced pressure. Purification by flash column chromatography 
(cyclohexane-EtOAc, 2:1) afforded the protected peptide 6S 119a (48 mg, 92%) as a 
colorless oil.  
Rf 0.15 (cyclohexane-EtOAc, 2:1); 
[α]D + 64.0 (c 1.0, CHCl3);  
1H NMR (CHCl3, 400MHz): δ 9.45, 9.25 (2 x br s, 2H, 2 x NH), 7.31 – 7.07 (m, 30H, H 
arom.), 6.60 (br s, 1H, NH amide), 5.47 (br s, 1H, NH), 5.14 (s, 2H, CH2Ph), 5.07 (d, 
1H, J = 12.7 Hz, CHPh), 5.03 (d, 1H, J = 12.7 Hz, CHPh), 4.98 – 4.92 (m, 3H, CH2Ph, 
H-6), 4.87 (d, 1H, J = 10.7 Hz, CHPh), 4.73 (d, 1H, J1,2 = 5.9 Hz, H-1), 4.71 (d, 1H, J = 
10.7 Hz, CHPh), 4.61 (dd, 1H, J5,6 = 2.9, J5,4 = 10.3, H-5), 4.55 (d, 1H, J = 11.4 Hz, 
CHPh), 4.50 (d, 1H, J = 12.1 Hz, CHPh), 4.48 (d, 1H, J = 11.4 Hz, CHPh), 4.37 (d, 1H, 
J = 12.1 Hz, CHPh), 4.21 – 4.02 (m, 6H, H-2, H-4, H-8, H-9a, H-9b, H-2’), 3.98 - 3.84 
(m, 2H, H-5’a, H-5’b), 3.42 (s, 3H, OCH3), 3.25 (s, 3H, OCH3), 1.70 – 1.48 (m, 4H, H-
3’a, H-3’b, H-4’a, H-4’b);  
13C NMR (CDCl3, 100MHz): δ 171.09, 169.53, 163.73, 160.58, 156.09, 155.75 (C=NH, 
5 x C=O), 138.76, 138.05, 137.91, 136.85, 136.13, 134.56 (6C arom. quat.), 128.80 - 
126.99 (30CH arom.), 99.17 (C-1), 89.78 (C-3), 85.29 (C-2 or C-8), 77.51 (C-2 or C-8), 
75.46 (C-9), 74.80 (C-4), 74.28 (CH2Ph), 72.96 (CH2Ph), 69.42 (C-5), 68.89 (CH2Ph), 
66.86 (2 x CH2Ph), 64.75 (CH2Ph), 55.30 (OCH3), 54.64 (C-2’), 54.63 (C-6), 52.23 
(OCH3), 44.15 (C-5’), 29.66 (C-3’ or C-4’), 24.84 (C-3’ or C-4’);  
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HRMS (FAB) m/z: [M+Na]+ calcd for C62H67O15N5Na, 1144.4531, found: 1144.4528. 
 
Methyl [methyl (1’S)-2,2’-anhydro-3,4-di-O-benzyl-6-{(2S)-2-(benzyloxycarbonyl) 
amino-5-[1,3-di(benzyloxycarbonyl)guanidino]pentanoylamino}-3-C-(1’-benzyloxy 
-2’-hydroxyethyl)-6-deoxy-D-glycero-α-D-gluco-heptopyranosid]uronate (119b): 
 
Triethylamine (14 µL, 100 µmol) was added at -
20 ºC under argon to a solution of protected L-
arginine 115 (29 mg, 50 µmol) in anhydrous THF 
(0.8 mL) followed by slow addition of isobutyl 
chloroformate (6.4 µL, 50 µmol). This solution 
was stirring for 45 min at -20 ºC and a solution of 
the amine 6R 131b (14 mg, 25 µmol) in anhydrous THF (0.8 mL) was added at -20 ºC 
under argon. After stirring for 2 h at -20 ºC under argon, the reaction mixture was 
quenched by addition of 1:1 CH2Cl2/MeOH mixture (2 mL) and the solvent was 
removed under reduced pressure. Purification by flash column chromatography 
(cyclohexane-EtOAc, 2:1) afforded the protected peptide 6R 119b (25 mg, 89%) as a 
colorless oil.  
Rf 0.23 (cyclohexane-EtOAc, 2:1);  
[α]D + 50.8 (c 1.0, CHCl3);  
1H NMR (CHCl3, 400MHz): δ 9.44, 9.21 (2 x br s, 2H, 2 x NH), 7.31 – 7.13 (m, 30H, H 
arom.), 7.04 (d, 1H, JNH,6 = 10.1 Hz, NH amide), 6.14 (br s, 1H, NH), 5.16 (dd, 1H, J6,5 = 
0.8, J6,NH = 10.1 Hz, H-6), 5.11 – 4.93 (m, 6H, 3 x CH2Ph), 4.78 (dd, 1H, J5,6 = 0.8 Hz, 
J5,4 = 10.1 Hz, H-5), 4.74 (d, 1H, J = 9.9 Hz, CHPh), 4.58 (d, 1H, J1,2 = 4.6 Hz, H-1), 
4.53 – 4.47 (m, 3H, 3 x CHPh), 4.38 – 4.34 (m, 3H, H-2’, 2 x CHPh), 4.19 (dd, 1H, J9a,8 
= 5.3, J9a,9b = 8.9, H-9a), 4.11 (dd, 1H, J8,9b = 1.2, J8,9a = 5.3, H-8), 4.05 (dd, 1H, J9b,8 = 
1.2, J9b,9a = 8.9, H-9b), 4.03 – 3.85 (m, 3H, H-2, H-5’a, H-5’b), 3.78 (d, 1H, J4,5 = 10.1 
Hz, H-4), 3.47 (s, 3H, OCH3), 3.14 (s, 3H, OCH3), 1.91 – 1.64 (m, 4H, H-3’a, H-3’b, H-
4’a, H-4’b);  
13C NMR (CDCl3, 100MHz): δ 172.22, 170.80, 163.56, 160.85, 156.31, 155.63 (C=NH, 
5 x C=O), 138.81, 138.32, 138.02, 136.95, 136.28, 134.41 (6C arom. quat.), 128.84 - 
126.84 (30CH arom.), 99.12 (C-1), 89.65 (C-3), 85.27 (C-2 or C-8), 76.93 (C-2 or C-8), 
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75.32 (CH2PH), 74.97 (C-9), 73.97 (C-4), 72.94 (2 x CH2Ph), 68.97 (CH2Ph), 68.41 (C-
5), 66.67 (CH2Ph), 64.55 (CH2Ph), 64.55 (CH2Ph), 55.59 (C-2’), 54.74 (OCH3), 52.14 
(C-6), 52.22 (OCH3), 44.13 (C-5’), 29.67 (C-3’ or C-4’), 25.22 (C-3’ or C-4’);  
HRMS (FAB) m/z: [M+Na]+ calcd for C62H67O15N5Na, 1144.4531, found: 1144.4528. 
 
Methyl [methyl (1’S)-6-{[(2S)-2-amino-5-guanidino]pentanoylamino}-2,2’-anhydro-
3-C-(1’,2’-dihydroxyethyl)-6-deoxy-L-glycero-α-D-gluco-heptopyranosid]uronate 
(121a): 
 
10% Pd/C (8 mg, 500 mg / mmol of starting 
material) was added to a solution of the protected 
peptide 6S 119a (18 mg, 16 µmol) in glacial 
AcOH (3 mL). The solution was degased three 
times and air was replaced by H2 (30 psi). After 
stirring 2.5h at room temperature, the mixture was filtered through a Rotilabo® Nylon 
0.45 µm filter eluted with MeOH and the solvent evaporated to afford the deprotected 
structure 6S 121a (7.2 mg, quant. yield) as a colorless oil.  
[α]D + 27 (c 0.2, MeOH); 
1H NMR (400MHz, D2O): δ  5.02 (br s, 1H, H-6), 4.89 (d, 1H, J1,2 = 5.0 Hz, H-1), 4.34 – 
4.25 (m, 3H, H-5, H-9a, H-9b), 4.14 – 4.09 (m, 2H, H-8, H-2’), 3.97 (d, 1H, J2,1 = 5.0, H-
2), 3.90 (d, 1H, J4,5 = 10.0, H-4), 3.77 (s, 3H, OCH3), 3.47 (s, 3H, OCH3), 3.24 -3.20 (m, 
2H, H-5’a, H-5’b), 1.98 – 1.92 (m, 2H, H-3’a, H-3’b), 1.73 – 1.62 (m, 2H, H-4’a, H-4’b);  
13C NMR (100MHz, D2O): δ 170.24, 169.41 (2 x C=O), 91.26 (C-1), 82.03 (C-3), 81.18 
(C-2), 76.80 (C-9), 76.45 (C-4), 71.86 (C-8), 70.69 (C-5), 55.92 (OCH3), 53.23 (C-6), 
53.05 (OCH3), 52.59 (C-2’), 40.31 (C-5’), 28.02 (C-3’), 23.39 (C-4’);  
HRMS (ESI) m/z: [M+Na]+ calcd for C17H31O9N5Na, 472.20195, found: 472.20451. 
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Methyl [methyl (1’S)-6-{[(2S)-2-amino-5-guanidino]pentanoylamino}-2,2’-anhydro-
3-C-(1’,2’-dihydroxyethyl)-6-deoxy-D-glycero-α-D-gluco-heptopyranosid]uronate 
(121b): 
 
10% Pd/C (9.8 mg, 500 mg / mmol of starting 
material) was added to a solution of the protected 
peptide 6R 119b (22 mg, 19.6 µmol) in glacial 
AcOH (3 mL). The solution was degased three 
times and air was replaced by H2 (30 psi). After 
stirring 2.5h at room temperature, the mixture 
was filtered through a Rotilabo® Nylon 0.45 µm filter eluted with MeOH and the solvent 
evaporated to afford the deprotected structure 6R 121b (8.8 mg, quant. yield) as a 
colorless oil. 
[α]D + 32 (c 0.2, MeOH);  
1H NMR (400MHz, D2O): δ  4.99 (d, 1H, J6,5 = 1.8 Hz, H-6), 4.81 (d, 1H, J1,2 = 5.4 Hz, 
H-1), 4.42 (dd, 1H, J5,6 = 1.8 Hz, J5,4 = 10.7 Hz, H-5), 4.26 (dd, 1H, J9a,8 = 5.2 Hz, J9a,9b 
= 10.1 Hz, H-9a), 4.20 (d, 1H, J8,9a = 5.2, H-8), 4.08 (t, 1H, J2’,3’a = J2’,3’b = 6.7, H-2’), 
3.89 (d, 1H, J2,1 = 5.4 Hz, H-2), 3.83 (d, 1H, J9b,9a = 10.1, H-9b), 3.71 (s, 3H, OCH3), 
3.55 (d, 1H, J4,5 = 10.7 Hz, H-4), 3.29 (s, 3H, OCH3), 3.16 – 3.13 (m, 2H, H-5’a, H-5’b), 
1.92 – 1.80 (m, 2H, H-3’a, H-3’b), 1.63 – 1.55 (m, 2H, H-4’a, H-4’b);  
13C NMR (100MHz, D2O): δ 171.38, 170.23 (2 x C=O), 97.78 (C-1), 81.68 (C-3), 80.64 
(C-2), 76.57 (C-9), 75.97 (C-8), 71.45 (C-4), 68.87 (C-5), 55.11 (OCH3), 53.05 (OCH3), 
52.51 (C-2’), 51.94 (C-6), 39.96 (C-5’), 27.90 (C-3’), 23.55 (C-4’);  
HRMS (ESI) m/z: [M+Na]+ calcd for C17H31O8N5Na, 472.20195, found: 472.20129. 
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Benzyl [(1’S)-1-O-acetyl-2,2’-anhydro-6-azido-3,4-di-O-benzyl-3-C-(1’-benzyloxy-
2’-hydroxyethyl)-6-deoxy-L-glycero-β-D-gluco-heptopyran]uronate (134a): 
 
A solution of conc. sulfuric acid (5% in AcOH, 70 µL) was 
added dropwise at – 20 ºC to a solution of benzyl azido ester 
6S 83a (170 mg, 255 µmol) in acetic anhydride (6 mL). The 
reaction mixture was allowed to warm to 0 ºC over a period of 
15 min., and then neutralized by slow addition of a NaHCO3 
saturated aqueous solution.
 
The organic layer was separated, and the aqueous layer 
was extracted with CH2Cl2 (3 x 50 mL). The organic layers were combined, dried 
(MgSO4), filtered and concentrated. Purification by flash column chromatography 
(cyclohexane-CH2Cl2-EtOAc, 10:1:1) afforded the glycosyl donor 6S 134a (64 mg, 
36%) as a colorless oil. 
Rf 0.46 (cyclohexane-CH2Cl2-EtOAc, 6:1:1);  
[α]D +23.8 (c 0.2, CHCl3); 
1H NMR (CDCl3, 400MHz): δ 7.50 - 7.00 (m, 20H, H arom.), 6.13 (d, 1H, J1,2 = 7.8 Hz, 
H-1), 5.01 (d, 1H, J = 12.0 Hz, CHPh), 4.99 (d, 1H, J = 9.8 Hz, CHPh), 4.79 (dd, 1H, 
J5,6 = 2.4 Hz, J5,4 = 9.8 Hz, H-5), 4.74 (d, 1H, J = 12.0 Hz, CHPh), 4.64 – 4.58 (m, 3H, 
CH2Ph, CHPh), 4.51 (d, 1H, J6,5 = 2.4 Hz, H-6), 4.45 – 4.42 (m, 3H, H-4, CH2Ph), 4.26 
(d, 1H, J2,1 = 7.8 Hz, H-2), 4.21 – 4.16 (m, 2H, H-8, H-9a), 3.95 (d, 1H, J9b,9a = 9.0 Hz, 
H-9b), 2.21 (s, 3H, OAc);  
13C NMR (CDCl3, 100MHz): δ 169.37, 169.09 (2 x C=O), 137.71, 137.33, 137.19, 
134.58 (4C arom. quat.), 128.70 - 127.45 (20CH arom.), 93.29 (C-1), 89.98 (C-3), 
84.25 (C-8), 77.31 (C-2), 74.98 (C-5), 74.56 (CH2Ph), 74.03 (C-9), 72.85 (C-4), 72.74 
(CH2Ph), 67.64 (CH2Ph), 64.84 (CH2Ph), 62.85 (C-6), 21.05 (OAc); 
HRMS (CI) m/z: [M+NH4]+ calcd for C39H43O9N4, 711.3030, found: 711.3025. 
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Benzyl [(1’S)-1-O-acetyl-2,2’-anhydro-6-azido-3,4-di-O-benzyl-3-C-(1’-benzyloxy-
2’-hydroxyethyl)-6-deoxy-D-glycero-β-D-gluco-heptopyran]uronate (134b): 
 
To a solution of benzyl azido ester 6R 83b (200 mg, 0.30 
mmol) in acetic anhydride (7 mL) was added dropwise sulfuric 
acid (21 µL) at 0 ºC. The reaction mixture was stirred at this 
temperature over 30 min and then neutralized by slow addition 
of a NaHCO3 saturated aqueous solution. The organic layer 
was separated, and the aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The 
organic layers were combined, dried (MgSO4), filtered and concentrated. Purification by 
flash column chromatography (cyclohexane-CH2Cl2-EtOAc, 10:1:1) afforded the 
glycosyl donor 6R 134b (131 mg, 63%) as a colorless oil.  
Rf 0.50 (cyclohexane-CH2Cl2-EtOAc, 6:1:1);  
[α]D +30.8 (c 0.2, CHCl3); 
1H NMR (CDCl3, 400MHz): δ 7.36 - 7.14 (m, 20H, H arom.), 5.96 (d, 1H, J1,2 = 7.8 Hz, 
H-1), 5.28 (d, 1H, J = 12.1 Hz, CHPh), 5.08 (d, 1H, J = 12.1 Hz, CHPh), 4.94 (d, 1H, J 
= 11.1 Hz, CHPh), 4.73 (dd, 1H, J5,6 = 2.5 Hz, J5,4 = 9.9 Hz, H-5), 4.67 (d, 1H, J = 11.1 
Hz, CHPh), 4.64 (d, 1H, J = 11.1 Hz, CHPh), 4.62 (d, 1H, J = 11.1 Hz, CHPh), 4.56 (s 
2H, CH2Ph), 4.30 (d, 1H, J4,5 = 9.9 Hz, H-4), 4.25 (d, 1H, J2,1 = 7.8 Hz, H-2), 4.23 – 4.21 
(m, 2H, H-6, H-8), 4.18 (dd, 1H, J9a,8 = 3.3 Hz, J9a,9b = 9.4 Hz, H-9a), 4.03 (d, 1H, J9b,9a = 
9.4 Hz, H-9b), 2.10 (s, 3H, OAc);  
13C NMR (CDCl3, 100MHz): δ 169.09, 169.02 (2 x C=O), 137.79, 137.36, 137.14, 
135.06 (4C arom. quat.), 128.55 - 127.80 (20CH arom.), 93.63 (C-1), 89.96 (C-3), 
84.33 (C-8), 77.65 (C-2), 75.19 (C-5), 74.74 (CH2Ph), 74.09 (C-4), 73.53 (C-9), 72.82 
(CH2Ph), 67.96 (CH2Ph), 65.03 (CH2Ph), 62.28 (C-6), 21.01 (OAc); 
HRMS (CI) m/z: [M+NH4]+ calcd for C39H43O9N4, 711.3030, found: 711.3021. 
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Benzyl [(1’S)-1-(2-acetamido-6-chloropurin-7-yl)-2,2’-anhydro-6-azido-3,4-di-O-
benzyl-3-C-(1’-benzyloxy-2’-hydroxyethyl)-1,6-di-deoxy-L-glycero-β-D-gluco-hepto 
pyran]uronate (132): 
 
BSA (54 µL, 216.3 µmol) was added to a 
suspension of the nucleobase 2-acetamido-6-
chloropurine 57 (23 mg, 108.2 µmol) in anhydrous 
CH3CN (1 mL) under argon. The mixture was 
heated to 60 ºC for 45 min to afford the crude silylated base. To this solution was 
added the glycosyl donor 6S 134a (50 mg, 72.1 µmol) dissolved in anhydrous CH3CN 
(1 mL) followed by slow addition of TMSOTf (104 µL, 576.8 µmol) under argon. The 
solution was stirred at 65 ºC for 90 min. The mixture was cooled to room temperature, 
CH2Cl2 (20 mL) was added and the organic layer was washed with NaHCO3 saturated 
aqueous solution (2 x 10 mL). The aqueous layer was extracted with CH2Cl2 (3 x 30 
mL), the organic layers were combined, dried (MgSO4), filtered and concentrated under 
reduced pressure. Purification by flash column chromatography (cyclohexane-EtOAc, 
1:1) afforded the N7 nucleoside 6S 132 (39 mg, 65%) as a colorless oil. 
Rf 0.22 (cyclohexane-EtOAc, 1:1); 
[α]D +33 (c 0.3, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 8.33 (s, 1H, H-8), 8.06 (br s, 1H, NH), 7.42 - 7.21 (m, 
20H, H arom.), 6.49 (d, 1H, J1’,2’ = 8.9 Hz, H-1’), 5.10 (d, 1H, J = 10.1 Hz, CHPh), 5.04 
(d, 1H, J = 12.0 Hz, CHPh), 4.87 (dd, 1H, J5’,6’ = 2.4 Hz, J5’,4’ = 9.8 Hz, H-5’), 4.78 (d, 
1H, J = 12.0 Hz, CHPh), 4.72 – 4.65 (m, 4H, H-4’, CH2Ph, CHPh), 4.61 – 4.58 (m, 2H, 
H-2’, CHPh), 4.55 (d, 1H, J6’,5’ = 2.4 Hz, H-6’), 4.48 (d, 1H, J = 10.8 Hz, CHPh), 4.39 (d, 
1H, J8’,9’a = 3.2 Hz, H-8’), 4.32 (dd, 1H, J9’a,8’ = 3.2 Hz, J9’a,9’b = 9.5 Hz, H-9’a), 4.09 (d, 
1H, J9’b,9’a = 9.5 Hz, H-9’b), 2.59 (s, 3H, NHAc);  
13C NMR (CDCl3, 100MHz): δ 171.80, 166.61 (2 x C=O), 162.99 (C-4), 152.47 (C-2 or 
C-6), 146.30 (C-8), 143.77 (C-2 or C-6), 137.48, 136.71, 136.61, 134.46 (4C arom. 
quat.), 128.66 - 127.82 (20CH arom.), 118.69 (C-5), 89.72 (C-3’), 84.51 (C-8’), 82.76 
(C-1’), 77.44 (C-5’), 77.37 (C-2’), 74.60 (CH2Ph), 74.48 (C-9’), 73.46 (CH2Ph), 72.67 
(C-4’), 67.80 (CH2Ph), 65.40 (CH2Ph), 62.81 (C-6’), 25.20 (NHAc);  
HRMS (FAB) m/z: [M+Na]+ calcd for C44H41O8N835ClNa, 867.2634, and 
C44H41O8N837ClNa, 869.2604, found: 867.2618 and 869.2678 respectively. 
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Benzyl [(1’S)-1-(2-acetamido-6-chloropurin-7-yl)-2,2’-anhydro-6-azido-3,4-di-O-
benzyl-3-C-(1’-benzyloxy-2’-hydroxyethyl)-1,6-di-deoxy-D-glycero-β-D-gluco-hepto 
pyran]uronate (133): 
 
BSA (65 µL, 259.5 µmol) was added to a 
suspension of the nucleobase 2-acetamido-6-
chloropurine 57 (28 mg, 129.8 µmol) in anhydrous 
CH3CN (1 mL) under argon. The mixture was heated 
to 60 ºC for 45 min to afford the crude silylated base. To this solution was added the 
glycosyl donor 6R 134b (60 mg, 86.5 µmol) dissolved in anhydrous CH3CN (1 mL) 
followed by slow addition of TMSOTf (125 µL, 692 µmol) under argon. The solution 
was stirred at 65 ºC for 90 min. The mixture was cooled to room temperature, CH2Cl2 
(20 mL) was added and the organic layer was washed with NaHCO3 saturated aqueous 
solution (2 x 10 mL). The aqueous layer was extracted with CH2Cl2 (3 x 30 mL), the 
organic layers were combined, dried (MgSO4), filtered and concentrated under reduced 
pressure. Purification by flash column chromatography (cyclohexane-EtOAc, 1:1) 
afforded the N7 nucleoside 6R 133 (44 mg, 58%) as a colorless oil. 
Rf 0.31 (cyclohexane-EtOAc, 1:1); 
[α]D +51.3 (c 0.2, CHCl3);  
1H NMR (CDCl3, 400MHz): δ 8.31 (s, 1H, H-8), 8.30 (br s, 1H, NH), 7.44 - 7.08 (m, 
20H, H arom.), 6.35 (d, 1H, J1’,2’ = 8.8 Hz, H-1’), 5.22 (d, 1H, J = 12.0 Hz, CHPh), 5.09 
(d, 1H, J = 11.2 Hz, CHPh), 5.05 (d, 1H, J = 12.0 Hz, CHPh), 4.83 (dd, 1H, J5’,6’ = 2.2 
Hz, J5’,4’ = 9.8 Hz, H-5’), 4.77 (d, 1H, J = 11.2 Hz, CHPh), 4.75 (s, 2H, CH2Ph), 4.70 (d, 
1H, J = 10.4 Hz, CHPh), 4.61 (d, 1H, J = 10.4 Hz, CHPh), 4.51 (d, 1H, J4’5’ = 9.8 Hz, H-
4), 4.44 – 4.42 (m, 2H, H-2’, H-8’), 4.31 (dd, 1H, J9’a,8’ = 3.3 Hz, J9’a,9’b = 9.5 Hz, H-9’a), 
4.22 – 4.19 (m, 2H, H-6’, H-9’b), 2.65 (s, 3H, NHAc);  
13C NMR (CDCl3, 100MHz): δ 171.61, 167.63 (2 x C=O), 162.84 (C-4), 152.36 (C-2 or 
C-6), 145.90 (C-8), 143.62 (C-2 or C-6), 137.48, 136.84, 136.65, 134.35 (4C arom. 
quat.), 128.69 - 127.27 (20CH arom.), 118.69 (C-5), 89.38 (C-3’), 84.42 (C-8’), 82.78 
(C-1’), 78.96 (C-2’), 78.14 (C-5’), 74.96 (CH2Ph), 74.19 (C-9’), 73.85 (C-4’), 73.60 
(CH2Ph), 67.66 (CH2Ph), 65.42 (CH2Ph), 61.02 (C-6’), 25.19 (NHAc);  
HRMS (FAB) m/z: [M+Na]+ calcd for C44H41O8N835ClNa, 867.2634, and 
C44H41O8N837ClNa, 869.2604, found: 867.2642 and 869.2612 respectively.   
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Crystal data A1  
 
 
Table 1.  Crystal data and structure refinement for 84a.  
   
      Identification code               compound 84a  
   
      Empirical formula                 C11 H17 N3 O8  
   
      Formula weight                    319.28  
   
      Temperature                       100(2) K  
   
      Wavelength                        0.71073 A  
   
      Crystal system, space group       Monoclinic,  P2(1)  
   
      Unit cell dimensions           a = 9.5575(3) A   alpha = 90 deg.  
                                     b = 6.1562(2) A    beta = 111.354(1) deg.  
                                     c = 12.1268(4) A  gamma = 90 deg.  
   
      Volume                            664.53(4) A^3  
   
      Z, Calculated density             2,  1.596 Mg/m^3  
   
      Absorption coefficient            0.137 mm^-1  
   
      F(000)                            336  
   
      Crystal size                      0.40 x 0.20 x 0.08 mm  
   
      Theta range for data collection   1.80 to 30.07 deg.  
   
      Limiting indices                  -13<=h<=13, -8<=k<=8, -17<=l<=17  
   
      Reflections collected / unique    38597 / 2118 [R(int) = 0.0243]  
   
      Completeness to theta = 30.07     99.8 %  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.9891 and 0.9472  
   
      Refinement method                 Full-matrix least-squares on F^2  
   
      Data / restraints / parameters    2118 / 1 / 204  
   
      Goodness-of-fit on F^2            1.164  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0223, wR2 = 0.0643  
   
      R indices (all data)              R1 = 0.0230, wR2 = 0.0745      
      Largest diff. peak and hole       0.362 and -0.191 e.A^-3 
Appendix – Crystal data A1 
 
Total Synthesis and Stereochemical Assignment of Miharamycins A2 
  
         Table 2.  Atomic coordinates (x 10^4) and equivalent isotropic  
         displacement parameters (A^2 x 10^3) for 84a.  
         U(eq) is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          C(1)        -2022(1)       4102(2)       6070(1)       10(1)  
          C(2)         -423(1)       3265(2)       6291(1)        9(1)  
          C(3)          761(1)       4280(2)       7381(1)        8(1)  
          C(4)         2398(1)       3784(2)       7489(1)        8(1)  
          C(5)         3284(1)       5811(2)       7339(1)       10(1)  
          C(6)         4246(1)       6405(2)       8628(1)       12(1)  
          O(7)         3606(1)       5267(2)       9370(1)       11(1)  
          C(8)         3149(1)       3224(2)       8809(1)        9(1)  
          C(9)         1883(1)       2314(2)       9147(1)       10(1)  
          O(10)         573(1)       3455(2)       8431(1)       10(1)  
          N(11)       -2016(1)       6487(2)       5932(1)       13(1)  
          N(12)       -3286(1)       7300(2)       5523(1)       13(1)  
          N(13)       -4372(1)       8243(2)       5144(1)       21(1)  
          C(14)       -2633(1)       3484(2)       7030(1)       11(1)  
          O(15)       -3058(1)       4761(2)       7594(1)       16(1)  
          O(16)       -2713(1)       1328(2)       7094(1)       13(1)  
          C(17)       -3461(2)        531(2)       7861(1)       18(1)  
          O(18)         -10(1)       3837(2)       5309(1)       11(1)  
          O(19)        2533(1)       1983(1)       6801(1)       10(1)  
          O(20)        2335(1)       7512(2)       6686(1)       14(1)  
          O(21)        1813(1)         80(2)       8909(1)       13(1)  
          C(22)         708(2)      -1007(2)       9254(1)       17(1)  
         ________________________________________________________________  
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           Table 3.  Bond lengths [A] and angles [deg] for 84a.  
           _____________________________________________________________  
   
            C(1)-N(11)                    1.4782(17)  
            C(1)-C(14)                    1.5282(16)  
            C(1)-C(2)                     1.5408(15)  
            C(1)-H(1)                     1.0000  
 
            C(2)-O(18)                    1.4281(12)  
            C(2)-C(3)                     1.5259(14)  
            C(2)-H(2)                     1.0000  
            C(3)-O(10)                    1.4416(12)  
            C(3)-C(4)                     1.5520(14)  
            C(3)-H(3)                     1.0000  
            C(4)-O(19)                    1.4214(13)  
            C(4)-C(8)                     1.5360(14)  
            C(4)-C(5)                     1.5554(16)  
            C(5)-O(20)                    1.4219(14)  
            C(5)-C(6)                     1.5412(15)  
            C(5)-H(5)                     1.0000  
            C(6)-O(7)                     1.4409(14)  
            C(6)-H(6A)                    0.9900  
            C(6)-H(6B)                    0.9900  
            O(7)-C(8)                     1.4209(15)  
            C(8)-C(9)                     1.5187(15)  
            C(8)-H(8)                     1.0000  
            C(9)-O(21)                    1.4016(15)  
            C(9)-O(10)                    1.4223(13)  
            C(9)-H(9)                     1.0000  
            N(11)-N(12)                   1.2377(15)  
            N(12)-N(13)                   1.1303(16)  
            C(14)-O(15)                   1.2053(16)  
            C(14)-O(16)                   1.3331(15)  
            O(16)-C(17)                   1.4499(14)  
            C(17)-H(17A)                  0.9800  
            C(17)-H(17B)                  0.9800  
            C(17)-H(17C)                  0.9800  
            O(18)-H(18)                   0.8400  
            O(19)-H(19)                   0.8400  
            O(20)-H(20)                   0.8400  
            O(21)-C(22)                   1.4348(15)  
            C(22)-H(22A)                  0.9800  
            C(22)-H(22B)                  0.9800  
            C(22)-H(22C)                  0.9800  
   
            N(11)-C(1)-C(14)            110.63(10)  
            N(11)-C(1)-C(2)             107.89(10)  
            C(14)-C(1)-C(2)             114.45(9)  
            N(11)-C(1)-H(1)             107.9  
            C(14)-C(1)-H(1)             107.9  
            C(2)-C(1)-H(1)              107.9  
            O(18)-C(2)-C(3)             106.15(8)  
            O(18)-C(2)-C(1)             109.28(9)  
            C(3)-C(2)-C(1)              112.94(9)  
            O(18)-C(2)-H(2)             109.5  
            C(3)-C(2)-H(2)              109.5  
            C(1)-C(2)-H(2)              109.5  
            O(10)-C(3)-C(2)             109.21(9)  
            O(10)-C(3)-C(4)             107.57(8)  
            C(2)-C(3)-C(4)              113.57(8)  
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            O(10)-C(3)-H(3)             108.8  
            C(2)-C(3)-H(3)              108.8  
            C(4)-C(3)-H(3)              108.8  
            O(19)-C(4)-C(8)             109.19(9)  
            O(19)-C(4)-C(3)             114.07(9)  
            C(8)-C(4)-C(3)              101.89(8)  
            O(19)-C(4)-C(5)             112.80(9)  
            C(8)-C(4)-C(5)              103.57(8)  
            C(3)-C(4)-C(5)              114.03(9)  
            O(20)-C(5)-C(6)             114.47(10)  
            O(20)-C(5)-C(4)             113.09(9)  
            C(6)-C(5)-C(4)              102.76(9)  
            O(20)-C(5)-H(5)             108.8  
            C(6)-C(5)-H(5)              108.8  
            C(4)-C(5)-H(5)              108.8  
            O(7)-C(6)-C(5)              106.59(9)  
            O(7)-C(6)-H(6A)             110.4  
            C(5)-C(6)-H(6A)             110.4  
            O(7)-C(6)-H(6B)             110.4  
            C(5)-C(6)-H(6B)             110.4  
            H(6A)-C(6)-H(6B)            108.6  
            C(8)-O(7)-C(6)              104.97(8)  
            O(7)-C(8)-C(9)              109.49(9)  
            O(7)-C(8)-C(4)              104.21(9)  
            C(9)-C(8)-C(4)              104.41(8)  
            O(7)-C(8)-H(8)              112.7  
            C(9)-C(8)-H(8)              112.7  
            C(4)-C(8)-H(8)              112.7  
            O(21)-C(9)-O(10)            113.15(10)  
            O(21)-C(9)-C(8)             106.81(9)  
            O(10)-C(9)-C(8)             105.25(9)  
            O(21)-C(9)-H(9)             110.5  
            O(10)-C(9)-H(9)             110.5  
            C(8)-C(9)-H(9)              110.5  
            C(9)-O(10)-C(3)             110.41(8)  
            N(12)-N(11)-C(1)            113.77(11)  
            N(13)-N(12)-N(11)           172.71(14)  
            O(15)-C(14)-O(16)           125.27(12)  
            O(15)-C(14)-C(1)            124.80(12)  
            O(16)-C(14)-C(1)            109.80(10)  
            C(14)-O(16)-C(17)           115.27(10)  
            O(16)-C(17)-H(17A)          109.5  
            O(16)-C(17)-H(17B)          109.5  
            H(17A)-C(17)-H(17B)         109.5  
            O(16)-C(17)-H(17C)          109.5  
            H(17A)-C(17)-H(17C)         109.5  
            H(17B)-C(17)-H(17C)         109.5  
            C(2)-O(18)-H(18)            109.5  
            C(4)-O(19)-H(19)            109.5  
            C(5)-O(20)-H(20)            109.5  
            C(9)-O(21)-C(22)            112.51(10)  
            O(21)-C(22)-H(22A)          109.5  
            O(21)-C(22)-H(22B)          109.5  
            H(22A)-C(22)-H(22B)         109.5  
            O(21)-C(22)-H(22C)          109.5  
            H(22A)-C(22)-H(22C)         109.5  
            H(22B)-C(22)-H(22C)         109.5  
           _____________________________________________________________  
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    Table 4.  Anisotropic displacement parameters (A^2 x 10^3) for 84a.  
    The anisotropic displacement factor exponent takes the form:  
    -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    C(1)      8(1)      10(1)      10(1)       1(1)       3(1)       1(1)  
    C(2)      7(1)      11(1)       8(1)       0(1)       2(1)       0(1)  
    C(3)      8(1)       9(1)       6(1)       0(1)       2(1)       1(1)  
    C(4)      8(1)       7(1)       8(1)      -1(1)       3(1)       1(1)  
    C(5)      9(1)       9(1)       9(1)       0(1)       2(1)       0(1)  
    C(6)     11(1)      13(1)       9(1)      -1(1)       1(1)      -3(1)  
    O(7)     12(1)      12(1)       9(1)      -2(1)       3(1)      -2(1)  
    C(8)      9(1)      10(1)       8(1)       0(1)       2(1)       1(1)  
    C(9)     10(1)      10(1)       8(1)       1(1)       2(1)       1(1)  
    O(10)    10(1)      14(1)       8(1)       3(1)       4(1)       3(1)  
    N(11)     9(1)      12(1)      17(1)       5(1)       5(1)       3(1)  
    N(12)    12(1)      13(1)      12(1)       0(1)       4(1)       0(1)  
    N(13)    13(1)      17(1)      27(1)       0(1)       2(1)       4(1)  
    C(14)     8(1)      12(1)      11(1)       1(1)       3(1)      -1(1)  
    O(15)    18(1)      17(1)      17(1)       0(1)      10(1)       3(1)  
    O(16)    14(1)      12(1)      15(1)       2(1)       8(1)      -1(1)  
    C(17)    19(1)      19(1)      20(1)       6(1)      12(1)      -1(1)  
    O(18)    10(1)      14(1)       7(1)      -2(1)       4(1)      -2(1)  
    O(19)    11(1)       9(1)       9(1)      -2(1)       3(1)       2(1)  
    O(20)    17(1)       9(1)      12(1)       2(1)      -2(1)      -1(1)  
    O(21)    17(1)       9(1)      16(1)       1(1)       9(1)       1(1)  
    C(22)    19(1)      14(1)      20(1)       2(1)      11(1)      -2(1)  
    _______________________________________________________________________  
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         Table 5.  Hydrogen coordinates ( x 10^4) and isotropic  
         displacement parameters (A^2 x 10^3) for 84a.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          H(1)        -2710          3474          5304          12  
          H(2)         -400          1649          6380          10  
          H(3)          613          5890          7349           9  
          H(5)         3966          5364          6920          11  
          H(6A)        5302          5953          8815          14  
          H(6B)        4223          7993          8750          14  
          H(8)         4004          2184          8970          11  
          H(9)         2086          2577         10005          11  
          H(17A)      -2962          1119          8660          27  
          H(17B)      -3413         -1059          7891          27  
          H(17C)      -4514           995          7552          27  
          H(18)        -565          3173          4702          16  
          H(19)        1933          2134          6100          15  
          H(20)        2554          8670          7077          22  
          H(22A)        827          -574         10060          25  
          H(22B)        842         -2582          9227          25  
          H(22C)       -299          -609          8709          25  
         ________________________________________________________________  
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Crystal data A2  
 
 
Table 1.  Crystal data and structure refinement for 85.  
   
   
      Identification code               compound 85  
   
      Empirical formula                 C17 H23 N3 O11  
   
      Formula weight                    445.38  
   
      Temperature                       293(2) K  
   
      Wavelength                        0.71073 A  
   
      Crystal system, space group       Orthorhombic,  P2(1)2(1)2(1)  
   
      Unit cell dimensions              a = 8.8751(3) A    alpha = 90 deg.  
                                        b = 13.7390(5) A    beta = 90 deg.  
                                        c = 34.8600(15) A  gamma = 90 deg.  
   
      Volume                            4250.7(3) A^3  
   
      Z, Calculated density             8,  1.392 Mg/m^3  
   
      Absorption coefficient            0.118 mm^-1  
   
      F(000)                            1872  
   
      Crystal size                      0.40 x 0.08 x 0.04 mm  
   
      Theta range for data collection   1.59 to 25.05 deg.  
   
      Limiting indices                  -10<=h<=10, -14<=k<=16, -39<=l<=41  
   
      Reflections collected / unique    35445 / 4249 [R(int) = 0.0400]  
   
      Completeness to theta = 25.05     99.6 %  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.9953 and 0.9544  
   
      Refinement method                 Full-matrix least-squares on F^2  
   
      Data / restraints / parameters    4249 / 0 / 569  
   
      Goodness-of-fit on F^2            1.128  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0349, wR2 = 0.0858  
   
      R indices (all data)              R1 = 0.0628, wR2 = 0.1122  
     
      Largest diff. peak and hole       0.207 and -0.197 e.A^-3  
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         Table 2.  Atomic coordinates ( x 10^4) and equivalent isotropic  
         displacement parameters (A^2 x 10^3) for 85.  
         U(eq) is defined as one third of the trace of the orthogonalized  
 
         Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
 
   
          C(1A)        2371(4)       9322(3)       8531(1)       45(1)  
          C(2A)        3209(3)       9188(3)       8150(1)       40(1)  
          C(3A)        4491(4)       8461(2)       8191(1)       40(1)  
          C(4A)        5545(4)       8366(2)       7835(1)       43(1)  
          C(5A)        5770(4)       7297(3)       7716(1)       52(1)  
          C(6A)        6944(5)       6962(3)       8003(1)       63(1)  
          O(7A)        7877(3)       7780(2)       8070(1)       77(1)  
          C(8A)        7104(4)       8662(3)       7995(1)       50(1)  
          C(9A)        6736(4)       9206(3)       8356(1)       48(1)  
          O(10A)       5433(3)       8734(2)       8507(1)       50(1)  
          N(11A)       1663(4)       8388(2)       8623(1)       64(1)  
          N(12A)        898(4)       8365(3)       8917(1)       66(1)  
          N(13A)        158(6)       8225(3)       9176(1)      103(2)  
          C(14A)       1255(4)      10157(3)       8507(1)       53(1)  
          O(15A)        -73(3)      10075(2)       8522(1)       88(1)  
          O(16A)       1974(3)      10995(2)       8471(1)       60(1)  
          C(17A)       1036(7)      11847(3)       8401(2)       97(2)  
          O(18A)       2188(3)       8770(2)       7872(1)       48(1)  
          C(19A)       1552(4)       9382(4)       7613(1)       57(1)  
          O(20A)       1726(4)      10238(2)       7619(1)       85(1)  
          C(21A)        636(5)       8820(4)       7329(1)       76(1)  
          O(22A)       4983(3)       8983(2)       7536(1)       45(1)  
          C(23A)       5716(4)       9009(3)       7193(1)       49(1)  
          O(24A)       6946(3)       8670(2)       7144(1)       66(1)  
          C(25A)       4789(5)       9502(3)       6898(1)       64(1)  
          O(26A)       4428(3)       6716(2)       7755(1)       57(1)  
          C(27A)       3408(5)       6779(3)       7466(1)       61(1)  
          O(28A)       3623(4)       7254(2)       7183(1)       71(1)  
 
          C(29A)       2033(5)       6215(3)       7557(2)       79(1)  
          O(30A)       6435(3)      10164(2)       8250(1)       53(1)  
          C(31A)       6243(5)      10825(3)       8565(1)       69(1)  
          C(1B)        7338(4)        -22(3)        659(1)       50(1)  
          C(2B)        5851(3)        171(2)        449(1)       38(1)  
          C(3B)        5401(3)       -695(2)        201(1)       38(1)  
          C(4B)        4029(4)       -527(2)        -69(1)       39(1)  
          C(5B)        2844(4)      -1328(2)        -34(1)       45(1)  
          C(6B)        3564(5)      -2144(3)       -261(1)       61(1)  
          O(7B)        4261(3)      -1663(2)       -577(1)       73(1)  
          C(8B)        4699(4)       -706(3)       -471(1)       47(1)  
          C(9B)        6363(4)       -613(3)       -414(1)       48(1)  
          O(10B)       6630(3)       -977(2)        -39(1)       49(1)  
          N(11B)       7285(5)       -888(3)        906(1)       71(1)  
          N(12B)       6476(7)       -842(3)       1191(2)       92(1)  
          N(13B)       5757(10)      -934(4)       1463(2)      150(3)  
          C(14B)       7848(5)        875(3)        877(1)       65(1)  
          O(15B)       7627(6)       1000(3)       1211(1)      115(1)  
          O(16B)       8523(3)       1511(2)        645(1)       76(1)  
          C(17B)       8976(7)       2419(3)        828(2)      106(2)  
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          O(18B)       4676(3)        274(2)        732(1)       44(1)  
          C(19B)       4232(4)       1195(3)        824(1)       52(1)  
          O(20B)       4745(4)       1905(2)        687(1)       71(1)  
          C(21B)       3008(6)       1154(4)       1119(2)       88(2)  
          O(22B)       3471(2)        438(2)          3(1)       43(1)  
          C(23B)       2327(4)        807(3)       -213(1)       52(1)  
          O(24B)       1866(3)        425(2)       -501(1)       68(1)  
          C(25B)       1755(5)       1719(3)        -38(1)       77(1)  
          O(26B)       2596(3)      -1644(2)        355(1)       48(1)  
          C(27B)       1554(5)      -1157(3)        561(1)       53(1)  
          O(28B)        844(3)       -483(2)        433(1)       75(1)  
          C(29B)       1426(6)      -1554(3)        955(1)       71(1)  
          O(30B)       6730(3)        370(2)       -448(1)       54(1)  
          C(31B)       8326(4)        558(4)       -445(1)       75(1)  
         ________________________________________________________________  
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           Table 3.  Bond lengths [A] and angles [deg] for 85.  
           _____________________________________________________________  
   
            C(1A)-N(11A)                  1.465(5)  
            C(1A)-C(14A)                  1.517(5)  
 
            C(1A)-C(2A)                   1.535(5)  
            C(1A)-H(1A)                   0.9800  
            C(2A)-O(18A)                  1.444(4)  
            C(2A)-C(3A)                   1.521(5)  
            C(2A)-H(2A)                   0.9800  
            C(3A)-O(10A)                  1.432(4)  
            C(3A)-C(4A)                   1.559(5)  
            C(3A)-H(3A)                   0.9800  
            C(4A)-O(22A)                  1.435(4)  
            C(4A)-C(5A)                   1.539(5)  
            C(4A)-C(8A)                   1.545(5)  
            C(5A)-O(26A)                  1.440(5)  
            C(5A)-C(6A)                   1.515(6)  
            C(5A)-H(5A)                   0.9800  
            C(6A)-O(7A)                   1.416(5)  
            C(6A)-H(6A1)                  0.9700  
            C(6A)-H(6A2)                  0.9700  
            O(7A)-C(8A)                   1.416(5)  
            C(8A)-C(9A)                   1.500(5)  
            C(8A)-H(8A)                   0.9800  
            C(9A)-O(30A)                  1.393(4)  
            C(9A)-O(10A)                  1.426(4)  
            C(9A)-H(9A)                   0.9800  
            N(11A)-N(12A)                 1.231(5)  
            N(12A)-N(13A)                 1.132(5)  
            C(14A)-O(15A)                 1.185(5)  
            C(14A)-O(16A)                 1.323(4)  
            O(16A)-C(17A)                 1.457(5)  
            C(17A)-H(17A)                 0.9600  
            C(17A)-H(17B)                 0.9600  
            C(17A)-H(17C)                 0.9600  
            O(18A)-C(19A)                 1.358(5)  
            C(19A)-O(20A)                 1.186(5)  
            C(19A)-C(21A)                 1.494(6)  
            C(21A)-H(21A)                 0.9600  
            C(21A)-H(21B)                 0.9600  
            C(21A)-H(21C)                 0.9600  
            O(22A)-C(23A)                 1.361(4)  
            C(23A)-O(24A)                 1.199(4)  
            C(23A)-C(25A)                 1.481(5)  
            C(25A)-H(25A)                 0.9600  
            C(25A)-H(25B)                 0.9600  
            C(25A)-H(25C)                 0.9600  
            O(26A)-C(27A)                 1.358(5)  
            C(27A)-O(28A)                 1.199(5)  
            C(27A)-C(29A)                 1.480(6)  
            C(29A)-H(29A)                 0.9600  
            C(29A)-H(29B)                 0.9600  
            C(29A)-H(29C)                 0.9600  
            O(30A)-C(31A)                 1.435(5)  
            C(31A)-H(31A)                 0.9600  
            C(31A)-H(31B)                 0.9600  
            C(31A)-H(31C)                 0.9600  
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            C(1B)-N(11B)                  1.469(5)  
 
            C(1B)-C(14B)                  1.516(6)  
            C(1B)-C(2B)                   1.533(5)  
            C(1B)-H(1B)                   0.9800  
            C(2B)-O(18B)                  1.442(4)  
            C(2B)-C(3B)                   1.524(5)  
            C(2B)-H(2B)                   0.9800  
            C(3B)-O(10B)                  1.429(4)  
            C(3B)-C(4B)                   1.555(4)  
            C(3B)-H(3B)                   0.9800  
            C(4B)-O(22B)                  1.438(4)  
            C(4B)-C(5B)                   1.526(5)  
            C(4B)-C(8B)                   1.543(5)  
            C(5B)-O(26B)                  1.443(4)  
            C(5B)-C(6B)                   1.513(5)  
            C(5B)-H(5B)                   0.9800  
            C(6B)-O(7B)                   1.428(5)  
            C(6B)-H(6B1)                  0.9700  
            C(6B)-H(6B2)                  0.9700  
            O(7B)-C(8B)                   1.421(5)  
            C(8B)-C(9B)                   1.495(5)  
            C(8B)-H(8B)                   0.9800  
            C(9B)-O(30B)                  1.394(4)  
            C(9B)-O(10B)                  1.419(4)  
            C(9B)-H(9B)                   0.9800  
            N(11B)-N(12B)                 1.227(6)  
            N(12B)-N(13B)                 1.149(7)  
            C(14B)-O(15B)                 1.191(5)  
            C(14B)-O(16B)                 1.333(6)  
            O(16B)-C(17B)                 1.457(5)  
            C(17B)-H(17D)                 0.9600  
            C(17B)-H(17E)                 0.9600  
            C(17B)-H(17F)                 0.9600  
            O(18B)-C(19B)                 1.364(4)  
            C(19B)-O(20B)                 1.179(5)  
            C(19B)-C(21B)                 1.494(6)  
            C(21B)-H(21D)                 0.9600  
            C(21B)-H(21E)                 0.9600  
            C(21B)-H(21F)                 0.9600  
            O(22B)-C(23B)                 1.362(4)  
            C(23B)-O(24B)                 1.204(5)  
            C(23B)-C(25B)                 1.483(6)  
            C(25B)-H(25D)                 0.9600  
            C(25B)-H(25E)                 0.9600  
            C(25B)-H(25F)                 0.9600  
            O(26B)-C(27B)                 1.348(5)  
            C(27B)-O(28B)                 1.205(5)  
            C(27B)-C(29B)                 1.481(5)  
            C(29B)-H(29D)                 0.9600  
            C(29B)-H(29E)                 0.9600  
            C(29B)-H(29F)                 0.9600  
            O(30B)-C(31B)                 1.441(4)  
            C(31B)-H(31D)                 0.9600  
            C(31B)-H(31E)                 0.9600  
            C(31B)-H(31F)                 0.9600  
 
   
            N(11A)-C(1A)-C(14A)         113.3(3)  
            N(11A)-C(1A)-C(2A)          107.0(3)  
            C(14A)-C(1A)-C(2A)          111.1(3)  
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            N(11A)-C(1A)-H(1A)          108.5  
            C(14A)-C(1A)-H(1A)          108.5  
            C(2A)-C(1A)-H(1A)           108.5  
            O(18A)-C(2A)-C(3A)          105.8(3)  
            O(18A)-C(2A)-C(1A)          108.9(2)  
            C(3A)-C(2A)-C(1A)           111.1(3)  
            O(18A)-C(2A)-H(2A)          110.3  
            C(3A)-C(2A)-H(2A)           110.3  
            C(1A)-C(2A)-H(2A)           110.3  
            O(10A)-C(3A)-C(2A)          109.8(3)  
            O(10A)-C(3A)-C(4A)          106.5(2)  
            C(2A)-C(3A)-C(4A)           115.4(3)  
            O(10A)-C(3A)-H(3A)          108.4  
            C(2A)-C(3A)-H(3A)           108.4  
            C(4A)-C(3A)-H(3A)           108.4  
            O(22A)-C(4A)-C(5A)          114.4(3)  
            O(22A)-C(4A)-C(8A)          114.7(3)  
            C(5A)-C(4A)-C(8A)           103.4(3)  
            O(22A)-C(4A)-C(3A)          108.7(3)  
            C(5A)-C(4A)-C(3A)           111.9(3)  
            C(8A)-C(4A)-C(3A)           103.2(3)  
            O(26A)-C(5A)-C(6A)          109.8(3)  
            O(26A)-C(5A)-C(4A)          113.4(3)  
            C(6A)-C(5A)-C(4A)           101.6(3)  
            O(26A)-C(5A)-H(5A)          110.6  
            C(6A)-C(5A)-H(5A)           110.6  
            C(4A)-C(5A)-H(5A)           110.6  
            O(7A)-C(6A)-C(5A)           105.7(3)  
            O(7A)-C(6A)-H(6A1)          110.6  
            C(5A)-C(6A)-H(6A1)          110.6  
            O(7A)-C(6A)-H(6A2)          110.6  
            C(5A)-C(6A)-H(6A2)          110.6  
            H(6A1)-C(6A)-H(6A2)         108.7  
            C(6A)-O(7A)-C(8A)           111.4(3)  
            O(7A)-C(8A)-C(9A)           112.2(3)  
            O(7A)-C(8A)-C(4A)           106.0(3)  
            C(9A)-C(8A)-C(4A)           103.8(3)  
            O(7A)-C(8A)-H(8A)           111.5  
            C(9A)-C(8A)-H(8A)           111.5  
            C(4A)-C(8A)-H(8A)           111.5  
            O(30A)-C(9A)-O(10A)         111.9(3)  
            O(30A)-C(9A)-C(8A)          106.8(3)  
            O(10A)-C(9A)-C(8A)          105.0(3)  
            O(30A)-C(9A)-H(9A)          111.0  
            O(10A)-C(9A)-H(9A)          111.0  
            C(8A)-C(9A)-H(9A)           111.0  
            C(9A)-O(10A)-C(3A)          108.0(2)  
            N(12A)-N(11A)-C(1A)         116.2(3)  
            N(13A)-N(12A)-N(11A)        171.2(5)  
            O(15A)-C(14A)-O(16A)        124.5(4)  
            O(15A)-C(14A)-C(1A)         125.1(4)  
            O(16A)-C(14A)-C(1A)         110.4(3)  
            C(14A)-O(16A)-C(17A)        116.1(3)  
            O(16A)-C(17A)-H(17A)        109.5  
            O(16A)-C(17A)-H(17B)        109.5  
            H(17A)-C(17A)-H(17B)        109.5  
            O(16A)-C(17A)-H(17C)        109.5  
            H(17A)-C(17A)-H(17C)        109.5  
            H(17B)-C(17A)-H(17C)        109.5  
            C(19A)-O(18A)-C(2A)         117.5(3)  
            O(20A)-C(19A)-O(18A)        123.2(4)  
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            O(20A)-C(19A)-C(21A)        126.5(4)  
            O(18A)-C(19A)-C(21A)        110.3(4)  
            C(19A)-C(21A)-H(21A)        109.5  
            C(19A)-C(21A)-H(21B)        109.5  
            H(21A)-C(21A)-H(21B)        109.5  
            C(19A)-C(21A)-H(21C)        109.5  
            H(21A)-C(21A)-H(21C)        109.5  
            H(21B)-C(21A)-H(21C)        109.5  
            C(23A)-O(22A)-C(4A)         119.3(3)  
            O(24A)-C(23A)-O(22A)        123.3(3)  
            O(24A)-C(23A)-C(25A)        125.8(4)  
            O(22A)-C(23A)-C(25A)        110.9(3)  
            C(23A)-C(25A)-H(25A)        109.5  
            C(23A)-C(25A)-H(25B)        109.5  
            H(25A)-C(25A)-H(25B)        109.5  
            C(23A)-C(25A)-H(25C)        109.5  
            H(25A)-C(25A)-H(25C)        109.5  
            H(25B)-C(25A)-H(25C)        109.5  
            C(27A)-O(26A)-C(5A)         116.6(3)  
            O(28A)-C(27A)-O(26A)        122.6(4)  
            O(28A)-C(27A)-C(29A)        126.4(4)  
            O(26A)-C(27A)-C(29A)        110.9(4)  
            C(27A)-C(29A)-H(29A)        109.5  
            C(27A)-C(29A)-H(29B)        109.5  
            H(29A)-C(29A)-H(29B)        109.5  
            C(27A)-C(29A)-H(29C)        109.5  
            H(29A)-C(29A)-H(29C)        109.5  
            H(29B)-C(29A)-H(29C)        109.5  
            C(9A)-O(30A)-C(31A)         114.6(3)  
            O(30A)-C(31A)-H(31A)        109.5  
            O(30A)-C(31A)-H(31B)        109.5  
            H(31A)-C(31A)-H(31B)        109.5  
            O(30A)-C(31A)-H(31C)        109.5  
            H(31A)-C(31A)-H(31C)        109.5  
            H(31B)-C(31A)-H(31C)        109.5  
            N(11B)-C(1B)-C(14B)         112.0(3)  
            N(11B)-C(1B)-C(2B)          113.1(3)  
            C(14B)-C(1B)-C(2B)          110.9(3)  
            N(11B)-C(1B)-H(1B)          106.8  
            C(14B)-C(1B)-H(1B)          106.8  
            C(2B)-C(1B)-H(1B)           106.8  
            O(18B)-C(2B)-C(3B)          105.9(2)  
            O(18B)-C(2B)-C(1B)          108.2(3)  
            C(3B)-C(2B)-C(1B)           111.2(3)  
            O(18B)-C(2B)-H(2B)          110.4  
            C(3B)-C(2B)-H(2B)           110.4  
            C(1B)-C(2B)-H(2B)           110.4  
            O(10B)-C(3B)-C(2B)          110.1(2)  
            O(10B)-C(3B)-C(4B)          106.5(2)  
            C(2B)-C(3B)-C(4B)           115.6(3)  
            O(10B)-C(3B)-H(3B)          108.1  
            C(2B)-C(3B)-H(3B)           108.1  
            C(4B)-C(3B)-H(3B)           108.1  
            O(22B)-C(4B)-C(5B)          114.5(3)  
            O(22B)-C(4B)-C(8B)          115.9(3)  
            C(5B)-C(4B)-C(8B)           102.9(3)  
            O(22B)-C(4B)-C(3B)          107.5(3)  
            C(5B)-C(4B)-C(3B)           112.7(3)  
            C(8B)-C(4B)-C(3B)           102.9(3)  
            O(26B)-C(5B)-C(6B)          109.4(3)  
            O(26B)-C(5B)-C(4B)          113.4(3)  
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            C(6B)-C(5B)-C(4B)           101.7(3)  
            O(26B)-C(5B)-H(5B)          110.7  
            C(6B)-C(5B)-H(5B)           110.7  
            C(4B)-C(5B)-H(5B)           110.7  
            O(7B)-C(6B)-C(5B)           104.1(3)  
            O(7B)-C(6B)-H(6B1)          110.9  
            C(5B)-C(6B)-H(6B1)          110.9  
            O(7B)-C(6B)-H(6B2)          110.9  
            C(5B)-C(6B)-H(6B2)          110.9  
            H(6B1)-C(6B)-H(6B2)         108.9  
            C(8B)-O(7B)-C(6B)           110.1(3)  
            O(7B)-C(8B)-C(9B)           112.5(3)  
            O(7B)-C(8B)-C(4B)           106.2(3)  
            C(9B)-C(8B)-C(4B)           104.3(3)  
            O(7B)-C(8B)-H(8B)           111.2  
            C(9B)-C(8B)-H(8B)           111.2  
            C(4B)-C(8B)-H(8B)           111.2  
            O(30B)-C(9B)-O(10B)         112.3(3)  
            O(30B)-C(9B)-C(8B)          107.6(3)  
            O(10B)-C(9B)-C(8B)          104.9(3)  
            O(30B)-C(9B)-H(9B)          110.6  
            O(10B)-C(9B)-H(9B)          110.6  
            C(8B)-C(9B)-H(9B)           110.6  
            C(9B)-O(10B)-C(3B)          108.5(2)  
            N(12B)-N(11B)-C(1B)         116.8(4)  
            N(13B)-N(12B)-N(11B)        170.6(5)  
            O(15B)-C(14B)-O(16B)        124.8(4)  
            O(15B)-C(14B)-C(1B)         123.8(5)  
            O(16B)-C(14B)-C(1B)         111.3(4)  
            C(14B)-O(16B)-C(17B)        114.9(4)  
            O(16B)-C(17B)-H(17D)        109.5  
            O(16B)-C(17B)-H(17E)        109.5  
            H(17D)-C(17B)-H(17E)        109.5  
            O(16B)-C(17B)-H(17F)        109.5  
            H(17D)-C(17B)-H(17F)        109.5  
            H(17E)-C(17B)-H(17F)        109.5  
            C(19B)-O(18B)-C(2B)         117.5(3)  
            O(20B)-C(19B)-O(18B)        124.0(3)  
            O(20B)-C(19B)-C(21B)        126.2(4)  
            O(18B)-C(19B)-C(21B)        109.8(4)  
            C(19B)-C(21B)-H(21D)        109.5  
            C(19B)-C(21B)-H(21E)        109.5  
            H(21D)-C(21B)-H(21E)        109.5  
            C(19B)-C(21B)-H(21F)        109.5  
            H(21D)-C(21B)-H(21F)        109.5  
            H(21E)-C(21B)-H(21F)        109.5  
            C(23B)-O(22B)-C(4B)         120.2(3)  
            O(24B)-C(23B)-O(22B)        123.5(4)  
            O(24B)-C(23B)-C(25B)        126.5(4)  
            O(22B)-C(23B)-C(25B)        110.0(4)  
            C(23B)-C(25B)-H(25D)        109.5  
            C(23B)-C(25B)-H(25E)        109.5  
            H(25D)-C(25B)-H(25E)        109.5  
            C(23B)-C(25B)-H(25F)        109.5  
            H(25D)-C(25B)-H(25F)        109.5  
            H(25E)-C(25B)-H(25F)        109.5  
            C(27B)-O(26B)-C(5B)         117.1(3)  
            O(28B)-C(27B)-O(26B)        123.0(3)  
            O(28B)-C(27B)-C(29B)        125.8(4)  
            O(26B)-C(27B)-C(29B)        111.2(4)  
            C(27B)-C(29B)-H(29D)        109.5  
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            C(27B)-C(29B)-H(29E)        109.5  
            H(29D)-C(29B)-H(29E)        109.5  
            C(27B)-C(29B)-H(29F)        109.5  
            H(29D)-C(29B)-H(29F)        109.5  
            H(29E)-C(29B)-H(29F)        109.5  
            C(9B)-O(30B)-C(31B)         113.8(3)  
            O(30B)-C(31B)-H(31D)        109.5  
            O(30B)-C(31B)-H(31E)        109.5  
            H(31D)-C(31B)-H(31E)        109.5  
            O(30B)-C(31B)-H(31F)        109.5  
            H(31D)-C(31B)-H(31F)        109.5  
            H(31E)-C(31B)-H(31F)        109.5  
           _____________________________________________________________  
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    Table 4.  Anisotropic displacement parameters (A^2 x 10^3) for 85.  
    The anisotropic displacement factor exponent takes the form:  
    -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    C(1A)    40(2)      50(2)      45(2)      -3(2)       3(2)      -8(2)  
    C(2A)    35(2)      48(2)      38(2)      -2(2)      -1(1)      -6(2)  
    C(3A)    37(2)      43(2)      41(2)       0(2)       2(2)      -4(2)  
    C(4A)    39(2)      41(2)      47(2)       2(2)       3(2)       3(2)  
    C(5A)    48(2)      50(2)      56(2)       1(2)       4(2)       5(2)  
    C(6A)    61(3)      53(2)      74(3)       1(2)      -7(2)      11(2)  
    O(7A)    51(2)      62(2)     120(3)      -5(2)     -22(2)      14(2)  
    C(8A)    38(2)      53(2)      58(2)       5(2)       1(2)       1(2)  
    C(9A)    39(2)      58(2)      45(2)       5(2)      -2(2)      -4(2)  
    O(10A)   41(1)      64(2)      45(1)       8(1)      -2(1)      -7(1)  
    N(11A)   71(2)      58(2)      62(2)       0(2)      27(2)      -9(2)  
    N(12A)   60(2)      64(2)      74(3)       4(2)      14(2)      -7(2)  
    N(13A)  111(4)     105(3)      94(3)       7(3)      55(3)     -23(3)  
    C(14A)   45(2)      62(3)      52(2)     -15(2)       4(2)      -6(2)  
    O(15A)   40(2)      82(2)     143(3)      -8(2)       7(2)       0(2)  
    O(16A)   56(2)      49(2)      74(2)     -12(1)       4(1)      -5(1)  
    C(17A)  107(4)      52(3)     131(5)      -9(3)      -4(4)      18(3)  
    O(18A)   41(1)      58(2)      44(1)      -6(1)      -4(1)      -4(1)  
    C(19A)   46(2)      79(3)      46(2)      -3(2)      -3(2)      14(2)  
    O(20A)  104(2)      69(2)      82(2)       3(2)     -29(2)      16(2)  
    C(21A)   56(2)     112(4)      61(3)     -18(3)     -15(2)      12(3)  
    O(22A)   46(1)      44(1)      44(1)       2(1)       5(1)       4(1)  
    C(23A)   52(2)      48(2)      46(2)      -4(2)       9(2)       1(2)  
    O(24A)   57(2)      85(2)      55(2)       2(1)      17(1)      12(2)  
    C(25A)   73(3)      71(3)      48(2)       2(2)       0(2)       8(2)  
    O(26A)   61(2)      47(2)      63(2)      -1(1)      -1(1)      -4(1)  
    C(27A)   69(3)      47(2)      68(3)     -14(2)      -7(2)       0(2)  
    O(28A)   88(2)      59(2)      66(2)      -4(2)     -12(2)      -8(2)  
    C(29A)   70(3)      65(3)     103(4)      -7(3)      -8(3)     -11(2)  
    O(30A)   60(2)      51(2)      47(1)      -3(1)       0(1)      -5(1)  
    C(31A)   81(3)      67(3)      59(3)     -19(2)       8(2)     -10(2)  
    C(1B)    48(2)      49(2)      52(2)      -9(2)     -16(2)       7(2)  
    C(2B)    36(2)      43(2)      34(2)      -2(2)       1(1)       3(2)  
    C(3B)    37(2)      38(2)      38(2)      -2(2)      -1(1)      -1(2)  
    C(4B)    39(2)      39(2)      40(2)       3(2)      -2(1)      -5(2)  
 
    C(5B)    46(2)      48(2)      39(2)       3(2)       1(2)      -9(2)  
    C(6B)    63(2)      56(2)      63(3)      -9(2)      13(2)     -17(2)  
    O(7B)    83(2)      84(2)      53(2)     -29(2)      21(2)     -40(2)  
    C(8B)    43(2)      61(2)      38(2)      -1(2)       2(2)     -11(2)  
    C(9B)    45(2)      57(2)      42(2)      -5(2)       4(2)      -4(2)  
    O(10B)   46(1)      54(2)      46(1)      -8(1)       1(1)      13(1)  
    N(11B)   85(3)      62(2)      67(2)       1(2)     -25(2)      23(2)  
    N(12B)  135(4)      76(3)      64(3)      17(3)     -23(3)      18(3)  
    N(13B)  242(8)     129(4)      78(4)      37(3)      12(5)      23(5)  
    C(14B)   62(3)      67(3)      67(3)      -7(2)     -32(2)      12(2)  
    O(15B)  194(4)      87(2)      63(2)     -16(2)     -46(3)     -13(3)  
    O(16B)   63(2)      59(2)     107(2)     -20(2)      -6(2)       0(2)  
    C(17B)   94(4)      64(3)     160(6)     -30(3)     -39(4)      -5(3)  
    O(18B)   50(1)      44(1)      39(1)       0(1)       5(1)       4(1)  
    C(19B)   55(2)      51(3)      51(2)     -11(2)       7(2)       9(2)  
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    O(20B)   85(2)      44(2)      85(2)      -6(2)      22(2)       5(2)  
    C(21B)   92(3)      80(3)      91(4)     -19(3)      47(3)       8(3)  
    O(22B)   37(1)      43(1)      50(1)       7(1)     -10(1)       0(1)  
    C(23B)   41(2)      55(2)      61(3)      19(2)      -8(2)      -7(2)  
    O(24B)   55(2)      84(2)      65(2)      16(2)     -21(1)      -7(2)  
    C(25B)   64(3)      70(3)      96(3)      18(3)     -18(3)      18(2)  
    O(26B)   51(1)      47(1)      47(1)       6(1)       9(1)      -5(1)  
    C(27B)   47(2)      59(2)      54(2)      -1(2)      10(2)     -11(2)  
    O(28B)   65(2)      81(2)      78(2)      19(2)      18(2)      19(2)  
    C(29B)   87(3)      75(3)      51(2)       8(2)      16(2)      -8(3)  
    O(30B)   39(1)      63(2)      61(2)      -1(1)       7(1)     -11(1)  
    C(31B)   45(2)      98(3)      81(3)       0(3)       3(2)     -25(2)  
    _______________________________________________________________________  
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         Table 5.  Hydrogen coordinates ( x 10^4) and isotropic  
         displacement parameters (A^2 x 10^3) for 85.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          H(1A)        3110          9473          8731          54  
          H(2A)        3594          9814          8057          48  
          H(3A)        4057          7820          8246          48  
          H(5A)        6165          7257          7454          62  
          H(6A1)       6468          6750          8239          75  
          H(6A2)       7527          6426          7899          75  
          H(8A)        7658          9071          7813          59  
          H(9A)        7574          9177          8539          57  
          H(17A)        440         11982          8624         145  
          H(17B)        383         11724          8187         145  
          H(17C)       1666         12397          8345         145  
          H(21A)       1291          8430          7173         114  
          H(21B)         85          9264          7169         114  
          H(21C)        -58          8406          7464         114  
          H(25A)       4167          9032          6770          96  
          H(25B)       5437          9812          6714          96  
          H(25C)       4162          9983          7018          96  
          H(29A)       1573          5995          7323         119  
          H(29B)       1337          6620          7694         119  
          H(29C)       2296          5663          7712         119  
          H(31A)       7143         10833          8717         104  
          H(31B)       5409         10617          8719         104  
          H(31C)       6050         11467          8468         104  
          H(1B)        8100          -148           462          60  
          H(2B)        5928           762           293          45  
          H(3B)        5164         -1241           371          45  
          H(5B)        1895         -1124          -153          53  
          H(6B1)       4305         -2486          -107          73  
          H(6B2)       2811         -2605          -348          73  
          H(8B)        4328          -225          -656          57  
          H(9B)        6909         -1000          -605          58  
          H(17D)       9440          2281          1071         159  
          H(17E)       8105          2821           867         159  
          H(17F)       9682          2754           666         159  
          H(21D)       2777          1802          1204         132  
          H(21E)       3337           770          1333         132  
          H(21F)       2124           865          1008         132  
          H(25D)       1149          2063          -222         115  
          H(25E)       2590          2120            37         115  
          H(25F)       1157          1566           183         115  
          H(29D)        913         -2169           947         106  
          H(29E)        867         -1108          1112         106  
          H(29F)       2415         -1642          1061         106  
          H(31D)       8796           214          -653         112  
          H(31E)       8748           342          -206         112  
          H(31F)       8500          1244          -474         112  
         ________________________________________________________________  
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Crystal data A3  
 
 
Table 1.  Crystal data and structure refinement for 89a.  
   
   
      Identification code               compound 89a  
   
      Empirical formula                 C17 H23 N3 O11  
   
      Formula weight                    445.38  
   
      Temperature                       100(2) K  
   
      Wavelength                        0.71073 A  
   
      Crystal system, space group       Monoclinic,  P2(1)  
   
      Unit cell dimensions           a = 8.3378(2) A   alpha = 90 deg.  
                                     b = 14.5058(3) A    beta = 99.579(1) deg.  
                                     c = 8.5855(2) A   gamma = 90 deg.  
   
      Volume                            1023.91(4) A^3  
   
      Z, Calculated density             2,  1.445 Mg/m^3  
   
      Absorption coefficient            0.122 mm^-1  
   
      F(000)                            468  
   
      Crystal size                      0.30 x 0.20 x 0.12 mm  
   
      Theta range for data collection   2.48 to 30.05 deg.  
   
      Limiting indices                  -11<=h<=11, -20<=k<=20, -12<=l<=12  
   
      Reflections collected / unique    38593 / 3112 [R(int) = 0.0260]  
   
      Completeness to theta = 30.05     99.9 %  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.9855 and 0.9642  
   
      Refinement method                 Full-matrix least-squares on F^2  
   
      Data / restraints / parameters    3112 / 1 / 285  
   
      Goodness-of-fit on F^2            1.054  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0272, wR2 = 0.0739  
   
      R indices (all data)              R1 = 0.0280, wR2 = 0.0750  
     
      Largest diff. peak and hole       0.605 and -0.389 e.A^-3  
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         Table 2.  Atomic coordinates ( x 10^4) and equivalent isotropic  
         displacement parameters (A^2 x 10^3) for 89a.  
         U(eq) is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          C(1)         6465(2)      10890(1)       5091(2)       18(1)  
          O(2)         5153(1)      10282(1)       4513(1)       18(1)  
          C(3)         5460(1)       9786(1)       3151(1)       14(1)  
          C(4)         6754(2)       9059(1)       3707(1)       13(1)  
          C(5)         8292(2)       9504(1)       4615(1)       14(1)  
          C(6)         7997(2)      10312(1)       5689(2)       20(1)  
          O(7)         9445(1)      10850(1)       5891(2)       34(1)  
          C(8)        10494(2)      10561(1)       4817(2)       29(1)  
          C(9)         9519(2)       9904(1)       3642(2)       18(1)  
          O(10)        6781(1)      11516(1)       3957(1)       20(1)  
          C(11)        5436(2)      12117(1)       3431(2)       23(1)  
          C(12)        3843(2)       9371(1)       2366(2)       17(1)  
          N(13)        3436(1)       8597(1)       3337(2)       24(1)  
          N(14)        2175(2)       8171(1)       2801(2)       21(1)  
          N(15)        1051(2)       7734(1)       2465(2)       30(1)  
          C(16)        3855(2)       9087(1)        650(2)       18(1)  
          O(17)        3567(1)       8322(1)        133(1)       23(1)  
          O(18)        4146(1)       9821(1)       -199(1)       21(1)  
          C(19)        4044(2)       9663(1)      -1886(2)       28(1)  
          O(20)        7112(1)       8581(1)       2333(1)       15(1)  
          C(21)        7111(2)       7637(1)       2392(2)       19(1)  
          C(22)        7285(2)       7232(1)        823(2)       26(1)  
          O(23)        6956(2)       7207(1)       3550(1)       30(1)  
          O(24)        9322(1)       8813(1)       5534(1)       16(1)  
          C(25)        8809(2)       8369(1)       6757(2)       18(1)  
          O(26)        7499(1)       8492(1)       7147(1)       23(1)  
          C(27)       10106(2)       7732(1)       7550(2)       28(1)  
          O(28)        8640(1)      10393(1)       2317(1)       18(1)  
          C(29)        9196(2)      10351(1)        939(2)       23(1)  
          O(30)       10368(2)       9900(2)        744(2)       55(1)  
          C(31)        8111(2)      10895(1)       -298(2)       24(1)  
         ________________________________________________________________  
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           Table 3.  Bond lengths [A] and angles [deg] for 89a.  
           _____________________________________________________________  
   
            C(1)-O(10)                    1.3888(16)  
            C(1)-O(2)                     1.4290(16)  
            C(1)-C(6)                     1.5420(18)  
            C(1)-H(1)                     1.0000  
            O(2)-C(3)                     1.4312(14)  
            C(3)-C(4)                     1.5268(16)  
            C(3)-C(12)                    1.5278(17)  
            C(3)-H(3)                     1.0000  
            C(4)-O(20)                    1.4425(14)  
            C(4)-C(5)                     1.5281(17)  
            C(4)-H(4)                     1.0000  
            C(5)-O(24)                    1.4620(14)  
            C(5)-C(6)                     1.5371(18)  
            C(5)-C(9)                     1.5385(17)  
            C(6)-O(7)                     1.4237(18)  
            C(6)-H(6)                     1.0000  
            O(7)-C(8)                     1.435(2)  
            C(8)-C(9)                     1.521(2)  
            C(8)-H(8A)                    0.9900  
            C(8)-H(8B)                    0.9900  
            C(9)-O(28)                    1.4340(15)  
            C(9)-H(9)                     1.0000  
            O(10)-C(11)                   1.4324(17)  
            C(11)-H(11A)                  0.9800  
            C(11)-H(11B)                  0.9800  
            C(11)-H(11C)                  0.9800  
            C(12)-N(13)                   1.4708(18)  
            C(12)-C(16)                   1.5309(18)  
            C(12)-H(12)                   1.0000  
            N(13)-N(14)                   1.2402(17)  
            N(14)-N(15)                   1.1290(19)  
            C(16)-O(17)                   1.2039(19)  
            C(16)-O(18)                   1.3350(17)  
            O(18)-C(19)                   1.4544(17)  
            C(19)-H(19A)                  0.9800  
            C(19)-H(19B)                  0.9800  
            C(19)-H(19C)                  0.9800  
            O(20)-C(21)                   1.3694(16)  
            C(21)-O(23)                   1.1991(18)  
            C(21)-C(22)                   1.4988(18)  
            C(22)-H(22A)                  0.9800  
            C(22)-H(22B)                  0.9800  
            C(22)-H(22C)                  0.9800  
            O(24)-C(25)                   1.3603(15)  
            C(25)-O(26)                   1.2075(17)  
            C(25)-C(27)                   1.4975(19)  
            C(27)-H(27A)                  0.9800  
            C(27)-H(27B)                  0.9800  
            C(27)-H(27C)                  0.9800  
            O(28)-C(29)                   1.3416(15)  
            C(29)-O(30)                   1.211(2)  
            C(29)-C(31)                   1.499(2)  
            C(31)-H(31A)                  0.9800  
            C(31)-H(31B)                  0.9800  
            C(31)-H(31C)                  0.9800  
   
            O(10)-C(1)-O(2)             112.57(10)  
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            O(10)-C(1)-C(6)             110.24(11)  
            O(2)-C(1)-C(6)              108.90(10)  
            O(10)-C(1)-H(1)             108.3  
            O(2)-C(1)-H(1)              108.3  
            C(6)-C(1)-H(1)              108.3  
            C(1)-O(2)-C(3)              111.29(9)  
            O(2)-C(3)-C(4)              107.74(9)  
            O(2)-C(3)-C(12)             107.08(10)  
            C(4)-C(3)-C(12)             113.06(11)  
            O(2)-C(3)-H(3)              109.6  
            C(4)-C(3)-H(3)              109.6  
            C(12)-C(3)-H(3)             109.6  
            O(20)-C(4)-C(3)             107.94(9)  
            O(20)-C(4)-C(5)             110.48(10)  
            C(3)-C(4)-C(5)              110.93(10)  
            O(20)-C(4)-H(4)             109.2  
            C(3)-C(4)-H(4)              109.2  
            C(5)-C(4)-H(4)              109.2  
            O(24)-C(5)-C(4)             110.73(10)  
            O(24)-C(5)-C(6)             109.71(10)  
            C(4)-C(5)-C(6)              115.05(10)  
            O(24)-C(5)-C(9)              99.65(9)  
            C(4)-C(5)-C(9)              117.40(10)  
 
            C(6)-C(5)-C(9)              103.00(10)  
            O(7)-C(6)-C(5)              105.91(11)  
            O(7)-C(6)-C(1)              112.44(11)  
            C(5)-C(6)-C(1)              114.92(10)  
            O(7)-C(6)-H(6)              107.8  
            C(5)-C(6)-H(6)              107.8  
            C(1)-C(6)-H(6)              107.8  
            C(6)-O(7)-C(8)              110.91(11)  
            O(7)-C(8)-C(9)              107.07(12)  
            O(7)-C(8)-H(8A)             110.3  
            C(9)-C(8)-H(8A)             110.3  
            O(7)-C(8)-H(8B)             110.3  
            C(9)-C(8)-H(8B)             110.3  
            H(8A)-C(8)-H(8B)            108.6  
            O(28)-C(9)-C(8)             111.25(11)  
            O(28)-C(9)-C(5)             108.58(10)  
            C(8)-C(9)-C(5)              101.94(11)  
            O(28)-C(9)-H(9)             111.6  
            C(8)-C(9)-H(9)              111.6  
            C(5)-C(9)-H(9)              111.6  
            C(1)-O(10)-C(11)            112.92(11)  
            O(10)-C(11)-H(11A)          109.5  
            O(10)-C(11)-H(11B)          109.5  
            H(11A)-C(11)-H(11B)         109.5  
            O(10)-C(11)-H(11C)          109.5  
            H(11A)-C(11)-H(11C)         109.5  
            H(11B)-C(11)-H(11C)         109.5  
            N(13)-C(12)-C(3)            108.66(10)  
            N(13)-C(12)-C(16)           112.31(12)  
            C(3)-C(12)-C(16)            112.58(10)  
            N(13)-C(12)-H(12)           107.7  
            C(3)-C(12)-H(12)            107.7  
            C(16)-C(12)-H(12)           107.7  
            N(14)-N(13)-C(12)           115.53(11)  
            N(15)-N(14)-N(13)           172.52(15)  
            O(17)-C(16)-O(18)           125.21(13)  
            O(17)-C(16)-C(12)           124.70(13)  
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            O(18)-C(16)-C(12)           110.01(12)  
            C(16)-O(18)-C(19)           115.62(12)  
            O(18)-C(19)-H(19A)          109.5  
            O(18)-C(19)-H(19B)          109.5  
            H(19A)-C(19)-H(19B)         109.5  
            O(18)-C(19)-H(19C)          109.5  
            H(19A)-C(19)-H(19C)         109.5  
            H(19B)-C(19)-H(19C)         109.5  
            C(21)-O(20)-C(4)            116.67(10)  
            O(23)-C(21)-O(20)           123.48(13)  
            O(23)-C(21)-C(22)           125.53(14)  
            O(20)-C(21)-C(22)           110.98(12)  
            C(21)-C(22)-H(22A)          109.5  
            C(21)-C(22)-H(22B)          109.5  
            H(22A)-C(22)-H(22B)         109.5  
            C(21)-C(22)-H(22C)          109.5  
            H(22A)-C(22)-H(22C)         109.5  
            H(22B)-C(22)-H(22C)         109.5  
            C(25)-O(24)-C(5)            120.59(10)  
            O(26)-C(25)-O(24)           124.01(12)  
            O(26)-C(25)-C(27)           125.67(13)  
            O(24)-C(25)-C(27)           110.31(12)  
            C(25)-C(27)-H(27A)          109.5  
            C(25)-C(27)-H(27B)          109.5  
            H(27A)-C(27)-H(27B)         109.5  
            C(25)-C(27)-H(27C)          109.5  
            H(27A)-C(27)-H(27C)         109.5  
            H(27B)-C(27)-H(27C)         109.5  
            C(29)-O(28)-C(9)            118.10(11)  
            O(30)-C(29)-O(28)           123.47(14)  
            O(30)-C(29)-C(31)           126.26(13)  
            O(28)-C(29)-C(31)           110.19(12)  
            C(29)-C(31)-H(31A)          109.5  
            C(29)-C(31)-H(31B)          109.5  
            H(31A)-C(31)-H(31B)         109.5  
            C(29)-C(31)-H(31C)          109.5  
            H(31A)-C(31)-H(31C)         109.5  
            H(31B)-C(31)-H(31C)         109.5  
           _____________________________________________________________  
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    Table 4.  Anisotropic displacement parameters (A^2 x 10^3) for 89a.  
    The anisotropic displacement factor exponent takes the form:  
    -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    C(1)     21(1)      17(1)      16(1)      -2(1)       3(1)       3(1)  
    O(2)     19(1)      18(1)      17(1)      -2(1)       6(1)       1(1)  
    C(3)     14(1)      15(1)      14(1)       0(1)       2(1)       3(1)  
    C(4)     14(1)      14(1)      11(1)      -1(1)       1(1)       1(1)  
    C(5)     16(1)      14(1)      12(1)       2(1)       0(1)       1(1)  
    C(6)     23(1)      17(1)      17(1)      -4(1)      -3(1)       3(1)  
    O(7)     23(1)      25(1)      49(1)     -18(1)      -8(1)      -1(1)  
    C(8)     27(1)      31(1)      25(1)       6(1)      -4(1)     -13(1)  
    C(9)     16(1)      19(1)      18(1)       6(1)       0(1)      -1(1)  
    O(10)    22(1)      15(1)      22(1)       1(1)       6(1)       3(1)  
    C(11)    28(1)      19(1)      23(1)       1(1)       4(1)       7(1)  
    C(12)    14(1)      19(1)      17(1)       2(1)       2(1)       1(1)  
    N(13)    18(1)      28(1)      24(1)       8(1)       2(1)      -4(1)  
    N(14)    21(1)      17(1)      27(1)       2(1)       6(1)       3(1)  
    N(15)    26(1)      23(1)      43(1)      -2(1)       6(1)      -6(1)  
    C(16)    13(1)      23(1)      17(1)       1(1)      -1(1)       1(1)  
    O(17)    23(1)      22(1)      23(1)      -2(1)       1(1)      -2(1)  
    O(18)    24(1)      23(1)      16(1)       3(1)       0(1)      -2(1)  
    C(19)    33(1)      35(1)      15(1)       3(1)      -1(1)      -8(1)  
    O(20)    18(1)      15(1)      13(1)      -2(1)       2(1)       2(1)  
    C(21)    19(1)      16(1)      21(1)      -3(1)       3(1)       2(1)  
    C(22)    31(1)      23(1)      23(1)      -8(1)       5(1)       1(1)  
    O(23)    47(1)      18(1)      30(1)       4(1)      16(1)       5(1)  
    O(24)    16(1)      17(1)      16(1)       4(1)       0(1)       2(1)  
    C(25)    20(1)      18(1)      15(1)       3(1)      -2(1)      -3(1)  
    O(26)    22(1)      29(1)      18(1)       5(1)       3(1)      -1(1)  
    C(27)    24(1)      26(1)      31(1)      14(1)      -5(1)       0(1)  
    O(28)    22(1)      19(1)      13(1)       4(1)       4(1)       4(1)  
    C(29)    16(1)      37(1)      16(1)       1(1)       3(1)      -3(1)  
    O(30)    32(1)     107(2)      30(1)      10(1)      12(1)      30(1)  
    C(31)    25(1)      33(1)      14(1)       2(1)       0(1)      -4(1)  
    _______________________________________________________________________  
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         Table 5.  Hydrogen coordinates ( x 10^4) and isotropic  
         displacement parameters (A^2 x 10^3) for 89a.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          H(1)         6171         11243          6004          21  
          H(3)         5871         10220          2403          17  
          H(4)         6314          8610          4412          16  
          H(6)         7879         10053          6743          23  
          H(8A)       11467         10246          5397          34  
          H(8B)       10856         11101          4260          34  
          H(9)        10225          9412          3299          22  
          H(11A)       5117         12431          4342          35  
          H(11B)       4517         11755          2888          35  
          H(11C)       5754         12576          2701          35  
          H(12)        2985          9853          2361          20  
          H(19A)       3025          9343         -2293          42  
          H(19B)       4966          9284         -2072          42  
          H(19C)       4072         10255         -2429          42  
          H(22A)       6206          7094           225          38  
          H(22B)       7925          6663           987          38  
          H(22C)       7839          7674           232          38  
          H(27A)       9615          7261          8141          42  
          H(27B)      10909          8084          8278          42  
          H(27C)      10643          7434          6751          42  
          H(31A)       7143         10530          -706          36  
          H(31B)       8700         11042         -1163          36  
          H(31C)       7782         11467           167          36  
         ________________________________________________________________  
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Crystal data A4  
 
 
Table 1.  Crystal data and structure refinement for 89b.  
   
   
      Identification code               compound 89b  
   
      Empirical formula                 C17 H23 N3 O11  
   
      Formula weight                    445.38  
   
      Temperature                       293(2) K  
   
      Wavelength                        0.71073 A  
   
      Crystal system, space group       Monoclinic,  P2(1)  
   
      Unit cell dimensions           a = 8.6590(2) A   alpha = 90 deg.  
                                     b = 17.9496(4) A    beta = 94.758(1) deg.  
                                     c = 13.6934(4) A   gamma = 90 deg.  
   
      Volume                            2120.97(9) A^3  
   
      Z, Calculated density             4,  1.395 Mg/m^3  
   
      Absorption coefficient            0.118 mm^-1  
   
      F(000)                            936  
   
      Crystal size                      0.40 x 0.30 x 0.30 mm  
   
      Theta range for data collection   1.49 to 28.00 deg.  
   
      Limiting indices                  -11<=h<=11, -22<=k<=22, -18<=l<=16  
   
      Reflections collected / unique    46547 / 5210 [R(int) = 0.0350]  
   
      Completeness to theta = 28.00     98.5 %  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.9654 and 0.9543  
   
      Refinement method                 Full-matrix least-squares on F^2  
   
      Data / restraints / parameters    5210 / 1 / 569  
   
      Goodness-of-fit on F^2            1.140  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0396, wR2 = 0.1097  
   
      R indices (all data)              R1 = 0.0580, wR2 = 0.1304  
     
      Largest diff. peak and hole       0.422 and -0.479 e.A^-3  
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         Table 2.  Atomic coordinates ( x 10^4) and equivalent isotropic  
         displacement parameters (A^2 x 10^3) for 89b.  
         U(eq) is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          C(1A)        1758(3)       7984(2)      -1599(2)       41(1)  
          O(2A)        2367(2)       8402(1)       -768(1)       44(1)  
          C(3A)        2304(3)       7993(1)        122(2)       41(1)  
          C(4A)        3646(3)       7444(2)        159(2)       45(1)  
          C(5A)        3416(3)       6909(2)       -708(2)       43(1)  
          C(6A)        2644(3)       7241(2)      -1675(2)       48(1)  
          O(7A)        1623(4)       6676(1)      -2085(2)       80(1)  
          C(8A)        1864(5)       6004(2)      -1582(3)       61(1)  
          C(9A)        2430(3)       6207(2)       -553(2)       48(1)  
          O(10A)        186(2)       7846(1)      -1559(2)       52(1)  
          C(11A)       -716(4)       8513(3)      -1673(3)       72(1)  
          C(12A)       2407(4)       8553(2)        966(2)       55(1)  
          N(13A)       3836(4)       8994(2)       1048(3)       79(1)  
          N(14A)       3953(4)       9473(2)        407(3)       83(1)  
          N(15A)       4221(6)       9935(3)       -119(4)      119(2)  
          C(16A)        951(4)       9035(2)        919(2)       55(1)  
          O(17A)        940(4)       9701(1)        894(3)       80(1)  
          O(18A)       -288(3)       8604(1)        921(2)       61(1)  
          C(19A)      -1793(5)       8963(2)        861(3)       74(1)  
          O(20A)       3661(3)       7036(1)       1067(2)       55(1)  
          C(21A)       5026(5)       6970(2)       1607(3)       70(1)  
          O(22A)       6230(4)       7204(3)       1341(3)      100(1)  
          C(23A)       4815(8)       6588(3)       2542(4)      106(2)  
          O(24A)       4888(2)       6555(1)       -900(2)       52(1)  
          C(25A)       6063(4)       6971(2)      -1212(3)       61(1)  
          O(26A)       5974(3)       7634(2)      -1322(3)       84(1)  
          C(27A)       7403(5)       6495(3)      -1405(4)       79(1)  
          O(28A)       1143(2)       6384(1)         -5(1)       45(1)  
          C(29A)        875(4)       5914(2)        734(2)       58(1)  
          O(30A)       1674(4)       5387(2)        956(2)       90(1)  
          C(31A)       -529(6)       6141(3)       1212(3)       90(1)  
          C(1B)        7713(3)       8166(1)       3481(2)       42(1)  
          O(2B)        7371(2)       7696(1)       4271(1)       44(1)  
          C(3B)        7651(3)       8059(1)       5201(2)       39(1)  
          C(4B)        6262(3)       8562(1)       5293(2)       39(1)  
 
          C(5B)        6241(3)       9160(1)       4493(2)       40(1)  
          C(6B)        6841(4)       8917(2)       3497(2)       47(1)  
          O(7B)        7798(4)       9511(1)       3207(2)       70(1)  
          C(8B)        7515(4)      10154(2)       3756(2)       55(1)  
          C(9B)        7213(3)       9863(1)       4760(2)       42(1)  
          O(10B)       9298(2)       8285(1)       3483(2)       54(1)  
          C(11B)      10084(5)       7637(2)       3174(3)       71(1)  
          C(12B)       7872(4)       7448(2)       5983(2)       49(1)  
          N(13B)       6492(4)       6980(2)       6056(3)       68(1)  
          N(14B)       6187(4)       6544(2)       5364(3)       74(1)  
          N(15B)       5749(6)       6116(3)       4810(4)      114(2)  
          C(16B)       9315(3)       6994(2)       5810(2)       49(1)  
          O(17B)       9350(3)       6337(1)       5691(2)       71(1)  
          O(18B)      10537(3)       7445(1)       5801(2)       58(1)  
          C(19B)      11985(4)       7121(2)       5583(3)       66(1)  
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          O(20B)       6375(2)       8913(1)       6244(1)       43(1)  
          C(21B)       5056(3)       8945(2)       6719(2)       50(1)  
          O(22B)       3853(3)       8678(2)       6402(2)       83(1)  
          C(23B)       5327(5)       9346(2)       7671(3)       65(1)  
          O(24B)       4710(2)       9494(1)       4324(2)       46(1)  
          C(25B)       3521(4)       9087(2)       3896(2)       52(1)  
          O(26B)       3637(3)       8439(1)       3686(2)       70(1)  
          C(27B)       2108(4)       9555(2)       3699(3)       74(1)  
          O(28B)       8682(2)       9660(1)       5261(2)       48(1)  
          C(29B)       9253(4)      10123(2)       5977(2)       54(1)  
          O(30B)       8578(4)      10651(2)       6245(2)       86(1)  
          C(31B)      10846(5)       9892(3)       6367(3)       82(1)  
         ________________________________________________________________  
 
Appendix – Crystal data A4 
Total Synthesis and Stereochemical Assignment of Miharamycins A29
  
           Table 3.  Bond lengths [A] and angles [deg] for 89b.  
           _____________________________________________________________  
   
            C(1A)-O(10A)                  1.389(3)  
            C(1A)-O(2A)                   1.427(3)  
            C(1A)-C(6A)                   1.546(4)  
            C(1A)-H(1A)                   0.9800  
            O(2A)-C(3A)                   1.428(3)  
            C(3A)-C(4A)                   1.521(4)  
            C(3A)-C(12A)                  1.530(4)  
            C(3A)-H(3A)                   0.9800  
            C(4A)-O(20A)                  1.441(4)  
            C(4A)-C(5A)                   1.528(4)  
            C(4A)-H(4A)                   0.9800  
            C(5A)-O(24A)                  1.467(3)  
            C(5A)-C(9A)                   1.547(4)  
            C(5A)-C(6A)                   1.552(4)  
            C(6A)-O(7A)                   1.429(4)  
            C(6A)-H(6A)                   0.9800  
            O(7A)-C(8A)                   1.397(5)  
            C(8A)-C(9A)                   1.497(5)  
            C(8A)-H(8A1)                  0.9700  
            C(8A)-H(8A2)                  0.9700  
            C(9A)-O(28A)                  1.431(3)  
            C(9A)-H(9A)                   0.9800  
            O(10A)-C(11A)                 1.432(5)  
            C(11A)-H(11A)                 0.9600  
            C(11A)-H(11B)                 0.9600  
            C(11A)-H(11C)                 0.9600  
            C(12A)-N(13A)                 1.465(5)  
            C(12A)-C(16A)                 1.526(5)  
            C(12A)-H(12A)                 0.9800  
            N(13A)-N(14A)                 1.239(6)  
            N(14A)-N(15A)                 1.135(7)  
            C(16A)-O(17A)                 1.196(4)  
            C(16A)-O(18A)                 1.322(4)  
            O(18A)-C(19A)                 1.450(5)  
            C(19A)-H(19A)                 0.9600  
            C(19A)-H(19B)                 0.9600  
            C(19A)-H(19C)                 0.9600  
            O(20A)-C(21A)                 1.347(4)  
            C(21A)-O(22A)                 1.208(6)  
            C(21A)-C(23A)                 1.477(6)  
            C(23A)-H(23A)                 0.9600  
            C(23A)-H(23B)                 0.9600  
            C(23A)-H(23C)                 0.9600  
            O(24A)-C(25A)                 1.360(4)  
            C(25A)-O(26A)                 1.201(5)  
            C(25A)-C(27A)                 1.482(5)  
            C(27A)-H(27A)                 0.9600  
            C(27A)-H(27B)                 0.9600  
            C(27A)-H(27C)                 0.9600  
            O(28A)-C(29A)                 1.352(4)  
            C(29A)-O(30A)                 1.196(5)  
            C(29A)-C(31A)                 1.485(6)  
            C(31A)-H(31A)                 0.9600  
            C(31A)-H(31B)                 0.9600  
            C(31A)-H(31C)                 0.9600  
            C(1B)-O(10B)                  1.389(3)  
            C(1B)-O(2B)                   1.423(3)  
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            C(1B)-C(6B)                   1.546(4)  
            C(1B)-H(1B)                   0.9800  
            O(2B)-C(3B)                   1.433(3)  
            C(3B)-C(4B)                   1.518(4)  
            C(3B)-C(12B)                  1.533(4)  
            C(3B)-H(3B)                   0.9800  
            C(4B)-O(20B)                  1.443(3)  
            C(4B)-C(5B)                   1.533(3)  
            C(4B)-H(4B)                   0.9800  
            C(5B)-O(24B)                  1.456(3)  
            C(5B)-C(9B)                   1.544(3)  
            C(5B)-C(6B)                   1.562(4)  
            C(6B)-O(7B)                   1.426(4)  
            C(6B)-H(6B)                   0.9800  
            O(7B)-C(8B)                   1.410(4)  
            C(8B)-C(9B)                   1.513(4)  
            C(8B)-H(8B1)                  0.9700  
            C(8B)-H(8B2)                  0.9700  
            C(9B)-O(28B)                  1.442(3)  
            C(9B)-H(9B)                   0.9800  
            O(10B)-C(11B)                 1.430(4)  
            C(11B)-H(11D)                 0.9600  
            C(11B)-H(11E)                 0.9600  
            C(11B)-H(11F)                 0.9600  
            C(12B)-N(13B)                 1.471(4)  
            C(12B)-C(16B)                 1.526(4)  
            C(12B)-H(12B)                 0.9800  
            N(13B)-N(14B)                 1.241(5)  
            N(14B)-N(15B)                 1.123(6)  
            C(16B)-O(17B)                 1.191(4)  
            C(16B)-O(18B)                 1.334(4)  
            O(18B)-C(19B)                 1.436(4)  
            C(19B)-H(19D)                 0.9600  
            C(19B)-H(19E)                 0.9600  
            C(19B)-H(19F)                 0.9600  
            O(20B)-C(21B)                 1.361(3)  
            C(21B)-O(22B)                 1.195(4)  
            C(21B)-C(23B)                 1.491(5)  
            C(23B)-H(23D)                 0.9600  
            C(23B)-H(23E)                 0.9600  
            C(23B)-H(23F)                 0.9600  
            O(24B)-C(25B)                 1.354(4)  
            C(25B)-O(26B)                 1.205(4)  
            C(25B)-C(27B)                 1.489(5)  
            C(27B)-H(27D)                 0.9600  
            C(27B)-H(27E)                 0.9600  
            C(27B)-H(27F)                 0.9600  
            O(28B)-C(29B)                 1.348(4)  
            C(29B)-O(30B)                 1.187(5)  
            C(29B)-C(31B)                 1.496(5)  
            C(31B)-H(31D)                 0.9600  
            C(31B)-H(31E)                 0.9600  
            C(31B)-H(31F)                 0.9600  
   
            O(10A)-C(1A)-O(2A)          111.2(2)  
            O(10A)-C(1A)-C(6A)          110.0(2)  
            O(2A)-C(1A)-C(6A)           110.8(2)  
            O(10A)-C(1A)-H(1A)          108.3  
            O(2A)-C(1A)-H(1A)           108.3  
            C(6A)-C(1A)-H(1A)           108.3  
            C(1A)-O(2A)-C(3A)           111.83(18)  
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            O(2A)-C(3A)-C(4A)           106.2(2)  
            O(2A)-C(3A)-C(12A)          107.6(2)  
            C(4A)-C(3A)-C(12A)          113.8(2)  
            O(2A)-C(3A)-H(3A)           109.7  
            C(4A)-C(3A)-H(3A)           109.7  
            C(12A)-C(3A)-H(3A)          109.7  
            O(20A)-C(4A)-C(3A)          108.1(2)  
            O(20A)-C(4A)-C(5A)          110.0(2)  
            C(3A)-C(4A)-C(5A)           109.3(2)  
            O(20A)-C(4A)-H(4A)          109.8  
            C(3A)-C(4A)-H(4A)           109.8  
            C(5A)-C(4A)-H(4A)           109.8  
            O(24A)-C(5A)-C(4A)          110.6(2)  
            O(24A)-C(5A)-C(9A)           99.7(2)  
            C(4A)-C(5A)-C(9A)           116.3(2)  
            O(24A)-C(5A)-C(6A)          109.5(2)  
            C(4A)-C(5A)-C(6A)           116.2(2)  
            C(9A)-C(5A)-C(6A)           103.1(2)  
            O(7A)-C(6A)-C(1A)           110.1(2)  
            O(7A)-C(6A)-C(5A)           105.8(2)  
            C(1A)-C(6A)-C(5A)           117.1(2)  
            O(7A)-C(6A)-H(6A)           107.9  
            C(1A)-C(6A)-H(6A)           107.9  
            C(5A)-C(6A)-H(6A)           107.9  
            C(8A)-O(7A)-C(6A)           110.9(2)  
            O(7A)-C(8A)-C(9A)           106.2(2)  
            O(7A)-C(8A)-H(8A1)          110.5  
            C(9A)-C(8A)-H(8A1)          110.5  
            O(7A)-C(8A)-H(8A2)          110.5  
            C(9A)-C(8A)-H(8A2)          110.5  
            H(8A1)-C(8A)-H(8A2)         108.7  
            O(28A)-C(9A)-C(8A)          109.8(3)  
            O(28A)-C(9A)-C(5A)          110.7(2)  
            C(8A)-C(9A)-C(5A)           102.1(2)  
 
            O(28A)-C(9A)-H(9A)          111.3  
            C(8A)-C(9A)-H(9A)           111.3  
            C(5A)-C(9A)-H(9A)           111.3  
            C(1A)-O(10A)-C(11A)         111.9(2)  
            O(10A)-C(11A)-H(11A)        109.5  
            O(10A)-C(11A)-H(11B)        109.5  
            H(11A)-C(11A)-H(11B)        109.5  
            O(10A)-C(11A)-H(11C)        109.5  
            H(11A)-C(11A)-H(11C)        109.5  
            H(11B)-C(11A)-H(11C)        109.5  
            N(13A)-C(12A)-C(16A)        112.7(3)  
            N(13A)-C(12A)-C(3A)         114.2(3)  
            C(16A)-C(12A)-C(3A)         110.2(2)  
            N(13A)-C(12A)-H(12A)        106.4  
            C(16A)-C(12A)-H(12A)        106.4  
            C(3A)-C(12A)-H(12A)         106.4  
            N(14A)-N(13A)-C(12A)        116.0(3)  
            N(15A)-N(14A)-N(13A)        171.9(5)  
            O(17A)-C(16A)-O(18A)        125.5(3)  
            O(17A)-C(16A)-C(12A)        124.9(3)  
            O(18A)-C(16A)-C(12A)        109.7(3)  
            C(16A)-O(18A)-C(19A)        117.7(3)  
            O(18A)-C(19A)-H(19A)        109.5  
            O(18A)-C(19A)-H(19B)        109.5  
            H(19A)-C(19A)-H(19B)        109.5  
            O(18A)-C(19A)-H(19C)        109.5  
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            H(19A)-C(19A)-H(19C)        109.5  
            H(19B)-C(19A)-H(19C)        109.5  
            C(21A)-O(20A)-C(4A)         117.6(3)  
            O(22A)-C(21A)-O(20A)        122.9(4)  
            O(22A)-C(21A)-C(23A)        126.5(4)  
            O(20A)-C(21A)-C(23A)        110.5(4)  
            C(21A)-C(23A)-H(23A)        109.5  
            C(21A)-C(23A)-H(23B)        109.5  
            H(23A)-C(23A)-H(23B)        109.5  
            C(21A)-C(23A)-H(23C)        109.5  
            H(23A)-C(23A)-H(23C)        109.5  
            H(23B)-C(23A)-H(23C)        109.5  
            C(25A)-O(24A)-C(5A)         120.1(2)  
            O(26A)-C(25A)-O(24A)        122.8(3)  
            O(26A)-C(25A)-C(27A)        126.3(3)  
            O(24A)-C(25A)-C(27A)        110.9(3)  
            C(25A)-C(27A)-H(27A)        109.5  
            C(25A)-C(27A)-H(27B)        109.5  
            H(27A)-C(27A)-H(27B)        109.5  
            C(25A)-C(27A)-H(27C)        109.5  
            H(27A)-C(27A)-H(27C)        109.5  
            H(27B)-C(27A)-H(27C)        109.5  
            C(29A)-O(28A)-C(9A)         116.3(2)  
            O(30A)-C(29A)-O(28A)        123.6(3)  
            O(30A)-C(29A)-C(31A)        125.6(4)  
            O(28A)-C(29A)-C(31A)        110.8(3)  
            C(29A)-C(31A)-H(31A)        109.5  
            C(29A)-C(31A)-H(31B)        109.5  
            H(31A)-C(31A)-H(31B)        109.5  
            C(29A)-C(31A)-H(31C)        109.5  
            H(31A)-C(31A)-H(31C)        109.5  
            H(31B)-C(31A)-H(31C)        109.5  
            O(10B)-C(1B)-O(2B)          111.0(2)  
            O(10B)-C(1B)-C(6B)          110.5(2)  
            O(2B)-C(1B)-C(6B)           112.0(2)  
            O(10B)-C(1B)-H(1B)          107.7  
            O(2B)-C(1B)-H(1B)           107.7  
            C(6B)-C(1B)-H(1B)           107.7  
            C(1B)-O(2B)-C(3B)           112.02(17)  
            O(2B)-C(3B)-C(4B)           105.5(2)  
            O(2B)-C(3B)-C(12B)          107.3(2)  
            C(4B)-C(3B)-C(12B)          114.9(2)  
            O(2B)-C(3B)-H(3B)           109.6  
            C(4B)-C(3B)-H(3B)           109.6  
            C(12B)-C(3B)-H(3B)          109.6  
            O(20B)-C(4B)-C(3B)          109.9(2)  
            O(20B)-C(4B)-C(5B)          109.6(2)  
            C(3B)-C(4B)-C(5B)           108.7(2)  
            O(20B)-C(4B)-H(4B)          109.5  
            C(3B)-C(4B)-H(4B)           109.5  
            C(5B)-C(4B)-H(4B)           109.5  
            O(24B)-C(5B)-C(4B)          111.0(2)  
            O(24B)-C(5B)-C(9B)          100.0(2)  
            C(4B)-C(5B)-C(9B)           115.4(2)  
            O(24B)-C(5B)-C(6B)          109.9(2)  
            C(4B)-C(5B)-C(6B)           116.3(2)  
            C(9B)-C(5B)-C(6B)           102.8(2)  
            O(7B)-C(6B)-C(1B)           110.6(2)  
            O(7B)-C(6B)-C(5B)           106.0(2)  
            C(1B)-C(6B)-C(5B)           117.0(2)  
            O(7B)-C(6B)-H(6B)           107.6  
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            C(1B)-C(6B)-H(6B)           107.6  
            C(5B)-C(6B)-H(6B)           107.6  
            C(8B)-O(7B)-C(6B)           109.5(2)  
            O(7B)-C(8B)-C(9B)           104.6(2)  
            O(7B)-C(8B)-H(8B1)          110.8  
            C(9B)-C(8B)-H(8B1)          110.8  
            O(7B)-C(8B)-H(8B2)          110.8  
            C(9B)-C(8B)-H(8B2)          110.8  
            H(8B1)-C(8B)-H(8B2)         108.9  
            O(28B)-C(9B)-C(8B)          107.9(2)  
            O(28B)-C(9B)-C(5B)          110.4(2)  
            C(8B)-C(9B)-C(5B)           101.5(2)  
            O(28B)-C(9B)-H(9B)          112.2  
            C(8B)-C(9B)-H(9B)           112.2  
            C(5B)-C(9B)-H(9B)           112.2  
            C(1B)-O(10B)-C(11B)         111.7(3)  
            O(10B)-C(11B)-H(11D)        109.5  
            O(10B)-C(11B)-H(11E)        109.5  
            H(11D)-C(11B)-H(11E)        109.5  
            O(10B)-C(11B)-H(11F)        109.5  
            H(11D)-C(11B)-H(11F)        109.5  
            H(11E)-C(11B)-H(11F)        109.5  
            N(13B)-C(12B)-C(16B)        112.6(2)  
            N(13B)-C(12B)-C(3B)         113.7(2)  
            C(16B)-C(12B)-C(3B)         109.3(2)  
            N(13B)-C(12B)-H(12B)        107.0  
            C(16B)-C(12B)-H(12B)        107.0  
            C(3B)-C(12B)-H(12B)         107.0  
            N(14B)-N(13B)-C(12B)        115.5(3)  
            N(15B)-N(14B)-N(13B)        170.4(4)  
            O(17B)-C(16B)-O(18B)        124.8(3)  
            O(17B)-C(16B)-C(12B)        125.5(3)  
            O(18B)-C(16B)-C(12B)        109.7(2)  
            C(16B)-O(18B)-C(19B)        117.6(2)  
            O(18B)-C(19B)-H(19D)        109.5  
            O(18B)-C(19B)-H(19E)        109.5  
            H(19D)-C(19B)-H(19E)        109.5  
            O(18B)-C(19B)-H(19F)        109.5  
            H(19D)-C(19B)-H(19F)        109.5  
            H(19E)-C(19B)-H(19F)        109.5  
            C(21B)-O(20B)-C(4B)         116.9(2)  
            O(22B)-C(21B)-O(20B)        123.4(3)  
            O(22B)-C(21B)-C(23B)        125.5(3)  
            O(20B)-C(21B)-C(23B)        111.1(3)  
            C(21B)-C(23B)-H(23D)        109.5  
            C(21B)-C(23B)-H(23E)        109.5  
            H(23D)-C(23B)-H(23E)        109.5  
            C(21B)-C(23B)-H(23F)        109.5  
            H(23D)-C(23B)-H(23F)        109.5  
            H(23E)-C(23B)-H(23F)        109.5  
            C(25B)-O(24B)-C(5B)         119.8(2)  
            O(26B)-C(25B)-O(24B)        123.2(3)  
            O(26B)-C(25B)-C(27B)        125.7(3)  
            O(24B)-C(25B)-C(27B)        111.0(3)  
            C(25B)-C(27B)-H(27D)        109.5  
            C(25B)-C(27B)-H(27E)        109.5  
            H(27D)-C(27B)-H(27E)        109.5  
            C(25B)-C(27B)-H(27F)        109.5  
            H(27D)-C(27B)-H(27F)        109.5  
            H(27E)-C(27B)-H(27F)        109.5  
            C(29B)-O(28B)-C(9B)         116.5(2)  
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            O(30B)-C(29B)-O(28B)        123.8(3)  
            O(30B)-C(29B)-C(31B)        125.0(3)  
            O(28B)-C(29B)-C(31B)        111.1(3)  
            C(29B)-C(31B)-H(31D)        109.5  
            C(29B)-C(31B)-H(31E)        109.5  
            H(31D)-C(31B)-H(31E)        109.5  
            C(29B)-C(31B)-H(31F)        109.5  
            H(31D)-C(31B)-H(31F)        109.5  
            H(31E)-C(31B)-H(31F)        109.5  
           _____________________________________________________________  
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    Table 4.  Anisotropic displacement parameters (A^2 x 10^3) for 89b.  
    The anisotropic displacement factor exponent takes the form:  
    -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    C(1A)    45(1)      36(1)      44(1)       3(1)       4(1)      -5(1)  
    O(2A)    50(1)      30(1)      50(1)       1(1)      -1(1)      -6(1)  
    C(3A)    46(1)      32(1)      44(1)      -4(1)      -2(1)      -4(1)  
    C(4A)    47(1)      37(1)      50(1)       4(1)      -4(1)      -3(1)  
    C(5A)    44(1)      32(1)      52(1)       2(1)       5(1)       0(1)  
    C(6A)    56(2)      40(1)      47(1)      -2(1)       3(1)       1(1)  
    O(7A)   113(2)      46(1)      74(2)     -11(1)     -35(2)      -6(1)  
    C(8A)    77(2)      48(2)      60(2)     -18(1)      16(2)     -14(2)  
    C(9A)    52(2)      33(1)      58(2)      -2(1)       9(1)      -5(1)  
    O(10A)   43(1)      54(1)      59(1)      -3(1)       0(1)      -6(1)  
    C(11A)   53(2)      82(3)      79(2)       0(2)      -5(2)      14(2)  
    C(12A)   67(2)      45(2)      52(2)     -11(1)      -2(1)      -4(1)  
    N(13A)   72(2)      66(2)      96(2)     -27(2)     -16(2)     -12(2)  
    N(14A)   77(2)      72(2)     103(3)     -45(2)      23(2)     -28(2)  
    N(15A)  136(4)      94(3)     136(4)     -45(3)      61(3)     -65(3)  
    C(16A)   74(2)      42(2)      48(2)      -7(1)      11(1)      -1(1)  
    O(17A)   88(2)      39(1)     115(2)     -15(1)      25(2)      -2(1)  
    O(18A)   69(1)      45(1)      70(1)       0(1)      18(1)      -1(1)  
    C(19A)   74(2)      64(2)      88(3)      -4(2)      35(2)       8(2)  
    O(20A)   64(1)      47(1)      53(1)       5(1)     -11(1)      -3(1)  
    C(21A)   81(2)      56(2)      67(2)      -2(2)     -30(2)      -1(2)  
    O(22A)   68(2)     126(3)      99(2)      10(2)     -31(2)       1(2)  
    C(23A)  146(5)      84(3)      78(3)      22(2)     -45(3)     -14(3)  
    O(24A)   47(1)      41(1)      69(1)       7(1)      13(1)       5(1)  
    C(25A)   53(2)      55(2)      76(2)      17(2)      13(2)       0(1)  
    O(26A)   66(2)      56(2)     135(3)      23(2)      27(2)      -4(1)  
    C(27A)   63(2)      80(3)      98(3)      24(2)      25(2)      14(2)  
    O(28A)   50(1)      39(1)      49(1)       0(1)       8(1)      -5(1)  
    C(29A)   77(2)      51(2)      44(2)      -3(1)       6(1)     -13(2)  
    O(30A)  126(3)      67(2)      80(2)      29(2)      16(2)      13(2)  
    C(31A)  106(3)     103(3)      68(2)      -3(2)      40(2)     -13(3)  
    C(1B)    54(1)      35(1)      38(1)      -4(1)       5(1)     -10(1)  
    O(2B)    56(1)      30(1)      46(1)      -2(1)       8(1)      -8(1)  
    C(3B)    45(1)      30(1)      42(1)      -1(1)       4(1)      -3(1)  
    C(4B)    43(1)      34(1)      41(1)      -1(1)       3(1)      -3(1)  
    C(5B)    39(1)      33(1)      46(1)      -1(1)       0(1)      -1(1)  
    C(6B)    62(2)      38(1)      41(1)       3(1)       4(1)      -2(1)  
    O(7B)   109(2)      39(1)      67(1)       7(1)      40(1)      -5(1)  
    C(8B)    69(2)      35(1)      61(2)       6(1)       6(1)      -6(1)  
    C(9B)    47(1)      28(1)      51(1)       2(1)       0(1)      -4(1)  
    O(10B)   55(1)      46(1)      61(1)       1(1)      14(1)      -7(1)  
    C(11B)   74(2)      64(2)      77(2)       2(2)      25(2)      11(2)  
    C(12B)   58(2)      39(1)      50(2)       8(1)       6(1)       3(1)  
    N(13B)   68(2)      58(2)      81(2)      25(2)      20(2)      -6(1)  
    N(14B)   64(2)      64(2)      90(2)      39(2)      -8(2)     -23(2)  
    N(15B)  126(4)      94(3)     114(3)      35(3)     -37(3)     -68(3)  
    C(16B)   54(2)      37(1)      56(2)       7(1)      -6(1)      -1(1)  
    O(17B)   65(1)      33(1)     112(2)       2(1)      -6(1)       0(1)  
    O(18B)   55(1)      38(1)      80(2)       2(1)      -4(1)      -2(1)  
    C(19B)   52(2)      59(2)      87(2)       2(2)      -3(2)      -2(1)  
    O(20B)   44(1)      45(1)      41(1)      -4(1)       5(1)      -3(1)  
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    C(21B)   51(2)      48(2)      51(2)      -1(1)      11(1)       6(1)  
    O(22B)   51(1)     114(2)      89(2)     -30(2)      24(1)     -14(1)  
    C(23B)   75(2)      64(2)      58(2)      -8(2)      15(2)       9(2)  
    O(24B)   46(1)      38(1)      54(1)      -4(1)      -4(1)       1(1)  
    C(25B)   49(1)      51(2)      56(2)      -6(1)      -4(1)      -2(1)  
    O(26B)   63(1)      50(1)      94(2)     -16(1)     -14(1)      -5(1)  
    C(27B)   55(2)      71(2)      93(3)     -13(2)     -15(2)       8(2)  
    O(28B)   44(1)      39(1)      62(1)       0(1)      -1(1)      -4(1)  
    C(29B)   61(2)      52(2)      47(2)       4(1)      -2(1)     -10(1)  
    O(30B)   99(2)      76(2)      80(2)     -33(2)     -21(2)      13(2)  
    C(31B)   64(2)      93(3)      86(3)       0(2)     -19(2)      -4(2)  
    _______________________________________________________________________  
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         Table 5.  Hydrogen coordinates ( x 10^4) and isotropic  
         displacement parameters (A^2 x 10^3) for 89b.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          H(1A)        1893          8277         -2189          49  
          H(3A)        1322          7720           110          49  
          H(4A)        4625          7714           132          54  
          H(6A)        3456          7318         -2122          57  
          H(8A1)       2628          5704         -1881          73  
          H(8A2)        905          5724         -1590          73  
          H(9A)        3061          5807          -238          57  
          H(11A)       -664          8704         -2325         108  
          H(11B)       -313          8878         -1207         108  
          H(11C)      -1774          8406         -1565         108  
          H(12A)       2409          8261          1570          66  
          H(19A)      -1905          9273           288         111  
          H(19B)      -1880          9263          1434         111  
          H(19C)      -2592          8591           821         111  
          H(23A)       4586          6949          3027         159  
          H(23B)       5748          6326          2758         159  
          H(23C)       3974          6240          2448         159  
          H(27A)       8347          6765         -1247         119  
          H(27B)       7333          6357         -2085         119  
          H(27C)       7397          6054         -1009         119  
          H(31A)       -297          6152          1910         136  
          H(31B)      -1348          5791          1049         136  
          H(31C)       -849          6628           987         136  
          H(1B)        7368          7911          2869          50  
          H(3B)        8595          8361          5205          47  
          H(4B)        5308          8267          5209          47  
          H(6B)        5942          8886          3014          56  
          H(8B1)       6623         10424          3463          66  
          H(8B2)       8408         10483          3796          66  
          H(9B)        6648         10224          5133          51  
          H(11D)       9867          7572          2480         106  
          H(11E)       9733          7208          3510         106  
          H(11F)      11180          7696          3323         106  
          H(12B)       8079          7699          6616          59  
          H(19D)      11848          6859          4971          99  
          H(19E)      12333          6780          6094          99  
          H(19F)      12742          7508          5538          99  
          H(23D)       5419          8991          8197          98  
          H(23E)       4471          9673          7755          98  
          H(23F)       6265          9631          7674          98  
          H(27D)       1203          9257          3772         111  
          H(27E)       2073          9746          3043         111  
          H(27F)       2137          9961          4156         111  
          H(31D)      10919          9907          7071         123  
          H(31E)      11594         10227          6129         123  
          H(31F)      11046          9395          6153         123  
         ________________________________________________________________  
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 List of compounds synthesized along this work 
 
 
 
                                         
 
                     
(6R) R = Me 80a
(6S) R = Me 80b
(6R) R = Bn 81a
(6S) R = Bn 81b
O
BnO
OMe
O
HO
BnO
BnO
COOR
        
(6S) R = Me 82a
(6R) R = Me 82b
(6S) R = Bn 83a
(6R) R = Bn 83b
O
BnO
OMe
O
N3
BnO
BnO
COOR
                    
(6S) 84a
(6R) 84b
O
O
OH
OMe
HO
N3 COOMe
HO
               
 
(6R) 86a
(6S) 86b
O
BnO
OMe
O
TBDMSO
BnO
BnO
COOMe
             
(6R) 87a
(6S) 87b
O
AcO
OMe
O
TBDMSO
AcO
AcO
COOMe
                               
R = H 90
R = Ac 91
R = Bn 92
R = Bz 100
O
RO
OMe
O
RO
RO
RO
            
93
O
O
OAc
OAc
AcO
AcO
AcO
 
 
                                     
X = H 56
X = Cl 57
N
NN
H
N
X
NHAc
             
106
O
BnO
O
(R)N3
BnO
BnO
COOMe
OH
               
(6S) 107
(6R) 109
O
BnO
O
N3
BnO
BnO
COOMe
N
NN
N
Cl
NHAc
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(6S) 120a
(6R) 120b
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HO
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(6S) 126a
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(6S) 121a
(6R) 121b
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(6S) 134a
(6R) 134b
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